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ABSTRACT	  Mutations	   in	   Leucine-­‐Rich	   Repeat	   Kinase	   2	   (LRRK2)	   are	   one	   of	   the	  most	   common	  causes	   of	   genetic	   Parkinson’s	   disease	   (PD),	   with	   mutations	   thought	   to	   account	   for	  around	  5%	  of	  all	   familial	   cases.	  LRRK2	   is	  a	   large	  protein	  with	  a	  kinase	  and	  GTPase	  domain	  and	  multiple	  protein-­‐protein	  interaction	  domains.	  Regulation	  of	  this	  protein	  is	  complex,	  with	  GTPase	  activity	  known	  to	  regulate	  kinase	  activity.	  Similarly,	  LRRK2	  can	   autophosphorylate	   and	   is	   thought	   to	   form	   a	   dimer	   when	   active.	   Mutations	   in	  LRRK2	  are	  numerous,	  with	  the	  most	  prevalent	  mutations	  occurring	  in	  the	  enzymatic	  core	  of	  this	  protein.	  	  	  This	   thesis	   describes	   work	   done	   to	   characterise	   the	   regulation	   and	   functioning	   of	  LRRK2,	  in	  order	  to	  further	  contribute	  towards	  understanding	  how	  mutations	  in	  this	  protein	   can	   lead	   to	   the	   pathogenesis	   of	   PD.	   Using	   BlueNative	   PAGE	   and	   glycerol	  gradient	   centrifugation,	   the	   quaternary	   structure	   of	   LRRK2	   was	   assessed.	   In	   vitro	  kinase	  assays	  were	  used	  to	  characterise	  kinase	  activity	  of	  recombinant	  LRRK2	  and	  a	  number	   of	   putative	   kinase	   substrates	   were	   also	   investigated.	   Identification	   of	   new	  kinase	  substrates	  was	  attempted	  and	  immunoprecipitation	  of	  LRRK2	  to	  identify	  novel	  binding	  partners	  was	  also	  performed.	  	  Results	  of	  these	  experiments	  showed	  that	  familial	  mutations	  do	  not	  affect	  the	  ability	  of	   LRRK2	   to	   form	   complexes.	   Instead,	   some	  mutations	   are	   affecting	   the	   enzymatic	  activity	   of	   LRRK2.	   Dephosphorylating	   LRRK2	   showed	   that	   dimer	   formation	   is	  dependent	  on	  phosphorylation.	  Dephosphorylated	  forms	  of	  LRRK2	  were	  more	  likely	  to	  be	  monomeric	  and	  displayed	   lower	  kinase	  activity	   than	  higher	  molecular	  weight	  forms.	   In	   vitro	   kinase	   assays	   to	   evaluate	   LRRK2	   kinase	   substrates	   showed	   that	   α-­‐synuclein	   is	   phosphorylated	   at	   low	   levels	   by	   G2019S	   but	   not	   wild-­‐type	   LRRK2.	  Attempts	   to	   identify	   novel	   kinase	   substrates	   and	   binding	   partners	   of	   LRRK2	   were	  unsuccessful,	  however	  evaluation	  of	  putative	  kinase	  substrates	   in	  vitro	   showed	   that	  DVL3	   and	   TUBB5	   may	   be	   good	   candidates	   for	   further	   investigation,	   as	   they	   were	  robustly	   phosphorylated	   by	   LRRK2.	   These	   results	   contribute	   towards	   our	  understanding	  of	  how	  LRRK2	  functions	  and	  future	  studies	  based	  on	  these	  results	  may	  prove	  useful	  in	  aiding	  our	  understanding	  of	  how	  LRRK2	  can	  cause	  PD	  pathogenesis.	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1.1	  	  SYMPTOMS	  OF	  PARKINSON’S	  DISEASE	  











Table	  1.1.	  Summary	  of	  the	  inclusive	  and	  exclusive	  criteria	  for	  a	  diagnosis	  of	  
Parkinson’s	  disease	  to	  be	  upheld.	  (Adapted	  from	  Litvan	  et	  al.	  2003).	  
Inclusive	  Criteria	   Exclusive	  criteria	  	  	  	  	  -­‐Bradykinesia	   	  Plus	  one	  of	  the	  following,	  	  -­‐Muscular	  rigidity	  -­‐	  5-­‐7	  Hz	  resting	  tremor	  -­‐Postural	  instability	  
	  
-­‐MPTP	  exposure	  -­‐History	   of	   strokes	   with	   progressive	  step-­‐wise	  parkinsonian	  features	  -­‐Repeated	  head	  injuries	  -­‐Cerebellar	  signs	  -­‐Supranuclear	  gaze	  palsy	  -­‐Sustained	  remission	  -­‐Oculogyric	  crises	  -­‐Unilateral	  symptoms	  after	  3	  years	  -­‐Neuroleptic	   treatment	   at	   the	   onset	   of	  symptoms	  -­‐Early	  severe	  autonomic	  involvement	  -­‐Babinski	  sign	  -­‐Cerebral	  tumour	  or	  hydrocephalus	  -­‐Negative	  response	  to	  L-­‐DOPA	  -­‐More	  than	  one	  affected	  relative	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According	   to	   the	   criteria	   outlined	   in	   Table	   1.1,	   PD	   is	   characterised	   clinically	   by	  symptoms	  of	   bradykinesia	   and	   accompanied	  by	   either	  muscle	   rigidity,	   tremor	   at	  between	  5-­‐7Hz	  and/or	  postural	  instability,	  which	  are	  responsive	  to	  the	  dopamine	  precursor	  L-­‐DOPA.	   Idiopathic,	  or	  sporadic	  PD	   is	  known	  to	  affect	  about	  2%	  of	   the	  European	   population	   aged	   over	   65,	   with	   the	   prevalence	   increasing	   as	   the	  population	  gets	  older	  (De	  Rijk	  et	  al.	  1995).	  	  	  The	  clinical	  features	  of	  PD	  are	  caused	  by	  the	  death	  of	  dopaminergic	  neurons	  in	  the	  Substantia	  Nigra	  pars	  compacta	  (SNpc),	  although	  many	  different	  cell	   types	  die	   in	  PD	   (reviewed	   in	   Surmeier	   et	   al.	   2011).	   Symptoms	   are	   thought	   to	   show	   when	  neuronal	   loss	   reaches	   about	   80%	   and	   it	   has	   been	   estimated	   that	   disease	  progression	   takes	  14	  years	   to	   reach	   a	  wheelchair-­‐bound	   state,	   from	   initial	   onset	  (Hoehn,	  1987).	  The	  progression	  of	  PD	  has	  been	  shown	  to	  occur	  in	  distinct	  stages,	  and	  is	  often	  quantified	  in	  terms	  of	  the	  Hoehn	  and	  Jahr	  scale	  (Hoehn	  et	  al.	  1967)	  or	  the	  unified	  PD	  rating	  scale	  (UPDRS)	  (Fahn,	  1987),	  which	  place	  symptoms	  in	  stages	  according	   to	   the	   restrictive	   effects	   that	   are	   placed	   on	   the	   life	   of	   a	   patient.	  Additionally	  the	  motor	  deficits	  characteristic	  of	  PD	  are	  accompanied	  by	  secondary	  symptoms	   and	   although	   these	   differ	   between	   patients,	   those	   most	   commonly	  observed	  are	  pain,	  impaired	  olfaction,	  personality	  change,	  mild	  executive	  cognitive	  deficits,	  dementia	  and	  depression	  (Quinn,	  1997).	  	  	  
1.1.2 Treatment	  of	  PD	  	  The	  discovery	  that	  dopamine	  depletion	  in	  mice	  results	   in	  parkinsonism,	  by	  Arvid	  Carlsson	   (Utley	   et	   al.	   1965)	   and	   the	   discovery	   by	   Oleh	   Hornykiewicz	   that	   PD	  sufferers	  have	  a	  dopamine	  depletion	   in	   the	  striatum	  (Hornykiewicz,	  1962),	  were	  instrumental	   in	   the	   development	   of	   drug	   therapies	   for	   PD.	   Use	   of	   the	   dopamine	  precursor	  L-­‐3,4-­‐dihydroxyphenylalanine	  (L-­‐DOPA)	  in	  the	  1960’s,	  showed	  that	  this	  drug	  can	  alleviate	  many	  PD	  motor	  symptoms	  (Birkmayer	  et	  al.	  1962,	  Cotzias	  et	  al.	  1968,	   Anden	   et	   al.	   1970).	   The	   addition	   of	   the	   peripheral	   aromatic	   L-­‐amino	   acid	  decarboxylase	   (AADC)	   inhibitor	   benserazide	   to	   L-­‐DOPA	   preparations	   prevents	  peripheral	   conversion	   of	   L-­‐DOPA	   to	   dopamine	   by	   AADC,	   as	   benserazide	   cannot	  cross	  the	  blood	  brain	  barrier.	  Instead	  conversion	  to	  dopamine	  occurs	  in	  the	  brain,	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minimising	  side	  effects	  in	  the	  peripheral	  nervous	  system	  and	  allowing	  the	  maximal	  amount	   of	   dopamine	   to	   be	   targeted	   to	   the	   basal	   ganglia	   (Birkmayer	   et	  al.	   1967,	  Papavasiliou	  et	  al.	  1972).	  	  	  L-­‐DOPA	  therapy	  is	  accompanied	  by	  many	  side	  effects.	  Dyskinesias	  often	  occur	  with	  higher	  doses	  of	  L-­‐DOPA	  and	  the	  ‘on/off’	  cycling	  of	  medication	  efficiency	  means	  that	  patients	  spend	  periods	  of	  time	  when	  their	  medication	  is	  not	  having	  any	  effect.	  As	  such,	   modern	   contributions	   to	   PD	   therapy	   aim	   to	   ensure	   that	   the	   effects	   of	  medication	   are	   exerted	   as	   evenly	   as	   possible,	   while	   trying	   to	   balance	   the	  dyskinesias	   induced	   by	   excessive	   dopamine.	   To	   this	   effect,	   L-­‐DOPA	   is	   frequently	  co-­‐prescribed	   with	   dopamine	   agonists	   such	   as	   ropinirole	   hydrochloride,	   which	  work	  by	  directly	  mimicking	  the	  action	  of	  dopamine	  by	  directly	  agonising	  dopamine	  receptors	  (Jenner,	  2003).	  Dopamine	  agonists	  are	  common	  in	  PD	  therapy,	  however	  they	   have	   recently	   been	   associated	   with	   a	   number	   of	   additional	   side	   effects	  including	   pathological	   gambling,	   hypersexuality	   and	   addictive	   behaviours	  (reviewed	   in	   O'sullivan	   et	   al.	   2009).	   PD	   treatment	   plans	   also	   often	   include	  monoamine	  oxidase-­‐B	   (MAO-­‐B)	   inhibitors,	  which	  act	  by	  stopping	   the	  breakdown	  of	  dopamine	  after	  it	  has	  been	  released	  into	  the	  synapse	  and	  prolong	  the	  effects	  of	  L-­‐DOPA.	   Catechol-­‐O-­‐methyl	   transferase	   (COMT)	   inhibitors	   are	   a	   more	   recent	  addition	   to	   the	   medications	   available	   to	   PD	   patients	   and	   also	   increase	   the	  availability	  of	  dopamine	  by	   inhibiting	   its	  breakdown	  (reviewed	   in	  Varanese	  et	  al.	  2010).	  	  
1.2	  	  PATHOLOGY	  Macroscopic	  changes	  in	  the	  brains	  of	  PD	  sufferers	  are	  visible	  as	  pallor	  of	  the	  SNpc	  and	   Locus	   Coeruleus,	   due	   to	   the	   death	   of	   dopaminergic	   neurons	   containing	   the	  pigment	  neuromelanin	   (Greenfield	  et	  al.	   1953).	   It	   has	  been	   shown	   that	  neuronal	  death	  in	  PD	  always	  starts	  with	  the	  SNpc	  and	  follows	  a	  very	  specific	  pattern,	  namely	  that	   neurons	   in	   the	   venterolateral	   tier	   die	   preferentially	   (Gibb	   et	   al.	   1990).	   The	  SNpc	   contains	   neurons	   involved	   in	   the	   nigrostriatal	   pathway,	   a	   descending	  pathway	  that	  is	  afferent	  to	  the	  striatum	  and	  serves	  as	  the	  main	  input	  to	  the	  basal	  ganglia.	   Loss	   of	   these	   neurons	   in	   the	   nigrostriatal	   pathway,	   means	   that	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dopaminergic	   input	   to	   the	   striatum	   is	   diminished	   and	  output	   dampened	   in	   turn,	  resulting	  in	  the	  motor	  deficits	  that	  present	  in	  PD	  (Hurtig	  et	  al.	  2000).	  	  	  Postmortem,	  a	  diagnosis	  of	  PD	   is	  upheld	   if	  Lewy	  bodies	  (LBs,	  see	  Figure	  1.1)	  are	  found	  in	  the	  SNpc	  and	  LC	  (Hughes	  et	  al.	  1992).	  LB	  accumulation	  and	  distribution	  has	  been	  shown	  to	  occur	  prescriptively,	  starting	  in	  the	  dorsal	  motor	  nucleus	  at	  the	  glossopharyngeal	   and	   vagal	   nerves,	   and	   anterior	   olfactory	   nucleus	   and/or	  intermediate	  reticular	  zone	  (stage	  I),	  cumulating	  in	  neocortex	  and	  premotor	  cortex	  deposition	  in	  severely	  affected	  individuals	  (stage	  VI).	  It	  is	  according	  to	  this	  staging	  that	   individuals	  are	  often	  classified	  post-­‐mortem	  (Braak	  et	  al.	  2003).	  Cortical	  LBs	  are	   frequently	   seen,	   but	   are	   thought	   to	   be	   indicative	   of	   secondary	   cognitive	  symptoms	   such	   as	   dementia	   (Hurtig	   et	   al.	   2000).	   LBs	   are	   cytoplasmic,	  proteinaceous	   inclusions	   (Lewy	   et	   al.	   1912)	   which	   stain	   positively	   for	   ubiquitin	  and	   consist	   predominantly	   of	   the	   134	   amino	   acid	   peptide	   α-­‐synuclein	   (α-­‐syn)	  (Ueda	  et	  al.	  1993).	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.1.	  Lewy	  body	  stained	  for	  α-­‐synuclein	  in	  the	  Substantia	  Nigra.	  Taken	  from	  (Spillantini	  et	  al.	  1997).	  	  
α-­‐Syn	   is	   a	   cytoplasmic	   protein	   that	   has	   been	   shown	   to	   exist	   both	   in	  membrane	  bound	  form	  (Zhu	  et	  al.	  2003),	  and	  free	  in	  the	  cytosol	  (Kahle	  et	  al.	  2000).	  α-­‐Syn	  is	  abundant	  in	  the	  synapse	  and	  localisation	  of	  this	  protein	  to	  presynaptic	  vesicles	  has	  been	   shown	   (Withers	   et	   al.	   1997).	   Although	   the	   exact	   function	   of	   α-­‐syn	   is	  unknown,	   the	   peptide	   has	   been	   implicated	   in	   a	   number	   of	   functions	   including	  SNARE	   formation	   (Chandra	   et	   al.	   2005),	   regulation	   of	   dopamine	   transmission	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(Perez	  et	  al.	  2002)	  and	  recently	  as	  a	   ferrireductase	  (Davies	  et	  al.	  2011),	  however	  there	   is	   still	  much	   debate	   about	   the	   physiological	   role	   of	   this	   protein	   in	   cellular	  functioning.	  α-­‐Syn	  is	  reported	  to	  share	  a	  40%	  sequence	  homology	  with	  the	  14-­‐3-­‐3	  proteins	  and	  interactions	  with	  the	  14-­‐3-­‐3	  proteins,	  protein	  kinase	  C	  (PKC)	  and	  the	  apoptosis	  related	  BAD	  protein,	  have	  been	  shown	  (Ostrerova	  et	  al.	  1999),	  as	  well	  as	  binding	  to	  synphillin-­‐1	  (Engelender	  et	  al.	  1999).	  	  	  
α-­‐Syn	   is	  unstructured	  when	   in	   the	  cytosol	  but	  has	  been	  shown	  to	   form	  α-­‐helices	  when	  membrane	  bound	  (Jao	  et	  al.	  2004).	  Atomic	  force	  microscopy	  has	  shown	  that	  
α-­‐syn	   structure	   forms	   an	   equilibrium	   between	   α-­‐helical,	   unstructured	   and	   β-­‐pleated	  sheet	  conformation	  when	  in	  solution	  (Sandal	  et	  al.	  2008).	  An	  abundance	  of	  
β-­‐sheet	  folding	  can	  cause	  hydrogen	  bonding	  between	  polypeptide	  strands	  and	  the	  aggregation	   and	   formation	   of	   fibrils.	   The	   self-­‐assembly	   of	   a	   fibril	   is	   thought	   to	  occur	  in	  stages	  which	  involve	  intermediates	  of	  possibly	  dimeric,	  or	  various	  forms	  of	  multimeric	  protofibril	  and	  are	   thought	   to	  be	   toxic	  (Lashuel	  et	  al.	  2002).	   In	  PD,	  accumulation	   of	   these	   aggregates	   has	   been	   shown	   to	   cause	   Golgi	   fragmentation	  and	  impairment	  of	  cellular	  trafficking	  (Gosavi	  et	  al.	  2002).	  	  
1.3	  SELECTIVE	  VULNERABILITY	  OF	  
DOPAMINGERGIC	  NEURONS	  IN	  PD	  Studies	   comparing	   the	   bioenergetic	   differences	   between	   neuronal	   types,	   have	  shown	   that	  dopaminergic	  neurons	   are	  more	   sensitive	   to	   changes	   in	  bioenergetic	  functioning	   than	   non-­‐dopaminergic	   neurons,	   as	   they	   rely	   more	   heavily	   on	  mitochondrial	  ATP	  (Gi-­‐Ryang	  Kweon	  et	  al.	  2004).	  The	  presence	  of	  dopamine	  is	  also	  thought	   to	   be	   an	   important	   contributory	   factor	   to	   PD	   neuronal	   pathogenesis	  (Stokes	  et	  al.	  1999)	  as	  cytosolic	  dopamine	  is	  involved	  in	  redox	  reactions,	  which	  can	  produce	   reactive	   quinones,	   superoxide	   species	   and	   hydrogen	   peroxidase	   (H2O2)	  (Graham	   et	   al.	   1978).	   This	   potentially	   exposes	   dopaminergic	   neurons	   to	   higher	  levels	   of	   oxidative	   stress	   than	   other	   cell	   types	   and	   means	   that	   dopaminergic	  neurons	  need	  to	  work	  harder	  at	  a	  basal	  level	  to	  combat	  oxidative	  stress	  (Berman	  et	  
al.	  1999).	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  The	  importance	  of	  alpha-­‐synuclein	  in	  the	  specificity	  of	  dopaminergic	  cell	   loss	  has	  been	   emphasised	   by	   many	   studies	   which	   suggest	   that	   α-­‐syn	   is	   likely	   to	   play	   a	  pivotal	  role	  in	  the	  synthesis	  and	  homeostasis	  of	  dopamine	  (reviewed	  in	  Lourenco	  Venda	  et	  al,	  2010).	  α-­‐Syn	  has	  been	  shown	  to	   localise	  to	  vesicles	  (Lee	  et	  al.	  2008)	  and	  studies	  in	  triple	  synuclein	  knockout	  mice	  have	  implicated	  the	  synuclein	  family	  in	   SNARE	   formation	   (Burre	   et	   al.	   2010).	   Supporting	   these	   ideas	   are	   the	   results	  from	  studies	  overexpressing	  human	  α-­‐syn	   in	  mouse	  primary	  neurons,	  which	  has	  been	  shown	  to	  cause	  a	  reduction	  in	  the	  synaptic	  vesicle	  pool.	  This	  suggests	  that	  α-­‐syn	   could	   be	   playing	   a	   role	   in	   vesicle	   formation	   and	   homeostasis	   (Nemani	   et	  al.	  2010).	   Synuclein	  null-­‐mutations	   in	  mice	  have	  been	   shown	   to	   cause	   an	   increased	  release	   of	   dopamine	   when	   neurons	   are	   stimulated	   electrically,	   with	   A30P	  overexpressing	   mice	   displaying	   decreased	   levels	   of	   stored	   dopamine	   prior	   to	  stimulation	  (Yavich	  et	  al.	  2004).	  In	  this	  case,	  changes	  to	  the	  homeostasis	  of	  α-­‐syn	  could	  be	  selectively	  detrimental	  to	  dopaminergic	  neurons.	  	  It	  is	  well	  established	  that	  melanin-­‐positive	  dopaminergic	  neurons	  in	  the	  SNpc	  die	  preferentially	   in	   PD	   (Hirsch	   et	   al.	  1988),	   however	   dopaminergic	   neurons	   in	   the	  nearby	   ventral	   tegmental	   area	   (VTA)	   are	   spared	   (Dauer	   et	   al.	   2003).	   The	  sequestering	  of	  dopamine	  into	  synaptic	  vesicles,	  has	  been	  shown	  to	  be	  facilitated	  by	  the	  vesicular	  monoamine	  transporter	  (VMAT)	  and	  reuptake	  of	  dopamine	  after	  release	  into	  the	  synapse,	  is	  facilitated	  by	  the	  (DAT)	  transporter	  (Henry	  et	  al.	  1994).	  Interestingly,	   the	  DAT:VMAT2	  ratio	   is	   reportedly	  higher	   in	  SNpc	  neurons	   than	   in	  those	   from	   the	   ventral	   tegmental	   area,	   suggesting	   that	   cytosolic	   dopamine	   is	  higher	   in	   SNpc	   neurons	   (Lourenco	   Venda	   et	   al.	  2010).	   This	   could	   explain	   the	  selective	  vulnerability	  of	  neurons	  in	  the	  SNpc	  in	  PD,	  as	  increased	  oxidative	  stress	  caused	  by	  increased	  levels	  of	  cytosolic	  dopamine	  and	  dopamine	  metabolism,	  could	  be	  occurring	  (Miller	  et	  al.	  1999).	  Taken	  together,	  a	  combination	  of	  impaired	  vesicle	  recycling	   and	   alterations	   to	   the	   amount	   of	   dopamine	   being	   released,	   could	   all	  contribute	  to	  a	  higher	  likelihood	  of	  pathological	  changes	  in	  dopaminergic	  neurons,	  and	  may	  explain	   the	  cell	   loss	   that	   is	   seen	   in	   the	  SNpc.	  A	   ‘multiple	  hit	   theory’	  has	  been	   proposed	   whereby	   oxidation	   of	   dopamine,	   combined	   with	   an	   increased	  sensitivity	  to	  mitochondrial	  damage	  and	  disruption	  of	  α-­‐syn	  homeostasis,	  combine	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to	  cause	  a	  selective	  sensitivity	  of	  dopaminergic	  neurons	  (Sulzer	  et	  al.	  2007).	  This	  theory	  also	  emphasises	  the	  importance	  of	  neuronal	  structure	  in	  PD	  pathogenesis.	  SNpc	  neurons	  are	  highly	  branched,	  with	   long	  poorly	  myelinated	  axons	  and	   large	  numbers	   of	   dendrites	   (Braak	   et	   al.	   2006),	   meaning	   that	   they	   are	   likely	   more	  sensitive	  to	  the	  disruption	  of	  axonal	  transport.	  These	  disruptions,	  which	  manifest	  themselves	   as	   protein	  deposition	   and	   changes	   to	   autophagy	   in	  PD,	   are	   therefore	  likely	   to	   affect	   midbrain	   neurons	   more	   acutely	   than	   other	   neuronal	   subtypes	  (reviewed	  in	  Daniela,	  2011).	  	  
1.3.1	  The	  role	  of	  calcium	  signaling	  in	  dopaminergic	  cell	  loss	  An	  important	  aspect	  of	  midbrain	  neuronal	  function	  is	  calcium	  signaling.	  The	  entry	  of	  Ca2+	   through	  L-­‐type	  channels	  has	  been	  implicated	   in	  the	  pacemaker	  activity	  of	  dopaminergic	  neurons	  and	  is	  thought	  to	  result	  in	  higher	  cytosolic	  calcium	  levels	  in	  these	   cells	   (reviewed	   in	   Surmeier	   et	   al.	  2010).	   Studies	   in	   rodents	   lesioned	  with	  MPTP	  and	  rotenone,	  have	  shown	  that	  preventing	  Ca2+	  entry	  using	  channel	  blockers	  is	   protective	   against	   these	   mitochondrial	   toxins	   (Surmeier	   et	   al.	   2007).	  Comparison	   of	   dopaminergic	   neurons	   from	   the	   VTA	   and	   SNpc,	   has	   shown	   that	  addition	  of	  the	  dopamine	  precursor	  L-­‐DOPA,	  results	  in	  approximately	  3	  fold	  higher	  accumulation	   of	   cytosolic	   dopamine	   in	   SNpc	   neurons	   than	   VTA.	   Intracellular	  dopamine	  levels	  were	  shown	  to	  correlate	  to	  that	  of	  intracellular	  Ca2+	  and	  addition	  of	   dihyropyridine	   to	   inhibit	   channel	   activity,	   caused	   a	   reduction	   of	   dopamine	   in	  SNpc	   but	   not	   VTA	   dopaminergic	   neurons,	   suggesting	   that	   calcium	   is	   playing	   an	  important	  role	  in	  the	  functioning	  of	  this	  particular	  subtype	  of	  neurons	  (Mosharov	  
et	   al.	  2009).	   It	   has	   also	   been	   shown	   that	   different	   L-­‐type	   calcium	   channels	   are	  expressed	  in	  the	  VTA	  than	  those	  in	  the	  SNpc	  (Rajadhyaksha	  et	  al.	  2004),	  which	  is	  thought	  to	  be	  playing	  an	  important	  role	  in	  the	  pathogenesis	  of	  PD	  in	  dopaminergic	  SNpc	  neurons	  also.	  
	  1.4	  PATHOGENESIS	  OF	  PD	  
1.4.1	  Protein	  accumulation	  Protein	   accumulation	   and	   subsequent	   deposition	   of	   insoluble	   aggregates,	   is	  observed	   in	   most	   major	   neurodegenerative	   disorders	   (reviewed	   in	   Sipe	   et	   al.	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2000).	  When	  proteins	  such	  as	  α-­‐syn	  need	  to	  be	  removed	  from	  the	  cytoplasm,	  they	  are	   tagged	   with	   poly-­‐ubiquitin	   chains	   at	   lysine	   residues	   by	   ubiquitin	   ligases.	  Chaperone	  proteins	  recognise	  these	  ubiquitin	  chains	  and	  tagged	  proteins	  are	  then	  trafficked	  to	  the	  proteasome,	  where	  they	  are	  unfolded	  and	  fed	  through	  its	  barrel-­‐like	  structure	  (Lowe	  et	  al.	  1995).	  Inside	  the	  proteasome,	  proteins	  are	  broken	  down	  into	  their	  amino	  acid	  components	  by	  proteases.	  When	  there	  is	  a	  large	  build-­‐up	  of	  protein,	  or	  when	  proteins	  become	  aggregated,	   this	  unfolding	   is	  not	  possible,	   and	  the	   proteasome	   can	   become	   overwhelmed,	   resulting	   in	   proteasomal	   inactivation	  (reviewed	   in	   Hochstrasser,	   1995).	   The	   presence	   of	   highly	   ubiquitinated	   α-­‐syn	  aggregation	   in	   PD,	   suggests	   that	   proteasome	   function	   is	   compromised.	   Indeed	  proteolytic	  stress	  caused	  by	  large	  amounts	  of	  protein	  to	  be	  degraded,	  or	  proteins	  that	   have	   become	   aggregated,	   have	   been	   shown	   to	   cause	   inhibition	   of	   the	  ubiquitin-­‐proteasome	   system	   (UPS)	   (Bence	   et	   al.	   2001).	   This	   causes	   protein	   to	  accumulate	   further	   and	   can	   thus	   trigger	   a	   downward	   spiral	   in	   which	   insoluble	  aggregates	  form,	  which	  become	  increasingly	  difficult	  to	  remove.	  	  High	   levels	   of	  misfolded	  proteins	   are	   known	   to	   cause	   an	   emergency	   response	   in	  which	  purpose	  built	  aggresomes	  are	  created	  by	  the	  cell	  to	  sequester	  accumulated	  protein.	  (Mcnaught	  et	  al.	  2002).	  Aggresomes	  are	  made	  by	  a	  rearrangement	  of	  the	  intermediate	  filament	  protein	  vimentin,	  to	  create	  a	  cage-­‐like	  structure	  surrounding	  the	  perinuclear	  core.	  Misfolded	  proteins	  are	  ubiquitinated	  and	  transported	  to	  the	  aggresome,	  where	   they	  are	  proteolysed	  and	  sequestered;	  aggresomes	  are	  known	  to	  occur	  in	  response	  to	  proteasome	  inactivation	  (Junn	  et	  al.	  2002).	  LBs	  are	  thought	  to	  form	  as	  a	  result	  of	  aggresome	  formation	  (Johnston	  et	  al.	  1998).	  	  	  	  
1.4.2	  Autophagy	  When	   the	  UPS	   is	   impaired,	   removal	  by	  autophagy	  appears	   to	  be	  a	  more	  efficient	  option	  (Rubinsztein,	  2006).	  Autophagy	  is	  negatively	  regulated	  by	  the	  mammalian	  target	   of	   rapamycin	   protein	   (mTOR)	   and	   activated	   in	   response	   to	   protein	  aggregation	  and	  oxidative	   stress	   (Ferraro	  et	  al.	  2007),	   although	   this	  process	  also	  functions	   to	   maintain	   normal	   cellular	   homeostasis.	   There	   are	   three	   forms	   of	  autophagy,	   which	   differ	   depending	   on	   the	   size	   of	   the	   material	   to	   be	   removed.	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Macroautophagy	   is	   the	  main	   process	   by	  which	   large	   or	   aggregated	   proteins	   are	  removed	   and	   is	   the	   process	   discussed	   here	   (referred	   to	   as	   autophagy	   hereafter	  unless	  otherwise	  stated).	  Removal	  of	  aggregated	  protein	  by	  autophagy	  is	  achieved	  by	  sequestering	  rogue	  proteins	  in	  a	  double-­‐membraned	  vacuole,	  prior	  to	  disposal	  by	   the	   lysosome	   (Martinez-­‐Vicente	   et	   al.	   2007).	   Autophagic	   vacuoles	   (AVs),	   are	  known	  to	  form	  randomly	  in	  the	  cytoplasm	  and	  then	  move	  along	  microtubules	  until	  they	  dock	  with	  the	  lysosome,	  either	  merging	  fully	  to	  form	  an	  autophagolysosome,	  or	   docking	   briefly	   to	   deliver	   their	   contents	   for	   degradation	   in	   the	   lysosome	  (Jahreiss	  et	  al.	  2008).	  In	  PD,	  ultrastructural	  examination	  of	  SNpc	  neurons	  from	  PD	  patients	  has	  shown	  an	  upregulation	  of	  autophagic	  vesicles	  (Anglade	  et	  al.	  1997).	  
1.4.3	  Mitochondrial	  damage	  in	  PD	  The	   accidental	   synthesis	   of	   the	   synthetic	   opiod	   1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine	  (MPTP)	  by	  a	  student	  trying	  to	  synthesize	  1-­‐methyl-­‐4-­‐phenyl-­‐4-­‐propionoxypiperidine	   (MPPP)	   in	   1976,	   was	   an	   important	   step	   forward	   in	  understanding	   possible	   mechanisms	   of	   neuronal	   death	   in	   PD,	   (Langston	   et	   al.	  1984),	   linking	   mitochondrial	   dysfunction	   to	   the	   aetiology	   of	   this	   disease.	   The	  MPTP	  metabolite,	  1-­‐methyl-­‐4-­‐phenylpyridinium	  ion	  (MPP+)	  is	  selectively	  toxic	  to	  dopaminergic	   neurons	   in	   the	   SNpc	   and	   has	   been	   shown	   to	   cause	   cog-­‐wheel	  rigidity,	   resting	   tremor	   and	   problems	   in	   initiating	   movement	   when	   injected	  intravenously	  (Langston	  et	  al.	  1983).	  The	  toxic	  effects	  of	  MPP+	  result	  in	  a	  decrease	  in	   membrane	   potential	   and	   decreased	   electron	   transport	   chain	   function	   due	   to	  Complex	   I	   damage	   (Ramsay	   et	   al.	   1986).	   Analysis	   of	   human	   post-­‐mortem	   tissue	  from	   individuals	   with	   PD	   has	   also	   shown	   Complex	   I	   damage,	   resulting	   in	   a	  reduction	   of	   Complex	   I	   enzymatic	   activity	   (Schapira	   et	   al.	   1990).	   Similarly,	  comparison	  of	  neurons	  treated	  with	  MPTP	  and	  those	  from	  patients	  with	  PD	  have	  been	  shown	   that	   these	  cells	   share	  many	  common	   features.	  Continuous,	   low-­‐level	  infusion	  of	  MPTP	  in	  mice	  has	  been	  shown	  to	  result	  in	  motor	  deficits	  caused	  by	  cell	  death	  and	  α-­‐syn	  and	  ubiquitin	  positive	  inclusions	  in	  the	  SNpc	  (Fornai	  et	  al.	  2005).	  Injection	  of	  the	  toxin	  MPTP	  into	  mice	  has	  shown	  an	  upregulation	  of	  α-­‐syn	  mouse	  homolog	  synuclein-­‐1	  (syn-­‐1)	  at	  the	  mRNA	  and	  protein	  level	  and	  an	  increase	  in	  syn-­‐1	  positive	  aggregates	  in	  the	  SNpc	  (Vila	  et	  al.	  2000).	  This	  increase	  has	  been	  shown	  in	   baboons	   (Kowall	   et	   al.	   2000)	   and	   also	   in	   primary	   neuronal	   cultures	   from	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rodents	   (Duka	   et	   al.	   2006).	   Importantly,	   cells	   lacking	   α-­‐syn	   are	   insensitive	   to	  mitochondrial	  toxicity	  induced	  by	  MPP+	  (Fornai	  et	  al.	  2005)	  and	  it	  has	  been	  shown	  that	   α-­‐syn	   could	   play	   an	   important	   role	   in	   mediating	   MPP+	   toxicity,	   perhaps	  through	  regulation	  of	  nitric	  oxide	  (NO)	  signaling	  (Fountaine	  et	  al.	  2008).	  MPTP	  and	  other	  complex	  I	  inhibitors	  such	  as	  rotenone,	  are	  commonly	  used	  in	  cell	  models	  of	  PD	  as	  a	  result	  of	  the	  MPP+	  phenomenon	  (Greenamyre	  et	  al.	  1999)	  	  	  In	   PD,	   it	   has	   been	   suggested	   that	   the	   vulnerability	   of	   dopaminergic	   neurons	  (although	   other	   non-­‐dopaminergic	   neurons	   die	   also)	   is	   facilitated	   in	   part	   by	   the	  presence	  of	  dopamine	  (Stokes	  et	  al.	  1999).	  The	  involvement	  of	  cytosolic	  dopamine	  is	   involved	   in	   redox	   reactions	  which	   can	   produce	   reactive	   quinones,	   superoxide	  species	  and	  hydrogen	  peroxidase	  (H2O2)	  (Graham	  et	  al.	  1978),	  which	  is	  thought	  to	  leave	   dopaminergic	   neurons	  more	   susceptible	   to	   oxidative	   stress	   (Berman	   et	   al.	  1999).	  One	  study	  has	  shown	  an	  increase	  in	  extracellular	  iron	  levels	  in	  port-­‐mortem	  SNpc	   tissue	   of	   PD	   sufferers	   (Dexter	   et	   al.	   1987).	   Iron	   can	   catalyse	   oxidation	  reactions	  in	  the	  presence	  of	  dopamine,	  generating	  free	  radicals,	  which	  cause	  tissue	  damage	  (Halliwell	  et	  al.	  1985).	  As	  such,	  although	  the	  exact	  etiology	  underlying	  PD	  is	   currently	   unknown,	   there	   are	   many	   strands	   of	   evidence	   suggesting	   that	  oxidative	   stress	   is	   a	   key	  mechanism	   in	   cell	   death,	   where	   oxidative	   stress	   in	   the	  neurons	   of	   PD	   patients	   is	   increased,	   compared	   to	   that	   of	   the	   normal	   aging	  population.	  	  
1.5	  COMMON	  MECHANISMS	  IN	  NEURODEGENERATION	  The	  mechanisms	  discussed	  for	  PD	  are	  common	  to	  a	  number	  of	  neurodegenerative	  diseases	   and	   emphasise	   the	   overlap	   between	   the	   many	   supposedly	   distinct	  disorders.	   Interestingly,	   these	  commonalities	  occur	  between	  motor	  and	  cognitive	  disorders,	  as	  well	  as	  within	  groups	  of	  symptoms.	  	  	  
1.5.1	  Protein	  aggregation	  The	   aggregation	   of	   certain	   proteins	   is	   a	   common	   feature	   of	   many	  neurodegenerative	  diseases	  and	  identification	  of	  these	  aggregates,	  is	  often	  part	  of	  the	  diagnostic	  criteria	  for	  post-­‐mortem	  confirmation	  (Table	  1.2).	  The	  prevalence	  of	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deposited	   protein	   aggregates	   in	   neurodegenerative	   disease,	   emphasises	   the	  importance	  of	  protein	  turnover	  and	  axonal	  transport	  in	  neuronal	  homeostasis.	  As	  discussed,	  disruptions	  to	  autophagy	  have	  been	  found	  in	  PD	  patients	  and	  increased	  numbers	   of	   autophagosomes	   have	   been	   documented	   in	   a	   number	   of	  neurodegenerative	   diseases,	   suggesting	   that	   an	   increased	   demand	   for	   protein	  degradation	  could	  be	  a	  common	  feature	  of	  these	  disorders	  (Nixon,	  2006).	  	  	  
Disease	   Protein	   Lesion	   Reference	  PD	   α-­‐synuclein	   Lewy	  bodies	   Lewy,	  1912	  
Alzheimer’s	  disease	   Aβ/	  tau	   Plaques/	  neurofibrilliary	  tangles	   Kidd	  et	  al.	  1963	  Nikaido	  et	  al.	  1970	  Huntington’s	  disease	   Huntingtin	   Huntingtin	  inclusions	   DiFiglia	  et	  al.	  1997	  
ALS/	  Motor	  Neuron	  Disease	   SOD1,	  ubiquitin	   Bunina	   bodies,	  skein-­‐like	   bodies,	  SOD1	  aggregates	   Bunina	  et	  al.	  1962	  Transmissible	  Spongiform	  Encephalopathies	   Prion	  protein	   Prion	  protein	  aggregates	   Prusiner	  et	  al.	  1980	  Fronto-­‐Temporal	  Dementia	   Tau/	  Aβ	   Neurofibrilliary	  tangles/	  plaques	   Kidd	  et	  al.	  1963	  	  Nikaido	  et	  al.	  1970	  
Trinucleotide	   repeat	  disorders	   Various-­‐	  often	  contain	  CAG	  	  repeats	  
Neuronal	  intranuclear	  inclusions	   Reviewed	  in	  Li,	  2010	  
Table	  1.2.	  Neurodegenerative	  diseases	  and	  their	  hallmark	  lesions.	  	  	  As	   axonal	   transport	   is	   a	   key	   mechanism	   for	   protein	   removal,	   it	   is	   perhaps	  unsurprising	  that	  disruptions	  to	  the	  cytoskeleton	  in	  Alzheimer’s	  disease	  are	  widely	  documented	  (reviewed	  in	  Lee	  et	  al.	  2006)	  and	  disruptions	  to	  the	  cytoskeleton	  are	  thought	   to	   precede	   motor	   symptoms	   in	   motor	   neuron	   disease	   (Bilsland	   et	   al.	  2010).	   Similarly	   ALS	   can	   be	   caused	   by	   mutations	   in	   the	   motor	   proteins	   dynein	  (Hafezparast	  et	  al.	  2003)	  and	  dynactin	  (Munch	  et	  al.	  2004).	  
	  INTRODUCTION	  
	   33	  
Many	   reports	   have	   shown	   that	   there	   can	   be	   considerable	   overlap	   between	   the	  neuropathological	  features	  of	  different	  neurodegenerative	  diseases.	  A	  fragment	  of	  
α-­‐syn,	  originally	  termed	  the	  non-­‐amyloid	  β	  component	  (NAC)	  of	  senile	  plaques	  has	  been	   shown	   to	   form	   aggregates	   in	   Alzheimer’s	   disease	   (Ueda	   et	   al.	   1993).	  	  Similarly,	  as	  will	  be	  discussed	  in	  more	  detail	   later,	  some	  proteins	  such	  as	  TDP-­‐43	  and	   tau	   can	   become	   aggregated	   and	   deposited	   in	   both	   frontotemporal	   dementia	  and	   some	   forms	   of	   PD.	   The	   lesions	   associated	   with	   many	   diseases	   are	   also	  ubiquitin	   positive,	   suggesting	   that	   there	   could	   be	   mechanisms	   common	   to	  neurodegenerative	  disease	  and	  neuronal	  death	  in	  general.	  The	  issue	  as	  to	  whether	  these	   lesions	   are	   neuroprotective	   or	   toxic	   to	   the	   cell	   is	   still	   hotly	   debated	  (reviewed	   in	   Ali,	   2010),	   however	   the	   overlap	   between	   fields	   suggests	   that	  potential	  therapeutic	  avenues	  for	  one	  disorder	  may	  also	  prove	  promising	  for	  other	  diseases.	  	  
1.5.2	  Oxidative	  stress	  and	  mitochondrial	  damage	  The	  reduced	  rate	  of	  glycolysis	   in	  neurons	  suggests	   that	  maintenance	  of	  oxidative	  status	   is	   crucial	   for	  neuronal	   survival	   (Herrero-­‐Mendez	  et	  al.	  2009).	  As	   such,	   the	  oxidative	   stress	   and	   mitochondrial	   damage	   widely	   documented	   in	   a	   number	   of	  neurodegenerative	   diseases,	   are	   likely	   to	   be	   important	   mechanisms	   in	   the	  pathogenesis	   of	   these	   diseases.	   Damage	   to	   respiratory	   chain	   enzymes	   has	   been	  reported	   in	   a	   number	   of	   diseases,	  with	   Alzheimer’s	   and	   ALS	   post-­‐mortem	   brain	  samples	   showing	  damage	   to	   complex	   IV.	   Individuals	  with	  Hungtingdon’s	   disease	  and	   Friedrich’s	   ataxia	   have	   been	   shown	   to	   have	   complex	   II	   and	   III	   dysfunction	  (reviewed	  in	  Kirkinezos	  et	  al.	  2001)	  and	  prion	  disease	  is	  associated	  with	  damage	  to	  complex	  II	  and	  IV	  (Siskova	  et	  al.	  2010).	  Damage	  to	  mitochondrial	  DNA	  has	  been	  reported	   for	   a	   number	   of	   neurodegenerative	   diseases	   (reviewed	   in	   Yang	   et	   al.	  2010)	  suggesting	  also	  that	  oxidative	  stress	  is	  a	  common	  feature	  of	  these	  diseases.	  	  The	   increasing	   number	   of	   genes	   shown	   to	   cause	   familial	   forms	   of	  neurodegeneration,	   have	   supported	   the	   idea	   that	  mitochondrial	   dysfunction	   is	   a	  common	  cause	  of	  many	  disorders.	  In	  ALS,	  mutations	  in	  the	  superoxide	  dismutase	  SOD1,	  have	  been	  shown	  to	  cause	  autosomal	  dominant	  forms	  of	  the	  disease	  (Rosen	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et	  al.	  1993)	  and	  hereditary	  spastic	  paraplegia	  is	  commonly	  caused	  by	  mutations	  in	  the	   mitochondrial	   protease	   paraplegin	   (reviewed	   in	   Tatsuta	   et	   al.	   2008).	   In	  Alzhimer’s	   disease,	   presenilin	   and	   the	   gamma	   secretase	   complex	   which	   are	  mutated	  in	  some	  familial	  forms	  of	  demetia,	  are	  localised	  to	  mitochondria	  (Hansson	  
et	  al.	   2004)	   and	  Aβ	   has	  been	   shown	   to	   interact	  with	   the	  mitochondrial	   protease	  HTRA2	  (Park	  et	  al.	  2004),	  which	  has	  also	  been	  linked	  to	  PD	  (Strauss	  et	  al.	  2005).	  Similarly,	  huntingtin	  interacts	  with	  transcription	  factors	  controlling	  mitochondrial	  integrity	   and	   apoptosis	   (reviewed	   in	   Sugars	   et	   al.	   2003).	   Taken	   together,	   these	  studies	  again	  suggest	  that,	  although	  the	  disorders	  discussed	  are	  separate	  clinically,	  the	  mechanisms	   underlying	   neurodegeneration	   in	   different	   disease	   are	   likely	   to	  share	  many	  common	  features	  that	  could	  be	  exploited	  as	  therapeutic	  avenues.	  
	  
	  	  	  	  1.6	  	  GENETIC	  CAUSES	  OF	  PARKINSON’S	  DISEASE	  In	  1997	  it	  was	  shown	  that	  a	  point	  mutation	  in	  SNCA,	  the	  gene	  coding	  for	  α-­‐syn,	  is	  sufficient	   to	  cause	   familial	  Parkinson’s	  disease	  (Polymeropoulos	  et	  al.	  1997).	  The	  discovery	  that	  PD	  can	  have	  a	  genetic	  cause	  has	  led	  the	  way	  for	  a	  wealth	  of	  genetic	  sequencing	  using	  PD	  patient	  samples	  and	  subsequently	  many	  more	  loci	  associated	  with	  familial	  PD	  have	  been	  identified.	  Familial	  PD	  is	  thought	  to	  make	  up	  between	  5	  and	  10%	  of	  all	  cases,	  depending	  on	  the	  populations	  in	  question	  (reviewed	  in	  Hardy	  
et	  al.	  2006).	  To	  date,	  there	  have	  been	  a	  total	  of	  16	  reported	  PARK	  loci,	  which	  are	  known	  to	  associate	  with	  genetic	  forms	  of	  PD	  and	  Parkinsonism	  (see	  Table	  1.2).	  	  
1.6.1 Autosomal	  dominant	  forms	  of	  PD	  
1.6.1.1	  α-­‐synuclein	  Early	  onset,	  autosomal	  dominant	  (AD)	  PD	  in	  41	  individuals	  of	  a	  large	  family	  from	  the	   small	   Italian	   village	   of	   Contursi	   Terme	   (Golbe	   et	   al.	   1996),	   led	   to	   the	  identification	  of	  the	  A53T	  point	  mutation	  in	  α-­‐syn	  (Polymeropoulos	  et	  al.	  1997).	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Table	   1.2.	   PARK	   loci	   and	   the	   genes	   implicated	   in	   parkinsonism	   and	   PD.	  Adapted	   from	   (Lees	   et	   al.	   2009).	   AD-­‐	   Autosomal	   dominant.	   AR-­‐	   Autosomal	  Recessive.	  Un-­‐Unknown.	  
	  
	  
PARK1/4	   SNCA	   α-­‐synuclein	   PD	   AD	   Un	  
PARK2	   PRKN	   Parkin	   Parkinsonism	   AR	   E3	  ligase	  
PARK3	   2p13.3-­‐2p13.1	   Unidentified	   Parkinsonism	   Un	   Un	  
PARK5	   UCHL1	   UCHL1	   Parkinsonism	   AD	   Cytosolic.	  Ubiquitin	  tagging	  
PARK6	   PINK1	   PINK1	   Parkinsonism	   AR	   Mitochondrial.	  Kinase?	  
PARK7	   DJ-­‐1	   DJ-­‐1	   Parkinsonism	   AR	   Cytosolic.	  Oxidative	  stress	  
PARK8	   LRRK2	   LRRK2	   PD	   AD	   Cytosolic.	  Kinase?	  
PARK9	   ATP13A2	   ATP13A2	   Parkinsonism	   AR	   Lysosomal	  
PARK10	   1p33-­‐1p32.2	   Unidentified	   Parkinsonism	   Un	   Un	  
PARK11	   2q36.1-­‐2q37.3	   GIGYF2	   Parkinsonism	   Un	   Cytosolic.	  Signal	  transduction?	  
PARK12	   Xq21-­‐q25	   Unidentified	   Parkinsonism	   Un	   Un	  
PARK13	   HTRA2	   HTRA2	   Parkinsonism	   Un	   Mitochondrial	  protease	  
PARK14	   18q11	   PLA2	   Parkinsonism	   AR	   Lipid	  metabolism	  
PARK15	   22q12-­‐13	   FBXO7	   Parkinsonism	   AR	   Mitochondrial	  
PARK16	   1q32	   Unidentified	   PD-­‐GWAS	  hit	   Un	   Un	  
-­‐	   GBA	   Glucocerebrosidase	   PD	   AD	   Ceramide	  metabolism	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This	  form	  of	  the	  disease	  is	  extremely	  aggressive	  in	  progression,	  with	  the	  average	  age	  of	  PD	  onset	  in	  this	  kindred	  at	  45,	  with	  death	  occurring	  approximately	  9	  years	  after	  diagnosis.	  Two	   further	  mutations	  causing	  an	  A30P	  (Kruger	  et	  al.	  1998)	  and	  E46K	  substitution	   (Zarranz	  et	  al.	  2004)	  were	  subsequently	   found	   to	   segregate	   in	  other	  families	  and	  duplications	  and	  triplications	  of	  the	  SNCA	  gene	  have	  also	  been	  shown	   to	   cause	   an	   aggressive,	   early	   onset	   form	   of	   the	   disease	   (Singleton	   et	   al.	  2003).	  The	  increased	  expression	  of	  α-­‐syn	  caused	  by	  duplications	  and	  triplications	  of	   SNCA	   is	   thought	   to	   induce	   accumulation	   of	   the	   protein	   in	   a	   dose-­‐dependent	  manner,	  which	  is	  likely	  to	  cause	  aggregation	  and	  deposition	  (Singleton	  et	  al.	  2003),	  (Chartier-­‐Harlin	   et	   al.	   2004)	   resulting	   in	   PD	   associated	   pathogenesis	   and	   LB	  formation.	  Bases	  changes	  that	  result	   in	  point	  mutations	  have	  also	  been	  shown	  to	  result	  in	  an	  increased	  propensity	  for	  aggregation.	  The	  A53T	  substitution	  is	  thought	  to	  promote	  beta	  sheet	  folding,	  which	  are	  prone	  to	  aggregation	  and	  the	  formation	  of	  so	  called	  ‘fibrils’	  (Lashuel	  et	  al.	  2002),	  and	  both	  A30P	  and	  A53T	  have	  been	  shown	  to	  change	   the	  conformational	  behavior	  of	  α-­‐syn	  (Li	   J.	  et	  al.	  2002).	  These	  changes	  are	   all	   thought	   to	   promote	   aggregation	   and	   deposition	   of	   α-­‐syn,	   resulting	   in	  neuronal	  death.	  In	  this	  way,	  changes	  to	  the	  gene	  product	  of	  SNCA	  have	  been	  shown	  to	   cause	   genetic	   PD,	   as	   well	   as	   playing	   an	   important	   role	   in	   the	   progression	   of	  sporadic	  PD.	  	  	  	  
1.6.1.2	  LRRK2	  Mutations	  in	  the	  putative	  kinase	  LRRK2,	  were	  first	  implicated	  in	  PD	  in	  2004	  with	  the	  discovery	  of	  point	  mutations	  in	  five	  families	  of	  Basque	  descent	  (Paisan-­‐Ruiz	  et	  
al.	  2004)	  and	  either	  point	  mutations	  or	  splice	  site	  mutation	  in	  two	  families,	  one	  of	  German-­‐Canadian	  descent	  and	  one	  kindred	  originally	  from	  Nebraska	  (Zimprich	  et	  
al.	   2004).	   Zimprich	   et	   al	   showed	   that	   LRRK2	   PD	   pathology	   is	   extremely	   varied,	  even	  between	   individuals	   carrying	   the	   same	  mutations.	  Brain	   stem	  degeneration	  accompanied	   by	   a	  mixture	   of	   diffuse	   LBs	  was	   shown	   in	   some	   cases,	   with	   nigral	  degeneration	  absent	  from	  additional	  histopathology	  and	  tau	  pathology	  resembling	  that	   found	   in	   progressive	   supranuclear	   palsy	   shown	   (PSP).	   In	   the	   Sagamihara	  kindred,	  where	  the	  PARK8	  locus	  was	  first	  implicated,	  a	  similar	  picture	  was	  found.	  Histochemical	   analysis	   of	   postmortem	   tissue	   showed	   pure	   nigral	   degeneration	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without	  LBs	  in	  six	  out	  of	  eight	  relatives.	  LBs	  were	  present	  in	  one	  case	  and	  MSA-­‐like	  pathology,	  characterized	  by	  cytoplasmic	  glial	  cell	  inclusions	  was	  found	  in	  another	  (Satake	   et	   al.	   2009).	   Recently,	   brain	   tissue	   from	   carriers	   of	   L1165P	   or	   R793M	  substitutions	   has	   broadened	   the	   pathology	   associated	   with	   LRRK2	   PD,	   with	  reports	   of	   neurofibrilliary	   tangles	   in	   the	   hippocampus,	   and	   TDP-­‐43	   positive	  inclusions	  also	   found	  (Covy	  et	  al.	  2009).	  LRRK2	  parkinsonism	  generally	  presents	  as	   PD	   that	   is	   indistinguishable	   clinically	   from	   idiopathic	   PD	   (Farrer	   et	  al.	   2005).	  LRRK2	  has	  been	  shown	  to	  be	  a	  component	  of	  nigral	  Lewy	  bodies	  and	  a	  component	  of	   granular	   inclusions	   found	   in	   the	   lower	   brain	   stem	   (Alegre-­‐Abarrategui	   et	   al.	  2008).	  	  A	   common	   feature	  of	   LRRK2	  PD	   is	   the	   lack	  of	   segregation	  with	   some	  mutations.	  The	  most	  common	  mutation,	  G2019S	   is	   found	   in	  an	  estimated	  6%	  of	  Parkinson’s	  patients,	  with	  the	  frequency	  as	  high	  as	  40%	  in	  some	  Ashkenazi	  Jewish	  and	  North	  African	  Berber	  populations	  (Lesage	  et	  al.	  2005)	  although	  the	  actual	  incidence	  of	  PD	  is	  considerably	  lower.	  In	  populations	  carrying	  the	  G2019S	  mutation,	  penetrance	  is	  incomplete	  (Saunders-­‐Pullman	  et	  al.	  2006)	  and	  the	  substitution	  is	  also	  present	  in	  control	  individuals,	  of	  note	  an	  octogenarian	  man	  with	  no	  signs	  of	  either	  motor	  or	  cognitive	  decline,	  who	  was	  shown	  to	  be	  a	  heterozygous	  carrier	   (Kay	  et	  al.	  2005).	  The	  risk	  of	  developing	  PD	  when	  carrying	  G2019S	  has	  been	  shown	  to	  increase	  over	  time,	  ranging	  from	  a	  28%	  likelihood	  at	  59	  years	  of	  age,	  to	  74%	  at	  79	  years	  (Healy	  
et	   al.	   2008)	   suggesting	   that	   there	   could	   be	   other	   factors	   contributing	   to	   the	  pathogenesis	  of	  this	  disease.	  	  
1.6.2 Autosomal	  Recessive	  forms	  of	  PD	  
1.4.2.1	  	  PINK1	  and	  Parkin	  Exon	   deletions	   in	   the	   PRKN	   gene,	   which	   encodes	   the	   E3	   ubiquitin	   ligase	   parkin	  (Shimura	  et	  al.	  2000),	  were	  first	  discovered	  in	  two	  Japanese	  families	  (Kitada	  et	  al.	  1998).	  These	  deletions	  spanned	  five	  exons	  in	  one	  individual	  and	  one	  exon	  in	  four	  individuals	  from	  three	  separate	  families.	  Meta-­‐analysis	  of	  parkin	  mutation	  carriers	  suggests	   that	   pathogenic	   alterations	   to	  PRKN	   account	   for	   up	   to	   50%	  of	  AR	   early	  onset	   parkinsonism	   in	   some	   populations	   (Lucking	   et	   al.	   2000)	   and	   PRKN	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alterations	  have	  been	  found	  in	  families	  from	  a	  wide	  range	  of	  ethic	  origins	  including	  European,	  Japanese	  and	  Indian	  origins	  (Morrison,	  2003).	  Point	  mutations	  in	  parkin	  are	  common,	  with	  as	  many	  as	  34	  variants	  described.	  Patients	  have	  been	  shown	  to	  carry	   single	   and	   compound	   mutations	   which	   can	   be	   homo	   or	   heterozygous	   in	  nature.	   Homozygous	   parkin	   mutations	   are	   associated	   with	   early	   onset	   PD,	  however	  heterozygous	  parkin	  mutations	  have	  been	  found	  in	  sporadic	  cases	  of	  PD	  and	   are	   present	   in	   some	   control	   individuals	   (Kay	   et	   al.	   2007).	   Interestingly,	  mutations	   in	   parkin	   have	   also	   been	   linked	   to	   cancer	   (Fujiwara	   et	   al.	   2008)	   and	  leprosy	   (Mira	   et	  al.	   2004),	   suggesting	   that	   this	   gene	   product	   plays	   an	   important	  role	  in	  the	  normal	  functioning	  of	  a	  number	  of	  cell	  types.	  	  	  The	   clinical	   presentation	   of	   PRKN	  mutation	   and	   deletion	   carriers	   is	   extremely	  heterologous,	  with	  age	  of	  onset	  reported	   to	  be	  between	  7	  and	  58	  years	  of	  age	   in	  one	   study.	   	   These	   patients	   presented	  with	   bradykinesia	   in	   94%	  of	   cases,	   resting	  tremor	  in	  74%	  of	  cases	  and	  showed	  additional	  symptoms	  such	  as	  dystonia	  in	  over	  half	   of	   all	   cases	   (Lucking	   et	   al.	   2000).	   Psychiatric	   symptoms,	   autonomic	  dysfunction	   and	   peripheral	   neuropathy	   have	   been	   reported	   in	   parkin	   mutation	  carriers	   in	   other	   studies	   (Morrison,	   2003).	   Neuropathological	   examination	   of	  individuals	  with	  parkinsonism	  caused	  by	  parkin,	  have	  shown	  that	  neuronal	  loss	  in	  the	  SNpc	  is	  commonly	  associated	  with	  a	  lack	  of	  LBs	  (Hattori	  et	  al.	  2000),	  however	  this	   is	   not	   always	   the	   case,	   with	   LBs	   found	   in	   some	   cases	   (Farrer	   et	   al.	   2001,	  Pramstaller	  et	  al.	  2005).	  	  	  Mutations	   in	   PTEN	   induced	   kinase	   (PINK1)	   were	   found	   in	   some	   cases	   of	   AR	  parkinsonism	  in	  2004	  (Valente	  et	  al.	  2004).	  Genetic	  sequencing	  of	  three	  families	  of	  Spanish	  and	  Italian	  consent	  who	  presented	  with	  early	  onset	  parkinsonism	  in	  their	  third	  and	  fourth	  decades,	  identified	  two	  different	  homozygous	  mutations	  resulting	  in	  a	  point	  mutation	  and	  a	  nonsense	  mutation	  which	  causes	  truncation	  of	  the	  PINK1	  protein.	   Since	   the	   initial	   report	   of	   PINK1	  mutations,	   there	   have	   been	   numerous	  variants	  reported,	  with	  one	  study	  in	  Irish	  patients	  with	  early	  onset	  parkinsonism,	  identifying	   27	   different	   variants	   (Rogaeva	   et	   al.	   2004).	   Mutations	   in	   PINK1	   are	  thought	   to	   represent	   ~4%	   of	   all	   early	   onset	   cases	   (Ibanez	   et	   al.	   2006)	  with	   the	  prevalence	   as	   high	   as	   10%	   in	   some	   populations	   (Bonifati	   et	   al.	   2005).	   These	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mutations	  have	  been	  reported	   in	  both	  homozygous	  and	  heterozygous	   form.	  Rare	  heterozygous	   forms	  of	   PINK1	   are	   known	   to	   be	   indistinguishable	   from	   idiopathic	  PD	  (Marongiu	  et	  al.	  2008)	  and	  late	  onset	  PINK1	  cases	  also	  resemble	  the	  sporadic	  form	  of	  the	  disease.	  In	  most	  cases,	  parkinsonism	  is	  slow	  in	  progression	  and	  typical	  disease	   presentation	   includes	   dystonia	   and	   depression	   as	   well	   as	   the	   classical	  symptoms	   of	   bradykinesia	   and	   rigidity	   (Ibanez	   et	   al.	   2006).	   Neuropathological	  examination	  of	  PINK1	  mutation	  carriers	  has	  long	  been	  absent	  from	  the	  literature,	  however	   the	   recent	   characterisation	   of	   one	   individual	   with	   heterozygous	  mutations	   has	   shown	   that	   neuronal	   loss	   in	   the	   SNpc	   is	   accompanied	   by	   Lewy	  bodies	  and	  Lewy	  neurites	  throughout	  the	  brain	  stem,	  however	  the	  LC	  was	  spared	  from	  any	  gross	  neuronal	  loss	  (Samaranch	  et	  al.	  2010).	  	  PINK1	   is	   a	   putative	   kinase,	   which	   is	   localised	   to	   the	   inner	   mitochondrial	  membrane	  (Silvestri	  et	  al.	  2005).	  As	  the	  name	  suggests,	  PINK1	  is	  involved	  in	  PTEN	  signalling	   (see	   Figure	   1.4)	   and	   has	   been	   shown	   to	   interact	   with	   HTRA2	   (Plun-­‐Favreau	  et	  al.	  2007),	  a	  protease	  well	  known	  for	  its	  involvement	  in	  apoptosis,	  which	  is	   liberated	   from	   the	   mitochondria	   to	   promote	   cell	   death.	   PINK1	   has	   also	   been	  shown	   to	   regulate	   calcium	   efflux	   from	   the	  mitochondria	   (Gandhi	   S.	   et	   al.	   2009).	  
Drosophila	   models	   suggest	   that	   PINK1	   and	   parkin	   may	   function	   in	   the	   same	  pathways	  to	  maintain	  mitochondrial	   integrity	  (Park	  et	  al	  2006,	  Clark	  et	  al.	  2006).	  Parkin	  has	  been	  shown	   to	  bind	  DNA	  and	  repress	   the	   tumour	  suppressor	  protein	  p53	   on	   a	   transcriptional	   level	   (Da	   Costa	   et	   al.	   2009)	   and	   studies	   with	   mouse	  embryonic	  fibroblasts	  (MEFs)	  from	  PINK1	  knockout	  mice,	  have	  shown	  that	  parkin	  is	   unable	   to	   localise	   to	   the	   mitochondria,	   suggesting	   that	   the	   mitochondrial	  function	  of	  Parkin	  may	  be	  dependent	  on	  PINK1	  (Matsuda	  et	  al	  2010,	  Ziviani	  et	  al.	  2010).	   Both	   proteins	   have	   been	   implicated	   in	   autophagy	   (Narendra	   et	   al.	   2008)	  and	  rapamycin	  activation	  of	  4E-­‐BP	  independent	  of	  autophagy	  has	  been	  shown	  to	  prevent	   parkinsonian	   dopaminergic	   neuron	   loss	   in	   PINK1	   and	   Parkin	  overexpressing	   drosophila	   models	   (Tain	   et	   al.	   2009).	   The	   overlap	   of	   these	  mechanisms	  with	  those	  associated	  with	   idiopathic	  PD,	  perhaps	  suggest	  a	  role	   for	  PINK1	  and	  Parkin	  in	  the	  pathogenesis	  of	  sporadic	  as	  well	  as	  familial	  forms	  of	  PD.	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1.6.2.2	  	  Rare	  forms	  of	  parkinsonism	  and	  genetic	  risk	  factors	  Another,	  rarer	  form	  of	  AR	  PD	  was	  identified	  in	  two	  consanguineous	  families	  from	  Italy	   and	   the	   Netherlands,	   who	   were	   shown	   to	   have	   deletions	   in	   the	  DJ-­‐1	   gene	  (Bonifati	   et	   al.	   2003),	   which	   codes	   for	   a	   cytosolic	   oxidative	   stress	   signalling	  molecule,	   first	   implicated	   in	   cancer	   (Nagakubo	   et	   al.	   1997).	   Mutations	   in	   this	  protein	   cause	   a	   loss	   of	   function,	   resulting	   in	   oxidative	   stress,	   ER	   stress	   and	  proteasome	  inhibition	  (Yokota	  et	  al.	  2003).	  The	  fourth	  and	  rarest	  genetic	  form	  of	  AR	  parkinsonism	  is	  caused	  by	  mutations	  in	  the	  PARK9	  locus,	  in	  the	  gene	  encoding	  the	  lysosomal	  ATPase	  ATP13A2	  (Ramirez	  et	  al.	  2006).	  Mutations	  in	  this	  gene	  have	  been	  shown	  to	  cause	  early	  and	  juvenile	  onset	  parkinsonism	  (onset	  at	  <	  21	  years	  of	  age)	  in	  a	  small	  number	  of	  families	  (Di	  Fonzo	  et	  al.	  2007).	  	  	  Five	   genes	   with	   possible	   involvement	   in	   ceramide	   production	   have	   been	  highlighted	  as	  possible	  genetic	  risk	  factors	  for	  PD,	  due	  to	  the	  Lewy	  body	  pathology	  associated	   with	   them.	   Of	   these,	   the	   most	   common	   is	   GBA,	   the	   gene	   encoding	  glucocerebrosidase,	   which	   is	   known	   to	   cause	   Gaucher’s	   disease	   in	   homozygotes	  and	  PD	  in	  heterozygotes	  (reviewed	  in	  (Bras	  et	  al.	  2008).	  Genome-­‐wide	  association	  studies	   (GWAS)	   have	   emphasised	   the	   importance	   of	   α-­‐syn	   and	   LRRK2	   in	   PD	  (Simon-­‐Sanchez	   et	   al.	   2009,	   Nalls	   et	   al.	   2011).	   Furthermore,	   GWAS	   consortiums	  have	   shown	   that	   a	   number	   of	   genes	   previously	   unassociated	   with	   PD	   reach	  significance,	   suggesting	   that	   there	   are	   a	   number	   of	   unexplored	   mechanisms	  underlying	   PD	   pathology.	   Of	   these,	   an	   interesting	   result	   was	   the	   association	   of	  
MAPT	   with	   PD	   (Pankratz	   et	   al.	   2009).	   The	  HLA	   locus,	  BST1	   and	  GAK	  are	   recent	  GWAS	  hits	   that	  have	  been	  replicated	   in	  a	  number	  of	   studies.	  Meta-­‐analyses	  have	  provided	   identification	   of	   six	   additional	   genes,	   including	   the	   gene	   encoding	   the	  serine/threonine	  kinase	  STK39,	  which	  are	  linked	  to	  PD	  (Nalls	  et	  al.	  2011).	  	  As	  family	  history	  is	  one	  of	  the	  exclusion	  criteria	  for	  PD,	  there	  is	  much	  debate	  about	  familial	   forms	   of	   PD	   and	   the	   extent	   to	   which	   they	   can	   be	   classified	   as	   true	  Parkinson’s	   diease	   (Lees	   et	  al.	   2009).	   The	  mixed	   clinical	   presentations	   shown	   in	  many	  of	  the	  early	  onset	  parkinsonism	  disorders	  and	  the	  mixed	  pathologies	  found	  in	   individuals	   carrying	   these	   genetic	   abnormalities,	   have	   added	   to	   the	   argument	  that	  these	  diseases	  may	  instead	  represent	  a	  spectrum	  of	  disorders	  of	  which	  PD	  is	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one.	  As	  such,	   it	  has	  been	  proposed	   that	  3	   forms	  of	  genetic	  parkinsonism,	  namely	  mutations	   in	  SNCA	   (Polymeropoulos	  et	  al.	  1997),	  LRRK2	   (Paisan-­‐Ruiz	  et	  al.	  2004,	  Zimprich	  et	  al.	  2004)	  and	  GBA	  (Lwin	  et	  al.	  2004)	  cause	  true	  PD	  whereas	  the	  other	  PARK	   loci	   are	   thought	   to	   produce	   disorders	   of	   which	   parkinsonism	   is	   a	   feature	  (Lees	  et	  al.	  2009).	  	  	  
1.7	  THE	  ROLE	  OF	  LRRK2	  IN	  PD	  
1.7.1	  	  LRRK2	  domain	  structure	  The	  varied	  pathology	  of	   LRRK2	  mutation	   carriers,	   has	   led	   to	   the	   suggestion	   that	  LRRK2	  may	  play	  a	  role	  at	  the	  intersection	  of	  many	  of	  the	  pathways	  associated	  with	  these	   pathologies,	   with	   a	   regulatory	   role	   in	   microtubule	   stability,	   regulation	   of	  transcription	   and	   mitochondrial	   functioning	   suggested	   by	   the	   presence	   of	   tau,	  TDP-­‐43	  and	  α-­‐syn	  respectively	   (Zimprich	  et	  al.	  2004).	  The	   fact	   that	  LRRK2	  PD	   is	  indistinguishable	   from	   sporadic	   PD,	   suggests	   that	   the	   physiological	   role	   of	   this	  protein	   may	   be	   important	   for	   sporadic,	   as	   well	   as	   genetic	   forms	   and	   as	   such,	  investigation	  of	   LRRK2	  may	  provide	   a	  possible	   therapeutic	   avenue	   as	  well	   as	   an	  important	   research	   target.	   For	   these	   reasons,	   understanding	   the	   relationship	  between	  mutations	   in	   LRRK2	   and	   the	   clinical	   presentation	   of	   PD,	   is	   seen	   as	   an	  important	  step	  towards	  understanding	  and	  finding	  treatments	  for	  sporadic	  PD.	  	  LRRK2	   is	   a	   large	   protein,	   consisting	   of	   2527	   amino	   acids.	   It	   contains	   a	  serine/threonine	   kinase	   domain,	   a	   GTPase	   domain	   and	  multiple	   protein-­‐protein	  interaction	  domains	  as	  shown	  in	  Figure	  1.2.	  	  	  
	  
Figure	  1.2.	  Linear	   representation	  of	  LRRK2	  domain	  structure.	  ANK-­‐	  Ankyrin	  repeats,	  LRR-­‐	  Leucine	  rich	  repeats,	  ROC-­‐Ras	  of	  complex	  proteins,	  COR-­‐	  C-­‐terminal	  of	  ROC.	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The	  ankyrin	  and	  leucine-­‐rich	  repeats,	  and	  the	  WD40	  domain	  of	  LRRK2	  are	  thought	  to	  mediate	  protein-­‐protein	   interactions	  (reviewed	   in	  Mata	  et	  al.	  2006)	  and	   it	  has	  been	  suggested	  that	  LRRK2	  is	  a	  scaffold	  protein	  (Liou	  et	  al.	  2008).	  The	  enzymatic	  core	   of	   LRRK2	   consists	   of	   a	   GTPase	   domain	   (Ras	   of	   Complex	   proteins	   or	   ROC	  domain)	   adjacent	   to	   the	   non-­‐enzymatic	   COR	   domain	   and	   a	   kinase	   domain.	   This	  ROC-­‐COR	   tandem	   is	   characteristic	   of	   the	   ROCO	   family	   of	   proteins,	   a	   family	  containing	  four	  members	   in	  humans	  which	  contain	  the	  ROC-­‐COR	  motif,	   including	  LRRK2	  and	   its	   closely	   related	  homolog	  LRRK1	   (Bosgraaf	  et	  al.	   2003).	  The	  kinase	  domain	  of	  LRRK2	  is	  closest	  in	  homology	  to	  kinase	  domains	  from	  the	  RIPK	  family,	  a	  group	   of	   predominantly	   serine/	   threonine	   kinases	   (reviewed	   in	   Meylan	   et	   al.	  2005).	  	  In	  analogy	  to	  the	  small	  GTPase	  Ras,	  which	  is	  known	  to	  activate	  kinase	  Raf-­‐1	  upon	  GTP	  binding	  to	  its	  GTPase	  domain	  (Maruta	  et	  al.	  1994),	  kinase	  activity	  of	  LRRK2	  is	  also	  activated	  upon	  GTP	  binding	  to	  the	  ROC	  domain.	  GTP	  hydrolysis	  by	  Ras	  causes	  conformational	   change	   and	   the	   switch	   to	   an	   ‘off’	   conformation,	   a	   state	   which	   is	  reversed	  upon	  GDP/GTP	  exchange	  (Feuerstein	  et	  al.	  1989).	   Investigation	   into	  the	  functional	  relationship	  of	  the	  ROC-­‐COR	  tandem	  and	  the	  kinase	  domain	  of	  LRRK1,	  showed	   that	   GTPase	   hydrolysis	   controls	   kinase	   activity	   (Korr	   et	   al.	   2006).	   Soon	  after,	  it	  was	  shown	  that	  GTP	  dead	  forms	  of	  LRRK2	  lack	  in	  kinase	  activity	  (Smith	  et	  
al.	   2006),	   and	   that	   the	   kinase	   activity	   of	   full-­‐length	   LRRK2	   overexpressed	   in	  mammalian	  cells,	   is	  also	  controlled	  by	  GTP	  binding	   to	   the	  ROC	  domain	   (Ito	  et	  al.	  2007).	  Binding	  of	  GTP	  appears	  to	  stimulate	  kinase	  activity,	  whereas	  GDP	  has	  been	  shown	  to	  inhibit	  LRRK2	  kinase	  activity.	  Non-­‐hydrolysable	  forms	  of	  GTP	  have	  been	  shown	  to	  increase	  LRRK2	  kinase	  activity,	  presumed	  to	  be	  due	  to	  an	  enhanced	  ‘on’	  state,	  when	  GTP	   is	  bound	   to	   the	  ROC	  domain	   (Li	  X.	  et	  al.	   2007,	  Guo	  et	  al.	   2007).	  These	  studies	  support	  a	  regulatory	  role	  for	  the	  ROC	  domain	  in	  controlling	  LRRK2	  kinase	  activity.	  	  
1.7.2	  	  Dimerisation	  of	  LRRK2	  Accumulating	   evidence	   suggests	   that	   LRRK2	   is	   able	   to	   form	   dimers.	   BlueNative	  (BN)	  and	  size	  exclusion	  analysis	  of	  full	   length	  LRRK2	  expressed	  in	  Hek293T	  cells	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and	  endogenous	  LRRK2	  from	  lymphoblasts,	  have	  shown	  that	  LRRK2	  is	  present	  in	  species	  of	  ~600	  kDa,	  which	  likely	  corresponds	  to	  dimeric	  species.	  LRRK2	  was	  also	  present	   in	   lower	   (~300	   kDa)	   and	   higher	   molecular	   weight	   form	   (~1.2	   MDa)	   in	  these	  studies	  (Greggio	  et	  al.	  2008,	  Sen	  et	  al.	  2009).	  Glycerol	  gradient	  centrifugation	  of	  overexpressed	  and	  endogenous	  LRRK2	  supports	  these	  results	  and	  suggests	  that	  the	   active	   form	   of	   LRRK2	   is	   dimeric,	   with	   kinase	   activity	   of	   higher	   molecular	  weight	   LRRK2	   species	   higher	   than	   that	   of	   lower	  molecular	  weight	   (Berger	   et	  al.	  2010).	  	  	  The	   resolved	   crystal	   structure	   of	   bacterially	   expressed	   fragments	   of	   the	   ROC	  domain,	  show	  that	  this	  domain	  is	  sufficient	  for	  dimerisation.	  The	  crystal	  structure	  suggests	  a	  domain-­‐swap	  interaction	  in	  which	  residues	  from	  one	  LRRK2	  molecule,	  form	  associations	  with	  those	  from	  another,	  in	  order	  to	  collectively	  make	  the	  active	  site	   (Deng	   et	   al.	   2008).	   Although	   the	   legitimacy	   of	   this	   ‘domain	   swap,’	   has	   been	  questioned	   (Gotthardt	   et	   al.	   2008),	   crystal	   structures	   from	   other	   ROCO	   proteins	  also	  support	  the	  idea	  that	  ROCO	  proteins	  are	  able	  to	  dimerise.	  Crystallization	  of	  the	  ROC/COR	   tandem	   from	   the	   C.	   Tepidium	   ROCO	   protein,	   has	   shown	   that	   this	  fragment	  of	  the	  protein	  can	  also	  dimerise.	  Fragments	  of	  the	  isolated	  COR	  domain	  are	  able	  to	  form	  dimers	  and	  mutating	  residues	  at	  the	  dimer	  interface	  is	  sufficient	  to	  cause	  separation	  of	   the	  dimer	   into	  monomeric	   species	   (Gotthardt	  et	  al.	  2008).	  Yeast	   II	   hybrid	   screens	   (Y2H)	   using	   various	   fragments	   of	   LRRK2	   have	   shown	  interaction	  between	  a	  number	  of	  domains;	  segments	  of	  LRRK2	  spanning	  residues	  13-­‐186	   (LRRs	   to	  ROC),	   as	  well	   as	   the	  N-­‐terminus	   and	   the	  WD40	   repeats	   (2084-­‐2217)	  have	  all	  shown	  the	  ability	  to	  self-­‐interact	  (Greggio	  et	  al.	  2008).	  	  
1.7.3	  	  Regulation	  of	  dimerisation	  Regulation	   of	   kinase	   activity	   by	   the	   ROC	   domain	   is	   thought	   to	   be	   induced	   by	  conformational	   change	   dependent	   on	   dimerisation	   of	   the	   GTPase	   domains.	   This	  has	   led	   to	   classification	   of	   LRRK2	   as	   a	   ‘G	   protein	   activated	   by	   nucleotide-­‐dependent	   dimerization	   (GAD)	   (Gasper	   et	   al.	   2009).’	   According	   to	   this	  classification,	   the	   active	   site	   of	   the	   GTPase	   domain	   contained	   within	   GAD	  monomers,	   requires	   interaction	   with	   a	   complementary	   active	   site	   in	   order	   to	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function	  (see	  Figure	  1.3).	  These	  proteins	  have	  a	  low	  nucleotide	  affinity	  in	  the	  µM	  range,	   and	   it	  has	  been	  shown	   in	  other	  GADs,	   that	   the	  high	   turnover	  of	  GDP/GTP	  negates	   the	   need	   for	   a	   guanine	   exchange	   factor	   (GEF)	   (Gasper	   et	  al.	   2009).	   GTP	  binding	   studies	   have	   shown	   that	   the	   ROC	   domain	   of	   the	   bacterial	   ROCO	   protein	  from	   C.	   Tepidium	   has	   a	   low	   affinity	   for	   GTP	   binding	   (13.4µM),	   and	   a	   fast	  dissociation	  rate	  (Gotthardt	  et	  al.	  2008)	  and	  it	  is	  thought	  that	  this	  is	  also	  the	  case	  for	  LRRK2.	  Other	  features	  displayed	  by	  GADs	  are	  shown	  by	  the	  GTPase	  dynamin,	  which	   has	   been	   described	   in	   terms	   of	   its	   interaction	   with	   GTPase	   co-­‐regulators	  (GCRs),	  which	  are	  proteins	  and	  factors	  that	  are	  necessary	  to	  aid	  GTPase	  function,	  but	   do	   not	   have	   any	   functional	   role	   in	   doing	   so.	   Dynamin	   interacts	   with	  phospholipids	  and	  microtubules	  and	  according	  to	  its	  classification	  as	  a	  GAD,	  these	  accessories	  are	  necessary	   for	  GTPase	  activity	   to	   function	  optimally.	  Similarly,	   the	  heat	   shock	   protein	   HSP90	   and	   its	   interactors	   have	   been	   shown	   to	   assist	   in	   the	  GTPase	  activity	  of	  the	  proteins	  they	  interact	  with	  (Gasper	  et	  al.	  2009).	  LRRK2	  has	  been	   shown	   to	  bind	   to	  membranes	   (Hatano	  et	  al.	   2007,	  Alegre-­‐Abarrategui	  et	  al.	  2009,	  Berger	  et	  al.	  2010),	  and	  the	  ROC	  domain	  has	  been	  shown	  to	  interact	  with	  β	  and	  α-­‐tubulin	  (Gandhi	  et	  al.	  2009).	  Similarly,	  association	  with	  HSP90	  has	  also	  been	  demonstrated	   (Hurtado-­‐Lorenzo	   et	   al.	   2008),	   supporting	   the	   classification	   of	  LRRK2	  as	  a	  GAD,	  but	  also	  suggesting	  that	  there	  are	  other	  factors	  affecting	  LRRK2	  GTP	  hydrolysis	  that	  have	  not	  yet	  been	  investigated.	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Figure	  1.3.	  Schematic	  model	  of	  LRRK2	  activation	  by	  dimerisation.	  	  Taken	  from	  Gasper	  et	  al,	  2009).	  The	  inactive	  ROC	  domain	  of	  GDP-­‐bound	  LRRK2	  is	  monomeric.	  Dissociation	  of	  GDP	  and	  binding	  of	  GTP	   causes	  dimerization	  of	   the	  ROC	  domain,	  which	   translates	   to	   kinase	   domain	   activation	   through	   conformational	   change.	  Hydrolysis	  of	  GTP	  to	  GDP	  causes	  monomerisation	  of	  the	  ROC	  domain,	  and	  the	  cycle	  starts	  again.	  
	  
1.7.4	  	  Effect	  of	  familial	  mutations	  on	  LRRK2	  functioning	  In	   Asian	   populations,	   the	   G2385R	   mutation	   situated	   in	   the	   WD40	   domain	   of	  LRRK2,	   is	   thought	   to	   be	   the	   most	   common	   PD	   causing	   mutation	   (Farrer	   et	   al.	  2007).	   Apart	   from	   this,	   many	   of	   the	   familial	   mutations	   known	   to	   cause	   PD,	   are	  situated	   in	   the	   enzymatic	   core	   of	   the	   protein	   (ROC-­‐COR-­‐kinase)	   and	   it	   has	   been	  shown	   that	   some	  of	   these	  mutations	   can	   affect	   the	   enzymatic	   outputs	   of	   LRRK2.	  This	  is	  important	  for	  PD,	  as	  cellular	  toxicity	  of	  LRRK2	  has	  been	  attributed	  to	  kinase	  activity	   (Greggio	  et	  al.	   2006,	   Smith	  et	  al.	   2006).	  G2019S,	  which	   is	   situated	   in	   the	  Mg2+	  binding	  loop	  of	  the	  kinase	  domain,	  has	  been	  consistently	  reported	  to	  display	  increased	  kinase	  activity	  when	  compared	  to	  WT	  protein	  (reviewed	  in	  Greggio	  et	  al.	  2009)	  and	  R1441C,	  found	  in	  the	  ROC	  domain,	  appears	  to	  affect	  GTPase	  efficiency,	  decreasing	  the	  ability	  of	  LRRK2	  to	  hydrolyse	  GTP	  (Lewis	  et	  al.	  2007).	  The	  crystal	  structure	  of	  the	  ROC	  domain	  purified	  from	  bacteria,	  suggests	  that	  R1441	  is	  found	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on	   the	   interface	   of	   ROC-­‐ROC	   dimers.	   The	   cysteine	   substitution	   may	   disrupt	  hydrogen	  bonding	  between	  the	  two	  GTPase	  domains	  (Deng	  et	  al.	  2008).	  Similarly,	  differential	  scanning	  fluorimetry	  has	  shown	  that	  the	  R1441C	  mutation	  is	  likely	  to	  change	  the	  folding	  properties	  of	  the	  ROC	  domain	  (Li	  Y.	  et	  al.	  2009).	   	  As	  such,	  this	  mutation	   is	   likely	   to	   be	   affecting	   GTP	   hydrolysis	   by	   causing	   subtle	   structural	  changes.	  Recently,	   Y1699C	  has	   also	  been	   shown	   to	   affect	   the	   activity	   of	   the	  ROC	  domain,	  causing	  a	  decrease	  in	  the	  rate	  of	  GTP	  hydrolysis.	  This	  mutation,	  situated	  in	  the	   COR	   domain	   of	   LRRK2,	   has	   been	   shown	   to	   decrease	   GTPase	   activity	   by	  strengthening	  the	  interaction	  between	  the	  ROC	  and	  COR	  domain,	  which	  results	  in	  a	  weaker	  bond	  between	  LRRK2	  monomers	  (Daniels	  et	  al.	  2011).	  	  	  
	  1.7.5	  	  Phosphorylation	  and	  autophosphorylation	  of	  LRRK2	  Ablating	  kinase	   activity	  with	   the	   artificial	  mutation	  K1906M	  and	  GTPase	  activity	  with	  the	  mutation	  K1347A	  (West	  et	  al	  2007,	  Gloeckner	  et	  al.	  2006),	  causes	  LRRK2	  to	  form	  higher	  molecular	  weight	  aggregates,	  presumably	  due	  to	  the	  stability	  of	  this	  protein	  being	  altered.	  In	  this	  case,	  it	  would	  appear	  that	  enzymatic	  activity	  forms	  a	  crucial	  mechanism	   to	   regulate	   LRRK2	   dimer	   formation	   (Greggio	   et	   al.	   2008).	   As	  LRRK2	  is	  known	  to	  autophosphorylate,	   it	   is	   likely	  that	  phosphorylation	  of	  LRRK2	  at	   certain	   residues	   is	   regulating	   complex	   formation.	   Treatment	   of	   transfected	  Hek293T	   cells	   and	   ΔN-­‐LRRK2	   recombinant	   protein	   with	   the	   kinase	   inhibitor	  staurosporine,	   has	   been	   shown	   to	   disrupt	   dimer	   formation	   (Sen	   et	   al.	   2009),	  supporting	   the	   idea	   that	   autophosphorylation	   or	   kinase	   activity-­‐mediated	  phosphorylation	   of	   LRRK2,	   provides	   some	   regulation	   over	   LRRK2	   complex	  formation.	  Kinase	  assays	  using	  immunoprecipitated	  LRRK2	  separated	  using	  FPLC	  size	  exclusion,	  have	  shown	  that	  the	  kinase	  activity	  of	  higher	  order	  LRRK2	  species	  of	   LRRK2	   is	   higher	   than	   that	   of	   lower	  weight	   LRRK2,	   suggesting	   that	   enzymatic	  activity	  is	  also	  affected	  by	  LRRK2	  complex	  formation.	  	  	  Overexpressed	  LRRK2,	  has	  been	  shown	  to	  be	  basally	  phosphorylated	  in	  Cos7	  cells	  (Greggio	   et	   al.	   2007),	   an	   idea	   supported	   by	   the	   analysis	   of	   phosphopeptides	   in	  cancer	  cells,	  which	  showed	  phosphorylation	  of	  LRRK2	  at	  Y707	  (Rush	  et	  al.	  2005).	  The	   kinase	   domain	   of	   LRRK2	   is	   highly	   homologous	   to	   that	   found	   in	   serine/	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threonine	   kinases	   (Declercq	   et	  al.	   2009,	   Lewis,	   2009),	   and	   an	   analysis	   of	   LRRK2	  consensus	   motifs	   for	   phosphorylation,	   supports	   the	   idea	   that	   LRRK2	  phosphorylates	   serine	   and	   threonine	   residues,	   with	   a	   preference	   for	   serine	  phosphorylation	  (Pungaliya	  et	  al.	  2010).	  This	  suggests	  that	  phosphorylation	  of	  this	  tyrosine	   residue	   is	   not	   caused	   by	   autophosphorylation,	   but	   likely	   by	   another	  interacting	   kinase.	   Tyrosine	   phosphorylation	   of	   LRRK2	   in	   general	   is	   not	   widely	  reported,	   perhaps	   due	   to	   the	   reduced	   stability	   of	   tyrosine	   phosphorylation	  compared	   to	   serine/threonine	   phosphorylation	   (Rush	   et	  al.	   2005).	   The	   reported	  membrane	   association	   of	   LRRK2	   (Hatano	   et	   al.	   2007,	   Alegre-­‐Abarrategui	   et	   al.	  2009,	  Berger	  et	  al.	  2010)	  could	  suggest	   that	   this	  phosphorylation	   is	  mediated	  by	  membrane	  interaction,	  due	  to	  the	  high	  concentration	  of	  receptor	  tyrosine	  kinases	  and	  receptor	  associated	  tyrosine	  kinases	  at	  membranes.	  	  	  Investigation	   into	   LRRK2	   substrates	   has	   reported	   that	   LRRK2	   is	   able	   to	   interact	  interact	   with	   isoforms	   of	   the	   14-­‐3-­‐3	   proteins,	   scaffolds	   involved	   in	   numerous	  signaling	   cascades,	   which	   bind	   to	   phosphorylated	   residues	   (Dzamko	   et	   al.	   2010,	  Nichols	  et	  al.	  2010,	  Li	  X.	  et	  al.	  2011).	  Dephosphorylation	  has	  been	  shown	  to	  disrupt	  this	   interaction	   and	   mass	   spectrometric	   analysis	   of	   phosphorylated	   residues	   in	  LRRK2	   has	   mapped	   the	   interaction	   to	   two	   serines	   at	   positions	   910	   and	   935.	  Mutation	   of	   these	   serines	   to	   alanines	   has	   been	   shown	   to	   disrupt	   14-­‐3-­‐3	   binding	  and	   dephosphorylation	   of	   LRRK2	   with	   phosphatase	   and	   subsequent	  rephosphorylation	   in	  vitro,	   shows	   that	   LRRK2	   is	   unable	   to	   autophosphorylate	   at	  these	   residues.	   This	   suggests	   that	   these	   residues	   are	   instead	   likely	   targets	   for	  regulation	  by	  other	  kinases	  (Dzamko	  et	  al.	  2010).	  	  	  Autophosphorylation	  of	  LRRK2	  has	  been	  shown	  to	  cluster	  in	  certain,	  discrete	  areas	  of	   LRRK2,	   namely	   the	   N-­‐terminus,	   ROC	   domain	   and	   kinase	   domains.	  Overexpression	  of	  TAP-­‐tagged	  LRRK2	  in	  Hek293T	  cells,	  with	  mass	  spectrometry	  to	  identify	  phosphorylation	  before	  and	  after	  a	  kinase	  assay,	  have	  shown	  that	  up	  to	  20	  sites	  can	  be	  identified	  (see	  Table	  1.3).	  These	  sites	  are	  found	  mainly	  between	  S850	  and	   S979	   in	   the	   N-­‐terminus	   (Gloeckner	   et	   al.	   2010).	   Additional	  autophosphorylation	  targets	  in	  the	  regulatory	  P-­‐loop	  of	  the	  ROC	  domain	  were	  also	  identified,	  namely	  T1343,	  S1345	  and	  T1348.	  	  Importantly,	  if	  these	  amino	  acids	  are	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superimposed	  on	  the	  crystal	  structure	  of	  ROCO	  from	  C.Tepidium,	  T1410	  sits	  right	  next	   to	   R1441	   and	   T1348	   is	   above.	   As	   mutation	   of	   R1441	   has	   been	   shown	   to	  decrease	  GTPase	  activity	  (Lewis	  et	  al.	  2007)	  autophosphorylation	  of	  these	  residues	  may	  play	  a	  role	   in	  the	  regulation	  of	  GTPase	  activity,	  and	  thus	  provide	  a	   feedback	  mechanism	  for	  kinase	  activity	  (Gloeckner	  et	  al.	  2010).	  	  	  Assessment	  of	  autophosphorylation	  in	  recombinant	  N-­‐terminally	  truncated	  LRRK2	  (ΔN-­‐LRRK2)	  using	  in	  vitro	  kinase	  assays,	  and	  full-­‐length	  FLAG-­‐tagged	  LRRK2	  using	  the	  ROC	  domain	  as	  a	  substrate,	  has	  supported	  the	  idea	  of	  T1343	  phosphorylation,	  as	   well	   as	   T1491	   and	   T2031	   (see	   Table	   1.3	   for	   a	   complete	   list	   of	   LRRK2	  autophosphorylation	   resides	   to	   date).	  When	   the	   N-­‐terminus	   is	   removed,	   LRRK2	  displays	   three	   times	   higher	   autophosphorylation	   activity,	   suggesting	   that	   this	  segment	  of	  LRRK2	  is	  involved	  in	  regulation	  of	  kinase	  activity	  (Greggio	  et	  al.	  2009).	  Mutation	   of	   residues	   in	   the	   active	   loop	   T2031,	   S2032,	   and	   T2035,	   to	   non-­‐phosphorylatable	   alanines,	   does	   not	   affect	   dimerization	   and	   importantly,	   the	  T2035A	   mutation	   is	   unable	   to	   autophosphorylate	   itself.	   The	   finding	   that	   WT	  cannot	  phosphorylate	  the	  kinase	  dead	  mutant,	  suggests	  that	  autophosphorylation	  is	   likely	   to	   occur	   in	   cis,	   rather	   than	   in	   trans	   as	   might	   be	   expected,	   although	  interacting	   proteins,	   absent	   from	   these	   assays	   may	   be	   necessary	   for	   trans-­‐phosphorylation	  of	  LRRK2.	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Table	  1.3.	  Reported	  LRRK2	  phosphorylation	  sites.	  (Taken	  from	  Gloeckner	  et	  al.	  2010)	  	  Purification	  and	  mass	  spectrometry	  analysis	  of	  phosphorylation	  sites	  in	  ΔN-­‐LRRK2	  from	   Sf9	   insect	   cells	   has	   shown	   phosphorylation	   at	   a	   number	   of	   residues	   in	   the	  kinase	   (T1967)	   and	  ROC	  domains	   (T1410,	   T1491).	   KD	  mutations	   in	   this	   protein	  showed	   a	   dramatic	   reduction	   in	   phosphorylation	   at	   these	   sites.	   Conversely,	  incubation	   of	   the	   protein	   with	   ATP	   increased	   phosphorylation	   at	   these	   sites,	  suggesting	   that	   these	   are	   autophosphorylation	   sites	   (Kamikawaji	   et	   al.	   2009).	  Studies	   by	   other	   groups	   have	   confirmed	   LRRK2	   phosphorylation	   at	   residues	  T2031,	  S2032,	  and	  T2035	  and	  perhaps	   importantly	   in	   terms	  of	  PD	  pathogenesis,	  phospho-­‐antibodies	   (p-­‐antibodies)	  against	   these	  residues,	  have	  shown	   that	   there	  is	   a	   30%	   increase	   in	   phosphorylation	   when	   transfected	   cells	   are	   subjected	   to	  
Residue	   Domain	   	   	   Reference(s)	  
S850	  S858	  S860	  S865	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  	  
S895	  S898	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  
S908	  S910	  S912	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  
S926	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  
S933	  S935	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  
S954	  S955	  S958	   N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  
S971	  S973	  S975	  S976	  
S979	  
N-­‐Terminus	   Gloeckner	  et	  al.	  2010	  	  
T1343	  S1345	  T1348	   ROC	   Greggio	  et	  al.	  2009	  Gloeckner	  et	  al.	  2010	  
T1410	   ROC	   Kamikawaji	  et	  al.	  2009	  
T1491	  	   ROC	   Kamikawaji	  et	  al.	  2009	  Greggio	  et	  al.	  2009	  
T1967	   Kinase	   Kamikawaji	  et	  al.	  2009	  
T2031	   Kinase	   Greggio	  et	  al.	  2009	  Li	  X.	  et	  al.	  2010	  
T2032	  T2035	   Kinase	   Li	  X.	  et	  al.	  2010	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oxidative	   stress	   due	   to	   exposure	   to	   H202	   (Li	   X.	   et	   al.	   2010),	   suggesting	   that	  oxidative	  stress	  may	  activate	  LRRK2.	  	  	  
1.8	  PUTATIVE	  FUNCTIONS	  OF	  LRRK2	  
1.8.1	  The	  role	  of	  LRRK2	  in	  signaling	  cascades-­‐clues	  from	  LRRK2	  
structure	  The	   RIPK	   family	   of	   proteins,	   have	   been	   shown	   to	   autophosphorylate	   and	  phosphorylate	   many	   targets	   including	   the	   mitogen	   activated	   protein	   (MAP)	  kinases	   JNK,	   p38	   and	   extracellular	   signal-­‐regulated	   kinase	   (ERK)	   (reviewed	   in	  Meylan	  et	  al.	  2005)	  (see	  Figure	  1.4).	  The	  ROCO	  proteins,	  to	  which	  LRRK2	  is	  closest	  phylogenetically,	   have	   also	   been	   shown	   to	   function	   as	   member	   of	   signaling	  cascades.	   The	   best-­‐studied	   member	   of	   the	   ROCO	   proteins	   is	   DAPK1,	   a	   well-­‐characterized	  serine/threonine	  kinase,	  which	  contains	  a	  death	  domain,	  as	  well	  as	  the	   characteristic	   ROC-­‐COR	   tandem.	  DAPK1	   is	   known	   to	   signal	   through	   the	   ERK	  pathway	  and	  functions	  upstream	  of	  p53	  in	  response	  to	  hyperproliferative	  signals	  to	   induce	  apoptosis	  by	   formation	  of	  autophagic	  vesicles	  and	  membrane	  blebbing	  (Harrison	  et	  al.	  2008).	  	  LRRK2	  is	  poorly	  tolerated	  by	  cells	  made	  to	  overexpress	  the	  protein,	   however	   the	   closely	   related	  homolg	  LRRK1,	  which	   is	   of	   almost	   identical	  domain	  structure,	  is	  not	  toxic	  and	  overexpression	  in	  cells	  is	  well	  tolerated	  (Korr	  et	  
al.	   2006).	   Recently,	   it	   has	   been	   suggested	   that	   LRRK1	   and	   LRRK2	   are	   able	   to	  heterodimerise	  and	  genetic	  analysis	  of	  LRRK2	  mutation	  carriers	  showed	  that	  some	  individuals	  also	  carry	  LRRK1	  mutations,	  which	  appear	  to	  modify	   the	  progression	  of	  PD	  (Dachsel	  et	  al.	  2010).	  Despite	  this,	  mutations	  in	  LRRK1	  alone	  have	  not	  been	  shown	  to	  cause	  PD	  and	  it	   is	  generally	  considered	  that	  LRRK1	  activity	   is	  not	  toxic	  (Greggio	   et	   al.	   2007).	   Apart	   from	   differences	   in	   sequence,	   the	   largest	   difference	  between	  these	  kinases	  lies	  in	  the	  N-­‐terminal,	  a	  clue	  perhaps	  to	  the	  cause	  of	  LRRK2	  toxicity.	  LRRK2	  is	  513	  amino	  acids	  longer	  and	  has	  additional	  leucine-­‐rich,	  ankyrin	  and	   putative	   armadillo	   repeats	   at	   this	   end	   of	   the	   protein,	   indicating	   a	   greater	  propensity	   for	   protein-­‐protein	   interaction.	   Indeed	   studies	   looking	   at	   the	   role	   of	  apoptosis	  in	  LRRK2	  mediated	  cell	  death	  further	  emphasise	  the	  role	  of	  LRRK2	  as	  a	  scaffold,	   with	   the	   discovery	   that	   LRRs	   and	   the	   WD40	   domain	   are	   essential	   for	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LRRK2	   toxicity	   (Iaccarino	  et	  al.	   2007).	   In	   this	   case,	   it	  would	   seem	   likely	   that	   the	  toxic	  effects	  of	  LRRK2	  are	  mediated	  in	  part	  by	  interaction	  of	  the	  N-­‐terminus	  with	  binding	  partners,	  which	  mediate	  this	  toxicity.	  	  Ankyrin	  repeats	  are	  found	  in	  a	  wide	  variety	  of	  proteins	  including	  the	  DAG	  kinases	  and	   ankyrins,	  which	   are	   known	   to	   signal	   in	   cell	   death	   pathways	   and	   function	   to	  link	  cytoplasmic	  structural	  proteins	  to	  integral	  membrane	  proteins	  in	  some	  cases	  (Bennett,	  1982).	  LRRK2	  has	  been	  reported	  to	  have	  an	  affinity	  for	  lipid	  structures	  in	  a	   number	   of	   studies.	   Immunostaining	   of	   rat	   and	   human	   brain	   tissue,	   and	   rat	  primary	  neurons	  showed	  association	  of	  LRRK2	  with	  vesicular	  structures	  and	  with	  the	  outer	  mitochondrial	  membrane	  (Biskup	  et	  al.	  2006).	  Similarly,	  fractionation	  of	  mouse	  primary	  neurons	  has	  showed	  the	  affinity	  of	  LRRK2	  for	  lipid	  rafts	  (Hatano	  et	  
al.	   2007)	   and	   investigations	   using	   a	   human	   genomic	   reporter	   model,	   have	  suggested	   a	   role	   for	   LRRK2	   in	   membrane	   microdomains	   and	   their	   associated	  functions	   (Alegre-­‐Abarrategui	   et	   al.	   2009).	   Subcellular	   fractionation	   has	   shown	  that	   LRRK2	   is	   in	   active	   form	   when	   membrane	   bound	   (Berger	   et	   al.	   2010),	  suggesting	   that	   there	   is	   an	   important	   membrane	   associated	   protein	   which	  activates	  LRRK2,	  or	  as	  been	  shown	  with	  MAO,	  that	  membrane	  interaction	  can	  itself	  activate	  LRRK2,	  perhaps	  through	  induced	  conformational	  change	  (Diatlovitskaia	  et	  
al.	  1977).	  This	  membrane	  association	  perhaps	  supports	  the	  idea	  that	  LRRK2	  could	  be	  involved	  in	  signaling	  through	  transduction	  cascades.	  	  
1.8.2	  Function	  of	  LRRK2-­‐	  MAP	  kinase	  cascade	  signaling.	  In	   line	  with	   the	  known	  functions	  of	  RIP	  kinases	  and	  some	  members	  of	   the	  ROCO	  proteins,	   there	   have	   been	  many	   reports	   that	   LRRK2	   interacts	  with	   proteins	   and	  controls	   functions	   that	   involve	   protein	   kinase	   B	   (Akt)	   signaling.	   Activation	   and	  perturbation	   of	   many	   MAP	   kinase	   pathways	   has	   been	   shown	   in	   PD	   and	   it	   is	  becoming	  apparent	  that	  cell	  death	  is	  not	  a	  stand-­‐alone	  process	  and	  is	  instead	  the	  other	   side	   of	   the	   coin	   in	   controlling	   homeostasis	   of	   cellular	   proliferation.	  Proliferation	  must	   be	   tightly	   regulated	   in	   order	   to	   ensure	   that	   this	   process	   does	  not	   become	   oncogenic,	   however,	   ‘applying	   the	   brakes’	   too	   forcefully,	   can	   tip	   the	  balance	  and	  cause	  cell	  death	  (reviewed	  in	  Plun-­‐Favreau	  et	  al.	  2010).	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  Extracellular	  stimulation	  of	  cell	  division,	  is	  mediated	  through	  ligand	  binding	  to	  cell	  surface	  receptors	  and	  is	  triggered	  by	  stimulants	  such	  as	  growth	  factors,	  insulin	  and	  other	   cytokines	   (reviewed	   in	   Rozengurt,	   1986).	   Mitogens,	   as	   these	   ligands	   are	  called,	   stimulate	   cell	   division	   cascades	   and	   their	   related	   processes,	   however	   in	  post-­‐mitotic	  neurons,	  signaling	  is	  not	  allowed	  to	  reach	  the	  stage	  where	  division	  is	  initiated-­‐short	   stimulations	   promote	   cell	   repair	   functions,	   however	   longer	  durations	   of	   pathway	   activation	   result	   in	   apoptosis	   (Naetzker	   et	   al.	   2006).	  Pathways	   activated	   by	  mitogens	   are	   characterised	   by	   the	   involvement	   of	   kinase	  cascades	   to	   transduce	   signals.	   p38,	   JNK	   (c-­‐Jun	   N-­‐terminal	   kinase),	   and	   ERK	   are	  MAPKs	   (Figure	   1.4)	   activated	   in	   response	   to	   various	   pro-­‐mitogenic	   stimuli.	  Activation	  of	  upstream	  kinases	  initiates	  a	  phosphorylation	  cascade,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  STIMULUS	  à	  MAPKKK	  à	  MAPKK	  à	  MAPK	  à	  RESPONSE	  	  which	   results	   in	   their	  activation	  and	  subsequent	   transcription	  of	   required	  genes.	  Early	   interaction	   studies	   looking	   at	   the	   possible	   role	   of	   LRRK2	   in	   MAP	   kinase	  signaling	  have	  showed	  that	  it	  can	  interact,	  and	  phosphorylate	  some	  MAPK	  kinases	  (MKKs	   4,	   6	   and	   7),	   linking	   the	   protein	   to	   p38	  mitogen-­‐activated	   protein	   kinase	  signaling	  (Gloeckner	  et	  al.	  2009).	  Another	  study	  looking	  at	  this	  in	  more	  detail	  has	  shown	  that	  LRRK2	  can	  bind	  to	  MKKs	  3,	  6	  and	  7	  through	  the	  ROC/kinase	  domain	  and	   control	   localization	   of	   some	   MKKs.	   Overexpression	   of	   LRRK2	   in	   Hek293T	  causes	  the	  amount	  of	  MKK6	  localised	  to	  the	  plasma	  membrane	  to	  increase	  by	  four-­‐fold,	   suggesting	   that	   the	   protein-­‐protein	   interaction	   domains	   of	   LRRK2	   may	   be	  important	  here	   too	   (Hsu	  et	  al.	   2010).	  A	   role	   for	   LRRK2	   functioning	   in	   the	  MAPK	  cascade	  involving	  ERK	  1/2	  has	  been	  proposed	  with	  studies	  showing	  that	  LRRK2-­‐induced	  neurite	  shortening	  (thought	  to	  be	  caused	  by	  autophagy),	  can	  be	  partially	  rescued	  by	  utilization	  of	  the	  MEK	  inhibitor	  U0126	  (Plowey	  et	  al.	  2008).	  Leukocytes	  from	   PD	   patients	   with	   sporadic	   and	   G2019S	   PD	   show	   a	   significant	   reduction	   in	  levels	  of	  phospho-­‐Src	  (p-­‐Src),	  HSP27	  and	  JNK	  when	  compared	  to	  normal	  controls.	  Interestingly	  p-­‐Src	  and	  p-­‐HSP27	  are	  also	  reduced	  in	  G2019S	  patients	  without	  the	  clinical	   symptoms	   of	   PD,	   suggesting	   that	   this	   activation	   may	   not	   necessarily	   be	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disease	  related,	  but	  instead	  due	  to	  the	  G2019S	  mutation	  and	  LRRK2	  itself	  (White	  et	  
al.	  2007).	  	  
	  
	  
Figure	   1.4.	   Overview	   of	   the	   main	   pathways	   that	   have	   been	   implicated	   in	  
LRRK2	  Parkinson’s	  disease.	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Hek293T	   cells	   transfected	   with	   WT	   and	   Y1699C	   LRRK2	   have	   been	   shown	   to	  display	   reduced	   basal	   levels	   of	   p-­‐ERK.	   Treatment	   of	   these	   cells	   with	   H2O2	   after	  transfection,	  causes	  a	  significant	  increase	  in	  p-­‐ERK	  levels	  for	  WT	  LRRK2	  compared	  to	   Y1699C	   and	   non-­‐transfected	   cells,	   and	   reduced	   cell	   death,	   again	   supporting	   a	  role	   for	   LRRK2	   in	   MAP	   kinase	   signaling	   (Liou	   et	   al.	   2008).	   The	   importance	   of	  kinase	  activity	  for	  this	  role	  has	  been	  shown	  by	  induction	  of	  LRRK2	  in	  transient	  and	  stably	   transfected	  Hek293T	   cells	  which	   results	   in	   increased	   levels	   of	   p-­‐ERK	   1/2	  that	   is	  not	  seen	  when	  kinase	  dead	  (KD)	  LRRK2	  carrying	   the	  K1906N	  mutation	   is	  expressed	  (Carballo-­‐Carbajal	  et	  al.	  2010).	  This	  activation	  of	  ERK	  can	  also	  be	  seen	  with	  G2019S	  and	  R1441C,	  but	  at	  decreased	   levels.	  When	  LRRK2	   is	  expressed	   for	  extended	  time	  periods,	  R1441C	  and	  G2019S	  show	  slower	  activation	  of	  ERK,	  which	  peaks	   at	   24	   and	   48	   hours	   respectively,	   compared	   to	   12	   hours	   with	   the	   WT.	  Importantly,	  expression	  of	  α-­‐syn	  was	  also	  shown	  to	  be	  upregulated	  by	  WT	  LRRK2	  to	  nearly	  1.8	  times	  basal	  levels	  in	  this	  study.	  For	  G2019S,	  this	  was	  increased,	  but	  at	  a	   reduced	   level	   of	   around	   1.5	   times,	   suggesting	   that	   LRRK2	   may	   play	   a	   role	   in	  controlling	  α-­‐synuclein	  levels	  through	  regulation	  of	  the	  ERK	  pathway.	  In	  this,	  case	  dysregulation	  caused	  by	  mutations	  could	  be	  a	  major	   factor	   in	  LRRK2	  induced	  PD	  pathogenesis.	  	  
1.8.3	  mTOR	  signaling	  and	  LRRK2	  LRRK2	   was	   first	   linked	   to	   mTOR	   signaling	   through	   studies	   showing	   that	  overexpression	  of	  G2019S	  in	  cells,	  can	  lead	  to	  upregulation	  of	  autophagy	  (MacLeod	  2006Plowey	   et	   al.	   2008).	   	   Similarly,	   LRRK2	   has	   been	   shown	   to	   localise	   to	   the	  endosomal-­‐autophagic	  pathway	  in	  human	  brain	  sections	  and	  knockdown	  of	  LRRK2	  in	  human	  cell	   lines	  has	  been	  shown	  to	  upregulate	  autophagy	  (Alegre-­‐Abarrategui	  
et	  al.	  2009).	  	  Initiation	   and	   control	   of	   autophagy	   occurs	   through	   mammalian	   target	   of	  rapamycin	   (mTOR)	   signaling	   (Beugnet	   et	   al.	   2003),	   which	   regulates	   the	   process	  through	  G-­‐proteins	  upon	  recruitment	  to	  autophagic	  membranes	  (Garcia-­‐Marcos	  et	  
al.	  2011).	  	  Mitogen	  activation	  of	  receptors	  results	  in	  upregulation	  of	  required	  gene	  products.	   Through	   the	   mTOR	   pathway,	   this	   upregulation	   is	   controlled	   at	   the	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translational	   level.	   Signalling	   through	   Akt	   results	   in	   activation	   of	   mTOR	   and	  phosphorylation	   of	   4E-­‐BP,	   an	   elongation	   factor,	   which	   serves	   as	   a	   negative	  regulator	  of	  translation	  by	  binding	  to	  translation	  factors.	  mTOR	  is	  inhibited	  by	  the	  compound	   rapamycin	   (Brown	   et	   al.	   1994)	   and	   is	   also	   regulated	   by	   intracellular	  amino	   acid	   levels	   (especially	   leucine)	   and	   nutrient	   deprivation	   (Beugnet	   et	   al.	  2003).	  	  	  In	   drosophila,	   LRRK2	   has	   been	   shown	   to	   demonstrate	   genetic	   interaction	   with	  components	   of	   the	   mTOR	   pathway,	   to	   regulate	   cell	   growth	   and	   cell	   size	   in	  development	   (Imai	   et	   al.	   2008).	   	   Knockout	   of	   the	   drosophila	   homolog	   LRRK	   in	  models	   overexpressing	  mTOR	   pathway	   components,	   has	   shown	   that	   LRRK2	   can	  exacerbate	   developmental	   defects	   in	   flies.	   Importantly,	   these	   phenotypes	   can	   be	  rescued	   by	   over-­‐expression	   of	   WT	   but	   not	   KD	   LRRK,	   suggesting	   that	   LRRK2	   is	  playing	  a	  functional	  role	   in	  these	  processes.	  Further	  investigation	  into	  the	  role	  of	  LRRK2	  kinase	  activity	  and	  mTOR	  signaling	   in	  vitro	   in	   these	  experiments,	   showed	  that	   human	   LRRK2	   overexpressed	   in	   Hek293T	   cells,	   is	   able	   to	   directly	  phosphorylate	   4E-­‐BP	   at	   residues	   T37	   and	   T46.	  Western	   blotting	   has	   supported	  these	  findings,	  as	  flies	  overexpressing	  LRRK	  showed	  increased	  phosphorylation	  at	  these	  residues.	  Similarly,	  LRRK	  knockout	  flies	  showed	  decreased	  phosphorylation	  at	   these	   residues	   (Imai	   et	   al.	   2008).	   Other	   groups	   have	   disputed	   the	   idea	   that	  LRRK2	   is	   able	   to	   phosphorylate	   4E-­‐BP	   directly	   in	   humans,	  with	   the	   finding	   that	  recombinant	  4E-­‐BP	  is	  a	  poor	  substrate	  for	  LRRK2	  in	  vitro	  (Kumar	  et	  al.	  2010).	  This	  may	  mean	  that	  LRRK2	  plays	  a	  different	  role	   in	  humans	  than	   in	   flies.	   In	   this	  case,	  interaction	  of	  LRRK2	  and	  4E-­‐BP	  in	  humans	  may	  be	  indirect	  and	  mediated	  instead	  by	  other	  proteins,	  or	  a	  shared	  signaling	  cascade.	  	  	  Links	  between	  4E-­‐BP	  and	  LRRK2	  in	  drosophila	  have	  been	  shown	  at	  the	  RNA	  level,	  however	   the	  differences	  caused	  by	  overexpression	  of	  WT	  and	  mutant	  LRRK2	   are	  not	   seen	   at	   protein	   level	   (Kanao	   et	   al.	   2010).	   4E-­‐BP	   expression	   is	   reportedly	  controlled	  by	  the	  forkhead	  transcription	  factor	  (Foxo)	  (Southgate	  et	  al.	  2007)	  and	  investigation	  into	  a	  possible	  relationship	  between	  Foxo	  and	  LRRK2	  has	  shown	  that	  overexpression	  of	  LRRK2	  can	  exacerbate	  Foxo-­‐mediated	  developmental	  defects.	  In	  
vitro	   kinase	   assays	  have	   also	   shown	   that	  human	  Foxo	   can	  be	  phosphorylated	  by	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LRRK2	  at	  S319	  (Kanao	  et	  al.	  2010).	  Endogenous	  phosphorylation	  at	  this	  residue,	  is	  increased	  by	  overexpression	  of	  LRRK2	  in	  WT	  and	  mutant	  flies,	  but	  not	  a	  triple	  KD	  form	   or	   when	   endogenous	   LRRK	   is	   knocked	   out.	   Further	   investigation	   into	  downstream	   mechanisms	   of	   possible	   LRRK2	   signaling,	   have	   shown	   that	   LRRK2	  induces	  expression	  of	  Hid,	  (the	  drosophila	  homolog	  of	  Bcl-­‐2	  family	  member	  Bim),	  which	  plays	  a	  mediatory	  role	  in	  apoptosis	  (Kanao	  et	  al.	  2010).	  	  	  Recent	  studies	  using	  manipulation	  of	  drosophila	  genetics	  have	  shown	  that	  LRRK2	  could	   be	   playing	   a	   role	   in	   the	   direct	   regulation	   of	   gene	   transcription	   and	  translation	  (Gehrke	  et	  al.	  2010).	  Using	  a	  microRNA	  (miRNA)	  reporter	  gene-­‐system,	  knockdown	   of	   LRRK	   in	   drosophila	  has	   been	   shown	   to	   cause	   decreased	   levels	   of	  RNA	   degradation	   through	   dysregulation	   of	   miRNA	   mediated	   degradation	  pathways.	   In	   this	   model,	   overexpression	   of	   kinase	   active,	   but	   not	   KD	   LRRK2	  decreases	   the	   protein	   levels	   of	   transcription	   factors	   E2F1	   and	   DP	   and	   reduces	  initiation	  of	  cell	  proliferation	  and	  p53-­‐dependent/independent	  apoptosis.	  E2Fs	  are	  activating	  factors	  which	  promote	  cell	  cycle	  G1/	  S	  transition	  (reviewed	  in	  Harbour	  
et	   al.	   2000).	   Similarly,	   overexpression	   and	   immunoprecipitation	   of	   LRRK2	   in	  Hek293T	  cells,	  and	  immunoprecipitation	  from	  drosophila	  head	  extracts,	  has	  shown	  that	  LRRK2	  can	  associate	  with	  the	  RNA	  silencing	  protein	  Argonaute.	  This	  suggests	  that,	   in	   drosophila	   at	   least,	   LRRK2	   may	   play	   an	   active	   role	   in	   RNA	   translation	  (Gehrke	   et	   al.	   2010).	   Studies	   reporting	   similar	   results	   in	   humans	   are	   yet	   to	   be	  published.	  	  
1.8.4	  LRRK2	  and	  α-­‐synuclein	  It	  has	  been	  suggested	  that	  the	  importance	  of	  LRRK2	  and	  α-­‐syn	  in	  the	  pathogenesis	  of	   genetic	   PD,	   points	   towards	   common	  pathways	   or	   functions	   for	   these	   proteins	  (Singleton,	  2005)	  an	  idea	  reinforced	  by	  both	  α-­‐syn	  and	  LRRK2	  being	  identified	  in	  genome	  wide	   association	   studies	   for	   idiopathic	  PD	   (Tan	  et	  al.	   2010,	   Satake	  et	  al.	  2009).	  Indeed,	  there	  is	  mounting	  evidence	  to	  suggest	  that	  this	  may	  be	  the	  case;	  it	  has	   been	   shown	   that	   α-­‐syn	   and	   LRRK2	   are	   co-­‐regulated	   in	   rodent	   striatum	  (Westerlund	   et	  al.	   2008),	   and	   overexpression	   of	  α-­‐syn	   and	   LRRK2	   in	   transgenic	  mice	   has	   shown	   that	   α-­‐syn	   accumulation	   and	   deposition	   is	   exacerbated	   by	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overexpression	   of	   LRRK2	   (Lin	   et	   al.	   2009).	   Ablation	   of	   LRRK2	   in	   this	   model	  reduced	   α-­‐syn	   pathology,	   although	   there	   was	   no	   evidence	   of	   a	   direct	  phosphorylation	   event	   (with	   the	   double	   transgenic	   displaying	   reduced	  phosphorylation	  of	  α-­‐syn).	  Overexpression	  of	  LRRK2	  in	  cell	  models	  has	  shown	  that	  expression	   of	   α-­‐syn	   may	   be	   regulated	   by	   LRRK2	   via	   involvement	   of	   the	   ERK	  pathway	   as	   increased	   expression	   of	   LRRK2	   linked	   to	   an	   upregulation	   of	   α-­‐syn	  (Carballo-­‐Carbajal	  et	  al.	  2010).	  	  	  Studies	   in	   mice	   have	   shown	   that	   α-­‐syn	   accumulation	   and	   deposition	   could	   be	  dependent	   on	   LRRK2	   expression	   (Lin	   et	   al.	   2009).	   Double	   transgenic	   mice	  overexpressing	  human	  LRRK2	  in	  WT	  and	  G2019S	  form,	  and	  α-­‐syn	  in	  WT	  and	  A53T	  form,	  show	  abnormal	  somatic	  accumulation	  of	  α-­‐syn	  that	   is	  not	  seen	   in	  single	  α-­‐syn	   or	   LRRK2	   transgenic	   mice.	   These	   double	   transgenic	   models	   also	   displayed	  fragmentation	   of	   the	   cis-­‐	   and	   trans-­‐Golgi,	   which	   was	   shown	   to	   correlate	   with	  somatic	   LRRK2	   accumulation.	   Solubility	   of	  βIII	   tubulin	  was	   decreased	   in	   double	  transgenic	  mice	  compared	  to	  single	  transgenic	  expressing	  α-­‐syn	  or	  LRRK2	  alone.	  Importantly,	  double	  transgenic	  mice	  showed	  neuronal	  death	  in	  the	  striatum,	  which	  was	   increased	   by	   about	   50%	   when	   compared	   to	   A53T	   overexpressing	   mice.	  Importantly,	   knockout	   of	   endogenous	   LRRK2	   was	   shown	   to	   ameliorate	   the	  pathological	   phenotypes	   and	   cell	   death	   observed	   in	   double	   transgenics	  overexpressing	  kinase-­‐active	  LRRK2.	  These	  experiments	  suggest	  that	  LRRK2	  may	  be	  mediating	  α-­‐syn	   induced	   changes	   in	   neurons,	   through	  mechanisms	   involving	  microtubule	  dynamics	  and	  stability	  (Lin	  et	  al.	  2009).	  	  
	  
1.8.5	  	  LRRK2	  and	  regulation	  of	  microtubules	  The	   presence	   of	   tau	   pathology	   in	   some	   familial	   LRRK2	   cases	   has	   prompted	  speculation	   that	   LRRK2	   may	   be	   involved	   with	   microtubule	   regulation.	   Indeed,	  there	  is	  accumulating	  evidence	  to	  suggest	  that	  LRRK2	  may	  play	  a	  role,	  either	  direct	  or	  regulatory,	   in	  cytoskeletal	  modeling	  and	  outgrowth.	  LRRK2	  interaction	  studies	  have	   consistently	   identified	   cytoskeletal	   proteins	   and	   related	   structural	  components,	  the	  first	  published	  LRRK2	  pull	  down,	  using	  overexpression	  in	  Hek293	  cells	  identified	  clathrin	  heavy	  chain,	  and	  to	  a	  lesser	  degree,	  vimentin	  as	  interactors	  
	  INTRODUCTION	  
	   58	  
of	  LRRK2	  (Dachsel	  et	  al.	  2007).	  Similarly,	  a	  glutathione-­‐S	  transferase-­‐tagged	  (GST)	  recombinant	   fragment	   consisting	   of	   the	   LRRK2	   ROC	   domain	   has	   been	   shown	   to	  interact	   directly	   with	   α/	   β-­‐tubulin	   heterodimers	   (Gandhi	   et	   al.	   2008).	   This	  interaction	  was	  also	  shown	  when	  endogenous	  mouse	  LRRK2	  was	  co-­‐purified	  with	  
β-­‐tubulin	  in	  brain	  and	  when	  LRRK2	  overexpression	  was	  switched	  on	  in	  inducible	  Hek293T	  cells	  (Gillardon,	  2009a,	  b).	  	  	  Studies	  to	  assess	  LRRK2	  kinase	  substrates,	  have	  again	  supported	  a	  role	  for	  LRRK2	  in	   cytoskeletal	   modeling.	   When	   the	   more	   active	   G2019S	   variant	   of	   LRRK2	   was	  incubated	   with	   protein	   extracted	   from	   whole	   mouse	   brain,	   it	   was	   shown	   that	  LRRK2	   can	  phosphorylate	   the	   actin/	  plasma	  membrane	   cross-­‐linker,	  membrane-­‐organizing	   extension	   spike	   protein	   (moesin)	   at	   a	   known	   threonine	  phosphorylation	  site,	  T558	  (Jaleel	  et	  al.	  2007).	  Moesin	  is	  a	  member	  of	  the	  so-­‐called	  ERM	  family	  of	  proteins,	  which	  are	  stereologically	  regulated	  by	  phosphorylation.	  In	  an	   unphosphorylated	   state,	   they	   have	   a	   closed,	   ‘inactive’	   conformation,	  which	   is	  reversed	  by	  addition	  of	  a	  phosphate	  to	  T558	  in	  the	  C-­‐terminal	  domain	  (Matsui	  et	  
al.	   1998).	   In	   mice,	   knock	   out	   of	   LRRK2	   has	   been	   shown	   to	   decrease	  phosphorylation	   of	   ERM	   proteins	   and	   inducible	   expression	   of	   G2019S	   causes	  accumulation	   of	   F-­‐actin	   in	   the	   filopodia	   of	   developing	   neurons	   and	   increased	  phosphorylation	  of	  ERM	  proteins	  (Parisiadou	  et	  al.	  2009).	  	  
Drosophila	  dendritic	  aborisation	  neurons	  overexpressing	  human	  LRRK2,	  have	  been	  shown	   to	   display	   shorter	   dendrite	   lengths	   and	   dendritic	   degeneration,	   which	   is	  more	  pronounced	  in	  G2019S,	  compared	  to	  WT,	  R1441C	  and	  G2385R	  mutants.	  In	  a	  subtype	  of	  these	  neurons,	  mislocalisation	  of	  tau	  has	  also	  been	  shown	  when	  G2019S	  but	  not	  WT	  is	  overexpressed	  (Lin	  et	  al.	  2009).	  In	  G2019S	  overexpressing	  models,	  levels	   of	   p-­‐tau	   (T212/S214)	   are	   increased,	   with	   mutation	   of	   this	   residue	   to	   an	  alanine	   shown	   to	   confer	   protection	   against	   LRRK2	   mediated	   neurogeneration.	  GSK3β	   is	   known	   to	   phosphorylate	   tau	   at	   this	   residue	   and	   overexpression	   of	   the	  
drosophila	   GSK3β	   homolog	   sgg	   also	   rescues	   DA	   neurons	   from	   LRRK2-­‐induced	  microtubule	   disruption	   and	   dendrite	   degeneration,	   suggesting	   that	   sgg	   may	   be	  mediating	  some	  of	  the	  effects	  of	  LRRK2	  mediated	  pathology	  in	  drosophila.	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Encouragingly,	  studies	   in	  mice	  have	  also	  reported	  changes	  to	  tau	  when	  LRRK2	  is	  overexpressed.	   BAC	   overexpressing	   human	   LRRK2,	   showed	   widespread	  mislocalisation	   of	   tau	   to	   cell	   bodies	   in	   G2019S	   mice,	   with	   WT	   LRRK2	  overexpressing	  mice	  showing	  a	  lower	  amount	  of	  tau	  accumulation	  in	  regions	  with	  highest	   LRRK2	   expression	   only.	   Again	   WT	   mice	   showed	   lower	   levels	   of	   tau	  accumulation	   than	  the	  G2019S	  mice,	  which	  was	   localised	   to	  regions	  with	  highest	  LRRK2	  expression.	  In	  G2019S	  mice,	  there	  was	  a	  marked	  and	  widespread	  increase	  in	   tau	  phosphorylation	  at	  S202	  and	  S262/356	  that	  was	  visible	   in	  mice	  aged	  over	  18	  months.	  Interestingly,	  when	  tau	  from	  G2019S	  was	  dephosphorylated,	  it	  showed	  a	  different	  migratory	  pattern	  than	  that	  from	  non-­‐transgenic	  mice,	  suggesting	  that	  LRRK2	  could	  be	  affecting	  post-­‐translational	  modification	  of	  tau,	  in	  ways	  other	  than	  phosphorylation	  (Melrose	  et	  al.	  2010).	  	  	  Regulatory	  roles	  for	  LRRK2	  in	  cytoskeletal	  modeling	  have	  been	  shown	  in	  a	  number	  of	  studies.	  Y2H	  screens	  have	  identified	  the	  DVLs	  as	  possible	  interactors	  of	  the	  ROC	  domain	  (Sancho	  et	  al.	  2009).	  The	  DVLs	  signal	  as	  part	  of	  the	  Wnt	  signaling	  cascade	  in	  numerous	  processes,	  such	  as	  neurite	  outgrowth	  during	  development	  and	  planar	  cell	   polarity	   during	   gastrulation	   (Sussman	   et	  al.	   1994).	   Of	   note,	   GSK3β	   and	   CK1,	  known	  to	  phosphorylate	  α-­‐syn	  and	  tau	  respectively,	  are	   involved	   in	  this	  cascade.	  Studies	  to	  identify	  LRRK2	  interactors	  using	  endogenous	  immunoprecipitation	  have	  pulled	  down	  many	  components	  of	  the	  actin	  cytoskeleton.	  Immunoprecipitation	  of	  LRRK2	  from	  NIH3T3	  compared	  to	  pulldowns	  from	  cells	  treated	  with	  LRRK2	  RNAi,	  have	   identified	   interactions	   with	   actin	   and	   numerous	   actin-­‐asociated	   proteins,	  including	  F-­‐actin	  capping	  protein	  subunits,	  myosin	  and	  tropomyosin	  isoforms	  and	  calmodulin.	   Co-­‐sedimentation	   assays	   showed	   that	   LRRK2	   seems	   to	   bind	   F-­‐actin	  and	  furthermore,	  that	  knockdown	  of	  LRRK2	  in	  developing	  dopaminergic	  midbrain	  primary	  neurons,	  causes	  neurite	  shortening	  (Meixner	  et	  al.	  2011).	  	  	  Protein	   microarrays	   of	   SH-­‐SY5Y	   LRRK2	   knockdown	   cells	   have	   suggested	   a	   link	  between	   LRRK2,	   ARHGEF7	   and	   Cdc42	   (Haebig	   et	   al.	   2010).	   Recently,	   this	   study	  was	  expanded	  to	  examine	  possible	  functional	  roles	  for	  these	  proteins	  (Haebig	  et	  al.	  2010).	  It	  was	  shown	  that	  the	  GTP	  exchange	  factor	  ARHGEF7,	  and	  the	  Rho-­‐GTPase,	  Cdc42	  which	  are	  both	  involved	  in	  the	  cell	  division	  cycle	  by	  regulating	  actin	  motility	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during	  development	  (Meyer	  et	  al.	  2002),	  can	  co-­‐precipitate	  when	  overexpressed	  in	  Hek293T	   cells	   and	   when	   LRRK2	   is	   immunoprecipitated	   from	   mouse	   brain.	  Interestingly,	   despite	   assertion	   that	   LRRK2	   does	   not	   need	   a	   GEF	   due	   to	   its	  classification	   as	   a	   GAD	   (Gasper	   et	   al.	   2009)	   ARHGEF7	  was	   shown	   to	   double	   the	  efficiency	   of	   GTP	   hydrolysis	   by	   LRRK2.	  Most	   recently,	   protein	  microarrays	   have	  suggested	   an	   interaction	   between	   LRRK2	   and	   the	   STE	   kinases	   TAOK3,	   STK3,	  STK24,	   STK25.	   PKCζ	   was	   shown	   to	   bind	   LRRK2,	   but	   is	   not	   a	   kinase	   substrate,	  however	  in	  vitro	  kinase	  assays	  showed	  that	  PKCζ	  is	  able	  to	  phosphorylate	  LRRK2	  (Zach	  et	  al.	  2010).	  This	  study	  suggests	  that	  LRRK2	  may	  function	  upstream	  of	  tau,	  via	   interaction	  with	  TAOK/	  MARKK,	   the	  kinase	  upstream	  of	  microtubule	  affinity-­‐regulating	  kinase	  (MARK),	  which	  has	  been	  shown	  to	  prime	  tau	  for	  phosphorylation	  by	  other	  kinases	  (Timm	  et	  al.	  2006).	  	  Studies	  by	  collaborators,	  have	  shown	  that	  the	  β-­‐tubulin	  isoform	  TUBB5	  (Law	  and	  Harvey,	   unpublished)	   and	   dishevelled	   (DVL)	   isoforms	   1,	   2	   and	   3	   (Sancho	   et	   al.	  2009)	  can	  cause	  transcription	  factor	  binding	  when	  the	  ROC	  domain	  is	  used	  as	  bait	  in	   a	   Y2H	   screen.	   Previous	   studies	   have	   shown	   that	   LRRK2	   can	  phosphorylate	  β-­‐tubulin	   in	  vitro	  (Gandhi	  et	  al.	  2008,	  Gillardon	  2009a,	  b),	  and	  ROC	  binding	   to	  DVL	  proteins	   is	   thought	   to	  be	  disrupted	  by	   familial	  mutations	  (Sancho	  et	  al.	  2009).	  β-­‐tubulin	  is	  phosphorylated	  by	  a	  number	  of	  kinases	  including	  PKC	  (Chen	  et	  al.	  2002),	  Cdk1	  (Fourest-­‐Lieuvin	  et	  al.	  2006)	  and	  the	  β-­‐adrenergic	  receptor	  associated	  kinase	  GRK2	  (also	  called	  β-­‐ARK2)	  (Yoshida	  et	  al.	  2003)	  to	  regulate	  microtubule	  extension	  and	   cytoskeletal	   rearrangement.	   Extension	   and	   polymerisation	   is	   known	   to	   be	  dependent	   on	   GTP	   hydrolysis	   by	   the	   tubulins,	   therefore	   it	   is	   a	   possibility	   that	  interaction	  with	  the	  ROC	  domain	  serves	  some	  functional	  purpose.	  
	  The	  DVL	   proteins	   are	   also	   involved	   in	   cytoskeletal	   dynamics	   as	  members	   of	   the	  ‘wingless	  and	   int	   (Wnt)	  signalling	  pathway.	  This	  pathway	  was	   first	  discovered	   in	  
drosophila	   and	   controls	   planar	   cell	   polarity,	   with	   an	   involvement	   in	   neurite	  outgrowth.	   LRRK2	   has	   previously	   been	   implicated	   in	   neurite	   outgrowth,	   with	  overexpression	  of	  WT	  and	  G2019S	  LRRK2	  in	  primary	  neuronal	  cultures,	  resulting	  in	   a	   reduction	   in	   neurite	   length	   and	   branching.	   Knockdown	   of	   LRRK2	   has	   been	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shown	   to	   promote	   the	   opposite	   effect,	   with	   neurites	   demonstrating	   increased	  length	  and	  branching	  (Macleod	  et	  al.	  2006).	  	  	  As	   previously	   discussed,	   LRRK2	   mutation	   carriers	   show	   different	   pathologies;	  some	   post	   mortem	   brains	   show	   α-­‐syn	   deposition,	   some	   have	   TDP-­‐43	   positive	  inclusions,	  while	   others	   have	   tau	   pathology,	  with	   neurofibrillary	   tangles	   and	   tau	  positive	   neurites	   (Rajput	   et	   al.	   2006).	   Because	   of	   this,	   it	   has	   been	   suggested	   on	  many	   occasions	   that	   LRRK2	   could	   act	   at	   the	   intersection	   of	   these	   pathways,	  bringing	   together	  many	  different	   strands	  of	  neurodegenerative	  disease.	  The	  Wnt	  signaling	   pathway	   is	   a	   good	   candidate	   for	   linking	  many	   of	   these	   pathways,	  with	  CK1	   and	   GSK3β	   both	   involved	   in	   this	   signaling	   cascade.	   CK1	   is	   known	   to	  phosphorylate	   α-­‐syn	   and	   GSK3β	   is	   well	   known	   for	   phosphorylating	   the	  microtubule	   binding	   protein	   tau,	   with	   mutations	   in	   tau	   known	   to	   cause	  Alzheimer’s,	   linking	   PD	   with	   many	   other	   movement	   disorders	   such	   as	   PSP	   and	  Pick’s	   disease.	   Recent	   studies	   in	   drosophila	   have	   shown	   that	   overexpression	   of	  LRRK2	  can	  result	  in	  recruitment	  of	  GSK3β.	  The	  DVL	  proteins	  interact	  directly	  with	  both	  CK1	  and	  GSK3β	   (Sakanaka	  et	  al.	  2000)	  suggesting	  a	  possible	  mechanism	  for	  linking	  α-­‐syn	  and	  tau	  pathology.	  	  Although	  the	  exact	  role	  of	  LRRK2	  is	  currently	  unknown,	  the	  studies	  that	  have	  been	  published	  to	  date	  are	  starting	  to	  converge	  with	  the	  publication	  of	  more	  data.	  The	  discovery	   that	   LRRK2	   interacts	   with	   14-­‐3-­‐3	   (Dzamko	   et	   al.	   2010,	   Nichols	   et	   al.	  2010,	  Li	  X.	  et	  al.	  2011)	  suggests	   that	  binding	  partners	  of	   this	  protein	   likely	   to	  be	  numerous,	  as	  14-­‐3-­‐3	   is	  known	  to	   function	   in	  a	  wide	  range	  of	   signaling	  pathways	  (Bridges	  et	  al.	  2005).	  In	  this	  case,	  the	  physiological	  role	  of	  LRRK2	  is	  also	  likely	  to	  span	  a	  wide	  range	  of	  functions.	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1.9	  	  EXPERIMENTAL	  AIMS	  The	  discovery	  that	  LRRK2	  is	  a	  cause	  of	  autosomal	  dominant	  PD,	  has	  provided	  an	  opportunity	   to	   investigate	   the	   pathogenesis	   of	   this	   form	   of	   the	   disease	   from	   a	  “bottom-­‐up”	   perspective.	   LRRK2	   is	   a	   good	   target	   for	   investigation,	   as	   PARK8-­‐linked	   PD	   is	   indistinguishable	   from	   sporadic	   PD	   and	   as	   such	   perhaps	   even	   a	  candidate	  for	  therapeutic	  intervention	  in	  sporadic	  PD.	  A	  reductionist	  approach	  to	  LRRK2	  function	  poses	  intrinsic	  questions	  about	  the	  regulation	  of	  this	  protein	  due	  to	   its	   domain	   structure,	   as	   well	   as	   its	   regulation	   by	   other	   proteins.	   The	   multi-­‐domain	  structure	  of	  LRRK2	  with	  both	  enzymatic	  and	  interaction	  domains,	  makes	  it	  apparent	   that	   there	   are	   many	   layers	   of	   regulation	   controlling	   the	   functional	  outputs	  of	  this	  protein.	  	  By	  understanding	  how	  LRRK2	  works	  on	  a	  molecular	  level	  therefore,	  we	  can	  slowly	  piece	  together	  how	  this	  protein	  controls	  its	  outputs	  and	  build	  on	  this	  knowledge	  with	  the	  intended	  result	  of	  perhaps	  understanding	  more	  about	  PD	  mechanisms	  in	  general.	  To	  this	  end,	  work	  done	  in	  this	  thesis	  was	  focused	  on	  three	  levels	  of	  LRRK2	  regulation	  and	  function,	  namely	  	   1) Understanding	  the	  factors	  controlling	  LRRK2	  dimer	  formation.	  2) Investigating	  the	  regulation	  of	  kinase	  activity.	  3) Identification	   and	   characterisation	   of	   LRRK2	   interacting	   proteins	   and	  kinase	  substrates.	  	  These	  issues	  were	  examined	  in	  terms	  of	  both	  WT	  and	  mutant	  LRRK2	  functioning.	  To	  do	  this,	  a	  number	  of	  models	  of	  LRRK2	  function	  have	  been	  used.	  The	  majority	  of	  studies	   looking	   at	   internal	   regulation	   of	   LRRK2	   kinase	   activity	   have	   been	  performed	   in	   protein	   immunoprecipitated	   from	   cells	   and	   likely	   have	   some	  interacting	  proteins	  present.	  In	  this	  case	  it	  is	  hard	  to	  differentiate	  intrinsic	  LRRK2	  enzymatic	  activity,	   from	  activity	  dependent	  on	  activation	  and	  promoted	  by	  other	  interacting	  proteins.	  To	  address	  this	  issue,	  recombinant	  LRRK2	  has	  been	  used	  as	  a	  model	   of	   intrinsic	   LRRK2	   activity.	   As	   this	   protein	   has	   undergone	   affinity	  purification	   under	   conditions	   more	   stringent	   than	   those	   used	   when	  immunoprecipitating	   overexpressed	   protein,	   there	   is	   less	   chance	   of	   LRRK2	  complexes	   being	   intact.	   To	   model	   endogenous	   LRRK2	   complex	   formation,	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fibroblasts	   taken	   from	   LRRK2	  mutation	   carriers	   with	   PD	   and	   their	   non-­‐affected	  siblings	  were	  used.	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2.1	  	  MATERIALS	  
	  2.1.1	  	  Buffers	  and	  solutions	  Pre-­‐made	  buffers	  are	  listed	  according	  to	  their	  manufacturer.	  For	  all	  other	  buffers,	  components	   were	   purchased	   from	   Sigma	   (unless	   otherwise	   stated)	   and	   are	   of	  molecular	  biology	  grade.	  	  
-­‐1X	  Anode	  buffer	  (Invitrogen).	  Contains	  50	  mM	  BisTris,	  50	  mM	  Tricine,	  pH	  6.8).	  
-­‐1X	   BlueNative	   transfer	   buffer	   (National	   Diagnostics).	   (25	   mM	   Tris,	   192	   mM	  glycine,	  20%	  (v/v)	  methanol,	  0.1%	  (w/v)	  sodium	  dodecyl	  sulfate	  (SDS)).	  
-­‐Cell	  lysis	  buffer	  (Cell	  signaling).	  Contains	  20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  150	  mM	  NaCl,	  1	  mM	  Na2EDTA,	  1	  mM	  EGTA,	  1%	  Triton,	  2.5	  mM	  sodium	  pyrophosphate,	  1	  mM	  β-­‐glycerophosphate,	  1	  mM	  Na3VO4,	  1	  µg/ml	  leupeptin.	  
-­‐5X	   Centrifuge	   buffer.	   Contains	   2.5%	   (v/v)	   Triton	   X-­‐100,	   250	  mM	   HEPES	   (pH	  7.4),	  450	  mM	  NaCl,	  10mM	  DTT.	  
-­‐1X	   Dark	   blue	   cathode	   buffer	   (Invitrogen).	   Contains	   50	   mM	   BisTris,	   50	   mM	  Tricine,	  pH	  6.8,	  0.02%	  (w/v)	  Coomassie	  G-­‐250.	  
-­‐Destain	  solution.	  50%	  (v/v)	  methanol,	  10%	  (v/v)	  acetic	  acid.	  -­‐6X	  DNA	  loading	  buffer.	  Contains	  30%	  glycerol	  (v/v),	  0.25%	  (w/v)	  bromophenol	  blue.	  
-­‐HEPES	  buffer.	  Contains	  150	  mM	  NaCl,	  20	  mM	  HEPES,	  pH	  7.4	  and	  5	  mM	  MgCl2.	  
-­‐HiSalt	  wash	  buffer.	  Contains	  1%	  (v/v)	  Triton	  X-­‐100,	  500mM	  NaCl	  made	  up	  in	  1X	  PBS.	  
-­‐Fixing	  solution.	  Contains	  40%	  (v/v)	  methanol,	  10%	  (v/v)	  acetic	  acid.	  
-­‐Kinase	   buffer	   (Cell	   signaling).	   Contains	   25	   mM	   Tris-­‐HCl	   (pH	   7.5)	   5	   mM	   β-­‐glycerophosphate,	  2	  mM	  dithiothreitol	  (DTT),	  0.1	  mM	  Na3VO4,	  10	  mM	  MgCl2.	  
-­‐4X	   LDS	   loading	   buffer	   (Invitrogen).	   Contains	   40%	   (v/v)	   glycerol,	   4%	   (w/v)	  lithium	   dodecyl	   sulfate	   (LDS),	   4%	   (v/v)	   Ficoll-­‐400,	   0.8	  M	   triethanolamine-­‐Cl	   pH	  7.6,	   0.025%	   (w/v)	   phenol	   red,	   0.025%	   (w/v)	   Coomassie	   G-­‐250,	   2mM	   EDTA	  disodium.	  
-­‐1X	   Light	   blue	   cathode	   buffer	   (Invitrogen).	   Contains	   50	   mM	   BisTris,	   50	   mM	  Tricine,	  pH	  6.8,	  0.002%	  	  (w/v)	  Coomassie	  G-­‐250.	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-­‐1X	  MES	   running	   buffer	   (Invitrogen).	   	  Contains	  50	  mM	  Tris	  base,	  50	  mM	  3–(N-­‐Morpholino)	  propanesulfonic	  acid,	  1	  mM	  EDTA,	  0.01%	  SDS	  at	  pH	  7.3.	  
-­‐Phosphate	  Buffered	  Saline	  (PBS).	  In	  tablet	  form.	  When	  dissolved	  contains	  0.14	  M	  NaCI,	  0.01	  M	  PO4	  Buffer,	  3mM	  KCI.	  
-­‐PBS-­‐Tween	  (PBST).	  1X	  PBS,	  supplemented	  with	  0.001%	  (v/v)	  Tween-­‐20.	  
-­‐1X	  TAE	  buffer.	  Contains	  40	  mM	  Tris	  acetate,	  1	  mM	  EDTA.	  
-­‐1X	  TLC	  Buffer.	  1.2M	  Formic	  acid,	  1M	  LiCl.	  
-­‐1X	  Transfer	  buffer	  (National	  Diagnostics).	  Contains	  25	  mM	  Tris,	  192	  mM	  glycine,	  20%	  (v/v)	  methanol.	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2.1.2.	  	  Cell	  culture	  
2.1.2.1	  	  Cell	  lines	  used	  in	  this	  thesis	  	  Numerous	  cell	  lines	  have	  been	  used	  for	  the	  work	  done	  in	  this	  thesis.	  As	  a	  model	  of	  endogenous	   LRRK2,	   human	   fibroblasts	   were	   taken	   from	   familial	   PD	   patients	  carrying	  G2019S	  R1441G	   and	  Y1699C	  heterozygous	  mutations	   and	   compared	   to	  age	  and	  sex	  matched,	  genetically	  linked	  controls	  (see	  Table	  2.1).	  	  
Table	  2.1.	  Details	  of	  patient	  fibroblasts	  used	  for	  this	  study.	  All	  cells	  were	  taken	  from	   females	   to	   minimize	   sex	   differences	   and	   have	   an	   average	   age	   of	   62	   years	  ±10.17	   years.	   Both	   controls	   are	   non-­‐affected	   siblings	   of	   the	   G2019S	   or	   R1441G	  mutation	  carriers.	  	  	  	  For	   overexpression	   and	   immunoprecipitation	   of	   LRRK2	   protein,	   Hek293T	   cells	  were	  used.	  Hek293T	  cells	  have	  been	  used	  successfully	  in	  the	  literature	  to	  express	  LRRK2	   from	   plasmids	   and	   as	   such,	   have	   been	   used	   in	   these	   studies	   to	   generate	  tagged	  forms	  of	  LRRK2	  for	  immunoprecipitation.	  To	  examine	  the	  expression	  levels	  of	  LRRK2	  in	  various	  laboratory	  cell	  types,	  three	  other	  adherent	  human	  lines	  were	  also	  used,	  namely	  HT1080i,	  a	   fibrosarcoma	   line,	   the	  neuroblastoma	   line	  SH-­‐SY5Y	  and	  the	  1321N1	  astrocytoma	  line.	  All	  non-­‐primary	  cell	  lines	  were	  purchased	  from	  ATCC.	  
Code	   Sex	   Phenotype	   Details	   D.O.B	   Age	  at	  biopsy	   Mutation	  found	  
A	   F	   Unaffected	   Sister	  of	  D	  	   	  unknown	   70	   Unaffected	  
B	   F	   Unaffected	   Sister	  of	  C	   28/03/1958	   50	   Unaffected	  
C	   F	   PD	   Sister	  of	  B	   28/05/1956	   52	   LRRK2	  G2019S	  
D	   F	   PD	   Sister	  of	  A	   	  unknown	   67	   LRRK2	  R1441G	  
E	   F	   PD	   Unrelated	   04/11/0936	   71	   LRRK2	  Y1699C	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2.1.2.3	  	  Reagents	  All	  cell	  culture	  reagents	  were	  purchased	  from	  Invitrogen	  unless	  otherwise	  stated.	  	  -­‐Complete	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM).	   	   1X,	   contains	   sodium	  pyruvate,	  phenol	  red,	  4.5g/L	  D-­‐glucose	  and	  4mM	  L-­‐glutamine.	  Supplemented	  with	  10%	  (w/v)	  Fetal	  Bovine	  Serum	  (FBS).	  -­‐DMSO,	  sterile	  filtered	  (Sigma).	  -­‐Dulbecco’s	  PBS	  (Without	  Ca	  and	  Mg.	  Without	  Phenol	  red).	  -­‐FBS,	  South	  American	  origin	  (heat-­‐inactivated).	  -­‐1X	  TryPLE	  EXPRESS,	  in	  1X	  DPBS,	  1mM	  EDTA.	  Contains	  phenol	  red.	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2.1.3	  	  Molecular	  biology	  
2.1.3.1	  	  Primers	  and	  Constructs	  Full-­‐length	   LRRK2	   plasmids	   with	   a	   2X	   N-­‐terminal	   myc-­‐tag	   (N-­‐myc-­‐LRRK2	  hereafter)	   were	   used	   for	   all	   experiments.	   Plasmids	   were	   kindly	   donated	   by	   Dr	  Mark	   Cookson	   (Cell	   biology	   and	   expression	   unit,	   NIH	   laboratories,	   Bethesda).	  Expression	   of	   these	   plasmids	   is	   driven	   by	   a	   pCMV	   promoter	   and	   a	   kanamycin	  resistance	   gene	   is	   also	   contained	   in	   the	   construct.	   KD	   forms	   of	   the	   plasmid	  containing	  the	  triple	  K1906A/D1994A/D2017A	  mutation	  were	  also	  used.	  
	  
2.1.3.2	  	  Oligonucleotides	  LRRK2	   PCR	   primers	   were	   designed	   by	   the	   primer	   design	   website	  http:\www.ncbi.nlm.nih.gov/tools/primer-­‐blast.	  All	  primers	  were	  designed	  across	  exon-­‐exon	  boundaries	   to	  ensure	  any	  contaminating	  genomic	  DNA	  present	  would	  not	  be	  amplified.	  	  	  
Primer	   Sequence	   Application	   Product	  	  LRRK2	  forward:	  LRRK2	  reverse:	   5’-­‐TCAATATAAAGGCTCGCGCT-­‐3’	  5’-­‐TACAAAGCCACTTGGGTTCC-­‐3’	   PCR	   507	  bps	  	  GAPDH	  forward:	  GAPDH	  reverse:	   5’-­‐CCATGGCACCGTCAAGGCTGA-­‐3’	  5’-­‐GCCAGTAGAGGCAGGGATGAT-­‐3’	   PCR	   469	  bps	  M1947A	  Forward:	  M1947A	  Reverse:	   5’	  CCCGGATGTTGGTGGCAGAGTTAGCCTCCAAG-­‐3’	  5'	  CTTGGAGGCTAACTCTGCCACCAACATCCGGG-­‐3’	   Mutagenesis	   N/A	  
Table	  2.2.	  Primers	  used	  for	  DNA	  amplification.	  PCR	  primers	  were	  synthesized	  by	  MWG	  Operon	  and	  purified	  by	  HPSF.	  Primers	  for	  mutagenesis	  were	  synthesized	  by	  MWG	  Operon	  and	  purified	  using	  HPLC.	  Bases	  corresponding	  to	  the	  amino	  acid	  change	  for	  mutagenesis	  primers	  are	  marked	  in	  red.	  	  The	   sequence	   for	   GAPDH	   primers	   was	   taken	   from	   Poomthavorn	   et	   al.	   (2009).	  Mutagenesis	  primers	  were	  designed	   to	   substitute	  LRRK2	  M1947	  with	  an	  alanine	  residue,	  using	  the	  primer	  design	  program	  at	  	  	  http://www.bioinformatics.org/primerx/.	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Primer	  parameters	  were	  set	  so	  that,	  -­‐ GC	  content	  >40%,	  -­‐ Primer	  should	  terminate	  in	  >1	  C/G	  bases,	  -­‐ Length	  should	  be	  between	  25	  and	  45	  bases,	  -­‐ Melting	  temperature	  should	  be	  close	  to	  or	  above	  78oC.	  	  
2.1.3.3	  	  Taqman	  probes	  	  Pre-­‐optimised	  probes	  for	  LRRK2	  and	  the	  housekeeper	  β-­‐Actin,	  were	  selected	  from	  the	   Applied	   Biosystems	   website	   www.appliedbiosystems.com	   (see	   Table	   2.3).	  These	   assays	   were	   produced	   with	   different	   fluorescent	   labeling,	   so	   that	   both	  reactions	  could	  be	  performed	  in	  a	  single	  well	  and	  are	  the	  recommended	  probes	  for	  each	  gene.	  	  
Table	  2.3.	  Taqman	  probes	  chosen	  for	  amplification	  of	  LRRK2	  and	  GAPDH.	  	  








length	  Hs00411194_m1	   44	  and	  45	   LRRK2-­‐	  Kinase/WD40	   FAM-­‐	  Emission	  520nm	   90bp	  Hs01597125_s1	   Exon	  1	   β-­‐Actin	   VIC-­‐	  Emission	  552nm	   132bp	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-­‐2-­‐Propanol	  (Molecular	  biology	  grade-­‐	  VWR).	  -­‐Stbl3	  chemically	  competent	  E-­‐Coli	  (Invitrogen).	  -­‐Taqman	  gene	  expression	  master	  mix	  (2X-­‐	  Applied	  Biosystems).	  -­‐TOP10	  chemically	  competent	  E-­‐Coli	  (Invitrogen).	  	  
2.1.3.5	  	  DNA	  standards	  DNA	  ladder	  standards	  were	  purchased	  from	  Promega.	  Bands	  ranged	  from	  250	  to	  10,000	  base	  pairs.	  	  -­‐1kb	  DNA	   ladder	   (DNA	  concentration	  0.1µg/µl	   in	  10mM	  Tris-­‐HCl	   (pH	  7.4),	   1mM	  EDTA).	  
	  
2.1.3.6	  	  Kits	  for	  DNA/RNA	  extraction	  and	  amplification	  Kits	  were	  purchased	  from	  Qiagen	  unless	  otherwise	  stated.	  	  -­‐Accuprime	  Pfx	  Supermix	  (Invitrogen).	  -­‐HiSpeed	  Maxiprep	  kit.	  -­‐Miniprep	  kit.	  -­‐QiAshredder	  cell	  homogenization	  kit.	  -­‐QuikChange	  XL	  mutagenesis	  kit	  (Stratagene).	  -­‐RNeasy	  Plus,	  RNA	  extraction	  kit.	  -­‐Superscript	  III	  First	  Strand	  Synthesis	  Supermix	  (Invitrogen).	  
	  
2.1.3.7	  	  Transfection	  -­‐DMEM,	  serum	  free.	  Contains	  sodium	  pyruvate,	  phenol	  red,	  4.5g/L	  D-­‐glucose	  and	  4	  mM	  L-­‐glutamine	  (Invitrogen).	  	  -­‐Fugene	  HD	  (Roche).	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2.1.4.	  	  	  Biochemical	  assays	  
2.1.4.1	  	  Protein	  extraction	  and	  purification	  	  Reagents	  were	  purchased	  from	  Sigma	  unless	  otherwise	  stated.	  	  -­‐Anti-­‐myc	  -­‐agarose	  (clone	  9E10).	  -­‐Cell	  lysis	  buffer	  (Cell	  signaling).	  -­‐cOmplete	  protease	  inhibitor	  tablets	  (Roche).	  -­‐Glutathione-­‐agarose.	  Beads	  were	  reconstituted	  in	  1X	  PBS.	  -­‐HALT	  phosphatase	  inhibitor	  (Pierce).	  -­‐Protein	  G-­‐Sepharose	  beads.	  
	  
2.1.4.2	  	  Recombinant	  Protein	  The	   following	  recombinant	  GST-­‐tagged	  proteins	  were	  purchased	   from	  Invitrogen	  and	  are	  guaranteed	  >80%	  purity.	  Contained	  in	  50	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  0.5	  mM	  EDTA,	  0.02%	  (w/v)	  Polysorbate	  20,	  2	  mM	  DTT,	  50%	  (v/v)	  glycerol.	  	  -­‐RIPK5	  -­‐LRRK2,	  wild	  type.	  -­‐LRRK2,	  D1994A.	  -­‐LRRK2,	  G2019S.	  -­‐LRRK2,	  I2020T.	  -­‐LRRK2,	  R1441C.	  -­‐LRRK2,	  Y1699C	  .	  	  LRRK2	  purchased	  from	  Invitrogen	  is	  lacking	  the	  N-­‐terminus	  to	  residue	  970	  and	  is	  fused	  instead	  to	  a	  GST-­‐tag	  (see	  Figure	  2.1).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  2.1.	  Linear	  representation	  of	  the	  ΔN-­‐LRRK2	  recombinant	  protein.	  GST-­‐tagged	  LRRK2,	  spanning	  residues	  970-­‐2527,	  was	  expressed	  in	  Sf9	  cells.	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The	  following	  recombinant	  GST-­‐tagged	  proteins	  were	  purchased	  from	  Abnova	  and	  are	  contained	  in	  50	  mM	  Tris-­‐HCI,	  10	  mM	  reduced	  Glutathione,	  pH	  8.0.	  	  -­‐DVL2.	  -­‐DVL3.	  -­‐TUBB5.	  
	  
2.1.4.3	  	  Kinase	  assays	  and	  Radiolabelling	  The	  following	  reagents	  were	  purchased	  from	  Sigma	  unless	  otherwise	  stated.	  	  -­‐100mM	  ATP.	  In	  H2O	  (adjusted	  to	  pH	  7	  with	  Tris-­‐base).	  -­‐32P	  γ-­‐labelled	  ATP,	  500µCi	  at	  10mCi/ml.	  In	  50mM	  Tricine	  pH	  7.6	  solution	  (Perkin	  
Elmer).	  -­‐G50	  spin	  columns	  (GE	  Healthcare).	  -­‐10X	  Kinase	  buffer	  (Cell	  signaling).	  -­‐Myelin	  Basic	  protein,	  from	  mouse	  (guaranteed	  purity	  ≥95%).	  Lyophilized	  powder	  reconstituted	  in	  1X	  PBS	  to	  200µg/ml.	  -­‐Nucleoside	  Diphosphate	  Kinase	  (NDPK).	  Produced	  in	  bakers	  yeast.	  	  -­‐N6(2-­‐Benzyl)-­‐ADP	  10mM.	  Sodium	  salt	  in	  aqueous	  solution	  (Biolog).	  -­‐N6(2-­‐Benzyl)-­‐ATP	  10mM.	  Sodium	  salt	  in	  aqueous	  solution	  (Biolog).	  -­‐N6(2-­‐Phenylethyl)-­‐ADP	  10mM.	  Sodium	  salt	  in	  aqueous	  solution	  (Biolog).	  	  -­‐N6(2-­‐Phenylethyl)-­‐ATP	  10mM.	  Sodium	  salt	  in	  aqueous	  solution	  (Biolog).	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2.1.5	  	  Western	  blotting	  All	  reagents	  were	  purchased	  from	  Invitrogen	  unless	  otherwise	  stated.	  	  
2.1.5.1	  	  SDS-­‐PAGE	  electrophoresis	  -­‐NuPAGE	  Bis-­‐Tris	  gels.	  4-­‐12%	  polyacrylamide.	  10	  well	  1.5mm	  wide.	  -­‐NuPAGE	  Bis-­‐Tris	  gels.	  4-­‐12%	  polyacrylamide.	  15	  well	  1.5mm	  wide.	  
	  
2.1.5.2	  	  BlueNative	  PAGE	  electrophoresis	  -­‐NativePage	  Bis-­‐Tris	  gels.	  3-­‐12%	  polyacrylamide.	  10	  well	  gels	  1.0mm	  wide.	  -­‐NativePage	  Bis-­‐Tris	  gels.	  4-­‐16%	  polyacrylamide.	  10	  well	  gels	  1.0mm	  wide.	  -­‐25%	  DDM	  (w/v).	  Made	  up	  in	  1X	  PBS.	  -­‐Sample	  Preperation	  Kit	  (DDM,	  Coomassie	  G-­‐250).	  -­‐Novex	  prestained	  standard.	  	  
2.1.5.3	  	  Protein	  standards	  Protein	  standards	  were	  purchased	  from	  Invitrogen	  in	  a	  pre-­‐mixed	  preparation.	  	  	  -­‐NativeMark	  unstained	  protein	  standard	  (range	  20-­‐1236	  kDa).	  -­‐Novex	  prestained	  protein	  standard	  (range	  3.5-­‐260	  kDa).	  	  
2.1.5.4	  	  Gel	  staining	  -­‐Acetic	  acid	  (glacial)	  100%.	  (VWR).	  -­‐Gelcode	  Blue	  Stain	  Reagent	  (Pierce).	  -­‐Methanol,	  HPLC	  grade	  (VWR).	  -­‐SilverXpress	  silver	  staining	  kit.	  	  
2.1.5.5	  	  Western	  blotting	  and	  transfer.	  -­‐CL-­‐Xposure	  photosensitive	  film	  (Pierce)	  -­‐Nitrocellulose	  membrane.	  0.45µm	  pore	  size	  (Pierce).	  -­‐Non-­‐fat	  dried	  milk	  powder	  (Marvel).	  -­‐Immobilon-­‐P,	   polyvinylidene	   fluoride	   (PVDF)	   membrane.	   0.45µm	   pore	   size	  (Millipore).	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-­‐Superblock	  T-­‐20	  (Pierce).	  -­‐Tween-­‐20	  (Sigma).	  -­‐Whatman	  Chromatography	  paper.	  -­‐Western	  blotting	  substrate	  (Electrochemical	  detection	  kit-­‐	  Pierce).	  
	  
2.1.5.6	  	  Glycerol	  gradient	  centrifugation	  Reagents	  and	  proteins	  were	  purchased	  from	  Sigma	  unless	  otherwise	  stated.	  	  -­‐Glycerol,	  molecular	  biology	  grade.	  -­‐Catalase,	  from	  bovine	  liver.	  Lyophilized	  powder,	  reconstitiuted	  in	  1X	  PBS	  (2,000-­‐5,000	  U/mg).	  -­‐L-­‐Lactic	   Dehydrogenase	   (LDH),	   from	   Lactobacillus	   leichmanii.	   Lyophilized	  powder,	  reconstituted	  in	  PBS	  (150-­‐300	  U/mg).	  -­‐Ferritin,	  from	  human	  spleen	  (type	  V).	  In	  0.15	  M	  NaCl,	  10	  mM	  Tris,	  pH	  8.0,	  contains	  0.1%	  (w/v)	  sodium	  azide.	  -­‐Bovine	   Serum	   Albumin	   (BSA).	   Guaranteed	   purity	   ≥98%.	   Lyophilized	   powder,	  reconstituted	  in	  1X	  PBS.	  -­‐Lambda	  phosphatase	   (NEB).	   Contained	   in	   50	  mM	  HEPES,	   100	  mM	  NaCl,	   0.1	  mM	  MnCl2,	   2	  mM	  Dithiothreitol,	   0.1	  mM	  EGTA,	   50%	  (w/v)	  Glycerol,	   0.01%	  (w/v)	  Brij	  35,	  pH	  7.5	  (400,000	  U/ml).	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2.2	  METHODS	  
2.2.1	   	  Cell	  culture	  
2.2.1.1	  Isolation	  of	  human	  fibroblasts	  Skin	   punch	   biopsies	  were	   performed	   by	  Dr.	  Daniel	  Healy	   on	   the	   forearm	  of	   two	  control	   patients	   and	   one	   individual	   each	   with	   G2019S,	   R1441G	   and	   Y1699C	  mutations	  in	  LRRK2	  (see	  Table	  2.1).	  Isolation	  of	  human	  fibroblasts	  was	  performed	  by	  Dr.	  Jan-­‐Willem	  Taanman	  at	  the	  Royal	  Free	  Hospital,	  London.	  	  	  
2.2.1.2	  	  	  Maintenance	  and	  passage	  of	  cells	  in	  culture	  All	  cell	  culture	  was	  performed	  in	  a	  class	  II	  safety	  cabinet	  using	  aseptic	  techniques.	  Cell	  lines	  were	  cultured	  in	  DMEM	  supplemented	  with	  10%	  FBS	  at	  37oC	  in	  a	  5%	  CO2	  humidified	   atmosphere.	   Media	   was	   replaced	   every	   3-­‐4	   days	   and	   cells	   passaged	  when	  ~95%	  confluent.	  Cells	  were	  grown	   in	   flasks	   for	  maintenance	  and	  split	   into	  dishes	   to	  perform	  experiments.	  When	  cells	   reached	  ~90%	  confluency,	  passaging	  was	  performed.	  Media	  was	  removed	  by	  pipetting	  and	  cells	  washed	  once	  with	  DPBS	  to	  remove	  residual	  media.	  Tryple-­‐Express	  was	  added	  and	  cells	   incubated	  at	  37oC	  for	   5-­‐10	   mins	   to	   facilitate	   detachment	   by	   the	   enzyme.	   After	   this	   time	   an	   equal	  amount	   of	   complete	   DMEM	   was	   added	   to	   quench	   enzyme	   activity	   and	   cell-­‐containing	  media	  removed	  from	  flasks.	  Cells	  were	  pelleted	  at	  1000	  x	  g	  in	  a	  Hettich	  Rotina	   35	   benchtop	   centrifuge	   at	   RT	   for	   3	   mins	   and	   the	   supernatant	   removed.	  Complete	  DMEM	  was	   added	   and	   cells	   resuspended	   in	   an	   appropriate	   amount	   of	  media.	  	  
2.2.2	  Molecular	  biology	  
2.2.2.1	  	  RNA	  extraction	  Cell	  pellets	  were	  obtained	  by	  trypsinisation	  of	  cells	  from	  one	  well	  of	  a	  6	  well	  plate	  for	   each	   condition.	  Pellets	  were	  washed	   twice	   in	  PBS,	   before	  RNA	  was	   extracted	  using	   the	   RNeasy	   Plus	   kit	   according	   to	  manufacturers	   instructions.	   Briefly,	   cells	  were	   lysed	   in	   lysis	   buffer	   (RNeasy	   kit)	   and	   cells	   homogenised	   by	   centrifugation	  through	   QIashredder	   columns.	   RNA	   was	   bound	   to	   the	   columns	   provided	   and	  contiminants	   removed	   by	   washing.	   RNA	   was	   eluted	   and	   integrity	   subsequently	  checked	  by	  analysis	  on	  an	  Agilent	  6000	  nanochip	  by	  Miss	  Daniah	  Trabzuni.	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2.2.2.2	  	  Reverse	  Transcriptase-­‐PCR	  1µg	  of	  RNA,	  ascertained	  by	  Nanodrop	  analysis,	  was	  used	  for	  each	  reaction.	  cDNA	  was	   made	   using	   Superscript	   III	   First	   Strand	   Synthesis	   kit	   (Invitrogen)	   using	  random	  hexamer	  primers.	  Primers	  were	  mixed	  with	  DNA	  and	   incubated	  at	  65oC	  for	  5	  mins	  before	  cooling	  on	  ice	  and	  addition	  of	  the	  reaction	  mix	  containing	  dNTPs	  and	   the	  reverse-­‐transcriptase	  (RT-­‐PCR)	  enzyme.	  Cycling	  conditions	  are	  shown	   in	  Table	  2.4.	  	  	  	  	  	  	  	  
	  
Table	  2.4.	  Cycling	  conditions	  used	  for	  RT-­‐PCR.	  	  
	  







Time	   Temperature	  
	  5	  mins	   65oC	  
Cool	  on	  ice	  for	  1	  min	  
10	  mins	   25oC	  
50	  mins	   50oC	  
5	  mins	   85oC	  
Leave	  at	  4oC	  until	  needed	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Table	  2.5.	  PCR	  cycling	  conditions.	  PCR	  products	  were	  added	  to	  6X	  DNA	   loading	  dye	  and	  run	  on	  a	  0.8%	  agarose	  gel	  with	  ethidium	  bromide	  added	  at	  1:25,000	  to	  visualise	  DNA.	  Products	  were	  run	  at	  120V	   for	   40	   mins	   and	   visualized	   using	   a	   UVP	   transilluminator.	   LRRK2	   PCR	  products	   were	   normalized	   to	   GAPDH	   for	   each	   condition	   and	   quantified	   using	  ImageJ	  software	  downloaded	  from	  http://rsbweb.nih.gov/ij/.	  	  
	  






Table	  2.6.	  Cycling	  conditions	  used	  for	  Taqman	  quantitative-­‐PCR.	  
	  
Time	   Temperature	   No	  of	  cycles	  
5	  mins	   95oC	   X1	  
15	  secs	   95oC	   	  X35	  30	  secs	   60oC	  
45	  secs	   68oC	  
Leave	  at	  4oC	  until	  needed	  
Time	   Temperature	   No	  of	  cycles	  
2	  mins	   50oC	   X1	  
10	  mins	   95oC	   X1	  
15	  secs	   95oC	   X40	  
1	  min	   60oC	  
METHODS	  AND	  MATERIALS	  
	   79	  
2.2.2.5	  	  Mutagenesis	  Primers	   used	   for	   mutagenesis	   are	   detailed	   in	   Table	   2.2.	   Mutagenesis	   was	  performed	   using	   the	   XL	  Quikchange	  mutagenesis	   kit.	   125ng	   of	   primer	  was	   used	  with	   20ng	   of	   plasmid	   template.	   Reaction	   mixtures	   were	   prepared	   according	   to	  manufacturers	  instructions	  and	  PCR	  was	  performed	  in	  an	  Eppendorf	  Mastercycler	  Gradient	  PCR	  machine,	  using	  the	  cycling	  conditions	  detailed	  in	  Table	  2.7.	  	  	  	  	  	  
	  
	  
Table	  2.7.	  Cycling	  conditions	  for	  mutagenesis	  reaction.	  PCR	   products	   were	   cooled	   on	   ice	   and	   transformed	   into	   XL10-­‐Gold	   chemically	  competent	   cells	   according	   to	   manufacturer’s	   instructions.	   Transformed	   E-­‐Coli	  were	  plated	  on	  LB	  Agar	  supplemented	  with	  100mM	  D-­‐glucose	  and	  grown	  for	  16	  h	  at	  37oC.	  	  
	  
2.2.2.6	  Plasmid	  purification	  Clones	  were	   picked,	   grown	   in	   15ml	   LB	   broth	   supplemented	  with	   10%	   (v/v)	   1M	  glucose	   and	   kanamycin	   100mg/ml	   at	   1:1000	   (v/v),	   purified	   and	   sequenced.	   The	  successful	   clone	   containing	   the	   relevant	  mutation	  was	   grown	   in	  600ml	  LB	  broth	  and	   purified	   using	   Qiagen	   HiSpeed	   maxiprep	   kit	   according	   to	   manufacturer’s	  instructions.	   Plasmids	   were	   digested	   in	   EcoRI	   for	   1	   h	   at	   37oC	   to	   ensure	   no	  rearrangements	   had	   occurred	   and	   run	   on	   a	   1%	   agarose	   gel	   prepared	   in	   TAE	   at	  120V	  for	  30	  mins,	  alongside	  a	  1kb	  ladder	  to	  allow	  for	  identification	  of	  band	  sizes.	  The	  plasmid	  sequence	  was	  digested	  in	  silico	  to	  verify	  correct	  fragment	  sizes	  using	  the	  following	  website	  	  http://tools.neb.com/NEBcutter2/index.php.	  	  	  
	  
Time	   Temperature	   No	  of	  cycles	  
1	  min	   95oC	   X1	  
50	  secs	   95oC	   	  X18	  50	  secs	   60oC	  
15	  mins	   68oC	  
7	  mins	   68oC	   X1	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2.2.3	  	  Biochemical	  assays	  
2.2.3.1	  	  Transfection	  Hek293T	   cells	   were	   seeded	   and	   grown	   to	   ~80%	   confluency	   in	   14cm2	   dishes	   in	  complete	   DMEM.	   Prior	   to	   transfection,	   DMEM	   was	   removed,	   cells	   washed	   with	  DPBS	   and	   serum-­‐free	   DMEM	   added.	   DNA-­‐Fugene	   HD	   complexes	   were	   made	  according	  to	  manifacturers	  at	  a	  ratio	  of	  1:3	  where	  20µg	  plasmid	  DNA	  was	  used	  for	  each	  plate	  with	  60µl	  Fugene	  HD.	  Complexed	  DNA	  was	  added	  drop-­‐wise	  to	  cells	  and	  left	  overnight	  before	  media	  was	  removed	  and	  replaced	  with	  complete	  DMEM.	  Cells	  were	  allowed	   to	   grow	   for	   a	   further	  24h	  before	   cells	  were	  harvested	  and	  protein	  extracted.	  	  
2.2.3.2	  	  Protein	  extraction	  and	  protein	  estimation	  Protein	  was	  extracted	  by	   scraping	   cells	   on	   ice	   into	  1X	   lysis	  buffer	   supplemented	  with	  protease	  inhibitors.	  Cells	  were	  left	  to	  lyse	  on	  ice	  for	  20	  mins	  with	  occasional	  vortexing	  and	  insoluble	  material	  removed	  by	  centrifugation	  at	  4oC	  for	  15	  mins	  at	  16,000g	  in	  a	  Beckman	  OptiMAX.	  Supernatents	  were	  removed	  and	  10µl	  used	  in	  BCA	  assays	  and	  compared	  to	  a	  BSA	  standard	  curve	  to	  ascertain	  protein	  concentration.	  Reaction	  mixtures	  were	  prepared	  according	  to	  manufacturer’s	  instructions.	  	  
	  
2.2.3.3	  	  Immunoprecipitation-­‐	  Antibody	  After	   extraction,	   lysates	   were	   pre-­‐cleared	   by	   addition	   of	   30µl	   agarose	   beads	  rotating	   at	   4oC	   for	   1	   h,	   before	   addition	   of	   5µg	   anti-­‐LRRK2	   polyclonal	   antibody,	  which	  was	   left	   to	  bind	  at	  4oC	  overnight	  while	  rotating.	  Protein	  recognised	  by	  the	  antibody	   was	   immunoprecipitated	   by	   addition	   of	   30µl	   protein	   G	   sepharose	   and	  incubation	  for	  2	  h	  rotating	  at	  4oC.	  Beads	  conjugated	  to	  immobilized	  protein,	  were	  collected	   by	   spinning	   for	   15	   seconds	   at	   16,000g	   and	   the	   supernatent	   removed.	  Beads	   were	   washed	   3	   times	   in	   HiSalt	   wash	   buffer	   with	   vortexing,	   and	   twice	   in	  HiSalt	  wash	  buffer,	  rotating	  at	  4oC	  for	  30	  mins.	  	  
	  
2.2.3.4	  	  Immunoprecipitation-­‐	  Agarose	  immobilized	  antibody	  Myc-­‐tagged	   proteins	   were	   extracted	   from	   whole	   cell	   lysates	   by	   incubating	  supernatants	  with	  anti-­‐myc	  agarose	  overnight,	  rotating	  at	  4oC.	  Prior	  to	  incubation,	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myc-­‐agarose	   beads	  were	   blocked	   in	   200ng/ml	   BSA	   at	   4oC	   for	   3	   h	  with	   rotation.	  Unbound	  BSA	  was	   removed	  by	  washing	   twice	  using	  HiSalt	  buffer	  with	  vortexing	  and	  once	  with	  1X	   lysis	  buffer.	   Beads	   containing	  bound	  LRRK2	  were	   collected	  by	  spinning	   for	   15	   secs	   at	   16,000	   x	   g	   and	   the	   supernatant	   removed.	   Beads	   were	  washed	   3	   times	   in	   HiSalt	   wash	   buffer	   with	   vortexing,	   and	   twice	   in	   HiSalt	   wash	  buffer	  rotating	  at	  4oC	  for	  30	  mins.	  An	  additional	  wash	  was	  performed	  in	  1X	  kinase	  buffer	  when	  protein	  was	  required	  for	  kinase	  assays.	  	  
2.2.3.5	  	  Affinity	  purification-­‐	  glutathione-­‐agarose	  	  Affinity	  purification	  of	  recombinant	  GST-­‐tagged	  proteins	  was	  performed	  using	  the	  cys-­‐glu-­‐gly	   tripeptide,	   glutathione	   conjugated	   to	   agarose	   beads.	   Beads	   were	  reconstituted	  by	  addition	  of	  PBS	  and	  vortexed.	  After	  incubation	  at	  4oC	  for	  20	  mins,	  GST-­‐agarose	   beads	   were	   washed	   twice	   in	   0.9%	   NaCl	   solution	   to	   remove	  preservatives	   from	   the	   suspension	   solution.	   As	   described,	   beads	   were	   blocked	  using	  10%	  BSA	   (w/v)	  at	  4oC	   for	  2h	  with	   rotation	  and	  unbound	  BSA	  removed	  by	  washing	   twice	   using	   HiSalt	   buffer	  with	   vortexing	   and	   once	  with	   1X	   lysis	   buffer.	  After	  incubation	  overnight	  at	  4oC	  rotating,	  beads	  were	  washed	  Beads	  were	  washed	  3	   times	   in	   HiSalt	   wash	   buffer	   with	   vortexing,	   and	   twice	   in	   HiSalt	   wash	   buffer	  rotating	  at	  4oC	  for	  30	  mins.	  An	  additional	  wash	  was	  performed	  in	  1X	  kinase	  buffer.	  	  
2.2.3.6	  	  Sample	  preparation	  for	  ESI-­‐QTOF	  mass	  spectrometry	  analysis	  Bound	  protein	  was	  eluted	   in	  4X	  LDS	  at	  100oC	   for	  20	  mins.	  Samples	  were	  run	  on	  SDS-­‐PAGE	   4-­‐12%	   gels	   and	   protein	   visualized	   by	   staining	   with	   Gelcode	   blue	   gel	  stain.	  When	  protein	  was	   required	   for	   analysis	  by	  mass	   spectometry,	  bands	  were	  excised	  with	  a	  scalpel.	  ESI-­‐QTOF	  mass	  spectrometry	  was	  performed	  by	  Dr	  Wendy	  Heywood	  (UCL	  Institute	  of	  Child	  Health,	  Biological	  Mass	  spectrometry	  centre).	  
	  
2.2.3.7	  	  Kinase	  assays	  All	  kinase	  assays	  using	  recombinant	  GST-­‐tagged	  kinases,	  were	  performed	  using	  a	  kinase:	  substrate	  molar	  ratio	  of	  1:	  50	  unless	  stated.	  Specifically,	  kinases	  were	  used	  at	  a	  concentration	  of	  10nM	  for	  each	  assay	  and	  substrates	  used	  at	  500nM.	  Assays	  were	   performed	   in	   1X	   kinase	   buffer,	  with	  myelin	   basic	   protein	   (MBP)	   used	   as	   a	  generic	   substrate	   and	   specific	   substrates	   chosen	   as	   described.	   Reactions	   were	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mixed	   on	   ice	   and	   the	   assay	   performed	   at	   18oC.	   1	   µl	   of	   32P	   γ-­‐labelled	   ATP	   was	  added	   to	   catalyse	   each	   reaction	   and	   reactions	   mixed	   by	   pipetting	   prior	   to	   the	  removal	  of	  a	  time	  point.	  For	  assays	  performed	  over	  a	  time	  course,	  10µl	  of	  reaction	  mixture	  was	  removed	  at	  each	  time	  point,	  including	  a	  ‘zero’	  time	  point,	  where	  ATP	  was	  added	  to	  the	  mixture	  and	  an	  aliquot	  taken	  immediately.	  Each	  time	  point	  was	  added	  straight	  to	  4X	  LDS	  loading	  buffer	  containing	  10%	  (v/v)	  β-­‐mercaptoethanol	  to	  stop	  the	  reaction.	  Proteins	  were	  denatured	  at	  100oC	  for	  10	  mins.	  	  For	   kinase	   assays	   with	   immunoprecipitated	   proteins,	   assays	   were	   performed	   at	  37oC	   and	   shaken	   at	   1000rpm	   in	   an	  Eppendorf	   Comfort	   thermomixer.	   The	  whole	  reaction	  mixture	  was	   added	   to	   4X	   LDS	   and	  boiled	   for	   20	  mins	   at	   100oC	   to	   elute	  immunoprecipitated	  proteins.	  
	  
2.2.3.8	  	  Kinase	  assays	  using	  modified	  forms	  of	  ATP	  Immunoprecipitated	  proteins	  were	  washed	  once	   in	   kinase	  buffer	   and	  25µg	  MBP	  added	  as	  a	  substrate	  in	  1X	  kinase	  buffer.	  ATP	  and	  N6-­‐modified	  ATPs	  were	  added	  to	  the	   reaction	   at	   a	   final	   concentration	  of	   1mM.	   	  Assays	  were	  performed	   for	  3	  h	   at	  37oC	  shaking	  at	  1000rpm	  in	  an	  Eppendorf	  Comfort	  thermomixer.	  
	  
2.2.3.9	  	  GTP	  Kinase	  assays	  	  For	   guanine	   nucleotide	   assays,	  ΔN-­‐LRRK2	   at	   a	   total	   concentration	   of	   10nM	  was	  used.	  Recombinant	  LRRK2	  was	  preincubated	  with	  10mM	  GDP,	  GTP	  or	  GTPβγOH	  in	  1X	  kinase	  buffer	  in	  a	  total	  volume	  of	  50µl	  for	  60	  mins	  at	  37oC	  celcius,	  to	  compete	  away	  any	  nucleotide	  bound	  to	  the	  ROC	  domain	  upon	  purification.	  The	  mixture	  was	  cooled	  on	  ice	  for	  ten	  mins	  before	  addition	  of	  MBP.	  MBP	  was	  used	  at	  50	  times	  molar	  excess	  compared	  to	  LRRK2.	  Assays	  were	  conducted	  over	  a	  time	  course	  with	  time	  points	  taken	  at	  various	  intervals.	  	  For	   guanine	   nucleotide	   assays,	   control	   reactions	   were	   incubated	   for	   60	  mins	   at	  37oC	   celcius	   prior	   to	   assaying,	   to	   ensure	   that	   this	   incubation	   did	   not	   affect	  comparison	  between	  experimental	  groups.	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2.2.3.10	  	  Kinase	  assay	  radiography	  Time-­‐points	   were	   electrophoresed	   as	   described	   and	   transferred	   to	   PVDF.	  Radiolabelled	  proteins	  were	  visualised	  by	  exposing	  to	  CL-­‐Xposure	  and	  developed	  using	   a	   Konica	   SRX-­‐10	   developer.	   Quantification	   of	   radioisptope	   incorporation,	  was	  performed	  by	  exposing	  membranes	  to	  a	  phosphorscreen	  and	  imaged	  using	  a	  Storm	   phosphorimager	   (GE	   Healthcare).	   Densitometry	   was	   performed	   using	  ImageJ.	  	  
2.2.3.11	  	  Separation	  using	  glycerol	  gradients	  Each	   sample	  was	  diluted	   to	   a	   total	   volume	  of	   100µl	   in	   1X	   glycerol	   buffer	   before	  centrifugation.	   100ul	   of	   9-­‐35%	  glycerol	   diluted	   in	   25	  mM	  HEPES	   (pH	  7.4),	   0.5%	  Triton	   X-­‐100	   (v/v)	   and	   1	   mM	   DTT	   (Berger	   et	   al.	   2010)	   was	   layered	   in	   1.5ml	  Beckmann	   polycarbonate	   centrifuge	   tubes	   on	   dry	   ice	   to	   prevent	   mixing	   of	   the	  layers.	   Samples	  were	   loaded	   on	   top	   and	   centrifuged	   at	   100,000	   x	   g,	   for	   8	   h	   in	   a	  Beckmann	   swing	  bucket	  TLS-­‐55	   rotor.	  After	   centrifugation,	   100ul	   fractions	  were	  removed	  by	  pipetting,	  for	  blotting	  and	  Coomassie	  staining.	  	  	  
2.2.3.12	  	  Modified-­‐ADP	  radiolabelling	  
γ-­‐Phosphate	  32P	  labeled	  ATP	  was	  used	  as	  a	  γ-­‐phosphate	  donor	  (see	  Figure	  2.2).	  100	  U	  of	  nucleoside	  diphosphate	  kinase	  (NDPK)	  from	  baker’s	  yeast	  was	  reconstituted	  in	   HBS	   to	   a	   concentration	   of	   10	   U/μl	   and	   mixed	   with	   350	   µCi	   of	   (γ-­‐32P)	   ATP	  (Perkin	  Elmer)	  for	  10	  mins	  at	  room	  temperature	  for	  NDPK	  autophosphorylation	  to	  occur.	  	  
	  
Figure	   2.1.	   Transfer	   of	   a	   phosphate	   from	   a	   donor	   nucleoside	   (D)	   to	   an	  
acceptor	   nucleoside	   (A)	   using	   NDPK	   to	   catalyse	   the	   reaction.	   1)	   NDPK	   is	  incubated	   with	   a	   donor	   nucleoside	   triphosphate	   (e.g	   GTP).	   Donor	   is	   bound	   by	  NDPK.	   2)	  NDPK	   hydrolyses	   γ-­‐phosphate	   from	   donor	   and	   autophosphorylates.	   3)	  Donor	  is	  removed	  and	  acceptor	  added.	  Acceptor	  nucleoside	  diphosphate	  is	  bound	  by	  NDPK	  and	  γ-­‐phosphate	  added	  to	  create	  acceptor	  nucleoside	  triphosphate.	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Unincorporated	   GTP	   and	   ADP	   were	   removed	   from	   the	   mixture	   with	   2	   spins	  through	  a	  G50	  biospin	  column	  (GE	  healthcare)	  at	  1100	  x	  g	   for	  2	  mins	  each.	  ADP	  analogs	  (1ul	  of	  0.1	  mM)	  were	  added	  to	  phosphorylated	  NDK	  and	  incubated	  at	  RT	  for	  10	  mins.	  NDPK	  was	  denatured	  at	  80oC	  for	  2	  min	  and	  collected	  by	  centrifugation	  at	  15,000g	  for	  2	  mins.	  γ-­‐32P	  PE-­‐ATP	  was	  resuspended	  in	  60µl	  double-­‐distilled	  H2O	  and	  the	  amount	  of	  incorporated	  γ-­‐32P	  assessed	  using	  TLC.	  	  
2.2.3.13	  	  Thin	  Layer	  Chromatography	  
γ-­‐32P	   ATP	   was	   spotted	   on	   the	   TLC	   plate	   as	   calibration	   guide	   alongside	   1µl	   of	  labeled	  PE-­‐ATP	  and	  left	  to	  dry	  for	  5	  mins.	  Plates	  were	  placed	  in	  a	  TLC	  chamber	  in	  1cm	   of	   TLC	   Running	   buffer	   and	   left	   for	   40	   mins	   to	   run,	   after	   which	   they	   were	  removed,	  air-­‐dried	   for	  10	  mins	  and	  exposed	   to	   film	   for	  2	  h.	  Film	  developing	  was	  performed	  using	  a	  Konica.	  SR-­‐X10	  developer.	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2.2.4	  Western	  blotting	  
2.2.4.1	  	  BlueNative	  PAGE	  For	   visualization	   of	   native	   protein	   complexes,	   both	   recombinant	   and	   whole	   cell	  lysate	  proteins	  were	  analysed	  using	  the	  NativePAGE	  non-­‐denaturing	  gel	  system.	  N-­‐dodecyl-­‐D-­‐maltoside	  (DDM)	  was	  added	  at	  a	  final	  concentration	  of	  5%	  (w/v),	  along	  with	  Coomassie	  G-­‐250	  at	  a	  final	  concentration	  of	  1.25%	  (w/v).	  Glycerol	  was	  added	  to	   a	   final	   concentration	   of	   10%	   (v/v)	   to	   assist	  with	   loading).	   Samples	  were	   run	  along	  side	  an	  unstained	  native	  ladder	  to	  assess	  complex	  size.	  4-­‐16%	  or	  3-­‐12%	  Bis-­‐Tris	   NativePAGE	   gels	  were	   assembled	  with	   dark	   blue	   cathode	   buffer	   and	   run	   at	  120V	   until	   the	   dye	   front	   covered	   one	   third	   of	   the	   gel.	   At	   this	   point,	   the	   cathode	  buffer	  was	  exchanged	  light	  blue	  cathode	  buffer	  and	  the	  gel	  run	  for	  a	  further	  4	  h	  at	  180v.	  Protein	  complexes	  were	  visualised	  by	  silver	  staining	  or	  western	  blotting	  and	  quantified	  using	  the	  NIH	  software	  ImageJ.	  
	  
2.2.4.2	  	  SDS-­‐PAGE	  electrophoresis	  Samples	  were	   loaded	  onto	  gradient	  4-­‐12%	  Bis-­‐Tris	   gels	  unless	  otherwise	   stated.	  Novex	   pre-­‐stained	   protein	   standard	  was	   also	   run	   alongside	   samples,	   in	   order	   to	  assess	   subsequent	   transfer	   and	   to	   calculate	   size	   of	   denatured	   proteins.	   All	   gels	  were	  run	  in	  1X	  MES	  buffer	  at	  180V	  and	  electrophoresis	  terminated	  when	  the	  dye	  front	  reached	  the	  bottom	  of	  the	  gel.	  	  
2.2.4.3	  	  BlueNative	  gel	  transfer	  For	  western	  blotting,	  native	  gels	  were	  incubated	  in	  BN	  transfer	  buffer	  overnight	  at	  room	   temperature.	   They	  were	   subsequently	   transferred	   to	   PVDF	   for	   80	  mins	   at	  80V.	  After	  membranes	  had	  air-­‐dried,	  they	  were	  incubated	  in	  9%	  (v/v)	  acetic	  acid	  to	  fix	  proteins	  and	  then	  soaked	  in	  Ponceau	  S	  staining	  solution	  for	  5	  mins.	  Removal	  of	   staining	   solution	   allowed	   visualisation	   of	   the	   native	   standard,	   which	   was	  subsequently	  marked	  on	  the	  membrane.	  After	  a	   further	  wash	   in	  PBST	  to	  remove	  residual	  Ponceau,	  western	  blotting	  was	  performed.	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2.2.4.4	  	  SDS-­‐PAGE	  transfer	  Gels	  were	  transferred	  to	  PVDF	  in	  1X	  transfer	  buffer	  at	  80V	  for	  80	  mins.	  Following	  transfer,	  membranes	  were	  left	  at	  10mins	  at	  RT	  to	  air-­‐dry	  and	  western	  blotting	  was	  subsequently	  performed.	  	  
2.2.4.5	  	  Western	  blotting	  Membranes	   were	   incubated	   in	   primary	   antibody	   at	   the	   concentrations	   listed	   in	  Table	   2.8	   for	   6	   h	   at	   room	   temperature	   in	   Superblock.	   Membranes	   were	   then	  washed	  twice	  in	  PBST	  for	  ten	  mins	  before	  blocking	  for	  15	  mins	  in	  15%	  (w/v)	  non-­‐fat	   milk.	   After	   washing	   again	   for	   10	   mins	   at	   room	   temperature	   in	   PBST,	  membranes	  were	  then	  incubated	  in	  horseradish-­‐peroxidase	  conjugated,	  secondary	  antibody	  diluted	  in	  Superblock	  for	  2	  h	  at	  room	  temperature.	  
Table	  2.8.	  Antibodies	  used	  for	  western	  blotting.	  	  	  Probed	  membranes	  were	  washed	  five	  times	  for	  a	  total	  of	  90	  mins	  before	  antibody	  binding	  was	  visualised	  using	  an	  electrochemiluminescent	  system	  (ECL).	  	  
	  
	  
Protein	   Species	   Company	   Concentration	  
LRRK2	   Goat	  polyclonal	   Everest	   1:1000	  
LRRK2	   Rabbit	  polyclonal	   Epitomics	   1:1000	  
β-­‐actin	   Mouse	  Monoclonal	  (AC-­‐40)	   Sigma	   1:5,000	  
α-­‐synuclein	   Mouse	  monoclonal	  (clone	  42)	   BD	  Transduction	  labs	   1:1000	  
p-­‐S129	  α-­‐synuclein	   Rabbit	   Abcam	   1:500	  
Myc	   Mouse	  monoclonal	  (9E10)	   Sigma	   1:2000	  
phosphoserine	   Mouse	  monoclonal	   Invitrogen	   1:500	  
Anti-­‐goat	   IgG	  produced	  in	  rabbit	   Sigma	   1:10,000	  
Anti-­‐mouse	   IgG	  (Fab	  specific)	  produced	  in	  goat	   Sigma	   1:10,000	  
Rabbit	   IgG	  produced	  in	  goat	   Sigma	   1:10,000	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2.2.4.6	  	  Electrochemiluminescent	  detection	  of	  antibodies	  Substrate	   was	   mixed	   according	   to	   manufacturer’s	   instructions	   and	   added	   to	  membranes	   for	   30	   secs.	   Excess	   substrate	   was	   removed	   by	   blotting	   with	   tissue	  paper	  and	  membranes	  were	  exposed	  to	  CL-­‐Xposure	  photosensitive	  film	  for	  varying	  amounts	  of	  time.	  Films	  were	  developed	  using	  a	  Konica	  SRX-­‐10	  developer.	  
	  
2.2.4.7	  	  Silver	  Staining	  Gels	  were	  fixed	  by	  incubation	  in	  fixing	  solution,	   for	  20	  mins.	  Subsequent	  staining	  was	   then	   performed	   according	   to	   manufacturer’s	   instructions,	   using	   the	  SilverXpress	  staining	  kit.	  	  
2.2.4.8	  	  Coomassie	  staining	  Gels	  were	  washed	  twice	  in	  double	  distilled	  water	  before	  staining	  with	  Gelcode	  blue	  stain,	  for	  2h.	  Gels	  were	  subsequently	  destained	  for	  around	  2	  h	  until	  bands	  could	  be	  visualised.	  	  
2.2.4.9	  	  Dephosphorylation	  of	  recombinant	  protein	  To	   remove	   phosphate	   groups	   from	  ΔN-­‐LRRK2,	   5µg	   of	   recombinant	   protein	   was	  incubated	  with	  2,000	  U	  of	  lambda	  phosphatase	  in	  the	  supplied	  buffer	  at	  30oC	  for	  4	  h.	  	  
2.2.4.10	  	  Dot-­‐blotting	  5µg	  of	  ΔN-­‐LRRK2	  was	  dotted	  onto	  nitrocellulose	  membranes	  and	  allowed	  to	  dry.	  Dried	  membranes	  were	   incubated	   in	  PBST	  for	  30	  mins	  at	  room	  temperature	  and	  subsequently	   probed	   with	   anti-­‐phosphoserine	   antibody	   for	   2	   h	   at	   room	  temperature	  (Table	  2.8).	  Membranes	  were	  washed	  twice	   in	  PBST	  for	   ten	  mins	  at	  room	  temperature	  and	  then	  blocked	  again	  with	  5%	  (w/v)	  non-­‐fat	  milk	  dissolved	  in	  PBST	   for	   10	   mins.	   Blots	   were	   re-­‐washed	   twice	   in	   PBST	   for	   10	   mins	   at	   room	  temperature	  and	  then	  incubated	  in	  anti-­‐rabbit	  secondary	  antibody	  (Table	  2.8)	  for	  45	  mins.	  Membranes	  were	  imaged	  using	  ECL.	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2.2.4.11	  	  LRRK2	  pulldowns	  SH-­‐SY5Y	  cells	  were	  grown	  to	  confluency	  in	  14cm2	  dishes	  as	  described.	  Cells	  were	  lysed	  on	  ice	   in	  cell	   lysis	  buffer	  containing	  protease	  inhibitor	  cocktail	   for	  20	  mins,	  before	   lysates	   were	   clarified	   by	   spinning	   at	   4oC	   for	   20	   mins	   at	   16,000	   x	   g	   in	   a	  Beckman	   5412	   centrifuge	   and	   the	   insoluble	   fraction	   discarded.	   Lysates	   were	  precleared	  by	  addition	  of	  30µl	  agarose	  beads	  rotating	  at	  4oC	  for	  1	  h	  before	  addition	  of	  5µg	  anti-­‐LRRK2	  (Everest)	  polyclonal	  antibody	  which	  was	  left	  to	  bind	  rotating	  at	  4oC	   overnight.	   Protein	   recognized	   by	   the	   antibody	   was	   immunoprecipitated	   by	  addition	   of	   30µl	   protein	   G	   sepharose	   and	   left	   for	   2	   h	   rotating	   at	   4oC.	   Beads	  containing	  immobilized	  protein	  were	  collected	  by	  spinning	  for	  15	  secs	  at	  14,000	  x	  g	   and	   the	   supernatent	   removed.	   Beads	   were	   washed	   5	   times	   in	   PBS	   containing	  300mM	  NaCl	  and	  1%	  Triton-­‐X100	  and	  bound	  protein	  eluted	  in	  4X	  LDS	  at	  100oC	  for	  20	   mins.	   Samples	   were	   run	   on	   SDS-­‐PAGE	   4-­‐12%	   gels	   as	   described	   and	   protein	  visualized	   using	   Gelcode	   blue	   gel	   stain	   (Pierce).	   A	   band	   of	   around	   280kDa	   was	  visible	  which	  was	  excised	  using	  a	  scalpel	  and	  subjected	  to	  tryptic	  digest	  and	  amino	  acid	  sequencing	  by	  ESI-­‐QTOF	  mass	  spectrometry.	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 3.	   CHARACTERISATION	  OF	  LRRK2	  
FUNCTIONING	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 3.1	  INTRODUCTION	  Full	  length	  LRRK2	  has	  been	  shown	  to	  dimerise	  in	  a	  number	  of	  studies	  (Greggio	  et	  
al.	  2008,	  Sen	  et	  al.	  2009,	  Berger	  et	  al.	  2010)	  and	  this	  dimerisation	  is	  thought	  to	  be	  important	  for	  GTPase	  and	  kinase	  function	  (Gasper	  et	  al.	  2009,	  Greggio	  et	  al.	  2008).	  As	   kinase	   function	   has	   been	   attributed	   to	   LRRK2	   toxicity	   (Greggio	   et	   al.	   2006,	  Smith	  et	  al.	  2006)	  understanding	  how	  this	  activity	  is	  regulated	  is	  an	  important	  step	  towards	   elucidating	   the	   mechanisms	   by	   which	   familial	   mutations	   affect	   LRRK2	  behaviour.	  Current	  opinion	  is	  that	  the	  active	  form	  of	  LRRK2	  is	  likely	  to	  be	  dimeric	  (Sen	  et	  al.	  2009,	  Berger	  et	  al.	  2010),	  with	  monomeric	  forms	  showing	  lower	  kinase	  activity.	   We	   do	   not	   know	   however,	   under	   what	   circumstances	   LRRK2	   does	  dimerise	  and	  how	  the	  transition	  from	  monomer	  to	  dimer	  is	  regulated.	  	  	  In	   order	   to	   characterise	   the	   internal	   regulation	   mechanisms	   of	   LRRK2,	  recombinant	  ΔN-­‐LRRK2	   produced	   in	   Sf9	   cells	   and	  made	   commercially	   available	  (Invitrogen)	  has	  been	  used	  to	  assess	  LRRK2	  self-­‐regulation	  in	  the	  absence	  of	  other	  interacting	   proteins.	   BN	   PAGE	   has	   been	   used	   in	   these	   experiments	   to	   evaluate	  changes	   that	   may	   be	   occurring	   to	   LRRK2	   quaternary	   structure	   as	   a	   result	   of	  familial	  mutations.	   BN	   PAGE	   is	   frequently	   used	   to	   separate	   and	   identify	   protein	  complexes	   in	   their	  native	  state.	  Solubilisation	  of	  proteins	   in	  non-­‐ionic	  detergents	  such	  as	  digitonin	  or	  n-­‐dodecyl-­‐beta-­‐D-­‐maltoside	  (DDM)	  and	  addition	  of	  Coomassie	  G-­‐250	   in	   order	   to	   give	   protein	   a	   negative	   charge,	   means	   that	   SDS	   and	   other	  denaturing	  agents	  can	  be	  omitted	  during	  sample	  preparation.	  As	  such,	  proteins	  are	  able	   to	  migrate	   in	  non-­‐denatured,	  complex	   form	  (reviewed	   in	  Wittig	  et	  al.	  2006).	  This	  system	  allowed	  the	  quaternary	  structure	  of	  LRRK2	  to	  be	  assessed.	  	  	  Phosphorylation	  of	  residues	  within	  a	  kinase,	  either	  through	  autophosphorylation,	  or	  phosphorylation	  by	  another	  kinase	  is	  a	  widely	  used	  mechanism	  to	  activate,	  and	  regulate	  complex	  formation	  and	  enzymatic	  activity.	  Mitogen	  activated	  kinases	  such	  as	  ERK	  and	  MEK	  are	  activated	  by	  phosphorylation	  (Boulton	  et	  al.	  1991),	  whereas	  phosphorylation	  of	  mTOR	   is	  deactivated	  by	  phosphorylation	   (Brunn	  et	  al.	   1996).	  The	   tight	   regulation	   of	   this	   process,	   through	   associated	  phosphatases	   allows	   the	  process	   to	   be	   highly	   controlled.	   Many	   kinases,	   such	   as	   the	   insulin	   receptor	   are	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commonly	   phosphorylated	   in	   response	   to	   ligand	   binding.	   Proteins	   containing	  domains	   such	   as	   SH2	   and	   PTB,	   which	   recognize	   p-­‐Tyrosine	   residues,	   mediate	  complex	   formation	   and	   facilitate	   interaction	   (reviewed	   in	   (Roque	   et	   al.	   2005).	  These	  domains	  are	   found	   in	   a	  number	  of	  proteins	   including	  SMAD	  and	  Polo-­‐Box	  domain	  containing	  proteins,	  and	  the	  14-­‐3-­‐3	  family	  of	  proteins,	  which	  have	  recently	  been	  shown	  to	  interact	  with	  LRRK2	  (Dzamko	  et	  al.	  2010,	  Nichols	  et	  al.	  2010,	  Li	  X.	  
et	  al.	  2011).	  LRRK2	  is	  known	  to	  be	  highly	  basally	  phosphorylated	  (Table	  1.3)	  and	  as	  such,	  phosphorylation	  is	  a	  likely	  mechanism	  to	  regulate	  complex	  formation	  and	  enzymatic	  activity.	  To	  assess	  the	  role	  of	  phosphorylation	  in	  dimer	  formation,	  ΔN-­‐LRRK2	  was	  dephosphorylated	  and	  quaternary	  structure	  analysed	  using	  BN	  PAGE.	  To	  assess	  the	  enzymatic	  activity	  of	  dephosphorylated	  forms	  of	  LRRK2,	  ΔN-­‐LRRK2	  was	   separated	   using	   a	   glycerol	   gradient	   system	   and	   in	   vitro	   kinase	   assays	  performed	  to	  assess	  the	  kinase	  activity	  of	  high	  and	  low	  molecular	  weight	  species.	  	  GTP	  binding	  has	   been	   shown	   to	   stimulate	   kinase	   activity	   of	   LRRK2	   and	  GTPase-­‐dead	  artificial	  mutants	  do	  not	  display	  kinase	  activity	   (Smith	  et	  al.	  2006).	  What	   is	  unclear	  however,	  is	  if	  the	  ablation	  of	  kinase	  activity	  is	  caused	  by	  structural	  changes	  due	   to	   an	   unoccupied	   GTP	   binding	   pocket,	   or	   because	   LRRK2	   cannot	   maintain	  kinase	   activity	  without	  GTP	  binding.	   Similarly,	   the	   role	  of	   interacting	  proteins	   in	  GTP	   binding	   and	   cycling	   is	   also	   still	   unclear.	   LRRK2	   has	   been	   shown	   to	   interact	  with	   the	  GEF	  ARHGEF7	   (Haebig	  et	  al.	   2010),	  which	   stimulates	  GTPase	  activity	   in	  
vitro,	   however	  LRRK2	   is	   able	   to	  hydrolyse	   and	   cycle	  GTP	  without	   a	  GEF	  present	  (Guo	  et	  al.	  2007).	  To	  assess	  the	  ability	  of	  the	  ROC	  domain	  to	  dimerise,	  quaternary	  structure	   has	   been	   assessed	   using	   a	   recombinant	   fragment	   expressed	   in	   E	   Coli	  (Deng	   et	  al.	   2007).	   The	   kinase	   activity	   of	  ΔN-­‐LRRK2	   in	   the	   presence	   of	   different	  guanine	  nucleotides	  was	  analysed	  using	  MBP	  as	  a	  substrate.	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3.1.1	  	  Hypotheses	  	  Experiments	  were	  designed	  to	  address	  the	  following	  hypotheses.	  	   1) LRRK2	  ROC	  domain	  is	  able	  to	  form	  dimers.	  2) LRRK2	  kinase	  activity	  is	  affected	  by	  guanine	  nucleotide	  binding.	  3) LRRK2	   dimer	   formation	   is	   mediated	   by	   autophosphorylation	   of	   residues	  within	  LRRK2.	  4) Monomeric	  LRRK2	  displays	  decreased	  kinase	  activity	  compared	  to	  dimeric	  LRRK2.	  
	  
3.1.2	  	  Aims	  	  These	  hypotheses	  will	  be	  tested	  through	  fulfillment	  of	  the	  following	  aims.	  	   1) To	  assess	  the	  propensity	  of	  ROC	  domain	  dimer	  formation	  using	  recombinant	  fragments	  of	  the	  GTPase	  domain.	  2) To	  assess	  the	  impact	  of	  guanine	  nucleotides	  on	  recombinant	  ΔN-­‐LRRK2	  kinase	  activity	  using	  the	  generic	  substrate	  MBP.	  3) To	  assess	  the	  effect	  of	  phosphorylation	  on	  dimer	  formation	  in	  vitro	  using	  dephosphorylated	  ΔN-­‐LRRK2.	  4) To	  perform	  kinase	  assays	  using	  immobilised	  LRRK2	  in	  monomeric	  and	  dimeric	  form.	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3.2	   RESULTS	  
3.2.1	  LRRK2	  ROC	  domain	  exists	  predominantly	  as	  a	  dimer	  GST-­‐ROC	  domain	  with	  an	  N-­‐terminal	  6X	  histidine-­‐tag	  and	  a	  TEV	  protease	  cleavage	  site	   (amino	  acids	  1333–1516)	  was	  expressed	  and	  purified	   from	  E.Coli	   (gift	  of	  Dr.	  Junpeng	  Deng,	  Oklahoma	  state	  University,	  California.	  For	  protocol	   see	  Deng	  et	  al.	  2008).	  As	  shown	  in	  Figure	  3.1a,	  the	  ROC	  domain	  is	  around	  25	  kDa	  when	  analysed	  by	  SDS-­‐PAGE.	  Dimeric	  forms	  of	  this	  domain	  can	  also	  be	  seen	  at	  ~	  50	  kDa.	  Analysis	  by	  BN	  PAGE	  (Figure	  3.1b)	  confirms	  that	  the	  ROC	  domain	  is	  dimeric,	  as	  the	  majority	  of	  this	  protein	  runs	  at	  ~50	  kDa.	  There	  is	  a	  fraction	  of	  this	  protein	  forming	  higher	  order	   structures	   of	   around	   100	   kDa,	   likely	   corresponding	   to	   tetramers.	  Denaturation	   of	   the	   ROC	   domain	   by	   heating	   at	   100oC	   for	   30	  mins	   (Figure	   3.1b)	  shows	  that	  the	  purified	  ROC	  domain	  is	  present	  in	  monomeric	  form	  and	  a	  dimeric	  form	  that	  is	  heat-­‐resistant	  and	  SDS-­‐insoluble	  (Figure	  3.1a).	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3.2.2	  	  Guanine	  nucleotide	  incubation	  decreases	  kinase	  activity	  GTP	  binding	  studies	  have	  shown	  that	  full	  length	  LRRK2	  has	  low	  affinity	  for	  GTP	  (Li	  X.	  et	  al.	   2007).	  The	  classification	  of	  LRRK2	  as	  a	  GAD	   is	  based	   in	  part	  on	   this	   low	  affinity	   for	  GTP	  (Gasper	  et	  al.	  2009).	   In	  order	   to	  ensure	   that	  nucleotide	  bound	  to	  
ΔN-­‐LRRK2	  was	  replaced	  with	  the	  experimental	  forms	  of	  guanine	  nucleotide,	  a	  vast	  molar	  excess	  of	  GTP	  (10mM)	  was	  used	  for	  each	  experiment.	  Some	  kinases,	  such	  as	  protein	  kinase	  C,	   are	  known	   to	  utilise	   the	   second	  messenger	   cyclic-­‐GMP	   (cGMP),	  which	   activates	   kinase	   activity	   by	   disinhibiting	   the	   kinase	   domain	   (Francis	   et	  al.	  1999).	   	  cGMP	  has	  also	  been	  shown	  to	  play	  a	  role	  in	  the	  activation	  of	  the	  bacterial	  ROCO	  protein	  GbpC	   in	  an	  activation	  cascade	  which	   involves	  cGMP	  activation	  of	  a	  GEF	   domain,	   leading	   to	   GDP/	   GTP	   cycling	   and	   kinase	   domain	   activation	   (Van	  Egmond	  et	  al.	  2008).	  To	  examine	  a	  role	  for	  cGMP	  in	  LRRK2	  signalling,	  this	  form	  of	  guanosine	  was	  also	  used	  for	  these	  experiments,	  along	  with	  GDP,	  GTP	  and	  the	  non-­‐hydrolysable	  GTPβγOH.	  	  	  Preincubation	  of	  ΔN-­‐LRRK2	  with	  guanine	  nucleotides	  was	   shown	   to	   significantly	  alter	  kinase	  activity	  (Figure	  3.2,	  p=0.0043,	  one-­‐way	  ANOVA).	   	  GDP	  and	  GTPβγOH	  significantly	   lowered	  kinase	  activity	   compared	   to	   the	   control	   condition,	   in	  which	  
ΔN-­‐LRRK2	  was	  incubated	  without	  nucleotide	  (p<0.05	  vs	  control	  for	  each,	  one-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐test).	  Similarly,	  despite	  the	  fact	  that	  GTP	  has	  been	  shown	  to	  stimulate	  kinase	  activity	  in	  full	  length	  LRRK2	  (Ito	  et	  al.	  2007),	  there	  was	   a	   significant	   decrease	   in	   MBP	   phosphorylation	   in	   these	   assays	   (p<0.05).	  Densitometry	   to	   quantify	   MBP	   phosphorylation	   by	   LRRK2	   preincubated	   with	  cGMP,	   again	   showed	   a	   significant	   decrease	   in	   kinase	   activity	   compared	   to	   the	  control	  condition	  (p<0.05).	  	  	  As	  the	  role	  of	  ROC-­‐COR	  regulation	  of	  the	  kinase	  domain	  has	  been	  well	  documented,	  it	   is	   unlikely	   that	   the	   disruption	   of	   kinase	   activity	   with	   all	   forms	   of	   guanine	  nucleotide	   is	   representative	   of	   LRRK2	   functioning	   in	   vivo	   and	   more	   likely	  attributed	  to	  the	  conditions	  used	  in	  these	  experiments.	  As	  such,	  it	  was	  decided	  that	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ΔN-­‐LRRK2	  is	  not	  suitable	  for	  further	  investigation	  regarding	  the	  impact	  of	  guanine	  nucleotides	  on	  LRRK2.	  
	  
Figure	   3.2a.	   Radiography	   showing	   LRRK2	   phosphorylation	   of	   MBP	   in	   the	  
presence	   of	   various	   guanine	   nucleotides.	   i-­‐Control-­‐	   wild	   type	   ΔN-­‐LRRK2,	   ii-­‐	  wild	   type	   incubated	   in	   10mM	   cyclic	   guanosine	  monophosphate	   (cGMP),	   iii-­‐	  wild	  type	  incubated	  in	  10mM	  guanosine	  diphosphate	  (GDP),	  iv-­‐	  wild	  type	  incubated	  in	  10mM	  cyclic-­‐guanosine	  monophosphate	  (cGMP),	  v-­‐	  wild	  type	  incubated	  in	  10mM	  GTPβγOH	   (a	   non-­‐hydrolysable	   form	   of	   GTP).	   Time	   points	   are	   indicated	   below	  (mins).	   Molecular	   weight	   markers	   are	   shown	   on	   the	   right	   (kDa).	   Images	   are	  representative	   of	   three	   experiments.	   3.2b.	   Quantification	   of	   MBP	  
phosphorylation	   by	   ΔN-­‐LRRK2	   when	   incubated	   with	   guanine	   nucleotides.	  Radiometric	   images	  were	  quantified	  using	  densitometry	  and	  results	  displayed	  as	  the	  mean	  of	  phosphorylation	  intensity	  (measured	  in	  arbitrary	  units)	  ±	  s.e.m.	  (n=3).	  
3.2c.	   MBP	   phosphorylation	   by	   ΔN-­‐LRRK2	   at	   60	   mins.	   Values	   for	   MBP	  phosphorylation	  at	  60	  mins	  are	  displayed	  as	  mean	  ±	  s.e.m.	  *p<0.05	  vs	  control,	  one-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐test	  (n=3).	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3.2.3	  	  Dephosphorylation	  disrupts	  LRRK2	  dimer	  formation.	  KD	  mutations	  in	  full	  length	  and	  truncated	  LRRK2	  overexpressed	  in	  cells	  have	  been	  shown	   to	   disrupt	   dimer	   formation,	   suggesting	   that	   kinase	   activity	   of	   LRRK2	   is	  important	   for	   complex	   formation.	   Similarly,	   LRRK2	  has	  been	   shown	   to	  be	  highly	  phosphorylated	   (Table	   1.3).	   To	   assess	   if	   phosphorylation	   of	   LRRK2	   could	   be	  controlling	   complex	   formation	   of	   LRRK2,	   recombinant	   ΔN-­‐LRRK2	   was	  dephosphorylated	  and	  the	  quaternary	  structure	  of	  the	  protein	  assessed.	  	  	  Dot-­‐blot	  analysis	  of	  basal	  LRRK2	  phosphorylation	  (Figure	  3.3a)	  shows	  that	  WT	  and	  KD	   forms	  are	  all	  phosphorylated.	  As	   shown	  by	  other	  groups,	  D1994A	  KD	  LRRK2	  shows	  lower	  levels	  of	  phosphorylation	  than	  the	  WT	  forms,	  which	  is	  thought	  to	  be	  due	   to	  autophosphorylation	   (Kamikawaji	  et	  al.	   2009).	  These	   results	   suggest	   that,	  although	  autophosphorylation	  may	  not	  occur	  in	  this	  protein,	  there	  are	  low	  levels	  of	  basal	   phosphorylation	   at	   serine	   residues,	   presumably	   due	   to	   post-­‐translational	  modification	   by	   endogenous	   Sf9	   kinases.	   Dephosphorylation	   of	   WT	   ΔN-­‐LRRK2	  using	  lambda	  phosphatase	  and	  subsequent	  analysis	  using	  a	  pan-­‐phosphoserine	  (p-­‐Serine)	   antibody,	   shows	   that	   the	   level	   of	   serine	   phosphorylation	   is	   markedly	  reduced	   and	   that	   this	   phosphatase	   is	   efficient	   in	   stripping	   phosphates	   from	  ΔN-­‐LRRK2.	  To	  assess	  the	  impact	  of	  this	  dephosphorylation	  on	  WT	  ΔN-­‐LRRK2	  complex	  formation,	  protein	  was	  run	  on	  BN	  PAGE	  and	  visualised	  by	  western	  blotting	  (Figure	  3.3b).	  	  As	  shown	  in	  Figure	  3.3,	  dephosphorylation	  of	  WT	  ΔN-­‐LRRK2,	  results	   in	  a	  shift	   in	  the	  dimeric	   species	   to	   a	   lower,	   seemingly	  monomeric	   species.	  Poor	   resolution	  of	  protein	   when	   subjected	   to	   western	   blotting	   after	   BN	   electrophoresis	   and	   the	  inhibition	  of	  transfer	  by	  Coomassie	  G-­‐250	  (Eubel	  et	  al.	  2005)	  however,	  meant	  that	  western	   blotting	   results	   were	   not	   optimally	   reproducible.	   As	   this	   was	   the	   case,	  another	   technique	   was	   sought	   to	   reliably	   separate	   various	   LRRK2	   species	   and	  investigate	  the	  effects	  of	  dephosphorylation	  on	  LRRK2	  complex	  formation.	  Due	  to	  the	   success	   of	   glycerol	   gradients	   in	   separating	   low	   and	   high	   molecular	   weight	  species	   from	   LRRK2	   in	   cell	  models	   (Berger	   et	  al.	   2010),	   it	  was	   decided	   to	   use	   a	  similar	   system	   for	   recombinant	   LRRK2	   in	   these	   experiments.	   This	   system	   was	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optimized	  for	  separation	  of	  lower	  molecular	  weight	  species	  (Figure	  3.4a)	  and	  used	  for	  subsequent	  experiments.	  	  
	  
Figure	  3.3a.	  Dot-­‐blot	  analysis	  of	  basal	  ΔN-­‐LRRK2	  phosphorylation.	  WT-­‐	  wild	  type,	   KD-­‐D1994A	   kinase	   dead	   LRRK2,	   Dephos-­‐	   Dephosphorylated	   WT	   LRRK2,	  previously	   incubated	   with	   lambda	   phosphatase	   to	   remove	   phosphate	   groups.	  Equal	   amounts	   of	   LRRK2	  were	   spotted	   for	   each	   condition	   and	   a	   p-­‐Ser	   antibody	  used	  to	  assess	  phosphorylation	  levels.	  Images	  are	  representative	  of	  three	  separate	  experiments.	  3.3b.	  BlueNative	  PAGE	  analysis	  of	  ΔN-­‐LRRK2	  complex	  formation	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  WT	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  G201	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phosphatase	   and	   subjected	   to	   centrifugation,	   these	   higher	  weight	   complexes	   are	  disrupted.	   LRRK2	   was	   contained	   instead	   in	   fractions	   corresponding	   to	   a	   lower	  weight	   and	   possibly	   monomeric	   species	   (~200kDa)	   and	   a	   higher	   weight,	  presumably	   dimeric	   species	   (lower	   than	   440	   but	   higher	   than	   260kDa)	   (Figure	  3.4a).	  Phosphatase	  treatment	  of	  the	  kinase	  dead	  form	  of	  ΔN-­‐LRRK2	  was	  shown	  to	  have	   little	   effect	   on	   the	   overall	   quaternary	   structure	   of	   this	   protein,	   supporting	  dot-­‐blot	  data	  (Figure	  3.3a)	  showing	  that	  D1994A	  is	  minimally	  phosphorylated.	  	  
3.2.4	  	  Low	  molecular	  weight	  LRRK2	  has	  decreased	  kinase	  activity	  	  Studies	  looking	  at	  the	  localisation	  and	  kinase	  activity	  of	  membrane	  bound	  LRRK2	  in	  comparison	  to	  membrane	  bound	  LRRK2,	  have	  shown	  that	  LRRK2	  is	  more	  likely	  to	   be	   monomeric	   when	   in	   the	   cytosol.	   Importantly,	   cytosolic	   LRRK2	   has	   been	  shown	  to	  display	  lower	  kinase	  activity	  than	  membrane	  bound	  LRRK2	  (Berger	  et	  al.	  2010).	  This	  could	  be	  due	  to	  the	  presence	  of	  interactors	  or	  a	  membrane	  associated	  conformation	   of	   LRRK2,	  which	   promotes	   kinase	   activity.	   To	   investigate	  whether	  low	   molecular	   weight	   (likely	   monomeric)	   LRRK2	   possesses	   intrinsically	   lower	  kinase	   activity	   than	   higher	   molecular	   weight	   LRRK2	   (likely	   to	   be	   dimeric),	   ΔN-­‐LRRK2	   was	   dephosphorylated	   and	   separated	   by	   size	   using	   glycerol	   gradient	  centrifugation	   and	   the	   kinase	   activity	   of	   the	   two	   groups	   assessed.	   Protein	   from	  fractions	  5-­‐8	   (17-­‐23%	  glycerol)	  were	  pooled	   and	  designated	   as	   lower	  molecular	  weight,	   and	   protein	   from	   fractions	   13	   and	   14	   (33-­‐35%)	   pooled	   and	   designated	  higher	   molecular	   weight	   LRRK2.	   To	   ensure	   that	   quaternary	   structure	   was	  preserved	  and	  that	  the	  addition	  of	  ATP	  was	  not	  able	  to	  promote	  the	  reoccurrence	  of	   complex	   formation,	   glutathione-­‐agarose	   beads	   were	   used	   to	   precipitate	   and	  immobilize	  LRRK2	  from	  both	  of	  these	  fractions.	  	  Incubation	  of	  protein	   from	  these	  two	  fractions	  with	  MBP	  in	  the	  presence	  of	  ATP,	  showed	   that	   the	   activity	   of	   lower	   weight	   LRRK2	   was	   significantly	   reduced	  compared	   to	   higher	  molecular	  weight	   LRRK2	   (Figure	   3.5.	   p=0.0024,	   unpaired	   t-­‐test).	   This	   supports	   the	   idea	   that	   monomeric	   LRRK2	   is	   likely	   to	   display	   lower	  kinase	   activity	   than	  dimeric	   LRRK2	  and	   that	   dimerisation	   is	   required	   for	   LRRK2	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kinase	   activity.	   These	   results	   also	   suggest	   that	   LRRK2	   kinase	   activity	   is	   likely	   to	  require	  phosphorylation	  at	  certain	  residues.	  	  
	  
Figure	  3.5a.	  MBP	  phosphorylation	  by	  low	  and	  high	  molecular	  weight	  LRRK2.	  Autoradiography	  of	  MBP	  phosphorylation	   from	  ΔN-­‐LRRK2	  precipitated	   from	   low	  and	  high	  molecular	  weight	  fractions,	  separated	  by	  glycerol	  gradient	  centrifugation.	  	  LRRK2	  inputs	  are	  shown	  above	  (western	  blotting).	  Molecular	  weight	  markers	  are	  shown	   on	   the	   keft	   (kDa).	   Images	   are	   respresentative	   of	   at	   least	   three	   separate	  experiments.	  3.5b.	   Quantification	   of	   high	   and	   low	   molecular	   weight	   kinase	  
activity	   towards	   MBP.	   Kinase	   activity	   from	   protein	   contained	   in	   high	   and	   low	  molecular	  weight	   fractions	  was	   quantified	   using	   densitometry	   and	   corrected	   for	  protein	   abundance	   (n=	   3).	   **	   p=0.0024,	   unpaired	   t-­‐test.	   Values	   shown	   are	  expressed	   as	   mean	   ±	   s.e.m	   and	   are	   representative	   of	   at	   least	   three	   separate	  experiments.	  	  
** p=0.0024
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3.	  3	  	  DISCUSSION	  LRRK2	  is	  a	  large	  protein	  containing	  many	  protein-­‐protein	  interaction	  domains	  and	  two	  enzymatic	  domains	  (Marin,	  2006).	  To	  regulate	  these	  domains,	  there	  are	  many	  layers	   of	   regulation	   controlling	   LRRK2,	   however	   the	   exact	   details	   of	   this	  functioning	  are	  yet	   to	  be	  conclusively	  characterised.	  These	  experiments	  aimed	  to	  better	  understand	  regulatory	  processes	  that	  are	  intrinsic	  to	  LRRK2,	  and	  to	  look	  at	  the	  behavior	  of	  this	  protein	  when	  in	  isolation,	  in	  order	  to	  contribute	  to	  building	  up	  a	  mechanism	  of	  LRRK2	  regulation,	  that	  can	  be	  used	  to	  understand	  how	  LRRK2	  may	  be	  contributing	  to	  AD	  PD.	  To	  do	  this,	  recombinant	  fragments	  of	  LRRK2	  were	  used,	  as	   this	  minimised	   the	  effects	   that	   interacting	  proteins	  could	  be	  having	  on	  LRRK2	  regulation.	   These	   experiments	   were	   successful	   in	   their	   aims	   to	   assess	   the	  propensity	   of	   the	   ROC	   domain	   to	   form	   dimers	   and	   in	   assessing	   the	   effect	   of	  phosphorylation	   on	   ΔN-­‐LRRK2	   dimer	   formation.	   Dephosphorylation	   of	  recombinant	   LRRK2	   separated	   higher	   molecular	   weight	   forms	   into	   lower	  molecular	   weight	   forms	   and	   the	   kinase	   activity	   of	   these	   different	   forms	   was	  assessed.	  Characterisation	  of	  LRRK2	  kinase	  activity	  when	  pre-­‐treated	  with	  guanine	  nucleotides	  was	   unsuccessful	   (Figure	   3.2),	   likely	   due	   to	   competition	   for	   the	  ATP	  binding	  pocket	  between	  the	  mM	  concentrations	  of	  GTP	  and	  the	  low	  concentration	  of	   radiolabelled	  ATP.	  Use	   of	  GTP	   as	   a	   phosphate	   donor	   instead	   of	  ATP	  has	   been	  well	   described	   for	   numerous	   kinases	   (Diaz-­‐Nido	   et	   al.	   1988)	   and	   as	   such	  phosphorylation	   of	   MBP	   could	   have	   been	   occuring	   using	   the	   non-­‐radioactive	  guanine	  nucleotides	  instead	  of	  the	  radiolabelled	  ATP,	  which	  would	  account	  for	  the	  lack	  of	  MBP	  radiolabelling.	   	   In	   this	   case,	  modification	  of	   the	  experimental	  design	  used	  for	  these	  experiments	  may	  prove	  successful	  in	  the	  future.	  	  The	  solved	  crystal	  structure	  of	  the	  ROC	  domain	  has	  shown	  that	  this	  single-­‐domain	  fragment	  is	  dimeric	  (Deng	  et	  al.	  2008).	  In	  these	  experiments,	  BN	  analysis	  supports	  data	  that	  this	  domain	  is	  able	  to	  form	  dimeric	  species	  (Figure	  3.1a).	  Denaturing	  the	  ROC	   domain	   fragment	   by	   boiling	   and	   adding	   SDS	   (Figure	   3.1a,	   b)	   shows	   that	   a	  proportion	  of	  the	  dimer	  species	  observed,	  are	  likely	  to	  have	  occurred	  as	  a	  result	  of	  the	  purification	  process,	  or	  represent	  an	  aggregation	  of	  this	  domain,	  as	  the	  dimers	  are	  not	  disrupted	  by	  these	  denaturation	  methods.	  As	  this	  ROC-­‐domain	  containing	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fragment	   of	   LRRK2	   was	   purified	   from	   E-­‐Coli,	  and	   SDS-­‐PAGE	   separation	   showed	  that	  there	  were	  no	  other	  bands	  visible,	  this	  protein	  is	  unlikely	  to	  be	  contaminated	  by	   other	   proteins.	   In	   this	   case,	   the	   dimerisation	   seen	   by	   BN	   PAGE	   analysis	   is	  probably	  mediated	  by	  high	   intermolecular	  affinity	  of	   the	  ROC	  domain	  with	   itself.	  GTPase	   assays	   using	   the	   ROC	   1333-­‐1516	   protein	   have	   shown	   robust	   GTPase	  activity	  (Deng	  J.	  et	  al.	  2008),	  which	  is	   likely	  to	  require	  dimerisation	  (Gasper	  et	  al.	  2009).	   It	   is	   unclear	   however,	   if	   the	   SDS-­‐insoluble	   dimers	   are	   also	   active.	   The	  complex	  mechanisms	   proposed	   for	   LRRK2	   GTPase	   function	   (Gasper	   et	   al.	   2009)	  suggest	  that	  these	  forms	  of	  the	  protein	  are	  less	  likely	  to	  be	  active.	  	  Analysis	   of	   quaternary	   structure	  when	  LRRK2	   is	  dephosphorylated,	   showed	   that	  removal	   of	   phosphate	   groups	   disrupts	   dimeric	   and	   higher	   order	   complex	  formation	   of	   ΔN-­‐LRRK2	   (Figure	   3.4a).	   The	   decreased	   levels	   of	   basal	  phosphorylation	  seen	  in	  KD	  compared	  to	  WT	  protein	  (Figure	  3.3a)	  support	  other	  studies	  in	  suggesting	  that	  this	  phosphorylation	  is	  likely	  to	  be	  autophosphorylation	  (Kamikawaji	   et	   al.	   2009),	   although	   phosphorylation	   may	   be	   occurring	   through	  kinase-­‐dependent	   interaction	   with	   other	   kinases.	   The	   finding	   that	  dephosphorylation	   of	   LRRK2	   disrupts	   higher	   molecular	   weight	   complexes	   is	  important,	  in	  that	  it	  provides	  a	  possible	  mechanism	  for	  regulation	  of	  dimerisation.	  Importantly,	   dephosphorylation	   of	   D1994A	   does	   not	   disrupt	   dimer	   formation,	  supporting	   the	   idea	   that	   LRRK2	   kinase-­‐dependent	   phosphorylation	   of	   LRRK2	  regulates	   complex	   formation.	   It	   is	   important	   to	   consider	   these	   results	   in	   the	  context	   of	   a	   GST-­‐tagged	   protein,	   as	   GST	   is	   well	   known	   to	   dimerise	   (Singh	   et	   al.	  1987).	  In	  this	  case,	  dimerisation	  of	  ΔN-­‐LRRK2,	  in	  particular	  the	  kinase	  dead	  form	  of	  the	  protein	  may	  mediated	  by	  the	  GST-­‐tag.	  	  	  Centrifugation	   of	   dephosphorylated	   ΔN-­‐LRRK2	   through	   glycerol	   gradients,	  allowed	  immunoprecipitation	  of	  different	  sized	  LRRK2	  species,	  and	  it	  was	  shown	  that	   lower	   molecular	   weight	   LRRK2	   displays	   lower	   kinase	   activity	   than	   higher	  molecular	   weight	   LRRK2	   (Figure	   3.5a).	   These	   results	   are	   supportive	   of	   data	  published	  by	  other	  groups	  using	   full	   length	  LRRK2	   (Sen	  et	  al.	   2009,	  Berger	  et	  al.	  2010)	   and	   therefore	   suggest	   that	  ΔN-­‐LRRK2	   is	   a	   good	  model	   for	   LRRK2	   kinase	  function.	   These	   results	   also	   suggest	   that	   the	   N-­‐terminus	   is	   not	   necessary	   for	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dimerisation	  or	  kinase	  activity,	  as	  the	  protein	  in	  truncated	  to	  residue	  970	  (Anand	  
et	   al.	   2009).	   The	   disruption	   of	   dimerisation	   by	   dephosphorylation,	   supports	   the	  idea	   that	   this	   mechanism	   is	   important	   for	   kinase	   activity	   and	   so	   in	   turn,	   that	  autophosphorylation	   is	   important	   for	   kinase	   activity.	   These	   results	   suggest	   that	  there	  are	  key	  residues,	  which	  need	  to	  be	  autophosphorylated	  in	  order	  to	  facilitate	  enzymatic	   activity.	   Taken	   together,	   these	   results	   support	   a	   model	   of	   LRRK2	  regulation	  in	  which	  enzymatic	  activity	  and	  quaternary	  structure	  are	  closely	  linked.	  	  
3.3.1	  	  Future	  directions	  The	  results	  of	  these	  experiments	  take	  steps	  towards	  understanding	  how	  full-­‐length	  LRRK2	  may	  be	   self-­‐regulating.	  As	   such,	   future	  experiments	   can	  build	  upon	   these	  findings.	   In	  particular,	  dephosphorylation	  of	  recombinant	  LRRK2	  and	  subsequent	  separation	   using	   glycerol	   gradients	   allows	   different	   species	   of	   LRRK2	   to	   be	  separated	   and	   characterised.	   In	   this	   study,	   kinase	   activity	   of	   monomeric	   and	  dimeric	  forms	  of	  LRRK2	  were	  assessed,	  however	  the	  technique	  allows	  for	  analysis	  of	  GTPase	  activity	  and	  assessment	  of	  GTP	  binding	  in	  these	  LRRK2	  species.	  	  Identification	   of	   the	   residues	   controlling	   dimerisation	   is	   an	   important	   goal	   in	  understanding	  LRRK2	  regulation.	   Identification	  of	   these	  residues	  could	  provide	  a	  marker	  for	  LRRK2	  activation	  in	  cell	  culture	  and	  allow	  the	  role	  of	  LRRK2	  in	  signal	  transduction	  to	  be	  better	  understood.	  There	  have	  been	  many	  attempts	  to	  map	  the	  phosphosites	  of	  LRRK2,	  with	  much	  success	  as	  detailed	  in	  Table	  1.3.	  As	  such,	  there	  are	   a	  number	  of	   possible	   candidates	   for	   the	   residues,	  which	   could	  be	  promoting	  LRRK2	  dimerisation.	  Of	  these,	  S971,	  S973,	  S975,	  S976	  and	  S979	  in	  the	  N-­‐terminus	  are	  contained	   in	   the	  ΔN-­‐LRRK2	   fusion	  protein	   (they	  appear	  after	   the	   truncation)	  and	  are	  good	  candidates	   for	  regulatory	  amino	  acids,	  as	   they	  are	  not	  contained	   in	  the	  enzymatic	  domains.	  In	  this	  case	  it	  is	  likely	  that	  they	  have	  an	  alternate	  function	  such	   as	  mediation	   of	   quaternary	   structure.	   Systematic	  mutagenesis	   of	   candidate	  residues	  to	  alanine	  or	  glycine,	  followed	  by	  analysis	  of	  quaternary	  structure,	  should	  allow	   important	   residues	   for	   dimer	   regulation	   to	   be	   identified.	   Once	   discovered,	  the	  effect	  of	  mutating	  these	  residues	  in	  overexpressed	  protein	  can	  be	  assessed	  in	  terms	   of	   enzymatic	   activity	   and	   quaternary	   structure.	   Generation	   of	   phospho-­‐
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antibodies	   could	   provide	   a	   readout	   of	   LRRK2	   activation	   in	   cell	   models	   and	  contribute	  to	  the	  understanding	  of	  LRRK2	  functioning	  in	  vivo.	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 4.	   THE	  EFFECT	  OF	  MUTATIONS	  ON	  
LRRK2	  STRUCTURE	  AND	  FUNCTION
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  4.	  1	  INTRODUCTION	  Mutations	   in	   LRRK2	   have	   been	   shown	   to	   cause	   autosomal	   dominant	   PD.	   The	  majority	  of	   these	  mutations	  are	   situated	   in	   the	  ROC,	  COR	  and	  kinase	  domains	  of	  LRRK2,	   suggesting	   that	   they	   are	   likely	   to	   affect	   the	   enzymatic	   outputs	   of	   this	  protein.	   Indeed	   in	  vitro	   analysis	   of	   the	  most	   common	  mutations	   has	   shown	   that	  G2019S	   consistently	   increases	   kinase	   activity	   (reviewed	   in	   Greggio	   et	   al.	   2009),	  and	  Y1699C	  and	  R1441C	  seem	  to	  be	  decreasing	  GTP	  hydrolysis	  (Lewis	  et	  al.	  2007,	  Daniels	  et	  al.	  2011).	  The	  relationship	  between	  enzymatic	  activity	  and	  quaternary	  structure	   has	   been	   shown	   in	   LRRK2	  with	   artificially	   induced	   kinase	   and	  GTPase	  dead	  mutations.	  These	  proteins	  overexpressed	  in	  cells	  have	  been	  shown	  to	  display	  an	  inability	  to	  form	  dimers	  and	  instead	  adopt	  higher	  molecular	  weight	  structures	  (>	   1MDa),	   which	   possibly	   consist	   of	   aggregated	   LRRK2	   (Greggio	   et	   al.	   2008).	   In	  mutation	   carriers,	   LRRK2	  has	   also	  been	   shown	   to	   aggregate	   in	  vivo,	  with	  LRRK2	  shown	   in	   some	   LBs	   and	   other	   intracellular	   inclusions	   in	   the	   brainstem	   (Alegre-­‐Abarrategui	   et	   al.	   2008).	   In	   this	   case,	   it	   would	   seem	   likely	   that	   LRRK2	   complex	  formation	  could	  be	  affected	  by	  familial	  mutations.	  LRRK2	  has	  been	  shown	  to	  form	  robust	  interactions	  with	  HSP90	  (Hurtado-­‐Lorenzo	  et	  al.	  2008)	  and	  14-­‐3-­‐3	  and	  for	  14-­‐3-­‐3,	   this	   interaction	   has	   been	   shown	   to	   be	   affected	   by	   familial	   mutations	  (Dzamko	  et	  al.	  2010,	  Nichols	  et	  al.	  2010,	  Li	  X.	  et	  al.	  2011).	   If	   the	  main	  function	  of	  LRRK2	   is	   to	   serve	   as	   a	   scaffold	   that	   is	   regulated	   by	   enzymatic	   activity,	   it	  would	  seem	   likely	   that	   complex	   formation	   is	   affected	   by	   the	   presence	   of	   familial	  mutations	  and	  that	  these	  mutations	  change	  the	  propensity	  of	  the	  protein	  to	  form	  dimers.	   In	   turn,	   mutations	   may	   alter	   the	   affinity	   of	   LRRK2	   for	   its	   interacting	  partners	  and	  therefore	  affect	  the	  size	  of	  the	  complexes	  that	  contain	  LRRK2.	  	  	  To	   assess	   the	   impact	   of	   familial	   mutations	   on	   the	   ability	   of	   LRRK2	   to	   form	  complexes,	   WT	   and	   mutated	   forms	   of	   ΔN-­‐LRRK2	   were	   analysed	   using	   BN	  electrophoresis	   and	   the	   difference	   between	   monomeric	   and	   dimeric	   LRRK2	  assessed	  for	  each	  of	  these	  mutants.	  These	  results	  were	  compared	  to	  BN	  analysis	  of	  LRRK2	  extracted	  from	  fibroblasts	  donated	  by	  patients	  carrying	  LRRK2	  mutations,	  in	  order	  to	  understand	  the	  role	  of	  interacting	  proteins	  in	  this	  process	  and	  to	  assess	  any	   changes	   in	   complex	   formation	   that	  may	   be	   occurring.	   The	   kinase	   activity	   of	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ΔN-­‐LRRK2	   in	   WT	   and	   mutated	   forms	   was	   assessed	   using	   MBP	   and	  autophosphorylation,	   to	   understand	   how	   familial	   mutations	   are	   affecting	   the	  enzymatic	  activity	  of	  LRRK2	   in	  vitro	   and	   the	  possible	   role	   they	  may	  be	  having	   in	  altering	  the	  behaviour	  of	  LRRK2,	  which	   leads	  to	   the	  pathogenesis	  of	  AD	  forms	  of	  PD.	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 4.1.1	  	  Hypotheses	  Experiments	  were	  designed	  to	  address	  the	  following	  hypotheses.	  	   1) ΔN-­‐LRRK2	  is	  able	  to	  form	  dimers.	  2) Familial	  mutations	   in	   LRRK2	   alter	   the	   propensity	   of	   this	   protein	   to	   form	  dimers	  and	  complexes.	   It	   is	  hypothesized	  that	  ΔN-­‐LRRK2	  carrying	   familial	  mutations	   are	   more	   likely	   for	   form	   dimeric	   as	   opposed	   to	   monomeric	  species.	  	  3) LRRK2	  forms	  complexes	  with	  other	  protein	  in	  vivo.	  4) The	   ability	   of	   LRRK2	   to	   form	   complexes	   in	   vivo	   is	   affected	   by	   familial	  mutations.	  	  
 4.1.2	   	  	  Aims	  These	  hypotheses	  will	  be	  tested	  through	  fulfillment	  of	  the	  following	  aims.	  	   1) To	  examine	  LRRK2	  dimer	  formation	  in	  WT	  and	  mutated	  forms	  using	  recombinant	  ΔN-­‐LRRK2	  and	  endogenous	  LRRK2	  from	  PD	  patient	  fibroblasts	  carrying	  LRRK2	  mutations.	  	  2) To	  assess	  any	  differences	  in	  binding	  partners	  of	  WT	  and	  mutated	  LRRK2.	  3) To	  determine	  the	  effect	  of	  familial	  mutations	  on	  the	  kinase	  activity	  of	  ΔN-­‐	  LRRK2.	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4.2	  RESULTS	  
4.2.1	  Assessment	  of	  endogenous	  LRRK2	  complex	  formation	  
4.2.1.1	  	  Mutant	  ΔN-­‐LRRK2	  forms	  monomeric	  and	  dimeric	  species	  Analysis	  of	  recombinant	  ΔN-­‐LRRK2,	  shows	  that	  both	  WT	  and	  mutant	  forms	  of	  the	  are	   present	   in	   dimeric	   and	   monomeric	   form	   (Figure	   4.1b).	   The	   kinase-­‐dead	  (D1994A)	  form	  of	  ΔN-­‐LRRK2	  is	  also	  dimeric,	  which	  contradicts	  data	  from	  analysis	  of	   full	   length	  LRRK2,	  both	   in	  endogenous	  and	  overexpressed	   form	  (Greggio	  et	  al.	  2008,	  Sen	  et	  al.	  2009,	  Berger	  et	  al.	  2010).	  Similarly,	   there	   is	  a	  high	  proportion	  of	  monomeric	   species	   in	   these	   experiments	   across	   mutant	   and	   wild	   type	   forms,	  which	   has	   been	   shown	   to	   be	   less	   abundant	   when	   LRRK2	   from	   cells	   has	   been	  analysed	  (Greggio	  et	  al.	  2008,	  Sen	  et	  al.	  2009).	  Plotting	  densitometry	  values	  along	  the	  path	  of	  LRRK2	  migration	  (Figure	  4.1c)	   to	  analyse	  the	  size	  distribution	  of	   this	  protein,	  confirmed	  that	  there	  are	  two	  peaks	  at	  around	  200	  and	  400	  kDa,	  with	  some	  protein	  corresponding	  to	  higher	  molecular	  weights	  (over	  400	  kDa).	  Interestingly,	  despite	   equal	   loading	   of	   protein,	   the	   I2020T	   and	   R1441C	   mutants	   consistently	  showed	   lower	   band	   intensity.	   As	   purity	   for	   all	   mutations	   is	   similar	   as	   >80%	  (Invitrogen),	  this	  raises	  the	  possibility	  that	  the	  solubility	  of	  these	  forms	  of	  LRRK2	  could	   be	   affected	   by	   the	   mutations,	   as	   BN	   analysis	   is	   dependent	   on	   protein	  solubility	  to	  facilitate	  migration.	  	  	  To	  assess	  if	  mutations	  are	  affecting	  the	  preference	  of	  protein	  to	  be	  in	  a	  monomeric	  or	   dimeric	   conformation,	   the	   ratio	   of	   dimer:	   monomer	   for	   each	   mutation	   was	  assessed.	   Average	   values	   for	   each	   peak,	   were	   generated	   by	   measuring	  densitometry	  values	  for	  a	  fixed	  area	  and	  ratios	  calculated.	  It	  was	  shown	  that	  there	  is	  no	  significant	  difference	  in	  the	  means	  of	  these	  ratios	  (p=0.0876).	  This	  suggests	  that	   point	   mutations	   are	   not	   affecting	   the	   preferred	   quaternary	   structure	   of	   Δ-­‐LRRK2.	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Figure	  4.1a.	   Coomassie	   stain	   of	  ΔN-­‐LRRK2	  protein.	  Equal	  amounts	  of	  protein	  were	  analysed	  for	  each	  mutant.	  LRRK2	  is	  present	  as	  a	  band	  of	  ~200kDa.	  Molecular	  weight	  markers	  are	   indicated	  on	  the	   left	   (kDa).	   4.1b.	   Silver	   stain	   of	  ΔN-­‐LRRK2	  
analysed	   under	   non-­‐denaturing	   conditions.	   Equal	   amounts	   of	   each	   protein	  were	  analysed	  under	  BlueNative	  conditions	  and	  gels	  subsequently	  silver-­‐stained	  to	  visualize	  complex	  formation.	   Image	   is	  representative	  of	   three	  experiments.	   4.1c.i	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Figure	  4.1c	   (continued).	   ii-­‐D1994A	  kinase	  dead	  iii-­‐G2019S	  iv-­‐I2020T	  v-­‐R1441C	  vi-­‐Y1699C.	   4.1d.	   Ratio	   of	   monomer:	   dimer	   formation	   for	   LRRK2	   WT	   and	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4.1.2.2	  	  Familial	  mutations	  do	  not	  affect	  LRRK2	  quaternary	  structure	  ex	  vivo	  To	  assess	   the	   impact	   of	   familial	  mutations	  on	  LRRK2	   in	  vivo,	   that	   is	   endogenous	  LRRK2	  in	  its	  native	  complexed	  state,	  protein	  was	  extracted	  from	  fibroblasts,	  which	  are	  heterozygous	  for	  the	  mutations	  R1441G,	  Y1699C	  and	  G2019S.	  This	  protein	  was	  used	   in	  BN	  PAGE	   to	  assess	  any	  changes	   to	  complex	   formation.	  Recently,	   a	   rabbit	  polyclonal	   raised	  against	   the	  C-­‐terminal	  peptide	  CELAEKMRRTSV,	  has	  been	  used	  successfully	   for	   immunohistochemistry	   on	   human	   brain	   tissue	   and	   shown	   to	  recognize	  endogenous	  LRRK2	  (Alegre-­‐Abarrategui	  et	  al.	  2009).	  This	  antibody	  has	  since	   been	   made	   commercially	   available	   and	   was	   therefore	   used	   for	   western	  blotting	  of	   protein	   extracted	   from	   fibroblasts	  with	  R1441G,	  Y1699C	  and	  G2019S	  mutations,	  and	  those	  from	  unaffected	  siblings	  used	  as	  controls	  (see	  Table	  2.1).	  
	  
Figure	  4.2a.	  SDS-­‐PAGE	  analysis	  of	  LRRK2	  levels	  in	  human	  fibroblasts.	  WT	  Fib	  –Wild	  Type	  human	   fibroblast	   lysate.	  Whole	   cell	   lysate	  was	   separated	  using	   SDS-­‐PAGE	  and	  probed	   for	  LRRK2	   (upper	  panel)	   and	  β-­‐actin	   (lower	  panel).	  Molecular	  weight	  markers	  are	  shown	  on	   the	   left	   (kDa).	  b.	   Blue	  Native	   analysis	   of	   LRRK2	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Western	   blotting	   showed	   that	   LRRK2	   is	   expressed	   at	   low	   levels	   in	   fibroblasts	  (Figure	  4.2a).	  Analysis	  using	  BN-­‐PAGE	  detected	  the	  presence	  of	  LRRK2	  at	  around	  600kDa,	  which	   is	   the	  expected	  size	   for	  a	  dimer	  and	  also	   lower	  molecular	  weight	  immunoreactivity	   around	   260kDa,	   which	   corresponds	   to	   a	   monomeric	   LRRK2	  species	   (Figure	   4.2).	   The	   resolution	   of	   these	   species	   is	   poor,	   likely	   due	   to	   the	  limitations	   of	  western-­‐blotting	   blue	   native	   protein	   caused	   by	   the	   interference	   of	  coomassie	  with	  the	  transfer	  process	  (Eubel	  et	  al.	  2005),	  however	  this	  data	  would	  appear	   to	   show	   that	   endogenous	   LRRK2	   extracted	   from	  patients	   expressing	  WT	  and	  mutated	   forms	  of	   the	   kinase	   is	   present	   in	   two	  main	   forms;	   lower	  molecular	  weight	   forms	   corresponding	   to	   monomeric	   and	   dimeric	   LRRK2	   and	   a	   higher	  weight	  complex	  at	  around	  1.2	  MDa.	  These	  protein	  complexes	  are	  not	  affected	  by	  the	  presence	  of	  familial	  mutations,	  suggesting	  that	  familial	  point	  mutations	  do	  not	  disrupt	   binding	   of	   LRRK2	   to	   interacting	   partners,	   or	   of	   dimer	   formation,	   as	  discussed.	  	  	  
4.1.2.3	  	  ΔN-­‐LRRK2	  displays	  kinase	  activity	  that	  is	  affected	  by	  familial	  
mutations	  The	   recombinant	   ΔN-­‐LRRK2	   GST-­‐fusion	   protein,	   has	   been	   shown	   to	   exhibit	  autophosphorylation	  activity	  and	  kinase	  activity	  towards	  the	  LRRKtide,	  a	  peptide	  derived	   in	   sequence	   from	   the	   ERM	  protein	  moesin	  (Jaleel	   et	  al.	   2007).	   Similarly,	  characterisation	  of	  this	  protein	  has	  shown	  robust	  autophosphorylation	  and	  kinase	  activity	   towards	   MBP	   when	   in	   WT	   and	   G2019S	   form	   (Anand	   et	   al.	   2009).	   The	  availablity	  of	  a	  recombinant	  form	  of	  LRRK2,	  means	  that	  the	  intrinsic	  kinase	  activity	  of	  the	  protein	  can	  be	  characterized,	  both	  in	  wild	  type	  (WT)	  and	  mutant	  form,	  as	  the	  G2019S,	   I2020T,	   R1441C	   and	   Y1699C	   substitutions	   are	   also	   commercially	  available.	  A	  kinase	  dead	  LRRK2	  mutant	  containing	  a	  D1994A	  substitution	  (West	  et	  
al.	   2007),	   was	   also	   used	   in	   these	   experiments	   to	   control	   for	   background	   kinase	  activity	  from	  co-­‐purified	  kinases.	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Figure	  4.3a.	  ΔN-­‐LRRK2	  phosphorylation	  of	  MBP	  assessed	  by	  radiography.	   i-­‐wild	   type.	   ii-­‐kinase	   dead.	   iii.	   G2019S.	   iv-­‐I2020T.	   v-­‐R1441C.	   vi-­‐Y1699C.	   Reaction	  mixtures	  were	   incubated	   for	   90	  mins,	  with	   time	   points	   taken	   as	   indicated.	  MBP	  consists	   of	   multiple	   isoforms	   with	   an	   average	   molecular	   weight	   of	   ~18kDa.	  Molecular	  weight	  markers	  are	  shown	  on	  the	  left	  (kDa).	  Images	  are	  representative	  of	   three	   experiments.	   4.3b.	   Quantification	   of	   MBP	   phosphorylation	   by	   ΔN-­‐
LRRK2.	  Radiometric	   images	  were	   quantified	   using	   densitometry	   and	   are	   shown	  here	  as	  mean	  values	  ±	  s.e.m	  (n=3).	  4.3c.	  MBP	  phosphorylation	  by	  LRRK2	  at	  90	  
mins.	   Final	   time	   points	   were	   taken	   and	   are	   displayed	   here	   as	   mean	   ±	   s.e.m	   *	  p<0.05,	  **	  p<0.01,	  (vs	  WT,	  One-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐test	  compared	  to	  WT).	  4.3d.	  Autophosphorylation	  of	  ΔN-­‐LRRK2.	  Autophosphorylation	  from	  MBP	  phosphorylation	   assays	   was	   quantified	   at	   the	   90	   mins	   time	   point	   using	  densitometry	  and	  is	  shown	  here	  as	  mean	  ±	  s.e.m	  (n=3).	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Quantification	  of	  MBP	  phosphorylation	  levels	  by	  ΔN-­‐LRRK2,	  showed	  that	  all	  forms	  of	  the	  protein	  displayed	  phosphorylation	  of	  MBP,	  apart	  from	  the	  artificial	  mutant	  D1994A.	   This	   lack	   of	   phosphorylation	   in	   this	   condition	   suggests	   there	   are	   low	  levels	   of	   co-­‐purified	   kinases	   with	   the	   ΔN-­‐LRRK2	   protein	   (Figure	   4.3aii,	   b).	  Statistical	   analysis	   of	   this	   increase	   showed	   it	   to	   be	   significant	   compared	   to	  WT	  (p<0.01).	   The	   I2020T	   substitution	   appeared	   to	   decrease	   kinase	   activity	   towards	  MBP	  when	  compared	  to	  WT,	  however	  this	  difference	  was	  not	  significant	  (p>0.05).	  Similarly	   Y1699C	   ΔN-­‐LRRK2	   showed	   a	   trend	   towards	   increased	   MBP	  phosphorylation	   compared	   to	   WT,	   but	   this	   difference	   was	   also	   non-­‐significant	  (p>0.05).	   R1441C	   was	   shown	   to	   have	   significantly	   decreased	   kinase	   activity	  compared	  to	  WT	  (p<0.05).	  	  
4.1.2.4	  	  The	  effect	  of	  familial	  mutations	  on	  autophosphorylation	  As	  well	   as	   pseudosubstrate	   phosphorylation,	   catalytically	   active	   forms	   of	   LRRK2	  exhibited	   robust	   autophosphorylation.	  As	   expected,	   kinase	  dead	  D1994A	  did	  not	  display	   autokinase	   activity.	   In	   order	   to	   compare	   activity	   between	   LRRK2	  mutations,	   autophosphorylation	   was	   quantified	   using	   densitometry.	   Similar	   to	  MBP	   phosphorylation	   (Figure	   4.3c),	   G2019S	   autophosphorylation	   activity	   was	  significantly	  increased	  compared	  to	  WT	  (p<0.01,	  One-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐test).	   Interestingly,	   Y1699C	   also	   showed	   a	   significantly	   increased	  autophosphorylation	   compared	   to	  WT	  ΔN-­‐LRRK2	   (p<0.01).	   I2020T	   and	   R1441C	  both	   displayed	   a	   trend	   towards	   reduced	   autophosphorylation	   compared	   to	  WT,	  however,	  this	  difference	  was	  not	  significant	  (p>0.05	  for	  both).	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4.3	  	  DISCUSSION	  These	   experiments	   were	   successful	   in	   their	   aims	   to	   investigate	   the	   effects	   of	  familial	  mutations	  on	  LRRK2	  quaternary	  structure	  and	  kinase	  activity.	  The	  results	  obtained	  suggest	  that	  these	  amino	  acid	  substitutions	  are	  more	  likely	  to	  be	  affecting	  the	   enzymatic	   outputs	   of	   this	   protein,	   than	   the	   ability	   to	   form	   complexes.	   BN	  analysis	  shows	  that	  ΔN-­‐LRRK2	  has	  the	  propensity	  to	  dimerise	  and	  that	  the	  ratio	  of	  monomeric:	   dimeric	   species	   is	   unchanged	   in	   the	   presence	   of	   point	   mutations	  (Figure	   4.1d).	   In	   protein	   extracted	   from	   fibroblasts,	   there	  was	   also	   no	   apparent	  change	   in	  complex	  size	   for	  mutant	  LRRK2	  compared	  to	  WT	  (Figure	  4.2b).	  Due	  to	  the	  limitations	  of	  BN	  analysis,	  differences	  in	  terms	  of	  monomer:	  dimer	  ratios	  could	  not	  be	  investigated	  in	  these	  experiments.	  Characterisation	  of	  the	  kinase	  activity	  of	  
ΔN-­‐LRRK2	  showed	  that	  this	  protein	  is	  kinase	  active	  when	  in	  WT	  and	  mutant	  forms,	  with	  the	  D1994A	  substitution	  reducing	  kinase	  activity	  to	  a	  negligible	  level	  (Figure	  4.3).	  G2019S	  was	  shown	  to	  increase	  the	  kinase	  activity	  of	  ΔN-­‐LRRK2	  and	  R1441C	  significantly	  reduced	  the	  kinase	  activity	  of	  this	  protein.	  Autophosphorylation	  was	  increased	   in	   both	   the	   G2019S	   and	   Y1699C	   conditions,	   with	   no	  autophosphorylation	  shown	  in	  assays	  with	  D1994A	  (Figure	  4.3d).	  	  	  The	  absence	  of	  the	  N-­‐terminal	  of	  ΔN-­‐LRRK2,	  shows	  that	  this	  region	  of	  the	  protein	  not	  is	  required	  for	  dimerisation	  or	  kinase	  activity,	  suggesting	  instead	  a	  regulatory	  role	   (Greggio	   et	   al.	   2009),	   or	   function	   in	   mediating	   the	   cellular	   localization	   of	  LRRK2.	  It	  is	  perhaps	  unsurprising	  that	  point	  mutations	  do	  not	  result	  in	  a	  complete	  disruption	  of	  dimerisation,	  given	  that	  this	  would	  translate	  to	  a	  loss	  of	  function.	  The	  data	   published	   regarding	   the	   kinase	   activity	   of	   G2019S	   (West	   et	   al.	   2005)	   have	  shown	   that	   this	   mutation	   increases	   the	   kinase	   activity	   of	   LRRK2,	   more	   likely	  resulting	  in	  a	  gain	  of	  function.	  Similarly,	  functioning	  of	  the	  ROC	  domain	  is	  thought	  to	   be	   dependent	   on	   dimerisation	   (Gasper	   et	  al.	   2009)	   and	   although	  R1441C	   and	  Y1699C	  have	  been	  shown	  to	  decrease	  GTP	  hydrolysis	  (Lewis	  et	  al.	  2007,	  Daniels	  et	  
al.	  2011),	  dimerisation	  is	  likely	  to	  be	  necessary	  for	  GTPase	  activity	  to	  occur	  at	  all.	  In	   this	   case	   it	   is	   likely	   that	   changes	   in	   the	   conformation	   of	   LRRK2	  mutants	   are	  occurring	  at	  a	  local	  level,	  as	  suggested	  by	  structural	  investigation	  into	  the	  R1441C	  mutation	  (Deng	  J.	  et	  al.	  2008,	  Li	  Y.	  et	  al.	  2009).	  To	  fully	  understand	  these	  changes,	  a	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crystal	  structure	  of	   full	   length	  LRRK2	  and	  therefore	  knowledge	  about	   the	  overall	  topology	  of	  LRRK2	  is	  needed.	  	  	  If	   dimeric	   LRRK2	   is	   the	   active	   form	   of	   this	   protein,	  with	  monomeric	   LRRK2	   the	  inactive	   form,	   it	  would	   seem	  plausible	   that	   familial	  mutations	   could	   increase	   the	  proportion	   of	   dimeric	   species.	   Similarly,	   if	   autophosphorylation	   mediates	   dimer	  formation	  and	  autophosphorylation	  is	  increased	  in	  G2019S	  and	  Y1699C	  ΔN-­‐LRRK2	  (Figure	  4.1)	  then	  it	  would	  be	  logical	  to	  assume	  that	  these	  mutants	  display	  a	  higher	  proportion	  of	  dimeric	  species.	  This	  was	  shown	  not	  to	  be	  the	  case	  in	  vitro	  for	  these	  experiments	   and	   monomer:	   dimer	   ratio	   was	   shown	   to	   be	   unchanged	   for	   all	  mutations,	   including	   the	   artificial	   kinase-­‐dead	   D1994A	   mutation	   (Figure	   4.1d).	  Importantly,	  the	  dimeric	  species	  seen	  in	  the	  D1994A	  mutant,	  are	  in	  stark	  contrast	  with	   results	   from	   other	   groups	   using	   full	   length	   forms	   of	   LRRK2,	   which	   have	  shown	  that	  kinase	  dead	  LRRK2	  is	  unable	  to	  dimerise	  (Greggio	  et	  al.	  2008,	  Berger	  et	  
al.	  2010)	  and	  (Sen	  et	  al.	  2009).	  The	  most	  likely	  explanation	  for	  this	  is	  the	  GST-­‐tag	  fused	  to	  the	  N-­‐terminus	  of	  the	  ΔN-­‐LRRK2	  protein.	  GST	  has	  been	  shown	  to	  dimerise	  (Hayes	  et	  al.	  1982),	  and	  a	  GST	  tag	  can	  be	  used	  in	  vitro	  to	  promote	  dimerisation	  in	  the	  absence	  of	  chaperone	  proteins	  or	  oligomerisation	  domains	  (Baer	  et	  al.	  2001).	  In	   this	   case,	   it	  would	   seem	   likely	   that	   the	   GST	   tag	   is	   affecting	   the	   ability	   of	  ΔN-­‐LRRK2	  to	  dimerise.	  Similarly,	  GST	  tags	  are	  often	  used	  to	  improve	  the	  solubility	  of	  proteins	  fused	  to	  them	  (reviewed	  in	  Esposito	  et	  al.	  2006).	  As	  such,	  the	  abundance	  of	   monomeric	   species	   seen	   in	   these	   experiments	   could	   be	   due	   to	   an	   improved	  solubility	  afforded	  by	  the	  tag,	  which	  is	  not	  seen	  in	  overexpressed	  LRRK2	  from	  cells.	  	  Silver	   staining	   of	   BN	   gels	   showed	   that	   the	   staining	   intensity	   for	   I2020T	   and	  R1441C	  was	   about	   half	   that	   of	   the	   other	  mutants	   (Figure	   4.1c	   iv,	   v),	   suggesting	  perhaps	   that	   these	   mutants	   are	   less	   soluble	   than	   WT.	   Indeed	   this	   has	   been	  previously	  suggested	  for	  the	  R1441C	  mutation	  (Li	  Y.	  et	  al.	  2009).	  The	  guaranteed	  purity	   of	   this	   protein	   is	   >80%	   (Invitrogen)	   suggesting	   that	   this	   is	   not	   due	   to	  differing	  concentrations	  of	  LRRK2	  (if	   this	  were	  the	  case,	  staining	   intensity	  would	  be	  at	  most	  ~20%	  less).	  This	  raises	  the	  possibility	  that	  decreased	  solubility	  of	  some	  mutations	  and	  therefore	  lower	  levels	  of	  LRRK2	  protein	  occur	  in	  patients	  with	  PD.	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As	   such,	   further	   investigation	   is	   needed	   to	   ascertain	   this	  mechanism	   could	   be	   a	  potential	  factor	  in	  the	  pathogenesis	  of	  PD	  in	  patients	  carrying	  familial	  mutations.	  	  The	   results	   of	   studies	   looking	   at	   the	   kinase	   activity	   of	   LRRK2	   carrying	   familial	  mutations	   are	   in	   agreement	   with	   those	   from	   existing	   studies,	   which	   show	  differential	   ability	   of	  ΔN-­‐LRRK2	   to	   phosphorylate	   a	   target	   protein	   depending	   on	  the	  mutation	  that	  is	  carried	  (Anand	  et	  al.	  2009).	  The	  ablation	  of	  kinase	  activity	  in	  the	   D1994A	   mutant,	   emphasizes	   the	   importance	   of	   this	   reside	   for	   functional	  enzyme	   activity.	   The	   lack	   of	   background	   kinase	   activity	   with	   this	   mutant	   also	  shows	   that	   minimal	   co-­‐purification	   of	   other	   kinases	   has	   occurred	   and	   that	   the	  kinase	   activity	   displayed	   in	   likely	   attributed	   to	   the	   ΔN-­‐LRRK2	   protein.	   In	   the	  Wyeth	   study,	   which	   originally	   characterized	   ΔN-­‐LRRK2,	   the	   G2019S	   mutant	  displayed	   significantly	   increased	   autophosphorylation	   activity	   compared	   to	   WT,	  findings	  which	  were	  replicated	  here.	  Similarly,	  phosphorylation	  of	  the	  LRRKtide	  by	  G2019S	   was	   also	   increased	   compared	   to	   WT,	   which	   was	   replicated	   in	   these	  experiments	   using	   MBP	   as	   a	   substrate	   (Figure	   4.3a).	   Interestingly,	   Anand	   et	   al	  (2009)	   showed	   that	   the	  G2019S	  mutation	   lowers	  affinity	   for	  ATP	   in	   this	  mutant,	  whilst	   increasing	   kinase	   activity	   by	   keeping	   the	   protein	   in	   an	   ‘on’	   conformation,	  which	   could	   explain	   the	   increased	   activity	   in	   these	   experiments.	   For	   the	   other	  mutations,	   assessing	   kinase	   activity	   using	   32P	   incorporation	   into	   the	   LRRK2tide	  showed	  no	  differences	  but	  specific	  activity	  of	  R1441C	  was	  higher	  and	  I2020T	  was	  lower.	   In	   these	   experiments	   R1441C	   exhibited	   lower	  MBP	   phosphorylation	   than	  WT,	   with	   no	   difference	   in	   the	   activity	   of	   I2020T.	   The	   reduced	   levels	   of	   soluble	  protein	   for	   R1441C	   and	   I2020T	   (Figure	   4.3a)	   suggests	   that	   the	   actual	   levels	   of	  kinase	  activity	  for	  these	  mutants	  may	  be	  higher.	  	  The	   differences	   in	   results	   between	   this	   study,	   and	   the	   experiments	   done	   by	   the	  Wyeth	  group,	  are	  likely	  attributed	  to	  differences	  in	  the	  techniques	  used.	  Anand	  et	  
al	  used	  the	  LRRK2tide	  as	  a	  substrate	  for	  their	  kinase	  assays,	  for	  which	  LRRK2	  has	  a	  higher	  affinity	  than	  MBP	  (Jaleel	  et	  al.	  2007).	  This	  may	  affect	  autophosphorylation,	  as	  autokinase	  activity	  of	  LRRK2	  can	  differ	  depending	  on	  the	  substrate	  being	  used.	  The	  different	  techniques	  used	  in	  the	  Wyeth	  paper	  and	  these	  experiments	  (FRET	  vs	  autoradiography	  followed	  by	  densitometry	  respectively)	  could	  account	  for	  some	  of	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the	   differences	   in	   results.	   Indeed,	   within	   experiments,	   different	   techniques	   gave	  different	  results	  for	  the	  activity	  of	  R1441C	  and	  I2020T	  in	  the	  results	  published	  by	  Anand	  et	  al.	  Differences	  between	  these	  mutants	  and	  WT	  were	  not	  identified	  using	  32P	  incorporation	  into	  the	  LRRK2tide	  to	  assess	  kinase	  activity,	  but	  only	  when	  FRET	  was	  used	  to	  look	  the	  activities	  of	  individual	  mutants.	  A	  review	  of	  the	  kinase	  results	  from	   different	   groups	   (Greggio	   et	   al.	   2009)	   also	   has	   shown	   that,	   apart	   from	  G2019S,	   data	   from	   other	   mutants	   is	   variable	   depending	   on	   technique	   used	   to	  analyse	   kinase	   activity.	   When	   compared	   to	   results	   from	   other	   groups,	   the	   data	  contained	  in	  these	  experiments	  also	  support	  this	  idea.	  	  
4.3.1	  Future	  directions.	  BN	  analysis	  of	  LRRK2	  extracted	  from	  cells	  shows	  that	  this	  protein	  is	  present	   in	  a	  high	   molecular	   weight	   complex	   of	   around	   1.2	   MDa.	   The	   next	   important	   step	   in	  understanding	   LRRK2	   functioning,	   for	   these	   experiments	   is	   to	   identify	   the	  components	  of	  this	  complex	  using	  immunoprecipitation.	  It	  has	  been	  suggested	  that	  LRRK2	  may	  function	  in	  a	  number	  of	  signaling	  cascades	  including	  ERK,	  mTOR	  and	  JNK.	   Activation	   of	   these	   pathways	   using	   the	   appropriate	   ligands	   or	   metabolic	  stimuli,	   should	   allow	   for	   analysis	   of	   any	   changes	   to	   this	   complex	   and	   possible	  identification	  of	  any	  new	  binding	  partners.	  	  The	  use	  of	  generic	  substrates	   to	  characterise	  LRRK2	  kinase	  activity	  perhaps	  tells	  us	   little	   about	   PD	   pathogenesis,	   as	   we	   cannot	   be	   sure	   that	   these	   results	   will	  translate	   to	   a	   cellular	   context	   in	   which	   LRRK2	   is	   heavily	   regulated	   and	  undoubtedly	  behaves	  differently	  than	  in	  vitro.	  As	  the	  exact	  details	  of	  this	  regulation	  are	   unknown,	   it	   could	   turn	   out	   that	   instead	   of	   hyperactivating	   a	   downstream	  component,	   familial	  mutations	  in	  LRRK2	  over-­‐repress	  interacting	  proteins,	  which	  results	   in	   reduced	   signaling.	   In	   this	   case,	   identifying	   LRRK2	   kinase	   substrates	   is	  crucial	  to	  assess	  the	  effect	  of	  familial	  mutations	  in	  vivo	  and	  to	  identify	  therapeutic	  targets.	   An	   interesting	   question	   regarding	   regulation	   of	   LRRK2,	   is	   the	   effect	   that	  14-­‐3-­‐3	   may	   be	   having	   on	   LRRK2	   kinase	   activity.	   This	   could	   be	   investigated	   by	  using	   recombinant	   14-­‐3-­‐3	   added	   to	   kinase	   assays,	   or	   co-­‐immunoprecipitation	   of	  overexpressed	  LRRK2	  and	  14-­‐3-­‐3.	   In	  this	  way,	   the	  effect	  of	   familial	  mutations	  on	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LRRK2	  kinase	  activity	  could	  also	  be	  assessed	  to	  characterise	  the	  role	  that	  changes	  in	  LRRK2	  kinase	  activity	  are	  playing	  in	  PD	  pathogenesis.	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 5.	   IDENTIFICATION	  OF	  NOVEL	  LRRK2	  
INTERACTING	  PROTEINS	  AND	  KINASE	  
SUBSTRATES
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5.1	  INTRODUCTION	  Although	   LRRK2	   is	   classified	   as	   a	   kinase,	   the	   large	   number	   of	   protein-­‐protein	  interaction	  domains	  it	  contains,	  suggests	  that	  a	  major	  function	  of	  the	  protein	  is	  to	  serve	   as	   a	   scaffold.	   LRRK2	   has	   been	   shown	   to	   associate	   with	   Hsp90	   in	   vivo	  (Hurtado-­‐Lorenzo	   et	   al.	   2008)	   and	   14-­‐3-­‐3	   has	   been	   shown	   to	   bind	   to	  phosphorylated	  residues	  in	  the	  N-­‐terminus	  of	  LRRK2	  (Dzamko	  et	  al.	  2010,	  Nichols	  
et	  al.	   2010,	   Li	  X.	  et	  al.	   2011).	  The	  phosphorylation	  of	   S910	  and	  S930	   residues	   in	  LRRK2	   has	   been	   attributed	   to	   an	   exogenous	   kinase,	   therefore	   LRRK2	   must	   be	  interacting	   with	   another	   kinase.	   Similarly,	   this	   must	   also	   mean	   that	   there	   is	   a	  phosphatase	  linked	  to	  LRRK2	  that	  is	  yet	  to	  be	  identified.	  	  	  Many	   kinase	   substrates	   for	   LRRK2	   have	   been	   suggested,	   however	   there	   is	   little	  consensus	   on	   a	   single	   target.	   There	   are	   many	   kinases	   with	   a	   large	   number	   of	  substrates,	   Cdk1	   is	   known	   to	   have	   more	   than	   200	   phosphorylation	   targets	  (Ubersax	  et	  al.	  2003).	  In	  this	  case	  it	   is	  possible	  that	  LRRK2	  also	  phosphorylates	  a	  high	   number	   of	   substrates.	   Despite	   this,	   no	   single	   kinase	   substrate	   has	   been	  confirmed	  by	  more	  than	  one	  group.	  Conversely,	  many	  groups	  believe	  that	  LRRK2	  is	  not	  a	  genuine	  kinase	  and	  uses	  kinase	  activity	   to	   instead	  regulate	   its	  own	  activity	  (reviewed	   in	   Greggio	   et	   al.	   2009).	   In	   order	   to	   understand	   the	   role	   of	   LRRK2	  physiological	   functioning,	   and	   in	   turn	   understand	   how	  mutations	   in	   this	   protein	  can	  contribute	  to	  Parkinson’s	  disease,	  it	  is	  important	  that	  these	  issues	  are	  clarified	  by	  identifying	  the	  binding	  partners	  and	  enzymatic	  targets	  of	  LRRK2.	  	  	  The	   transient	   nature	   of	   phosphorylation	   events	   makes	   identification	   of	   kinase	  substrates	  extremely	  difficult	  and	  many	  interactions	  are	  easily	  missed,	  even	  when	  cross	   linking	   by	   photoamino	   acids	   or	   disulphide	   linkers	   are	   used.	   Similarly	   ATP	  and	   organic	   phosphate	   are	   ubiquitous	   in	   cells	   and	   are	   used	   by	   all	   kinases,	   so	  tagging	  substrates,	   for	  example	  with	  32P	   is	  non-­‐specific	   for	   the	  kinase	  of	   interest.	  Using	  a	  technique	  coined	  ‘chemical	  genetics’	  (Shah	  et	  al.	  1997),	  Kevan	  Shokat’s	  lab	  first	   addressed	   the	   issue	   of	   kinase	   substrate	   tagging,	   through	   a	   combination	   of	  mutagenesis	   to	   change	   the	   structure	   of	   the	   ATP	   binding	   pocket,	   and	   addition	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chemistry	   to	   generate	   substituted	   forms	   of	   ATP,	   which	   do	   not	   occur	   naturally	  (Figure	  5.1).	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.1.	  N6-­‐modified	  ATPs	  commonly	  used	  to	  identify	  kinase	  substrates.	  a-­‐N6	  (2-­‐Benzyl)-­‐ATP.	  b-­‐N6(2-­‐Phenethyl)-­‐ATP	  .	  	  	  	  	  	  	  	  	  	  Using	   the	   tyrosine	   kinase	   v-­‐Src,	   the	   ATP	   pocket	  mutations	   V323A/	   I338A,	  were	  engineered	   into	   the	   overexpressed	   kinase	   and	   allowed	   v-­‐Src	   to	   accept	   the	   ATP	  analog	   N6-­‐(cyclopentyl)-­‐ATP	   preferentially	   to	   normal	   ATP.	   By	   incubating	   v-­‐Src	  with	   whole	   cell	   lysates,	   Shokat	   and	   colleagues	   were	   able	   to	   identifiably	   tag	   its	  substrates	   using	   32P	   γ-­‐labelled	   forms	   of	   the	   N6-­‐modified	   nucleotide.	   The	   group	  have	   since	   refined	   this	   method	   and	   identified	   a	   single	   residue,	   termed	   the	  ‘gatekeeper’	  which	  controls	  orientation	  of	  the	  γ-­‐phosphate	  and	  therefore	  entry	  of	  ATP	  to	  the	  ATP	  binding	  pocket	  (Liu	  et	  al.	  1998).	  LRRK2	  kinase	  substrates	  have	  yet	  to	   be	   convincingly	   shown	   in	   vivo,	   however	   serine/threonine	   kinases	   are	   best	  documented	   in	   terms	   of	   gatekeeper	   identification	   and	   mutation,	   and	   as	   such,	  LRRK2	  is	  a	  good	  candidate	  for	  modification	  using	  this	  approach.	  	  	  Immunoprecipitation	   is	   the	   most	   commonly	   used	   method	   for	   identifying	  interacting	   proteins.	   Tagged	   forms	   of	   overexpressed	   LRRK2	   were	   successfully	  utilised	  to	  identify	  14-­‐3-­‐3	  as	  LRRK2	  interactors	  (Dzamko	  et	  al.	  2010,	  Nichols	  et	  al.	  2010,	   Li	   X.	   et	   al.	   2011),	   however	   this	   technique	   also	   commonly	   causes	   false	  positive	  results	  due	  to	  the	  spatial	  constraints	  of	  overexpressing	  a	  single	  protein	  in	  vast	   numbers	   in	   a	   single	   cell.	   In	   successful	   immunoprecipitation	   of	   endogenous	  protein	  complexes	  remains	  to	  be	  the	  gold	  standard	  in	   identifying	  protein-­‐protein	  
a. b.
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interactions.	   The	   success	   of	   this	   technique	   depends	   on	   having	   a	   highly	   specific	  antibody	   that	   can	   recognise	   its	   target	   protein	   in	   native	   form.	   For	  many	   areas	   of	  research,	  including	  the	  LRRK2	  field	  it	  is	  the	  lack	  of	  specific	  antibodies	  that	  forms	  a	  bottleneck	   in	   the	   identification	   of	   proteins	   interacting	   with	   a	   gene	   product	   of	  interest.	   Recently,	   a	   rabbit	   polyclonal	   raised	   against	   the	   C-­‐terminal	   peptide	  CELAEKMRRTSV,	  has	  been	  used	  successfully	  for	  immunohistochemistry	  on	  human	  brain	  tissue	  and	  shown	  to	  recognize	  endogenous	  LRRK2	  (Alegre-­‐Abarrategui	  et	  al.	  2009).	  As	  such,	  this	  antibody	  is	  a	  possible	  candidate	  for	  use	  in	  endogenous	  LRRK2	  precipitation.	   Since	   publication,	   this	   antibody	   has	   been	   made	   commercially	  available	   (Everest	   Biotechnologies)	   and	   was	   used	   in	   these	   experiments	   to	  immunoprecipitate	   endogenous	   LRRK2	   from	   SH-­‐SY5Y	   cells,	   in	   an	   attempt	   to	  identify	  LRRK2	  interacting	  proteins.	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5.1.1	  	  Hypotheses	  	  Experiments	  were	  designed	  to	  address	  the	  following	  hypotheses.	  	  	   1) 	  LRRK2	  forms	  part	  of	  a	  complex	  in	  vivo.	  2) 	  LRRK2	  is	  a	  functional	  kinase	  and	  phosphorylates	  other	  proteins	  as	  a	  	  	  	  member	  of	  a	  signal	  transduction	  cascade.	  
5.1.2	  	  Aims	  	  These	  hypotheses	  will	  be	  tested	  through	  fulfillment	  of	  the	  following	  aims.	  	   1) To	   assess	   levels	   of	   LRRK2	   expression	   in	   laboratory	   cell	   types	   and	  subsequently	  evaluate	  LRRK2	  anti-­‐bodies	  for	  immunoprecipitation.	  	  2) To	  identify	  and	  modify	  the	  LRRK2	  gatekeeper	  residue	  3) To	  generate	  a	  modified	  form	  of	  LRRK2	  which	  accepts	  an	  N6-­‐modifed	  form	  of	  ATP.	  	  4) To	   use	   gatekeeper	   modified	   LRRK2	   and	   its	   corresponding	   ATP	  analogue	  to	  identify	  and	  validate	  LRRK2	  kinase	  substrates.	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5.2	   RESULTS	  
5.2.1	   Identification	  of	  LRRK2	  complex	  components.	  In	   order	   to	   identify	   the	   components	   of	   the	   1.2MDa	   complex	   observed	   from	   BN	  analysis	  (Figure	  4.2b),	  the	  expression	  levels	  of	  LRRK2	  in	  quickly	  dividing	  cell	  lines	  (as	   opposed	   to	   the	   primary	   fibroblast	   lines,	   which	   grow	   extremely	   slowly)	   was	  assessed	  using	  PCR	  based	   techniques,	  with	   the	  ultimate	  aim	  of	  using	   the	  Everest	  anti-­‐body	   to	   immunoprecipitate	   endogenous	   LRRK2.	   RNA	   was	   extracted	   from	  Hek293T,	  HT1080i,	  SH-­‐SY5Y	  and	  1321N1	  cells.	  To	  establish	  the	  quality	  of	  the	  RNA,	  1µl	  of	  total	  RNA	  was	  analysed	  using	  an	  Aglient	  2000	  chip	  to	  calculate	  RNA	  integrity	  (RIN,	  Schroeder	  et	  al.	  2006).	  	  	  
5.2.2.1.	  	  LRRK2	  expression	  assessed	  by	  Semi-­‐Quantitive	  PCR	  	  Analysis	  showed	  that	  the	  RNA	  was	  of	  good	  quality,	  as	  all	  samples	  had	  RIN	  numbers	  close	   to,	   or	   over	   9	   and	   are	   therefore	   suitable	   for	   reverse	   transcription	   and	  downstream	  analysis	  by	  PCR.	  Total	   cDNA	   from	  cell	   lines	  was	  generated	  and	  PCR	  performed.	  The	   level	  of	  LRRK2	  was	  normalised	   to	   that	  of	   a	  GAPDH	  PCR	  product	  from	   the	   same	   cDNA,	   in	  order	   to	   control	   for	  differences	   in	   the	   efficiency	  of	   each	  RT-­‐PCR	  reaction.	  All	  PCR	  reactions	  were	  performed	  in	  triplicate.	  	  Quantification	  of	  LRRK2	  PCR	  products	  from	  each	  cell	  type	  showed	  that	  there	  was	  a	  similar	  level	  of	  LRRK2	  mRNA	  in	  each	  sample	  (Figure	  5.2d).	  There	  was	  a	  trend	  for	  higher	  levels	  of	  LRRK2	  expression	  in	  Hek293T	  cells,	  but	  this	  difference	  was	  shown	  to	  be	  non-­‐significant	  (One-­‐way	  ANOVA	  p=0.1133).	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Figure	  5.2a.	  Electrophoresis	  of	  RNA	  extracted	  from	  human	  cell	  lines.	  RNA	  was	  run	  on	  an	  Agilent	  2000	  chip	  to	  verify	  RNA	  integrity	  and	  the	  resulting	  agarose	  gel	  images	  shown	  here.	  1µl	  of	  RNA	  from	  each	  extraction	  was	  used	  per	  assay.	  Base	  pair	  markers	   are	   shown	  on	   the	   left.	  Table	   5.1b.	   Data	   obtained	   from	   Agilent	   2000	  
chip	   analysis	   of	   RNA.	   High	   RIN	   numbers	   for	   each	   sample,	   show	   that	   RNA	  degraded	  very	  little	  since	  being	  extracted.	  Figure	  5.2c.	  Semi-­‐quantitative	  PCR	  of	  
LRRK2	   and	   GAPDH.	   Total	  RNA	  was	   extracted	   from	  various	   cell	   lines	   and	   cDNA	  generated.	   PCR	   products	   for	   LRRK2	   and	   GAPDH	   were	   amplified.	   5.2d.	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5.2.2.2	  	  Taqman	  PCR	  to	  assess	  the	  levels	  of	  LRRK2	  in	  various	  laboratory	  lines.	  To	  analyse	  the	  expression	  levels	  of	  LRRK2	  using	  a	  more	  sensitive	  technique,	  it	  was	  decided	  that	  Taqman	  quantitative	  PCR	  (qPCR)	  would	  be	  used	  (Bonetta,	  2005).	  The	  use	  of	  ready-­‐calibrated	  probes	  in	  this	  system,	  means	  that	  generation	  of	  a	  standard	  curve	  and	  calculation	  of	  absolute	  amounts	  of	   cDNA	   is	  not	  necessary.	   Instead,	   the	  levels	  of	  amplification	  relative	  to	  a	  control,	  are	  calculated	  using	  a	  threshold	  value,	  referred	  to	  as	  CT.	  The	  cycle	  number	  at	  which	  the	   fluorescence	   levels	   intersect	   the	  threshold	   is	   used	   to	   calculate	   the	   fold	   gene	   change	   between	   samples,	   providing	  that	   they	  were	   amplified	   in	   the	   same	   run,	   as	  PCR	  efficiencies	   are	  known	   to	   vary	  between	   experiments	   (Rebrikov	   et	  al.	   2006).	   Fold	   change	   is	   calculated	  using	   the	  equation	  detailed	  in	  Equation	  5.1.	  	  
Equation	  5.1.	  Fold	  change	  calculation	  using	  the	  2-­‐ΔΔCT	  method.	  	  	  







Fold	  change	  =	  2-­‐ΔΔCT	  	  2-­‐ΔΔCT	  =	  [(CT	  gene	  of	  interest-­‐	  CT	  internal	  control)Sample	  A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐(CT	  gene	  of	  interest-­‐	  CT	  internal	  control)Sample	  B]	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Table	  5.2.	  Taqman	  PCR	  CT	  values	  for	  LRRK2	  and	  β-­‐actin.	  A,	  B	  and	  C	  represent	  individual	  replicates	  for	  each	  condition.	  From	  these	  values	  it	  is	  immediately	  apparent	  that	  LRRK2	  has	  quite	  low	  expression	  in	  Hek293T	  cells,	  as	  the	  CT	  value	  for	  LRRK2	  is	  high.	  Cycle	  numbers	  of	  36	  or	  over	  are	   considered	   to	   be	   obsolete	   as	   the	   assays	   lack	   sensitivity	   over	   this	   value	  (Lindecrona	  et	  al.	  2002).	  The	  fold	  change	  between	  conditions	  was	  calculated	  using	  the	   equation	   for	   2-­‐ΔΔCT	   and	   it	   was	   demonstrated	   that	   10ng	   is	   the	   optimal	  concentration	   for	   these	   experiments	   as	   this	   concentration	   provided	   the	   highest	  amplification	   of	   LRRK2	   (Figure	   5.3).	   25ng	   cDNA	   was	   shown	   to	   reduce	   LRRK2	  amplification	  by	  ~1.4	  times	  and	  50ng	  showed	  a	  decrease	  of	  around	  two	  thirds.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   5.3.	   Fold	   change	   in	   gene	   expression	   for	   LRRK2	   when	   different	  
concentrations	   of	   cDNA	   are	   used.	   cDNA	   was	   generated	   from	   Hek293T	   and	  LRRK2	  and	  β-­‐actin	  amplified	  using	   the	  Taqman	  gene	  expression	  system.	  Varying	  amounts	  of	  total	  cDNA	  were	  used	  and	  each	  PCR	  was	  performed	  in	  triplicate,	  with	  results	  normalized	  to	  β-­‐actin	  expression.	  	  
LRRK2	  CT	  values	   10ng	   25ng	   50ng	  A	   32.05	   31.13	   31.19	  B	   31.98	   30.98	   31.16	  C	   32.50	   31.31	   31.96	  
β-­‐Actin	  CT	  values	   10ng	   25ng	   50ng	  A	   21.23	   18.93	   20.08	  B	   20.99	   18.72	   19.56	  C	   21.36	   18.75	   19.51	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Examining	   the	   amplification	   plots	   for	   the	   β-­‐actin	   probe,	   shows	   that	   the	   final	  fluorescence	  levels	  are	  similar	  for	  the	  10ng	  and	  25ng	  conditions,	  but	  are	  reduced	  in	   the	   50ng	   condition,	   suggesting	   that	   PCR	   kinetics	   are	   affected	   by	   increased	  amounts	  of	  cDNA	  template	  for	  this	  probe	  (Figure	  5.4).	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   5.4.	   Amplification	   plots	   for	   β-­‐actin	   from	   Hek293T	   cDNA.	   cDNA	  was	  generated	   from	  Hek293T,	  cells	  and	  the	  PCR	  for	  each	  condition	  done	   in	   triplicate.	  Replicates	  are	  shown	  as	  averages	  of	  CT	  values	  (n=3).	  Green-­‐50ng,	  Red-­‐	  25ng,	  Blue	  10ng.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   5.5.	   Amplification	   plots	   for	   LRRK2	   from	   Hek293T	   cDNA.	   cDNA	   was	  generated	   from	  Hek293T,	  cells	  and	  the	  PCR	  for	  each	  condition	  done	   in	   triplicate.	  Replicates	  are	  shown	  as	  averages	  of	  CT	  values	  (n=3).	  Green-­‐50ng,	  Red-­‐	  25ng,	  Blue	  10ng.	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Amplification	  plots	  for	  LRRK2	  also	  support	  the	  CT	  calculations	  that	  higher	  amounts	  of	   cDNA	  are	   inhibiting	   the	   amplification	   reaction	   (Figure	  5.5).	   Final	   fluorescence	  values	   at	   40	   cycles	   are	   lower	   as	   the	   amount	   of	   template	   increases.	   To	   ensure	  optimal	   amplification	   of	   LRRK2,	   it	   was	   decided	   that	   10ng	   of	   template	  would	   be	  used	  for	  subsequent	  assays.	  	  
5.2.2.4	  	  Taqman	  analysis	  of	  LRRK2	  expression	  in	  various	  cell	  types.	  RNA	   from	   SH-­‐SY5Y,	   1321N1,	   HT1080i	   and	   Hek293T	   cell	   lines	   was	   reverse	  transcribed	   in	  triplicate	  and	  the	  resulting	  cDNA	  used	   in	  Taqman	  assays	  to	  assess	  the	   relative	   levels	   of	   LRRK2	   from	   each.	   The	   LRRK2	   CT	   values	   generated	   were	  corrected	   to	   corresponding	   β-­‐actin	   CT	   values	   and	   the	   2-­‐ΔΔCT	   equation	   used	   to	  calculate	   relative	   levels	   of	   LRRK2	   in	   each	   line	   (Figure	   5.1).	   LRRK2	   values	   were	  normalised	  to	  β-­‐actin	  measurements,	  generated	  in	  the	  same	  PCR	  reaction	  for	  each	  sample.	   Taqman	   assays	   were	   performed	   twice	   on	   separate	   occasions,	   and	   the	  results	  compared	  to	  ensure	  accuracy.	  
	  
Figure	  5.6a.	  LRRK2	  expression	  in	  various	  laboratory	  cell	  types.	  Results	  were	  normalized	  to	  β-­‐actin	  expression.	  Each	  PCR	  was	  done	  in	  duplicate	  and	  three	  cDNA	  samples	  from	  each	  cell	  line	  were	  used.	  n=3	  for	  each	  cell	  line,	  PCRs	  were	  conducted	  in	  duplicate	  and	  the	  average	  fold-­‐change	  for	  each	  plotted.	  5.6b.	  Repeat	  of	  LRRK2	  
expression	  assay.	  As	  5.6a.	  	  
	  	  	  
a. b.
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Taqman	  analysis	  of	  LRRK2	  expression	  in	  various	  cell	  types	  showed	  that	  there	  was	  no	  difference	  in	  expression	  between	  the	  lines	  used	  (Figure	  5.6a,	  One-­‐way	  ANOVA	  p=0.4373.	   Figure	   5.6b,	   p=0.3267).	   These	   results	   and	   the	   results	   of	   a	   repeated	  experiment	   (Figure	   5.6a	   and	   b)	   showed	   that	   the	   results	   obtained	   were	   highly	  variable.	  CT	  values	  for	  these	  assays	  were	  in	  the	  region	  of	  35	  for	  both	  experiments,	  accounting	   for	   the	   variability	   of	   the	   results.	   These	   values	   also	   show	   that	   LRRK2	  expression	  in	  the	  cell	  types	  chosen	  is	  extremely	  low.	  	  	  
5.2.3	   Immunoprecipitation	  of	  LRRK2	  from	  SH-­‐SY5Y	  cells	  Analysis	  of	  LRRK2	  mRNA	  expression	  by	  PCR	  and	  qPCR	  showed	  that	  there	  was	  no	  difference	  in	  expression	  between	  the	  cell	  types	  used.	  As	  such,	  it	  was	  decided	  that	  immunoprecipitation	  would	  be	  performed	  using	  protein	  extracted	   from	  SH-­‐SY5Y	  cells.	   They	   are	   the	  most	   neuronal-­‐like	   cell	   type	   of	   the	   cells	   used	   and	   successful	  immunoprecipitation	   from	   this	   cell	   line	  would	   therefore	  be	  most	   relevant	   to	  PD.	  LRRK2	  was	  therefore	  immunoprecipitated	  from	  SH-­‐SY5Y	  cells	  and	  the	  analysed	  by	  SDS-­‐PAGE.	  Western	  blotting	  confirmed	  that	  LRRK2	  expression	  levels	  in	  these	  cells	  is	   low	   (Figure	   5.7a).	   Immunoprecipitation	   resulted	   in	   a	   single	   band	   of	   around	  260kDa	  being	  extracted	  (Figure	  5.7b).	  	  The	   excised	   band	  was	   sent	   for	   peptide	   sequencing	   using	   Nanoflow	  HPLC-­‐linked	  ESI-­‐QTOF	   mass	   spectrometry.	   Mass	   spectrometry	   was	   kindly	   performed	   by	   Dr	  Wendy	   Heywood	   (Biological	   Mass	   Spectrometry	   centre,	   UCL	   Institute	   of	   Child	  Health,	  London).	  A	  total	  of	  16	  peptides	  were	  generated	  and	  sequenced,	  which	  were	  mapped	  with	  high	  confidence	   to	   the	  microtubule	  associated	  protein	  1B	  (MAP1B)	  protein.	  These	  peptides	  represent	  an	  8.6%	  coverage	  of	  the	  protein.	  The	  ESI-­‐QTOF	  system	   used	   has	   a	   detection	   threshold	   for	   proteins	   in	   the	   femtomolar	   range,	  suggesting	  that	  if	  LRRK2	  was	  present	  in	  these	  samples,	  it	  was	  at	  levels	  lower	  than	  the	  detection	  threshold.	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Figure	   5.7a.	  Western	   blot	   analysis	   of	   endogenous	   LRRK2	   levels	   in	   SH-­‐SY5Y	  
cells.	  SH-­‐SY5Y	  lysates	  were	  separated	  by	  SDS-­‐PAGE	  and	  probed	  for	  LRRK2	  (upper	  panel)	  and	  β-­‐actin	   (lower	  panel).	  Molecular	  weight	  markers	  are	   indicated	  on	   the	  left	   (kDa).	   b.	   Immunoprecipitated	   protein	   sent	   for	   analysis	   by	   mass	  
spectrometry.	   A	   single	   faint	   band	   of	   around	   270kDa	   was	   seen	   when	  immunoprecipitation	  was	  performed	  on	  SH-­‐SY5Y	  cells	  using	  the	  anti-­‐LRRK2	  goat	  polyclonal	  (Everest).	  Eluted	  protein	  was	  run	  on	  SDS-­‐PAGE	  and	  the	  resulting	  band	  visualised	  by	   coomassie	   staining.	  This	  band	  was	  cut	  out	  and	  sent	   for	  analysis	  by	  Nanoflow	   HPLC-­‐linked	   ESI-­‐QTOF	  mass	   spectrometry.	   Molecular	   weight	   markers	  are	   indicated	   on	   the	   left	   (kDa).	   Table	   5.3c.	   Peptide	   map	   of	   protein	  










INVESTIGATION	  OF	  PUTATIVE	  INTERACTORS	  AND	  KINASE	  SUBSTRATES	  
	   134	  
5.2.3	  Modification	  of	  the	  LRRK2	  gatekeeper	  residue	  
5.2.3.1	  	  Identification	  of	  the	  gatekeeper	  residue	  Mutation	  of	  the	  gatekeeper	  residue	  in	  many	  serine/threonine	  kinases	  has	  allowed	  successful	  identification	  of	  kinase	  substrates	  for	  these	  proteins	  (Shah	  et	  al.	  1997).	  To	  identify	  the	  gatekeeper	  residue	  in	  LRRK2,	  sequence	  alignment	  was	  performed	  using	  a	  number	  of	  kinases	  successfully	  modified	  using	  the	  Shokat	  method.	  
	  
Figure	   5.8.	   Sequence	   alignment	   of	   LRRK2	   with	   other	   kinases	   successfully	  
engineered	   to	  accept	  a	  modified	   form	  of	  ATP.	  Sequence	  alignment	  shows	  that	  the	  corresponding	  residue	  of	  LRRK2	  is	  methionine,	  in	  position	  1947.	  	  	  According	   to	   the	   original	   experiments,	   the	   gatekeeper	   residue	   must	   be	   a	  hydrophobic	   residue	   in	   subdomain	   V.	   Sequence	   alignment	   of	   LRRK2	   with	  subdomain	  V	  of	  other	  kinases,	  shows	  that	  a	  methionine	  in	  position	  1947	  is	  likely	  to	  be	   the	   gatekeeper	   residue.	   There	   can	   be	   high	   confidence	   in	   this	   result,	   as	  methionine	  is	  the	  most	  commonly	  found	  gatekeeper	  residue	  (Zhang	  et	  al.	  2005).	  	  	  
5.2.3.2	  	  M1947A	  can	  be	  successfully	  expressed	  in	  HEK293T	  	  Site-­‐directed	   mutagenesis	   was	   performed	   using	   full	   length	   N-­‐terminally	   myc-­‐tagged	  LRRK2	  in	  WT	  and	  KD	  forms,	  to	  change	  the	  methionine	  at	  position	  1947	  to	  an	   alanine.	   Overexpression	   of	   this	   protein	   in	   Hek293T	   cells	   and	   subsequent	  western	  blotting	  and	  Coomassie	  staining,	  showed	  that	  the	  M1947A	  artificial	  mutant	  can	   be	   expressed	   and	   immunoprecipitated	   from	   Hek293T	   cells	   (Figure	   5.9).	   KD	  LRRK2	  showed	  consistently	  lower	  expression	  and	  precipitation	  than	  WT	  LRRK2	  in	  these	  experiments.	  This	  has	  also	  been	  reported	  by	  other	  groups,	  perhaps	  due	  to	  the	  reduced	  stability	  of	  this	  protein	  (Greggio	  et	  al.	  2006).	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Figure	   5.9a.	   Expression	   of	   M1947A	   in	   Hek293T	   cells.	   UT-­‐Mock	   transfected	  Hek293T	   cells.	   WT-­‐Wild	   type	   N-­‐myc-­‐LRRK2,	   KD-­‐	   Triple	   mutant	  K1906M/D1994A/D2017A	   kinase	   dead	   N-­‐myc-­‐LRRK2.	   MA-­‐M1947A	   N-­‐myc-­‐LRRK2.	   LRRK2	   was	   overexpressed	   in	   Hek293T	   cells	   and	   western	   blotting	  performed	   to	   assess	   expression	   (LRRK2	   visualised	   using	   anti-­‐myc	   antibody).	  Molecular	  weight	  markers	  are	  shown	  on	  the	  left	  (kDa).	  Images	  are	  representative	  of	  at	  least	  three	  experiments.	  5.9b.	  Coomassie	  staining	  of	  immunoprecipitated	  
LRRK2.	  Myc-­‐LRRK2	  was	   overexpressed	   and	   immunoprecipitated	   from	  Hek293T	  cells.	  Gels	  were	  coomassie	  stained	  to	  assess	  levels	  of	  LRRK2	  immunoprecipitation.	  Images	  are	  representative	  of	  at	  least	  three	  experiments.	  	  	  
5.2.3.3	  	  Radiolabelling	  of	  N6-­‐modified	  	  ADP	  	  To	   tag	   and	   differentiate	   substrates	   phosphorylated	   using	   N6-­‐Modified	   ATPs,	   N6-­‐modified	   ADPs	   were	   radiolabelled	   using	   the	   phosphotransferase	   nucleoside	  diphosphate	  kinase	  (NDPK,	  see	  Figure	  2.2).	  NDPK	  is	  an	  enzyme	  found	  in	  a	  number	  of	   species,	   including	  humans,	  which	  catalyses	   the	  removal	  of	  a	  γ-­‐phosphate	   from	  ATP,	  to	  be	  repositioned	  on	  a	  nucleoside	  diphosphate	  other	  than	  ADP,	  eg	  GDP.	  It	  has	  been	   used	   successfully	   to	   radiolabel	   N6-­‐modified	   ATPs	   (Habelhah	   et	   al.	   2001).	  NDPK	   was	   used	   in	   these	   experiments	   to	   remove	   the	   32P	   γ-­‐phosphate	   from	   32P	  labeled	   GTP	   and	   add	   it	   to	   N6-­‐phenylethyl-­‐ATP	   to	   generate	   radiolabelled	   ATP	  analogues.	   GTP	   was	   used	   as	   a	   donor	   to	   minimise	   background	   levels	   of	   kinase	  activity	  from	  co-­‐purified	  kinases.	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Figure	  5.10.	  TLC	  analysis	  of	  32P	  labeled	  ATP	  analogs.	  NDPK	  was	  used	  to	  label	  PE-­‐ADP	   with	   a	   32P	   γ-­‐phosphate.	   Radioactive	   nucleotides	   were	   subsequently	  analysed	   by	   TLC.	   Lane	   1-­‐	   0.25ul	   32P-­‐labelled	   GTP.	   Efficiency	   of	   reaction	   can	   be	  estimated	  by	  comparing	  to	  this	  reaction.	  Lane	  2-­‐	  1µl	  of	  radiolabelled	  PE-­‐ATP.	  Lane	  
3-­‐	   Flowthrough	   from	   radiolabelling	   reaction.	   Consists	   of	   unused	   GTP.	   Lane	   4-­‐Radiolabelling	  control	  reaction	  performed	  without	  PE-­‐ADP.	  Radioactivity	  is	  due	  to	  32P-­‐labelled	  GTP	   from	   the	  donation	   reaction	   that	   has	  not	   been	   removed	   and	  has	  carried	  over.	  Lane	  5-­‐	  Unused	  GTP	  from	  the	  control	  reaction.	  	  
	  TLC	   plate	   analysis	   of	   32P	   transfer	   from	   ATP	   to	   PE-­‐ADP,	   showed	   that	   transfer	   is	  occurring,	  however	  the	  efficiency	  is	  poor	  as	  there	  is	  a	  low	  amount	  of	  radiolabelled	  PE-­‐ATP	  (Figure	  5.10,	  Lane	  2.).	   In	   the	  control	  reaction	  completed	  without	  PE-­‐ADP	  as	  the	  acceptor,	  it	  is	  apparent	  that	  carry	  over	  of	  32P-­‐labeled	  GTP	  from	  the	  donation	  reaction	  is	  occurring.	  This	  suggests	  that,	  the	  radiation	  shown	  from	  labeling	  of	  PE-­‐ATP,	  also	  consists	  of	   residual	  GTP.	  For	  optimal	  efficiency	  of	   this	   technique,	   there	  cannot	  be	  radiolabelled	  GTP	  present,	  otherwise	  false-­‐positives	  may	  occur	  from	  WT	  kinases	   utilising	   this	   nucleotide	   as	   a	   phosphate	   donor.	   In	   order	   to	   address	   this	  issue,	  it	  was	  decided	  that	  subsequent	  experiments	  would	  be	  performed	  using	  cold	  N6-­‐modified	  ATPs	  and	  phosphorylation	  visualised	  using	  pan-­‐p-­‐Serine	  antibodies.	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  3.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4.	  	  	  	  	  	  	  	  	  	  	  	  	  	  5. ATP	  analogues
	  P	  Donor	  P	  Acceptor	  	  	  	  	  	  	  32	  	  +++_ __+ _ 	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  __
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5.2.3.4	  	  M1947A	  mutants	  are	  unable	  to	  utilize	  normal	  ATP.	  Shokat	  and	  colleagues	  have	  successfully	  engineered	  kinases	  to	  accept	  ATP	  carrying	  benzyl	  and	  phenethyl	  moieties	  (Figure	  5.1)	  at	   the	  N6	  position,	  and	  as	  such	  it	  was	  decided	   that	   these	   ATPs	   would	   be	   good	   candidates	   for	   experimentation.	   Kinase	  assays	   using	   immunoprecipitated	   LRRK2	   showed	   that	   the	   M1947A	   mutant	   is	  unable	  to	  utilise	  ATP	  (Figure	  5.11a).	  	  
	  
Figure	  5.11a.	  LRRK2	  phosphorylation	  of	  MBP	  using	  ATP	  analogues.	  WT-­‐	  wild	  type	   LRRK2,	  KD-­‐	   triple	  mutant	   kinase	  dead	  LRRK2,	  MA-­‐M1947A	  LRRK2.	  Results	  shown	   are	   representative	   of	   three	   experiments.	   Phosphorylation	   of	   MBP	   was	  visualised	   using	   western	   blotting	   and	   pan-­‐p-­‐Ser	   antibodies.	   LRRK2	   inputs	   were	  visualised	  using	  anti-­‐myc	  antibodies.	  MBP	  inputs	  are	  taken	  from	  ponceau	  stains	  of	  PVDF	  membranes.	  Molecular	  weight	  markers	  are	  shown	  on	  the	  left	  (kDa).	  Results	  shown	   are	   representative	   of	   three	   experiments.	   5.11b.	   Quantification	   of	   MBP	  
phosphorylation	  using	  non-­‐modified	  ATP.	  Bar	  chart	  shows	  mean	  values	  ±	  s.e.m	  (n=3).	  5.11c.	  Autoradiography	  of	  kinase	  assays	  using	  modified	  forms	  of	  ATP.	  Results	  are	  representative	  of	  three	  experiments	  and	  show	  western	  blot	  analysis	  of	  MBP	  p-­‐Ser	  residues.	  5.11d.	  As	  5.11c.	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Most	  WT	  kinases	  are	  unable	  to	  use	  N6-­‐modified	  forms	  of	  ATP	  (Shah	  et	  al.	  1997).	  As	  confirmed	   in	   Figure	   5.11a,	  WT	   LRRK2	   is	   unable	   to	   use	   these	  modified	   forms	   of	  ATP.	  Changing	   the	  amino	  acid	   in	   the	  gatekeeper	  position	   lowers	   the	  affinity	  of	   a	  kinase	  to	  normal	  ATP	  so	  that	  it	  preferentially	  accepts	  the	  modified	  form,	  however,	  there	   is	  also	  no	  MBP	  phosphorylation	   from	   the	  M1947A	  mutant	  when	   incubated	  with	  unmodified	  ATP	  (Figure	  5.11a).	  Looking	  at	   the	  ability	  of	  M1947A	  LRRK2	   to	  use	  PE-­‐ATP	  or	  Ben-­‐ATP	  analogs,	  shows	  that	  this	  mutant	  is	  also	  unable	  to	  use	  these	  forms	  of	  ATP	  (Figure	  5.11	  b,c).	  	  	  
5.2.3.5	  	  Quaternary	  structure	  of	  M1947A	  LRRK2	  As	  LRRK2	  kinase	  activity	  is	  required	  for	  dimer	  formation,	  to	  identify	  if	  the	  M1947A	  is	  affecting	  overall	  kinase	  activity	  of	  the	  protein,	  or	  to	  see	  if	  changes	  to	  the	  current	  protocol	   such	   as	   trying	   different	  ATP	   analogues	  were	   likely	   to	   be	   successful,	   BN	  western	  blots	  were	  performed	  (Figure	  5.12).	  As	  shown,	  N-­‐myc-­‐LRRK2	  is	  present	  in	  mostly	  higher	  order	  complexes,	  with	  some	  protein	  shown	  to	  be	  present	  at	  around	  monomeric	  and	  dimeric	  size.	  The	  triple	  kinase	  mutant	  shows	  a	  different	  pattern	  of	  electrophoresis,	   with	   higher	   order	   complexes	   seemingly	   disrupted	   and	   more	  protein	  present	  at	  lower	  weight	  fractions.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5.12.	  BlueNative	  analysis	  of	  N-­‐Myc-­‐LRRK2	  overexpressed	  in	  Hek293T	  
cells.	  WT-­‐Wild	  type,	  full	  length	  N-­‐terminally	  tagged	  Myc-­‐LRRK2,	  KD-­‐	  kinase	  dead	  N-­‐Myc-­‐LRRK2.	  MA-­‐M1947A	  N-­‐myc-­‐LRRK2.	  Whole	   cell	   lysate	   from	  Hek293T	  cells	  was	  transfected	  with	  N-­‐myc-­‐LRRK2	  was	  run	  out	  on	  BlueNative	  PAGE	  and	  analysed	  using	   western	   blotting.	   Image	   is	   representative	   of	   at	   least	   three	   separate	  experiments.	  Molecular	  weight	  markers	  are	  shown	  on	  the	  left	  (kDa).	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The	   M1947A	  mutant	   shows	   a	   similar	   electrophoretic	   pattern	   to	   the	   KD,	   in	   that	  higher	  order	  complexes	  are	  disrupted	  and	  there	  is	  more	  protein	  present	  in	  lower	  weight	  fractions.	  This	  suggests	  that	  the	  M1947A	  substitution	  is	  affecting	  LRRK2	  in	  a	  similar	  manner	  to	  the	  kinase	  dead	  mutations.	  In	  this	  case	  it	  is	  unlikely	  that	  trying	  other	   forms	  of	  ATP,	  would	  be	  beneficial.	   Interestingly,	   the	  disruption	  of	   complex	  formation	   in	   the	   overexpressed	   kinase-­‐dead	   mutants	   represents	   a	   shift	   from	  higher	   order	   complexes,	   to	   seemingly	   dimeric	   species.	   This	   suggests	   that	   in	   this	  protein,	   it	   is	   interaction	  with	   other	   proteins	   that	   is	   being	   disrupted	   and	   not	   the	  ability	   to	   dimerise.	   It	   has	   been	   reported	   that	   some	   kinases	   are	   ‘intolerant’	   to	  gatekeeper	   residue	   mutation	   and	   require	   additional	   ‘rescue’	   mutations,	   which	  restore	  kinase	  function	  (Zhang	  et	  al.	  2005).	  In	  this	  case,	  it	  would	  seem	  that	  LRRK2	  is	   intolerant	   to	   the	  M1947A	  mutation	   and	   requires	   further	  modification	   for	   this	  technique	  to	  be	  successful.	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5.3	   DISCUSSION	  As	  a	  large	  protein	  with	  multiple	  protein	  interaction	  domains,	  complex	  formation	  is	  likely	  to	  play	  an	  important	  part	  in	  LRRK2	  functioning.	  The	  aim	  of	  this	  study	  was	  to	  identify	   LRRK2	   interacting	   proteins	   and	   kinase	   substrates,	   in	   order	   to	   better	  understand	   how	   LRRK2	   acts	   in	   a	   cellular	   context	   and	   how	   it	   may	   be	   causing	  neuronal	  death	  in	  familial	  forms	  of	  PD.	  Because	  of	  technical	  issues	  associated	  with	  these	   techniques	   however,	   these	   aims	   were	   not	   successful.	   Analysis	   of	   LRRK2	  expression	   in	   commonly	   used	   cell	   lines	   emphasised	   the	   difficulties	   faced	   in	  addressing	  these	  aims,	  as	  LRRK2	  expression	  is	  extremely	  low,	  making	  purification	  of	  this	  protein	  more	  difficult.	  Attempts	  to	   immunoprecipitate	  endogenous	  LRRK2	  were	  unsuccessful,	  most	  likely	  due	  to	  the	  low	  expression	  levels	  of	  LRRK2	  in	  the	  cell	  types	   used.	   This	   low	   expression	   of	   LRRK2	   suggests	   that	   nonspecific	   binding	   of	  abundant	   proteins,	   such	   as	   MAPs	   was	   more	   likely	   to	   occur	   during	  immunoprecipitation.	   This	   may	   explain	   why	   MAP1A	   was	   immunoprecipitated	  from	  SH-­‐SY5Y	  cells	  using	  an	  antibody	  specific	  to	  LRRK2	  (Table	  5.3b).	  	  Attempts	   to	   identify	   LRRK2	   kinase	   substrates	   through	   engineering	   a	   gatekeeper	  pocket	   mutation	   into	   the	   ATP	   binding	   pocket	   of	   LRRK2	   also	   proved	   to	   be	  unsuccessful,	   as	   mutation	   of	   M1947	   to	   an	   alanine	   disrupted	   kinase	   activity	   of	  LRRK2	   (Figure	  5.11a).	  Ablation	  of	   kinase	   activity	  was	   shown	   to	  disrupt	   complex	  formation	   of	   the	   M1947A	  mutant,	   however	   this	   protein	   is	   still	   able	   to	   dimerise	  (Figure	  5.12).	  This	  is	  contrary	  to	  the	  findings	  of	  many	  other	  groups	  (Greggio	  et	  al.	  2008,	   Sen	  et	  al.	   2009,	  Berger	  et	  al.	   2010)	   and	  perhaps	   suggests	   a	  more	   complex	  mechanism	  of	  dimer	  formation	  in	  which	  LRRK2	  is	  able	  to	  adopt	  active	  and	  inactive	  dimer	   conformations,	   which	   differ	   according	   to	   the	   other	   proteins	   complexed.	  These	   forms	  may	  have	  differing	  stabilities.	  The	  difference	   in	  results	  compared	  to	  those	  from	  other	  studies	  (Greggio	  et	  al.	  2008,	  Sen	  et	  al.	  2009,	  Berger	  et	  al.	  2010)	  is	  perhaps	  due	  to	  different	  conditions	  used.	  In	  the	  experiments	  described	  here,	  a	  high	  concentration	  of	  detergent	  was	  used	  (5%	  DDM,	  w/v)	  to	  maximise	  the	  solubility	  of	  LRRK2.	   This	   may	   affect	   the	   species	   that	   were	   able	   to	   migrate	   when	   BN	  electrophoresis	  was	  performed.	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5.3.1	  	  Future	  directions	  Success	   of	   the	   gatekeeper	   technique	   for	   identification	   of	   kinase	   substrates	   is	  intimately	   linked	   to	   the	   structure	  of	   the	  ATP	  pocket	   for	  each	  kinase.	  For	  kinases	  with	   determined	   crystal	   structures,	   the	   chance	   of	   success	   can	   be	   more	   easily	  estimated,	   however	   for	   kinases	   such	   as	   LRRK2,	   which	   are	   without	   a	   crystal	  structure,	  the	  success	  of	  engineering	  a	  pocket	  mutation	  can	  only	  be	  determined	  by	  trial	   and	   error.	   	   The	   ‘second	   site	   suppressor	   strategy’	   allows	   rescue	   of	   kinases,	  which	   are	   rendered	   inactive	  when	   the	   first	  mutation	   is	   engineered	   (Zhang	   et	  al.	  2005).	  To	  rescue	  intolerant	  kinases,	  mutation	  of	  residues	  around	  a	  hotspot	  in	  the	  
β-­‐sheet	  in	  the	  N-­‐terminal	  subdomain	  has	  been	  shown	  to	  revive	  kinase	  activity	  and	  allow	   identification	   of	   kinase	   substrates	   for	   previously	   unmodifiable	   kinases.	   In	  this	  case,	   sequence	  alignment	  of	  LRRK2	  with	  other	  kinases	  successfully	  modified	  using	   the	   second	   site	   suppressor	   strategy,	   could	   allow	   for	   identification	   of	  potential	   rescue	   mutations	   and	   allow	   kinase	   substrates	   for	   LRRK2	   to	   be	  characterised.	  	  	  These	   experiments	   have	   shown	   that	   LRRK2	   expression	   is	   low	   in	   many	   of	   the	  laboratory	   cell	   types	   that	   are	   commonly	   used.	   In	   depth	   analysis	   of	   LRRK2	  expression	  in	  pre	  and	  post-­‐natal	  mice	  has	  also	  reported	  low	  levels	  of	  LRRK2	  mRNA	  (Biskup	  et	  al.	  2007).	  An	  explanation	  for	  this	  could	  be	  that	  LRRK2	  expression	  levels	  are	  repressed	  at	  a	  transcriptional	  level	  and	  perhaps	  induced	  in	  response	  to	  some	  sort	   of	   stimulus.	   In	   order	   to	   assess	   factors	   regulating	   the	   expression	   of	   LRRK2,	  Analysis	   of	   expression	   levels	   in	   response	   to	   stimuli,	   could	   be	   performed	   by	  examining	   potential	   changes	   in	   LRRK2	   expression,	   when	   cells	   are	   subjected	   to	  stressors	  such	  as	  H2O2.	  Similarly,	  examining	  possible	  changes	  in	  LRRK2	  expression	  in	   response	   to	  MAP	  kinase	   cascade	   activation,	  would	   allow	   the	   role	   of	   LRRK2	   in	  these	  cascades	  to	  be	  better	  understood.	  Addition	  of	  mitogens	  to	  cells	  in	  culture	  and	  subsequent	   analysis	   of	   changes	   to	   gene	   expression,	   could	   provide	   information	  regarding	  the	  potential	  role	  of	  LRRK2	  in	  these	  cascades.	  	  Although	   the	   immunoprecipitation	   of	   LRRK2	   using	   the	   Everest	   antibody	   was	  unsuccessful	   in	   these	   experiments,	  modifying	   the	   techniques	  used	  may	  allow	   for	  successful	  purification	  of	  this	  protein	  in	  the	  future	  for	  example	  using	  size	  exclusion	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to	   enrich	   the	   concentration	   of	   LRRK2	   before	   immunoprecipitation.	   The	   Everest	  antibody	  has	  previously	  been	  used	  for	  immunohistochemistry	  (Alegre-­‐Abarrategui	  
et	  al.	  2009)	  and	  western	  blotting.	  These	  techniques	  all	  involve	  denaturing	  proteins	  before	   identification	   and	   therefore	   it	   is	   possible	   that	   this	   antibody	   is	   useful	   for	  pulling	   down	   denatured	   LRRK2.	   Chemical	   and	   photo-­‐crosslinkers	   allow	  interactions	   to	   endure	   treatment	   by	   SDS	   and	   other	   denaturing	   chemicals	   and	  therefore,	  this	  antibody	  could	  be	  used	  in	  combination	  with	  crosslinkers	  in	  attempt	  to	  identify	  LRRK2	  complex	  components.	  Alternative	  methods	  to	  pull	  down	  LRRK2	  such	  as	   immobilising	  ΔN-­‐LRRK2	  on	  GST-­‐beads	  before	   incubation	  with	  whole	  cell	  lysate,	   or	   immunoprecipitation	   of	   14-­‐3-­‐3	   and	   screening	   for	   LRRK2	   containing	  complexes,	  could	  also	  be	  used	  to	  identify	  the	  cellular	  context	  that	  LRRK2	  functions	  within	  in	  vivo.	  This	  could	  contribute	  further	  to	  our	  understanding	  of	  how	  LRRK2	  is	  contributing	  to	  the	  pathogenesis	  of	  PD,	  by	  identifying	  potential	  signaling	  pathways	  that	  are	  perturbed	  in	  this	  disease.	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6.	  INVESTIGATION	  OF	  PUTATIVE	  LRRK2	  
KINASE	  SUBSTRATES	  IN	  VITRO	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6.1	   INTRODUCTION	  The	  kinase	  domain	  of	  LRRK2	  shares	  a	  high	  degree	  of	  homology	  to	  those	  contained	  in	  RIP	  kinase	  family	  members	  (Meylan	  et	  al.	  2005).	  These	  proteins	  are	  functional	  kinases	   in	   vivo	   with	   functions	   centred	   around	   regulation	   of	   apoptotic	   and	   pro-­‐survival	   signaling	   (Declercq	   et	   al.	   2009).	   Identification	   of	   kinase	   substrates	   for	  LRRK2	  has	  provided	  many	  possible	  candidates,	  and	  there	  is	  consensus	  that	  LRRK2	  targets	  serine	  and	   threonine	  residues	   for	  phosphorylation	   (Pungaliya	  et	  al.	  2010,	  	  Anand	  et	  al.	  2009).	  Despite	  the	  many	  substrates	  reported,	  a	  single	  kinase	  substrate	  is	  yet	  to	  be	  confirmed	  by	  more	  than	  one	  group.	  In	  these	  experiments,	  a	  number	  of	  putative	  LRRK2	  kinase	  substrates	  have	  been	  assessed	   in	  vitro.	  α-­‐Syn	  was	  chosen	  because	   of	   the	   important	   role	   it	   plays	   in	   PD	   pathogenesis.	   Y2H	   studies	   from	   a	  collaborating	  group	  have	  identified	  TUBB5	  and	  the	  DVLs	  as	  potential	  interactors	  of	  the	   ROC	   domain	   (Sancho	   and	   Harvey.	   Unpublished,	   Sancho	   et	   al.	   2009).	   GTPase	  experiments	  with	  these	  proteins	  have	  proved	  to	  be	  technically	  challenging	  and	  as	  such,	  these	  protein	  have	  instead	  been	  assessed	  here,	  as	  possible	  kinase	  substrates	  of	  LRRK2.	  	  	  The	  prevalence	  of	  α-­‐syn	  pathology	   in	  LRRK2	   familial	  PD,	   and	   the	   strong	  overlap	  between	  idiopathic	  and	  PARK8-­‐linked	  PD,	  has	  led	  to	  the	  suggestion	  that	  there	  may	  be	   some	   sort	   of	   interaction	   between	   LRRK2	   and	   α-­‐syn,	   either	   directly,	   or	   in	   a	  common	  pathway	  (Singleton,	  2005).	  Other	  groups	  have	  shown	  that	  LRRK2	  and	  α-­‐syn	   can	   be	   co–immunoprecipitated	   from	   post-­‐mortem	   brain	   tissue	   from	  individuals	  with	   dementia	  with	   Lewy	  bodies	   and	   (Qing	   et	  al.	   2009a)	   and	   LRRK2	  has	  been	  shown	  to	  directly	  phosphorylate	  α-­‐syn	  at	  S129	  (Qing	  et	  al.	  2009b).	  The	  efficiency	  of	  this	  phosphorylation	  was	  not	  explored	  in	  depth	  however,	  and	  as	  such,	  it	  is	  unclear	  whether	  this	  phosphorylation	  is	  likely	  to	  be	  physiological.	  In	  order	  to	  address	   these	   issues,	   LRRK2	   phosphorylation	   of	   α-­‐syn	   has	   been	   assessed	   here	  using	   in	  vitro	   kinase	  assays.	  The	  β	   and	  γ	   varients	  of	   synuclein	  were	  also	  used,	   to	  assess	  if	  LRRK2	  is	  also	  able	  to	  phosphorylate	  these	  peptides	  and	  if	  so,	  to	  determine	  if	  there	  is	  a	  preference	  for	  any	  one	  varient.	  α,	  β	  and	  γ-­‐synuclein	  are	  140,	  134	  and	  127	   amino	   acids	   long	   respectively,	   with	   β	   and	   γ-­‐syn	   showing	   considerable	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sequence	   homology	   to	   α-­‐syn.	   Each	   form	   of	   synuclein	   contains	   a	   hydrophobic	  region	  in	  the	  middle	  section	  and	  a	  conserved	  region	  of	  KTKEGV	  N-­‐terminal	  repeats	  (Pandey	   et	   al.	   2006).	   γ-­‐synuclein	   has	   been	   shown	   to	   share	   a	   55.9	   and	   54.3%	  similarity,	  with	  the	  α-­‐	  and	  β-­‐synucleins	  respectively	  (Lavedan	  et	  al.	  1998).	  As	  such	  it	   is	   likely	   that	   if	   LRRK2	   is	   able	   to	   phosphorylate	  α-­‐syn,	   these	   members	   of	   the	  synuclein	  family	  could	  also	  be	  kinase	  substrates.	  	  	  To	   characterise	   the	   nature	   of	   the	   LRRK2-­‐DVL	   interaction	   identified	   by	   Y2H,	   by	  examining	   the	   DVL	   family	   as	   phosphorylation	   targets	   for	   LRRK2,	   recombinant	  DVL2	  and	  DVL3	  have	  been	  used	  in	  kinase	  assays	  with	  WT	  and	  mutant	  recombinant	  LRRK2	   protein.	   Similarly,	   the	   β-­‐tubulin	   isoform	   TUBB5	   was	   also	   assessed	   as	   a	  kinase	   substrate	   by	   performing	   in	   vitro	   kinase	   assays	   with	   LRRK2,	   to	   assess	  phosphorylation	  of	  this	  isoform.	  For	  each	  experiment,	  a	  positive	  control	  was	  used	  to	  model	  physiological	  phosphorylation	  of	  each	  substrate	  under	  in	  vitro	  conditions.	  CK1	  has	  been	  shown	  to	  phosphorylate	  DVLs	  in	  response	  to	  Wnt	  activation	  of	  the	  frizzled	  receptor	  (Korr	  et	  al.	  2006).	  CK1	  has	  also	  been	  shown	  to	  phosphorylate	  α-­‐syn	  in	  vitro	  and	  in	  vivo	  (Okochi	  et	  al.	  2000)	  and	  so	  this	  protein	  was	  used	  in	  kinase	  assays	  as	  a	  positive	  control	  for	  α-­‐synuclein,	  DVL2	  and	  DVL3.	  DVL1	  is	  not	  currently	  available	   commercially	   so	   was	   not	   used	   for	   these	   experiments.	   GRK2	   has	   been	  shown	   to	   phosphorylate	  β-­‐tubulin	   in	  vitro	   and	   in	   cells	   (Yoshida	   et	  al.	   2003)	   and	  was	  therefore	  used	  as	  a	  positive	  control	  for	  TUBB5	  kinase	  assays.	  To	  ensure	  that	  recombinant	  proteins	  used	  in	  these	  assays	  are	  not	  co-­‐purified	  with	  other	  kinases,	  kinase	   dead	   D1994A	   ΔN-­‐LRRK2	   was	   used	   as	   a	   negative	   control	   for	   each	  experiment.	  To	  try	  and	  account	  for	  the	  likelihood	  of	  false	  positive	  results,	  the	  RIP	  kinase,	   RIPK5	   was	   included	   in	   kinase	   assays.	   RIPK5	   is	   involved	   in	   apoptosis	  signalling	  (Zha	  et	  al.	  2004)	  and	  has	  not	  been	  shown	  to	  interact	  with,	  or	  be	  involved	  in	  signalling	  pathways	  with	  the	  synuclein	  family,	  DVL2	  or	  3,	  or	  TUBB5	  to	  date.	  As	  such,	   it	   is	   a	   good	   candidate	   for	   inclusion	   as	   a	   non-­‐specific	   kinase	   in	   these	  experiments.	  	  	  Many	  kinases	  require	  cofactors	  such	  as	  cAMP,	  or	  interaction	  with	  other	  proteins	  in	  order	   to	   function	   properly.	   Similarly,	   all	   kinases	   have	   different	   kinetics	   and	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substrate	   affinities.	   In	   order	   to	   take	   the	   differences	   in	   basal	   kinase	   activity	   into	  account,	   efficiency	   values	   were	   calculated	   for	   each	   condition,	   by	   taking	   into	  account	   the	   levels	   of	   autophosphorylation	   and	   MBP	   phosphorylation	   for	   each	  kinase.	  These	  calculations	  were	  made	  on	   the	  assumption	   that	  a	  kinase	  should	  be	  able	   to	   phosphorylate	   its	   own	   substrate	   more	   efficiently	   than	   a	   non-­‐specific	  substrate.	  As	  such,	  substrate	  phosphorylation	  was	  divided	  by	  both	  of	  these	  values	  and	  the	  ratio	  used	  as	  an	  indicator	  of	  substrate	  affinity;	  a	  value	  above	  one	  indicates	  a	   higher	   affinity	   for	   the	   substrate	   compared	   to	   autophosphorylation	   or	   MBP.	   A	  value	   below	   one	   suggests	   that	   substrate	   affinity	   is	   poor	   and	   that	  autophosphorylation	  or	  MBP	  phosphorylation	  is	  more	  efficient.	  In	  this	  case,	  it	  can	  be	   argued	   that	   substrate	   phosphorylation	   is	   more	   likely	   to	   be	   occurring	   due	   to	  assay	  conditions	  rather	  than	  a	  physiological	  interaction.	  For	  each	  assay	  LRRK2	  was	  used	  in	  WT	  and	  G2019S	  form.	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6.1.1	  	  Hypotheses	  	  Experiments	  were	  designed	  to	  address	  the	  following	  hypotheses.	  	   1) LRRK2	  is	  a	  functional	  kinase	  and	  is	  able	  to	  phosphorylate	  other	  proteins	  in	  
vitro.	  2) α-­‐synuclein	  is	  unlikely	  to	  be	  a	  physiological	  interactor	  of	  LRRK2.	  3) LRRK2	  is	  able	  to	  phosphorylate	  the	  TUBB5	  isoform	  of	  β-­‐tubulin.	  4) LRRK2	  is	  able	  to	  phosphorylate	  DVL	  isoforms	  2	  and	  3.	  
6.1.2	  	  Aims	  	  These	  hypotheses	  were	  investigated	  by	  fulfilling	  the	  following	  aims.	  	   1) To	  compare	  phosphorylation	   of	  α,	  β	   and	   γ-­‐synuclein	   family	  members	   by	  LRRK2.	  2) To	  assess	  the	  efficiency	  of	  α-­‐synuclein	  phosphorylation	  by	  LRRK2	  in	  vitro.	  	  3) To	  assess	  LRRK2	  phosphorylation	  of	  β-­‐tubulin	  in	  vitro	   for	  possible	  future	  experiments.	  4) To	  assess	  the	  ability	  of	  LRRK2	  to	  phosphorylate	  DVL2	  and	  DVL3	  in	  vitro.	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6.2	   RESULTS	  
6.2.1	  Assessment	  of	  α-­‐synuclein	  phosphorylation	  by	  LRRK2	  
6.2.1.1	  	  Synuclein	  family	  phosphorylation	  by	  LRRK2	  To	  look	  at	   the	  specificity	  of	  kinase	  activity	  towards	  α,	  as	  opposed	  to	  β	  or	  γ-­‐synuclein	  (β-­‐syn,	   γ-­‐syn),	   kinase	   assays	   were	   performed	   using	   these	   forms	   of	   synuclein.	  Phosphorylation	   of	   each	   substrate	   was	   quantified	   at	   90	   mins.	   Radiography	   and	  subsequent	   quantification	   of	   synuclein	   phosphorylation	   showed	   that	   there	   are	  undetectable	   levels	   of	   phosphorylation	  by	   co-­‐purified	   kinases	   in	   these	   assays	   and	   as	  such,	  phosphorylation	  values	  obtained	  and	  are	   instead	   likely	  attributed	   to	   the	  kinase	  being	   investigated	   (Figure	   6.1a).	   	   CK1	   was	   shown	   to	   phosphorylate	   all	   forms	   of	  synuclein,	  with	  RIPK5	  and	  ΔN-­‐LRRK2	  phosphorylation	  of	   these	  varients	  occurring	  at	  low	  levels.	  Quantification	  of	  phosphorylation	  and	  comparison	  between	  groups	  showed	  that	   CK1	   phosphorylation	   was	   significantly	   higher	   than	   the	   non-­‐specific	   activity	   of	  RIPK5	  (p<0.001,	  one	  way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐test,	  Figure	  6.1b).	  RIPK5	  phosphorylation	  of	  α-­‐syn	  was	  not	  significantly	  higher	  than	  background	  (p>0.05,	  Figure	  6.1b).	   This	   was	   also	   the	   case	   for	   LRRK2	   (p>0.05).	   Phosphorylation	   for	   all	   synuclein	  varients	  was	  shown	  to	  be	  the	  same	  for	  each	  kinase	  (Figure	  6.1c).	  These	  results	  show	  that	   WT	   LRRK2	   is	   unable	   to	   phosphorylate	   α-­‐syn	   in	   vitro.	   LRRK2	   does	   not	   show	  preferential	  phosphorylation	  of	  β	  or	  γ-­‐syn	  compared	  to	  α-­‐syn	  in	  vitro	  (p>0.05).	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Figure	   6.1a.	   Autoradiography	   of	   Synuclein	   phosphorylation.	   RIPK5-­‐	   Receptor	  interacting	  protein	  kinase	  5,	  132.7	  kDa.	  CK1-­‐	  Casein	  kinase	  1,	  78.9	  kDa.	  WT-­‐	  Wild	  type	  
ΔN-­‐LRRK2,	  204.9	  kDa.	  KD-­‐D1944A	  ΔN-­‐LRRK2,	  204.9	  kDa.	  	  i-­‐α-­‐synuclein,	  16	  kDa.	  ii-­‐β-­‐synuclein,	  14	  kDa.	  iii-­‐γ-­‐synuclein,	  17	  kDa.	  	  Time	  points	  were	  taken	  at	  0	  and	  90	  mins	  as	  indicated	  below.	  Molecular	  weight	  markers	  are	  indicated	  on	  the	  left	  (kDa).	  Images	  are	  representative	   of	   at	   least	   three	   experiments.	   6.1b.	   Quantification	   of	   α-­‐synuclein	  
phosphorylation	   by	   various	   kinases.	   The	   90	   mins	   time	   point	   for	   each	   condition	  (taken	  from	  6.1ai),	  was	  quantified	  and	  displayed	  as	  a	  bar	  chart	  showing	  the	  mean	  and	  s.e.m	   of	   phosphorylation	   values	   (N=3).	   ***	   p<0.001,	   CK1	   vs	   RIPK5,	   one-­‐way	   ANOVA	  between	   all	   groups	   with	   a	   Bonferroni	   post-­‐test.	   6.1c.	   Comparison	   of	   synuclein	  
phosphorylation	   by	   various	   kinases.	  There	  was	  no	  difference	  between	  α,	  β	   and	  γ-­‐synuclein	  for	  each	  kinase	  (p>0.05).	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6.2.1.2	  	  Impact	  of	  familial	  mutations	  on	  α-­‐synuclein	  phosphorylation	  by	  LRRK2	  It	   has	   been	   shown	   in	   numerous	   studies	   that	   the	   G2019S	  mutation	   causes	   increased	  kinase	   activity	   in	   vitro	   (reviewed	   in	   Greggio	   et	   al.	   2009).	   To	   assess	   if	   LRRK2	  phosphorylation	   of	   α-­‐syn	   is	   affected	   by	   familial	   mutations,	   kinase	   assays	   were	  performed	   using	   mutant	   forms	   of	   ΔN-­‐LRRK2.	   Quantification	   of	   phosphorylation,	  showed	   that	  mutant	   forms	  of	  LRRK2	  displayed	   little	  or	  no	  phosphorylation	  of	  α-­‐syn.	  These	  results	  were	  not	  significantly	  higher	   than	   in	   the	  negative	  control	  condition	   for	  each	   mutant	   (p.0.05	   vs	   KD),	   with	   the	   exception	   of	   G2019S,	   which	   displayed	   higher	  phosphorylation	  of	  α-­‐syn	   than	   the	  KD	  condition	   (p<0.05).	  These	   results	   suggest	   that	  G2019S	  ΔN-­‐LRRK2	  is	  the	  only	  form	  of	  LRRK2	  able	  to	  phosphorylate	  α-­‐syn	  in	  vitro.	  
	  
Figure	   6.2a.	   α-­‐synuclein	   phosphorylation	   by	   mutant	   ΔN-­‐LRRK2.	   i-­‐WT.	   ii-­‐KD	  (D1994A).	  iii-­‐G2019S.	  iv-­‐I2020T.	  v-­‐R1441C.	  vi-­‐Y1699C.	  ΔN-­‐LRRK2	  was	  incubated	  with	  alpha-­‐synuclein	   for	  90	  mins	  and	   time	  points	   taken	  as	  shown	  underneath.	   Images	  are	  representative	  of	   three	  experiments.	  Molecular	  weigh	  markers	  are	   shown	  on	   the	   left	  (kDa).	   6.2b.	   Quantification	   of	   α-­‐synuclein	   phosphorylation.	   Kinase	   assays	   were	  transferred	   to	   phosphor	   screen	   and	   phosphorylation	   quantified	   using	   densitometry.	  Values	   shown	   are	   mean	   ±	   s.e.m	   over	   time	   (n=3).	   6.2c.	   Quantification	   of	   α-­‐syn	  
phosphorylation	  at	  90	  mins.	  The	  values	  for	  phosphorylation	  at	  90	  mins	  were	  taken	  and	  plotted	  as	  means	  ±	   s.e.m	  on	  a	  bar	   chart	   (n=3).	   *	  p<0.05	  vs	  KD,	  one	  way	  ANOVA	  with	  Bonferroni	  post-­‐test.	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6.2.1.3	  	  Assessment	  α-­‐syn	  phosphorylation	  efficiency	  To	   look	  at	  α-­‐syn	  phosphorylation	   in	  relation	  to	   the	   level	  of	  kinase	  activity	   towards	  a	  non-­‐physiological	  substrate,	  α-­‐syn	  phosphorylation	  was	  compared	  to	  phosphorylation	  of	   MBP.	   Figure	   6.3a	   shows	   the	   radiographic	   images	   of	   these	   experiments.	  Quantification	   of	  MBP	  phosphorylation	  by	  densitometry	   and	   expression	  of	  MBP	   as	   a	  ratio	   to	   α-­‐syn	   phosphorylation,	   shows	   that	   the	   positive	   control,	   CK1	   displays	   a	  preference	  for	  α-­‐syn	  phosphorylation	  over	  MBP	  phosphorylation,	  as	  the	  ratio	  of	  α-­‐syn:	  MBP	  phosphorylation	   is	  greater	   than	  one	  (Figure	  6.3b).	  For	  both	  RIPK5,	  and	  G2019S	  LRRK2,	   these	   values	   are	   less	   than	   one,	   showing	   that	   MBP	   phosphorylation	   is	  preferential	  to	  α-­‐syn	  phosphorylation	  for	  these	  kinases.	  	  	  Calculation	   of	   an	   efficiency	   value	   for	   α-­‐syn	   phosphorylation,	   which	   considers	  autophosphorylation,	  shows	  that	  this	  value	  is	  below	  1	  for	  all	  kinases	  (Figure	  6.3c).	  This	  suggests	   that	  α-­‐syn	  phosphorylation	   is	   less	  efficient	   than	  autophosphorylation	   for	  all	  kinases.	  Interestingly,	  this	  is	  also	  the	  case	  with	  the	  positive	  control	  CK1.	  
Figure	   6.3a.	   Phosphorylation	   of	  MBP	   shown	  by	   radiography.	  Phosphorylation	  of	  MBP	  at	  0	  and	  90	  mins	  is	  shown	  .	  Time	  points	  are	  indicated	  below.	  MBP	  is	  a	  mixture	  of	  different	   isoforms	   with	   an	   average	   molecular	   weight	   of	   18	   kDa.	   Molecular	   weight	  markers	   shown	   on	   the	   left	   (kDa).	   Images	   are	   representative	   of	   three	   experiments.	  
6.3b.	  Ratio	  of	  α-­‐synuclein:	  MBP	  phosphorylation	  at	  90	  mins.	  The	  values	  for	  α-­‐syn	  phosphorylation	   at	   90	  mins	  were	   divided	   by	   values	   for	  MBP	   phosphorylation	   at	   90	  mins	   for	   each	   kinase	   and	   are	   displayed	   as	   mean	   ±	   s.e.m	   (n=3).	   6.3c.	   Ratio	   of	   α-­‐
synuclein:	  autophosphorylation	  at	  90	  mins.	  The	  values	  for	  α-­‐syn	  phosphorylation	  at	  90	  mins	   were	   divided	   by	   the	   values	   for	   autophosphorylation	   in	   each	   assay	   and	   are	  displayed	  as	  mean	  ±	  s.e.m	  (n=3).	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6.2.1.4	  S129	  phosphorylation	  of	  α-­‐synuclein	  
α-­‐Syn	  phosphorylation	   at	   S129	  has	   been	   shown	   to	   be	   important	   in	   PD	  pathogenesis	  (Smith	  et	  al.	  2005).	  It	  has	  been	  shown	  that	  CK1	  can	  phosphorylate	  α-­‐syn	  at	  this	  residue	  (Okochi	   et	   al.	   2000).	   As	   G2019S	   LRRK2	   is	   able	   to	   phosphorylate	  α-­‐syn	   in	   vitro,	   the	  ability	  of	  this	  mutant	  for	  of	  LRRK2	  to	  phosphorylate	  S129	  and	  perhaps	  provide	  a	  link	  between	  LRRK2	  and	  pathogenic	  changes	  to	  α-­‐syn,	  was	  assessed	  using	  phosphospecific	  antibodies.	  Kinase	  assays	  were	  performed	  and	  analysed	  using	  western	  blotting	  with	  a	  p-­‐S129	  antibody	  (Table	  2.8).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6.4.	  S129	  phosphorylation	  of	  α-­‐synuclein	  by	  RIPK5,	  CK1	  and	  LRRK2.	  WT-­‐	  Wild	  type,	  GS-­‐	  G2019S,	  KD-­‐D1994A,	  kinase	  dead	  LRRK2.	  Higher	  weight	  species	  at	  ~28	  kDa	   are	   likely	   to	   be	   SDS-­‐insoluble	   dimers	   of	  α-­‐syn	   that	   have	   formed	   due	   to	   protein	  incubation	  at	  37oC.	  Images	  shown	  are	  representative	  of	  three	  assays.	  Equal	  amounts	  of	  protein	  were	  loaded	  for	  each	  condition.	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Western	  blotting	  showed	  that	  the	  positive	  control	  CK1,	  was	  able	  to	  phosphorylate	  α-­‐syn	   at	   S129.	   SDS-­‐insoluble	   dimers	   that	   formed	   during	   the	   kinase	   assay	   were	   also	  phosphorylated	  at	  this	  residue.	  As	  expected,	  no	  immunoreactivity	  at	  this	  residue	  was	  shown	  in	  the	  RIPK5	  condition,	  however	  none	  of	  the	  LRRK2	  forms	  used	  in	  these	  assays	  were	  able	  to	  phosphorylate	  α-­‐syn	  at	  S129	  either	  (Figure	  6.4),	  suggesting	  that	  S129	  is	  an	  unlikely	  kinase	  target	  for	  G2019S	  LRRK2	  .	  
6.2.2	  	  Assessment	  of	  TUBB5	  phosphorylation	  	  
6.2.2.1	  	  TUBB5	  by	  LRRK2	  Y2H	   experiments	   by	   collaborators	   have	   identified	   TUBB5	   as	   a	   potential	   binding	  partner	  of	  the	  ROC	  domain	  (Sancho	  and	  Harvey,	  unpublished	  results).	  Interaction	  and	  phosphorylation	   of	  β-­‐tubulin	   by	   LRRK2	   has	   been	   shown	   by	   other	   groups	   (Gillardon	  2009a,	  b),	  and	  as	  such	  phosphorylation	  of	  the	  TUBB5	  isoform	  by	  LRRK2	  was	  assessed	  in	  these	  experiments.	  	  	  Incubation	  of	  TUBB5	  with	  ΔN-­‐LRRK2	   in	   the	  presence	  of	  32P	   γ-­‐labelled	  ATP,	   showed	  that	   LRRK2	   is	   able	   to	   phosphorylate	   this	   isoform	   of	  β-­‐tubulin	   in	   vitro	   (Figure	   6.5a).	  Phosphorylation	  of	  TUBB5	  was	  also	  seen	  in	  the	  negative	  control,	  suggesting	  low-­‐level	  contamination	   of	   the	   purified	   substrate	   with	   other	   kinases.	   When	   values	   were	  corrected	   for	   background	  phosphorylation,	   statistical	   analysis	   showed	   that	   all	   active	  kinases,	  including	  the	  non-­‐specific	  kinase	  RIPK5,	  were	  able	  to	  phosphorylate	  TUBB5	  at	  a	   level	   significantly	   higher	   than	   in	   the	   KD	   condition	   (p=0.0001,	   One-­‐way	   ANOVA).	  Interestingly,	   quantification	   and	   analysis	   of	   TUBB5	   phosphorylation	   for	   the	   positive	  control	   GRK2	   and	   RIPK5,	   showed	   that	   there	   was	   no	   difference	   in	   TUBB5	  phosphorylation	   between	   these	   conditions	   (p>0.05,	   one-­‐way	   ANOVA,	   followed	   by	  Bonferroni	   post-­‐test).	   LRRK2	   phosphorylation	   of	   TUBB5	   on	   the	   other	   hand	   was	  significantly	  higher	   than	   in	   the	  GRK2	  condition	   for	  both	  WT	  and	  G2019S	  (p<0.05	   for	  each).	   Interestingly,	   there	  was	   no	   difference	   in	   absolute	   phosphorylation	   by	  G2019S	  compared	   to	  WT	   (p>0.05),	   despite	   the	   fact	   that	   higher	   activity	   of	   G2019S	   has	   been	  commonly	  reported	  (reviewed	  in	  Greggio	  et	  al.	  2009).	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Figure	   6.5a.	   Autoradiography	   of	   TUBB5	   phosphorylation.	   RIPK5-­‐	   Receptor	  interacting	   protein	   kinase	   5,	   132.7	   kDa.	   GRK2-­‐	   G-­‐protein	   coupled	   receptor	   kinase	   2,	  82.3	   kDa.	  WT-­‐	  Wild	   type	  ΔN-­‐LRRK2,	   204.9	   kDa.	   KD-­‐D1944A	  ΔN-­‐LRRK2,	   204.9	   kDa.	  	  TUBB5	  has	  a	  molecular	  weight	  of	  74.9	  kDa.	  	  Time	  points	  were	  taken	  at	  0	  and	  90	  mins	  as	   indicated	  below.	  Molecular	  weight	  markers	  are	   indicated	  on	  the	   left	  (kDa).	   Images	  are	   representative	   of	   three	   experiments.	   6.5b.	   Quantification	   of	   TUBB5	  
phosphorylation.	   Densitometry	  was	   used	   to	   quantify	   phosphorylation	   of	   TUBB5	   by	  each	   of	   the	   kinases	   used	   in	   this	   assay.	   Values	   obtained	   for	   the	   KD	   condition	   were	  subtracted	  and	  TUBB5	  phosphorylation	  shown	  as	  values	  above	  background.	  Bar	  charts	  show	   mean	   ±	   s.e.m	   for	   each	   condition	   (n=3).	   *	   p<0.05	   vs	   RIPK5.	   One-­‐way	   ANOVA	  followed	   by	   Bonferroni	   post-­‐test.	   6.5c.	   Phosphorylation	   of	   MBP	   shown	   by	  
radiography.	   Phosphorylation	   of	   MBP	   at	   0	   and	   90	  mins	   is	   shown.	   Time	   points	   are	  indicated	   below.	   MBP	   is	   a	   mixture	   of	   different	   isoforms	   with	   an	   average	   molecular	  weight	  of	  18	  kDa.	  Molecular	  weight	  markers	  are	  shown	  on	  the	   left	   (kDa),	   images	  are	  representative	   of	   three	   experiments.	  6.5d.	   Ratio	   of	   TUBB5	   phosphorylation:	   MBP	  
phosphorylation	   for	   various	   kinases.	   Phosphorylation	   values	   for	   TUBB5	   were	  divided	  by	  MBP	  phosphorylation	  values	  for	  each	  kinase.	  Values	  show	  mean	  ±	  s.e.m	  for	  each	  condition	  (n=3).	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6.2.2.2	  	  Assessment	  of	  the	  efficiency	  of	  TUBB5	  phosphorylation	  Results	   obtained	   from	   these	   experiments	   showed	   that	   GRK2	   did	   not	   display	  quantifiable	   autophosphorylation,	   despite	   the	   fact	   that	   GRK2	   is	   known	   to	  autophosphorylate	   (Sarnago	   et	   al.	   1999).	   As	   such,	   the	   efficiency	   of	   TUBB5	  phosphorylation	  was	  instead	  assessed,	  by	  comparing	  to	  phosphate	  incorporation	  into	  MBP	  (Figure	  6.5d).	  Comparison	  of	  TUBB5	  with	  MBP	  phosphorylation	  for	  the	  positive	  control	  GRK2,	  showed	  that	  phosphorylation	  of	  the	  physiological	  substrate	  in	  vitro	  was	  more	  efficient	  than	  of	  MBP	  by	  more	  than	  five	  times,	  as	  might	  be	  expected	  (Figure	  6.5d).	  Wild	  type	  ΔN-­‐LRRK2	  showed	  around	  two-­‐fold	  higher	  phosphorylation	  of	  TUBB5	  than	  MBP,	   suggesting	   that	   TUBB5	   phosphorylation	   is	   higher	   in	   efficiency	   than	   MBP	  phosphorylation.	   G2019S	   ΔN-­‐LRRK2	   phosphorylation	   of	   TUBB5	   was	   shown	   to	   be	  higher	   than	  MBP	  by	   around	  1.3	   times,	   a	   value	   that	   suggests	   a	   lower	   efficiency	  when	  compared	   to	   WT.	   Non-­‐specific	   phosphorylation	   of	   TUBB5	   by	   RIPK5	   showed	  preferential	   phosphorylation	   of	   MBP	   when	   values	   were	   compared,	   with	   β-­‐tubulin	  phosphorylated	  at	  around	  half	   the	  efficiency	  of	   the	  pseudosubstrate.	  Taken	   together,	  these	  results	  suggest	  that	  TUBB5	  is	  a	  good	  candidate	  for	  interaction	  with	  LRRK2	  and	  as	  such	  are	  good	  targets	  for	  further	  investigation.	  	  
6.2.3	  	  Assessment	  of	  DVL	  phosphorylation	  by	  LRRK2	  
6.2.3.1	  	  LRRK2	  phosphorylation	  of	  DVL3	  is	  higher	  than	  DVL2	  Y2H	  studies	  have	  shown	  that	   the	  DVL	  proteins	  may	   interact	  with	   the	  ROC	  domain	  of	  LRRK2,	  and	  that	  this	  interaction	  is	  perturbed	  by	  familial	  mutants	  of	  LRRK2	  (Sancho	  et	  
al.	   2009).	   To	   investigate	   these	   proteins	   as	   potential	   kinase	   substrates	   for	   LRRK2,	   in	  
vitro	  kinase	  assays	  were	  performed	  using	  DVL2	  and	  DVL3	  as	  substrates.	  	  	  
In	   vitro	   kinase	   assays	   using	   DVL2	   as	   a	   substrate,	   showed	   that	   all	   active	   kinases	  investigated,	  displayed	  low-­‐level	  phosphorylation	  of	  DVL2	  (Figure	  6.6a).	  The	  negative	  control	   KD	  ΔN-­‐LRRK2,	   showed	   no	   DVL2	   phosphorylation,	   suggesting	   that	   there	   are	  undetectable	   levels	   of	   phosphorylation	   by	   co-­‐purified	   kinases	   in	   these	   experiments.	  Analysis	  of	  DVL2	  phosphorylation	  by	  CK1	  at	  90	  mins,	  showed	  that	  phosphorylation	  of	  the	  positive	   control	   is	   higher	   than	  background	  as	  would	  be	   expected	   (p<0.05	  vs	  KD,	  one-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐test),	  but	  no	  higher	  than	  the	  non-­‐specific	  phosphorylation	  showed	  in	  the	  RIPK5	  condition	  (p>0.05	  vs	  RIPK5).	  Phosphorylation	  of	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DVL2	  by	  WT	  and	  G2019S	  LRRK2	  were	  shown	  to	  be	  no	  higher	  than	  background	  (p>0.05	  vs	  KD),	  although	  RIPK5	  showed	  significantly	  higher	  phosphorylation	  of	  DVL2	  than	   in	  the	  KD	  condition	  (p<0.05	  vs	  KD).	  These	  results	  suggest	  that	  LRRK2	  in	  WT	  and	  G2019S	  forms	  are	  unable	  to	  phosphorylate	  DVL2	  in	  vitro.	  	  Quantification	  of	  DVL3	  phosphorylation	  at	  90	  mins	  (Figure	  6.6f)	  showed	  that	  there	  is	  robust	  phosphorylation	  of	  DVL3	  by	  all	  active	  kinases	  (p>0.05	  vs	  KD	  for	  all	  conditions,	  one-­‐way	  ANOVA	   followed	   by	   Bonferroni	   post-­‐test).	   Again,	   there	  was	   no	   quantifiable	  phosphorylation	   displayed	   in	   the	   KD	   condition.	   CK1	   phosphorylation	   of	   DVL3	   was	  higher	  than	  background	  (p<0.001	  vs	  KD,	  one-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐test),	   but	   not	   higher	   than	   the	   non-­‐specific	   phosphorylation	   displayed	   by	   RIPK5	  (p>0.05).	   LRRK2	   phosphorylation	   for	   both	  WT	   and	   G2019S	   forms	  was	   shown	   to	   be	  higher	  than	  background	  (p<0.001	  vs	  KD)	  but	  was	  again,	  no	  higher	  than	   in	   the	  RIPK5	  condition	   (p>0.05).	   There	   was	   no	   difference	   between	   WT	   ΔN-­‐LRRK2	   and	   G2019S	  phosphorylation	  of	  DVL3	  (p>0.05).	  This	  shows	  that,	  although	  LRRK2	  phosphorylation	  of	   DVL3	   occurred	   at	   seemingly	   high	   levels,	   DVL3	   is	   also	   highly	   phosphorylated	   by	  RIPK5	  meaning	  that	  this	  phosphorylation	  is	  less	  likely	  to	  be	  physiological.	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Figure	  6.6a.	  Autoradiography	  of	  DVL2	  phosphorylation.	  RIPK5-­‐	  Receptor	  interacting	  protein	  kinase	  5,	  132.7	  kDa.	  CK1-­‐	  Casein	  kinase	  1,	  78.9	  kDa.	  WT-­‐	  Wild	  type	  ΔN-­‐LRRK2,	  204.9	  kDa.	  KD-­‐D1944A	  ΔN-­‐LRRK2,	  204.9	  kDa.	   	  DVL2	  has	   a	  molecular	  weight	  of	  105.9	  kDa.	  	  Time	  points	  were	  taken	  as	  indicated	  below	  (mins).	  Molecular	  weight	  markers	  are	  indicated	   on	   the	   left	   (kDa).	   Images	   are	   representative	   of	   three	   experiments.	   6.6b.	  
Quantification	   of	   DVL2	   phosphorylation.	   Densitometry	   was	   used	   to	   quantify	  phosphorylation	  of	  DVL2	  at	  90	  mins	  for	  each	  kinase.	  Bar	  charts	  show	  mean	  ±	  s.e.m	  for	  each	   condition	   (n=3).	   6.6c.	   Autoradiography	   of	   DVL3	   phosphorylation.	   As	   Figure	  6.6a.	   DVL3	   has	   a	   molecular	   weight	   of	   104.7	   kDa.	   6.6d	   Quantification	   of	   DVL2	  
phosphorylation.	  As	  Figure	  6.6b.	  
0	  	  	  15	  	  	  45	  	  90
RIPK5 CK1
0	  	  	  15	  	  	  45	  	  90
WT
0	  	  	  15	  	  	  45	  	  90
G2019S
0	  	  	  15	  	  	  45	  	  90
KD
0	  	  	  15	  	  	  45	  	  90
DVL30	  	  	  15	  	  	  45	  	  90
RIPK5110 CK1
0	  	  	  15	  	  	  45	  	  90
WT
0	  	  	  15	  	  	  45	  	  90
G2019S
0	  	  	  15	  	  	  45	  	  90
KD
0	  	  	  15	  	  	  45	  	  90
110 110 110 110
DVL2
DVL2phosphoryation




ii. iii. iv. v.
bi. ii. iii. iv. v.
INVESTIGATION	  OF	  PUTATIVE	  LRRK2	  KINASE	  SUBSTRATES	  IN	  VITRO	  
	   158	  
6.2.3.2.	  	  	  Comparison	  of	  DVL3	  phosphorylation	  to	  MBP	  phosphorylation	  Autophosphorylation	   occurred	   at	   low	   levels	   for	   all	   kinases	   in	   these	   experiments.	   For	  LRRK2,	   autophosphorylation	   occurred	   at	   low,	   but	   visible	   levels.	   For	   RIPK5	   and	   CK1	  however,	  no	  autophosphorylation	  was	  detectable	  (Figure	  6.6a	  and	  b).	  Analysis	  of	  DVL2	  phosphorylation,	   showed	   that	  values	  were	  no	  higher	   than	  background	   for	  each	  kinase	  except	   the	   positive	   control	   (p>0.05	   vs	   KD	   for	   each	   condition).	   As	   such,	   substrate	  phosphorylation	  in	  these	  experiments	  was	  not	  analysed	  further.	  DVL3	  phosphorylation	  was	   shown	   to	  be	  higher	   than	  background	   for	   all	   active	  kinases	   assayed,	   therefore	   the	  levels	  of	  DVL3	  phosphorylation	  were	  compared	  to	  MBP,	  in	  order	  to	  assess	  the	  efficiency	  of	  phosphorylation	  for	  each	  kinase	  (Figure	  6.7).	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6.7.	  Ratio	  of	  MBP:	  DVL3	  phosphorylation	  for	  enzymatically	  active	  kinases.	  Phosphorylation	  values	  for	  DVL3	  were	  divided	  by	  MBP	  phosphorylation	  values	  for	  each	  kinase.	  Values	  show	  mean	  ±	  s.e.m	  for	  each	  condition	  (n=3).	  	  Comparison	  of	  CK1	  phosphorylation	  of	  DVL3,	   shows	   that	  MBP	  was	  phosphorylated	   at	  around	  three	  times	  lower	  levels	  than	  substrate	  phosphorylation	  (Figure	  6.7).	  WT	  LRRK2	  phosphorylation	  of	  DVL3	  is	  around	  3	  times	  higher	  than	  MBP	  phosphorylation,	  with	  the	  G2019S	  mutant	  showing	  MBP	  phosphorylation	  of	  MBP	  at	  around	  half	   the	  efficiency	  of	  DVL3.	   Non-­‐specific	   phosphorylation	   of	   DVL3	   by	   RIPK5	   shows	   an	   efficiency	   ratio	   less	  than	  one,	  despite	  the	  robust	  phosphorylation	  of	  DVL3	  displayed	  (Figure	  6.6	  c,	  d).	  These	  results	  suggest	  that	  MBP	  is	  phosphorylated	  at	  around	  twice	  the	   level	  of	  DVL3.	  As	  such	  DVL3	  may	  be	  a	  good	  candidate	  for	  further	  investigation	  as	  a	  LRRK2	  kinase	  substrate.	  
INVESTIGATION	  OF	  PUTATIVE	  LRRK2	  KINASE	  SUBSTRATES	  IN	  VITRO	  
	   159	  
6.3	  	  DISCUSSION	  LRRK2	   is	  known	  to	  be	   toxic	  when	  overexpressed	   in	  cells,	  and	   it	  has	  been	  shown	  that	   this	   toxicity	   is	  mediated	  by	  kinase	   function	   (Greggio	  et	  al.	   2006,	  Smith	  et	  al.	  2006).	  As	  a	  putative	  kinase,	   identifying	  the	  kinase	  substrates	  of	  LRRK2	  is	  vital	   in	  order	  to	  understand	  how	  mutations	  in	  LRRK2	  cause	  AD	  PD.	  In	  these	  experiments,	  proposed	  interactors	  of	  LRRK2	  were	  used	  in	  kinase	  assays	  to	  assess	  the	  likelihood	  of	   being	   physiological	   kinase	   substrates.	   Using	   ΔN-­‐LRRK2	   allowed	   highly	  controlled	   kinase	   assays	   to	   be	   performed,	   in	  which	   the	   concentration	   of	   LRRK2	  and	  the	  molar	  excess	  of	  each	  substrate	  could	  be	  carefully	  manipulated.	  This	  system	  allowed	   the	  aims	   to	  be	   successfully	  achieved	  and	   the	   synuclein	   family,	  DVLs	  and	  TUBB5	  were	  assessed	  as	  kinase	  substrates.	  From	  the	  results	  of	  all	   in	  vitro	  kinase	  assays	   described	   here,	   it	   would	   seem	   that	   DVL3	   is	   the	   best	   candidate	   for	  interaction	  with	  LRRK2,	  as	  phosphorylation	  of	  this	  protein	  was	  shown	  to	  occur	  at	  levels	  three	  times	  higher	  than	  the	  generic	  substrate	  MBP.	  Other	  substrates	  assayed	  did	  not	  show	  the	  same	  level	  of	  preference	  when	  compared	  to	  LRRK2.	  	  	  
6.3.1	  	  Synuclein	  phosphorylation	  Examination	  of	  α-­‐syn	   as	   a	   potential	   kinase	   substrate,	   showed	   that	  WT	  LRRK2	   is	  unable	   to	   phosphorylate	   α-­‐syn	   in	   vitro	   (Figure	   6.1a,	   b).	   β	   and	   γ-­‐syn	   were	   not	  preferable	   as	   kinase	   substrates	   (Figure	   6.1c).	   The	   presence	   of	   the	   G2019S	  hyperactivating	  mutation,	   induced	  phosphorylation	  of	  α-­‐syn	  that	  was	  statistically	  significant,	  however	  comparison	  of	   this	  phosphorylation	   to	  autophosphorylation,	  showed	   that	   autophosphorylation	   is	   more	   efficient	   in	   this	   system.	   Similarly,	  G2019S	   kinase	   activity	   towards	   the	   generic	   substrate	  MBP	  was	   also	   higher	   than	  towards	   α-­‐syn.	   It	   could	   be	   hypothesised	   that	   G2019S	   induces	   abnormal	  phosphorylation	   of	   α-­‐syn,	   which	   does	   not	   occur	   in	   the	   WT	   form.	   This	   would	  provide	   a	   possible	   mechanism	   for	   LRRK2	   mutations	   and	   PD	   pathogenesis,	  however	   the	   lack	   of	   phosphorylation	   at	   S129	   makes	   this	   seem	   less	   likely.	   The	  G2019S	  substitution	   is	  unlikely	   to	   cause	   structural	   changes	  on	  a	   scale	   that	   could	  induce	   differential	   substrate	   recognition,	   especially	   as	   these	   functions	   are	   likely	  mediated	   by	   the	   protein-­‐protein	   interaction	   domains	   and	   not	   by	   the	   kinase	  
INVESTIGATION	  OF	  PUTATIVE	  LRRK2	  KINASE	  SUBSTRATES	  IN	  VITRO	  
	   160	  
domain,	   From	   the	   data	   shown	   in	   this	   study,	   it	   can	   be	   concluded	   that	   α-­‐syn	   is	  unlikely	   to	   be	   a	   LRRK2	   kinase	   substrate	   in	   vitro	  and	   also,	   that	   LRRK2	   does	   not	  phosphorylate	   the	   S129	   residue	   under	   these	   conditions.	   As	   such,	   it	  would	   seem	  less	  likely	  that	  α-­‐syn	  is	  a	  kinase	  substrate	  for	  LRRK2	  in	  vivo	  also.	  	  	  Other	  groups	  have	  shown	  an	  interaction	  between	  α-­‐syn	  and	  LRRK2	  in	  vitro	  (Qing	  
et	  al.	   2009a,	   b),	  however	   these	   experiments	   utilised	  whole	   cell	   lysate	   containing	  overexpressed	  LRRK2,	  instead	  of	  purified	  LRRK2.	  The	  phosphorylation	  of	  α-­‐syn	  at	  S129	   in	   these	   experiments	   could	  be	   a	   response	   to	   the	  overexpression	  of	   LRRK2,	  and	   not	   necessarily	   caused	   by	   LRRK2	   itself.	   Combining	   the	   results	   of	   the	   two	  studies,	  it	  seems	  more	  likely	  that	  if	  LRRK2	  and	  α-­‐syn	  do	  share	  a	  common	  signalling	  function,	   this	  may	   be	   due	   to	   a	   common	   signalling	   pathway,	   rather	   than	   a	   direct	  interaction.	   Indeed	  α-­‐syn	   and	   the	  14-­‐3-­‐3	  proteins	  have	  been	   shown	   to	  display	   a	  high	   degree	   of	   homology	   and	   it	   has	   been	   shown	   that	  α-­‐syn	   can	   bind	   to	   14-­‐3-­‐3	  (Ostrerova	   et	   al.	   1999).	   If	   this	   is	   the	   case,	   the	   recently	   discovered	   interaction	  between	   LRRK2	   and	   14-­‐3-­‐3	   could	   provide	   a	   functional	   link	   between	   these	   two	  proteins	  (Dzamko	  et	  al.	  2010,	  Nichols	  et	  al.	  2010,	  Li	  X.	  et	  al.	  2011).	  
6.3.2.TUBB5	  Initial	   analysis	   of	   TUBB5	   phosphorylation	   by	   LRRK2	   shows	   that	   the	   GST-­‐fusion	  protein	   is	  able	   to	  phosphorylate	  TUBB5	   in	  vitro,	  with	  a	  higher	  affinity	   for	   this	  β-­‐tubulin	   isoform	   than	   the	   psuedosubstrate	  MBP.	   Surprisingly,	   phosphorylation	   of	  TUBB5	   by	   G2019S	   ΔN-­‐LRRK2	   in	   these	   experiments	   was	   shown	   to	   occur	   at	   the	  same	  level	  as	  WT.	  When	  compared	  to	  MBP	  phosphorylation,	  the	  affinity	  of	  G2019S	  
ΔN-­‐LRRK2	  was	  lower	  than	  the	  WT	  condition	  (~2	  times	  compared	  to	  ~1.3	  times),	  however	  the	  ratio	  still	  showed	  a	  preference	  for	  TUBB5	  over	  MBP.	  	  	  Previous	   studies	   investigating	   putative	   substrates	   of	   LRRK2	   have	   shown	   that	  G2019S	  displays	  consistently	  higher	  kinase	  activity	  compared	  to	  compared	  to	  WT	  (West	   et	   al.	   2005,	   Anand	   et	   al.	   2009,	   Pungaliya	   et	   al.	   2010).	   Similarly,	   in	   vitro	  kinase	  assays	  performed	  by	  other	  groups	  have	  shown	  that	  the	  ΔN-­‐LRRK2	  protein	  can	   phosphorylate	   β-­‐tubulin	   in	   vitro	   and	   that	   G2019S	   increases	   tubulin	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phosphorylation	  by	  ~3	  fold	  (Gillardon,	  2009a,	  b).	  In	  this	  study,	  β-­‐tubulin	  isoforms	  were	  purified	  from	  bovine	  brain	  and	  were	  perhaps	  more	  likely	  to	  have	  interacting	  proteins	   present	   which	   could	   have	   affected	   the	   outcome	   of	   these	   assays.	   The	  results	   from	   the	   experiments	   detailed	  here	   raise	   interesting	  questions	   regarding	  the	   role	   of	   the	   G2019S	   mutation,	   because	   they	   suggest	   that	   the	   effect	   of	   this	  mutation	  on	  kinase	  activity	  may	  be	  more	  nuanced	   than	  a	  mere	  blanket	   increase.	  Instead	  it	  could	  be	  hypothesised	  that	  G2019S	  does	  not	  increase	  kinase	  activity	  per	  
se,	   but	   perhaps	   effects	   some	   sort	   of	   intra-­‐molecular	   regulation,	   such	   as	   delaying	  the	  ‘off’	  mechanism	  for	  kinase	  activity.	  When	  a	  robust	  cellular	  readout	  for	  LRRK2	  function	  has	  been	  identified,	  these	  questions	  can	  be	  answered	  more	  fully.	  	  Initial	  analysis	  of	  the	  results	  obtained,	  suggest	  that	  TUBB5	  is	  a	  good	  candidate	  for	  LRRK2	   interaction.	   As	   with	   the	   positive	   control,	   WT	   and	   G2019S	   ΔN-­‐LRRK2	  phosphorylation	   of	   the	   structural	   protein	   was	   shown	   to	   be	   more	   efficient	   than	  MBP,	  suggesting	  that	  it	  is	  less	  likely	  that	  the	  interaction	  is	  solely	  due	  to	  the	  in	  vitro	  conditions	   used.	   As	   such,	   interaction	   of	   LRRK2	   and	   TUBB5	   would	   be	   good	  candidate	   for	   further	   investigation	   in	   cellular	   models,	   as	   the	   tubulins	   provide	   a	  direct	  link	  to	  the	  tau	  pathology	  that	  is	  seen	  in	  the	  brains	  of	  some	  LRRK2	  mutation	  carriers.	  
6.3.3	  	  DVLs	  In	   the	   present	   study,	   LRRK2	  was	  demonstrated	   to	   phosphorylate	  DVL3	   at	   levels	  with	  no	  significant	  differece	   from	  those	  displayed	  by	   the	  positive	  control	   (Figure	  6.6e).	   LRRK2	   was	   shown	   to	   phosphorylate	   DVL3	   at	   a	   higher	   level	   than	   MBP,	  suggesting	  that	  LRRK2	  has	  a	  higher	  affinity	  for	  DVL3	  in	  vitro	  (Figure	  6.7).	  As	  with	  TUBB5,	   the	   absolute	   phosphorylation	   values	   for	   DVL3	   are	   similar	   for	   WT	   and	  G2019S.	   As	   the	   presence	   of	   familial	   mutations	   has	   been	   shown	   to	   decrease	   the	  strength	   of	   any	   proposed	   interaction	   between	   LRRK2	   and	   DVLs	   (Sancho	   et	   al.	  2009),	  it	  would	  be	  expected	  that	  phosphorylation	  of	  a	  DVL2	  or	  3	  would	  be	  lower	  in	  G2019S	   than	  WT.	   For	   DVL3,	   when	   kinase	   activity	   towards	   MBP	   was	   taken	   into	  account,	  G2019S	  actually	  showed	  a	  decreased	  affinity	  for	  DVL	  compared	  to	  WT.	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The	  functional	  implications	  of	  LRRK2	  involvement	  in	  Wnt	  signalling,	  suggest	  that	  if	  LRRK2	   is	   a	   member	   of	   this	   pathway,	   it	   is	   likely	   to	   play	   an	   important	   role	   in	  development.	   If	   so,	   if	   LRRK2	  and	  DVL3	  do	   interact	   in	   vivo,	  why	  do	  mutations	   in	  LRRK2	   cause	   PD	   and	   not	   developmental	   disorders?	   Further	   experimentation	   in	  cell	  models	  will	  allow	  this	  interaction	  to	  be	  explored	  in	  more	  detail.	  	  
6.3.4	  The	  role	  of	  interacting	  proteins	  Phosphorylation	   of	   a	   substrate	   is	   often	   dependent	   on	   cellular	   context	   and	  interactions	  with	  other	  proteins.	  As	  all	  kinase	  assays	  described	  in	  this	  thesis	  were	  performed	   in	  vitro,	   there	  are	  numerous	   factors	   that	  were	  not	  present.	  As	  such,	   it	  cannot	  be	  concluded	  that	  LRRK2	  does	  not	  phosphorylate	  α-­‐syn	  (Figures	  6.1,	  6,2)	  or	  DVL2	   (Figure	  6.6a,	   c,	   d)	   in	  vivo.	   The	   lack	  of	   cellular	   context	   in	   these	   assays	   is	  exacerbated	  by	  the	   fact	   that	  LRRK2	   is	  missing	  a	  region	  of	  around	  100kDa,	  which	  could	   be	   crucial	   for	   mediating	   protein-­‐protein	   interaction.	   In	   terms	   of	   α-­‐syn	   it	  means	  that	  there	  could	  still	  be	  possibility	  that	  LRRK2	  and	  α-­‐syn	  are	  physiological	  interactors,	   however	   more	   investigation	   is	   needed	   to	   elucidate	   the	   role	   LRRK2	  kinase	  activity	  is	  playing	  in	  α-­‐syn	  signalling	  and	  pathogenesis.	  The	  fact	  that	  GRK2	  displayed	   the	   lowest	   phosphorylation	   of	   TUBB5,	   emphasises	   the	   importance	   to	  interacting	   proteins	   for	   kinase	   to	   function	   optimally.	   GRK2	   has	   been	   shown	   to	  require	   numerous	   cofactors	   to	   function	   including	   phosphorylation	   at	   certain	  residues	  and	  G-­‐protein	  interactions,	  (Pitcher	  et	  al.	  1998).	  The	  lack	  of	  these	  factors	  
in	  vitro	   likely	  offers	  some	  explanation	  for	  the	  low	  kinase	  activity	  seen	  by	  GRK2	  in	  these	  experiments.	  	  	  
6.3.5	  	  Future	  directions	  The	  experiments	  using	  RIPK5	  that	  are	  detailed	  here,	  have	  shown	  that	  non-­‐specific	  phosphorylation	  of	  a	  substrate	  in	  vitro	  is	  able	  to	  occur	  at	  robust	  levels	  (Figure	  6.1,	  6.5,	   6.6).	   In	   this	   case,	   results	   from	   in	   vitro	   experiments	   must	   be	   interpreted	  cautiously	   and	   interpreted	   in	   the	   context	   of	   functional	   data	   obtained	   from	   cell	  culture	   or	   animal	   studies.	   For	   TUBB5,	   and	   DVL3,	   this	   means	   comparison	   to	  functional	   studies	   using	   known	   outputs	   of	   Wnt	   activation	   such	   a	   β-­‐catenin	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degradation	   and	   tubulin	   function,	   such	   as	   cytoskeletal	   dynamics.	   Mass	  spectrometric	  analysis	  of	  phosphorylation	  sites	  generated	  by	  LRRK2	  in	  vitro,	  could	  provide	   possible	   functional	   readouts	   of	   LRRK2	   involvement	   in	   these	   cascades.	  Generation	   of	   phosphospecific	   antibodies	   against	   residues	   phosphorylated	   by	  LRRK2	   and	   mutation	   of	   these	   phosphorylation	   sites	   in	   overexpressed	   mutants,	  should	   allow	   further	   examination	   of	   potential	   LRRK2	   involvement	   in	   these	  pathways.	  	  	  Although	  WT	  ΔN-­‐LRRK2	  was	  unable	   to	  phosphorylate	  α-­‐syn,	   the	  G2019S	  mutant	  was	   able	   to	   phosphorylate	   the	   peptide	   at	   low	   levels	   (Figure	   6.2c).	   It	   has	   been	  shown	   that	  G2019S	   is	  unlikely	   to	  phosphorylate	  α-­‐syn	  at	   S129	   in	  vitro,	   however	  there	   is	   a	   possibility	   that	   the	   S87	   residue	   (Okochi	   et	   al.	   2000)	   may	   be	   a	   target	  instead.	   To	   determine	   this,	   and	   to	   identify	   other	   possible	   phosphorylation	   sites,	  mass	  spectrometry	  of	  α-­‐syn	  phosphorylated	  by	  G2019S	  could	  also	  be	  performed.	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7.	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7.1	  EVALUATION	  OF	  METHODS	  The	   experiments	   in	   this	   thesis	   were	   designed	   to	   ask	   questions	   about	   the	   most	  basic	   level	   of	   LRRK2	   functioning	   and	   as	   such,	   focused	   mainly	   on	   LRRK2	   dimer	  formation	   and	   the	   effects	   of	   familial	   mutations	   on	   LRRK2	   structure	   and	   kinase	  function.	   These	   questions	   were	   asked,	   with	   the	   long-­‐term	   aim	   of	   being	   able	   to	  build	   on	   this	   knowledge	   and	   contribute	   to	   a	   holistic	   knowledge	   of	   LRRK2	  functioning,	   in	   order	   to	   understand	   the	   contribution	   of	   this	   protein	   to	   PD	  pathogenesis.	  In	  order	  to	  achieve	  these	  aims,	  experiments	  were	  largely	  performed	  using	   in	   vitro	   conditions,	   to	   isolate	   elements	   of	   functioning	   that	   are	   intrinsic	   to	  LRRK2.	   This	   meant	   that	   results	   could	   be	   interpreted	   without	   the	   influence	   of	  LRRK2	  interacting	  proteins.	  These	  conditions	  meant	  that	  each	  experiment	  could	  be	  carefully	  controlled	  and	  was	  optimally	  reproducible,	  as	  results	  could	  be	  corrected	  for	  the	  amount	  of	  protein	  used.	  When	  investigating	  the	  role	  of	   familial	  mutations	  on	  dimer	  formation	  (Figures	  4.1,	  4.2)	  and	  kinase	  activity	  (Figure	  4.3),	  this	  element	  of	  control	  was	  crucial	  in	  order	  to	  interpret	  results	  properly,	  as	  the	  most	  important	  factor	   in	   each	   experiment	   was	   to	   delineate	   LRRK2	   functioning	   from	   the	  functioning,	   or	   influence	   of	   any	   other	   protein.	   Using	   other	   methods,	   such	   as	  immunoprecipitation	   of	   tagged	   proteins	   would	   not	   allow	   such	   accurate	  quantification	  of	  protein	  or	  guarantee	  of	  purity.	  Experiments	  using	  phosphatase	  to	  look	  at	  the	  importance	  of	  phosphorylation	  on	  the	  dimerisation	  of	  LRRK2	  (Figures	  3.3b,	  3.4),	  were	  also	  able	  to	  be	  performed	  by	  virtue	  of	  their	  in	  vitro	  conditions,	  as	  this	   meant	   that	   the	   results	   could	   not	   be	   confounded	   by	   the	   presence	   of	   other	  proteins	  or	  kinases.	  	  	  
7.1.1	  Use	  of	  recombinant	  protein	  Technically,	  LRRK2	  is	  challenging	  to	  examine	  experimentally,	  because	  of	  the	  high	  levels	  of	  toxicity	  caused	  when	  the	  protein	  is	  overexpressed	  in	  cells.	  The	  large	  size	  of	  LRRK2,	  means	  that	  plasmid	  production	  and	  manipulation	  can	  be	  difficult	  and	  as	  yet,	   full	   length	  recombinant	  LRRK2	   is	  unavailable.	  Currently,	   the	  most	   successful	  system	   for	   purifying	   the	   largest	   possible	   fragment	   of	   LRRK2,	   remains	   to	   be	  producing	   an	  N-­‐terminally	   truncated	   GST-­‐fusion	   protein	   spanning	   residues	   970-­‐
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2527	   in	   Sf9	   cells,	   which	   has	   been	   shown	   to	   produce	   a	   relatively	   clean	   and	  enzymatically	   active	   protein	   (Jaleel	   et	   al.	   2007).	   The	   GST	   tag	   is	   likely	   beneficial	  with	   regard	   to	   the	   solubility	   of	  ΔN-­‐LRRK2.	   This	   25	   kDa	   protein,	   which	   replaces	  ~100kDa	  of	   the	  N-­‐terminal	   region	  of	   LRRK2,	  has	  been	   shown	  dimerise	  however	  (Hayes	  et	  al.	  1982)	  and	  so	  the	  presence	  of	  the	  tag	  could	  be	  affecting	  the	  structure	  and	   functioning	   of	   this	   protein.	   More	   generally,	   performing	   experiments	   using	  recombinant	   protein	   in	   vitro,	   means	   that	   in	   vitro	   characterisation	   of	   protein	  behaviour	  will	  not	  necessarily	  translate	  to	  a	  physiological	  setting.	  For	  LRRK2	  and	  the	   experiments	   described	   in	   this	   thesis,	   this	   means	   that	   the	   changes	   in	   kinase	  activity	   seen	   with	   the	   introduction	   of	   familial	   mutations	   to	  ΔN-­‐LRRK2,	   must	   be	  compared	   to	   results	   from	   experiments	   using	   techniques	   such	   as	   cell	   or	   animal	  models,	   in	   order	   to	   assess	   the	   value	   of	   this	   data.	   As	  MBP	   is	   not	   a	   physiological	  kinase	   substrate	   of	   LRRK2,	   the	   increase	   in	   kinase	   activity	   seen	   for	   G2019S	   and	  decreased	  displayed	  by	  R1441C	  (Figure	  4.3)	  must	  be	  interpreted	  with	  caution,	  as	  behaviour	   towards	   a	   genuine	   substrate,	   which	   will	   interact	   with	   different	  electrostatic	  bonding,	  may	  be	  dissimilar.	  	  	  	  
7.1.2	  Use	  of	  in	  vitro	  assay	  conditions	  An	  important	  observation	  from	  the	  in	  vitro	  kinase	  assays	  performed	  in	  this	  thesis,	  was	  that	  for	  all	  proteins	  apart	  from	  α-­‐syn,	  RIPK5	  was	  able	  to	  demonstrate	  robust	  phosphorylation	  of	  each	  putative	  LRRK2	  substrate,	  despite	   this	  kinase	  having	  no	  documented	  links	  to	  any	  of	  these	  proteins	  (Figures	  6.5,	  6.6).	  This	  emphasises	  how	  easily	   false-­‐positive	   results	   are	  obtained	  under	   in	  vitro	   conditions	   and	  highlights	  the	   importance	  of	  using	  additional	   controls	   to	  analyse	   in	  vitro	   kinase	  assay	  data.	  Comparison	   of	   putative	   substrate	   phosphorylation,	   to	   phosphorylation	   of	   MBP,	  provided	   an	   accurate	   benchmark	   for	   non-­‐specific	   kinase	   activity	   and	   for	   each	  condition	  it	  was	  shown	  that	  the	  negative	  control	  had	  a	  higher	  affinity	  for	  MBP	  than	  the	  putative	  substrate	  (Figures	  6.3,	  6.5d,	  6.7).	  Similarly,	   for	  each	  positive	  control,	  apart	   from	   CK1	   in	   the	   DVL2	   condition,	   phosphorylation	   of	   the	   physiological	  substrate	  was	  higher	  than	  MBP	  phosphorylation,	  supporting	  the	  idea	  that	  a	  generic	  substrate	  is	  less	  likely	  to	  be	  phosphorylated	  than	  a	  physiological	  one.	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Quantification	   of	   kinase	   autophosphorylation	   in	   these	   experiments,	   showed	   that	  the	   efficiency	  of	   autophosphorylation	   is	  highly	   variable	   and	  does	  not	  necessarily	  depend	   on	   the	   affinity	   of	   a	   kinase	   to	   a	   substrate.	   Autophosphorylation	   in	  experiments	  with	  DVL2	  (Figure	  6.6a,	  b)	  was	  negligible	  for	  all	  kinases,	  despite	  low	  phosphorylation	  of	  DVL2.	  Conversely,	  autophosphorylation	  in	  the	  DVL3	  condition	  was	  also	  negligible,	  whereas	  substrate	  phosphorylation	  in	  this	  case	  was	  extremely	  efficient.	  In	  this	  case,	  the	  50	  times	  molar	  excess	  of	  substrate	  used	  for	  these	  assays	  could	   be	   inducing	   interactions	   between	   the	   substrate	   and	   kinase	   which	   are	  affecting	  the	  ability	  to	  autophosphorylate.	  This	  would	  suggest	  that	  some	  proteins	  are	  more	  ‘sticky’	  than	  others,	  which	  could	  be	  affecting	  autophosphorylation	  due	  to	  conformational	  constraints	  induced	  by	  protein-­‐protein	  interactions.	  	  	  
In	   vitro	   analysis	   of	   LRRK2	   substrate	   phosphorylation	   in	   this	   thesis	   (Chapter	   6),	  highlighted	   issues	  with	   the	   assumptions	  usually	  made	   about	  phosphorylation.	   In	  
vitro	   kinase	   assays	   are	   often	   based	   upon	   the	   assumption	   that	   higher	   levels	   of	  phosphorylation	   mean	   that	   a	   reaction	   is	   more	   likely	   to	   be	   physiological.	   GRK2	  phosphorylation	  of	  TUBB5	  in	  vitro	  however,	  shows	  that	  this	  is	  not	  always	  the	  case,	  as	   GRK2	   showed	   the	   lowest	   phosphorylation	   of	   TUBB5	   (Figure	   6.5b).	   GRK2	  phosphorylation	   of	   MBP	   was	   also	   low,	   likely	   due	   to	   the	   numerous	   co-­‐factors	  required	  by	  GRK2	  in	  vivo	  (Pitcher	  et	  al.	  1998)	  that	  were	  not	  present	  in	  vitro.	  These	  results	   emphasise	   the	   importance	   of	   scaffold	   proteins	   and	   other	   environmental	  factors	  such	  as	  lipid	  or	  cytoskeletal	  association.	  The	  fact	  that	  this	  cellular	  context	  is	  missing	  from	  in	  vitro	  assays,	  means	  that	  we	  can	  only	  be	  truly	  sure	  of	  the	  validity	  of	  results	   obtained	   in	   vitro,	   when	   we	   fully	   understand	   functioning	   in	   vivo.	   Signal	  transduction	  by	  kinases	  in	  vivo,	  is	  largely	  dependent	  on	  phosphorylation	  of	  a	  target	  residue	  in	  a	  manner	  that	  is	  highly	  controlled.	  Phosphorylation	  of	  Akt	  is	  an	  example	  of	  this,	  as	  stimulation	  of	  cells	  with	  insulin	  or	  EGF	  results	  in	  a	  peak	  of	  activity	  that	  lasts	  for	  only	  ten	  mins	  before	  phosphates	  are	  removed	  by	  PP2A	  (Ugi	  et	  al.	  2004).	  Transduction	  of	  a	  signal	  therefore,	  may	  require	  phosphorylation	  of	  a	  small	  number	  of	  proteins	  to	  ensure	  that	  over-­‐amplification	  does	  not	  occur.	  In	  this	  case,	  perhaps	  it	  is	  more	   important	  to	   look	  at	  the	  accuracy	  of	  phosphorylation	   in	  vitro	  rather	  than	  total	   levels	   of	   phosphorylation,	   as	   it	   could	   be	   argued	   that	   false-­‐positive	  phosphorylation	   in	   vitro	   is	   less	   likely	   to	   occur	   at	   a	   residue	   that	   has	   important	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downstream	   effects.	   Instead	   perhaps,	   kinase	   assays	   should	   focus	   on	   the	  phosphorylation	  of	  individual	  residues	  when	  they	  are	  known,	  rather	  than	  looking	  at	  the	  cumulative	  effect	  of	  numerous	  residues,	  the	  majority	  of	  which	  are	  likely	  to	  be	  non-­‐specific.	  	  	  
7.1.2	  	  Evaluation	  of	  other	  techniques	  used	  in	  this	  thesis	  
7.1.2.1	  	  Analysis	  of	  quaternary	  structure	  BN	   analysis	   has	   been	  widely	   used	   to	   analyse	   the	   complex	   formation	   of	   proteins	  since	   the	   technique	   was	   devised	   in	   the	   early	   1990’s	   (Schagger	   et	   al.	   1991).	   By	  allowing	  proteins	  to	  migrate	  in	  their	  complexed	  forms,	  the	  technique	  can	  be	  used	  to	  characterise	  the	  quaternary	  structure	  of	  target	  proteins	  and	  analyse	  changes	  in	  these	   complexes	   in	   response	   to	  different	   stimuli.	  The	   rate	  of	  migration	  using	  BN	  PAGE,	  is	  affected	  by	  the	  total	  area	  of	  a	  protein	  and	  how	  compact	  it	  is;	  proteins	  with	  a	  more	   tightly	   packed	   structure	   appear	   smaller	   than	   those	  with	   a	  more	   relaxed	  conformation	  that	  occupies	  a	  larger	  volume.	  Similarly,	  the	  use	  of	  detergent	  is	  also	  a	  factor	  when	  comparing	  protein	  migration,	  as	  the	   loosening	  of	  electrostatic	  bonds	  by	  detergents	  affect	  the	  overall	  shape	  of	  the	  protein	  and	  thus	  its	  migration	  pattern.	  This	  means	   that	   changes	   to	   the	   conformation	   of	   a	   protein	   can	   be	   viewed	   as	   an	  electrophoretic	   shift	   (Wittig	   et	   al.	   2006),	   however	   estimation	   of	   size	   using	   this	  technique	   is	   less	  precise	  and	  the	  poor	  resolution	  of	  complexes	  means	  that	  minor	  changes	   to	   protein	   conformation	   are	   not	   detectable	   using	   this	   technique.	   For	  comparison	  of	  ΔN-­‐LRRK2	  in	  WT	  and	  mutated	  form,	  this	  means	  that	  minor	  changes	  to	  quaternary	  structure	  may	  be	  occurring,	  however	  BN	  electrophoresis	  is	  unable	  to	  detect	   these	   changes.	   In	   this	   case,	   analysis	   of	   the	  protein	  using	  other	   techniques	  such	   as	   analytical	   ultracentrifugation	   may	   allow	   for	   more	   accurate	   analysis	   of	  mutated	  LRRK2.	  	  The	   presence	   of	   Coomassie	   in	   BN	   PAGE	   analysis,	   to	   facilitate	   migration	   by	  induction	  of	  a	  negative	  charge	  allows	  visualisation	  of	  abundant	  protein,	  however	  the	   dye	   also	   affects	   the	   efficiency	   and	   reproducibility	   of	   transfer	   when	   western	  blotting	   is	   performed,	   this	   reducing	   the	   downstream	   applications	   that	   this	  technique	   can	   be	   used	   for.	   In	   the	   experiments	   described	   here,	   these	   constraints	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meant	   that	   use	   of	   BN	   analysis	   to	   determine	   the	   quaternary	   structure	   of	  dephosphorylated	   ΔN-­‐LRRK2	   was	   impractical	   (Figure	   3.3b)	   and	   BN	   PAGE	   was	  discontinued	   in	   favour	   of	   glycerol	   gradient	   centrifugation	   (Figure	   3.4).	   This	  technique	  was	   utilised	   to	   successfully	   analyse	   changes	   to	  ΔN-­‐LRRK2	   quaternary	  structure,	  when	  phosphate	  groups	  were	  removed.	  	  
7.1.2.2	  	  Glycerol	  gradient	  centrifugation	  Glycerol	   gradient	   centrifugation	   has	   been	   used	   successfully	   by	   other	   groups	   to	  separate	   LRRK2	   according	   to	   size	   and	   examine	   the	   enzymatic	   properties	   of	  different	   sized	   complexes	   (Berger	   et	  al.	   2010).	   Analysis	   of	   LRRK2	   from	  different	  fractions	   showed	   that	   although	   this	   technique	   is	   also	   lacking	   in	   resolution,	  separation	   of	   low	   and	   higher	   weight	  ΔN-­‐LRRK2	   (thought	   to	   be	   monomeric	   and	  dimeric	  species)	  was	  highly	  reproducible	  and	  allowed	  the	  kinase	  activity	  of	  these	  species	  to	  be	  examined.	  As	  such,	  although	  complexes	  over	  440	  kDa	  were	  unable	  to	  be	   separated,	   the	   gradients	   used	   allowed	   lower	   molecular	   weight	   LRRK2	   to	   be	  analysed,	  providing	  results	  that	  are	  in	  agreement	  with	  those	  from	  full	   length	  and	  endogenous	  LRRK2	  (Berger	  et	  al.	  2010,	  Sen	  et	  al.	  2009).	  Future	  studies	  using	  size-­‐exclusion	  gel-­‐filtration,	   as	  used	  previously	  by	   a	  number	  of	   groups	   (Greggio	  et	  al.	  2008,	   Jorgensen	   et	   al.	   2009,	   Sen	   et	   al.	   2009)	   could	   be	   used	   alongside	   glycerol	  gradient	  centrifugation	  to	  analyse	  the	  complex	  size	  of	  LRRK2.	  	  
7.1.2.3	  	  ATP	  pocket	  modification	  for	  identification	  of	  kinase	  substrates	  Modification	   of	   the	   ATP	   pocket	   and	   subsequent	   overexpression	   of	   modified	  kinases	   in	   cells,	   is	   associated	   with	   a	   reduction	   of	   false-­‐positive	   results	   when	  identifying	  kinase	  substrates	  (Shah	  et	  al.	  1997).	  Other	  approaches,	  such	  as	  whole	  proteome	   screens	   using	   protein	   arrays	   or	   denatured	   proteins,	   are	   less	   likely	   to	  yield	   genuine	   results,	   as	   phosphorylation	   that	   occurs	   is	   independent	   of	   cellular	  context.	   In	   this	   case,	   necessary	   cofactors	   and	   other	   proteins	   needed	   to	   mediate	  phosphorylation	   are	   absent	   and	   the	   chance	   of	   both	   false-­‐positive	   and	   false-­‐negative	   results	   are	   also	   increased.	   By	   overexpressing	   ‘gatekeeper’	   modified	  kinases	  and	  performing	  kinase	  assays	  in	  situ	  in	  cells,	  the	  technique	  is	  more	  likely	  to	  yield	   genuine	   results.	   The	   use	   of	   protein	   overexpression	   in	   these	   experiments	  increases	   the	   likelihood	   of	   false-­‐positive	   results,	   however	   the	   ATP	   modification	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technique	   has	   been	   well	   documented	   to	   yield	   physiologically	   relevant	   results	  (Specht	  et	  al.	  2002)	  and	  the	  risk	  of	  false-­‐positive	  results	  can	  be	  minimised	  by	  using	  the	   correct	   controls	   and	   validating	   results	   in	   other	   models.	   Advances	   in	   gene	  technology	  mean	  that	  point	  mutations	  can	  now	  be	  engineered	  into	  the	  genome	  of	  cells	   or	   animals	  without	   the	   need	   for	   overexpression	   (Urnov	   et	  al.	   2005)	   and	   as	  such,	   ATP	   pocket	   mutations	   can	   be	   produced	   in	   place	   of	   WT,	   however	   these	  approaches	   are	   expensive	   and	   therefore	   less	   commonly	   used.	   In	   this	   case,	  ‘gatekeeper’	  modification	   of	   a	   kinase	   and	   overexpression	   in	   cell	  models	   remains	  the	  best	  chance	  of	  minimising	  the	  false-­‐positive	  results	  often	  obtained	  when	  trying	  to	   identify	   kinase	   substrates.	   The	   identification	   of	   residues	   that	   can	   rescue	  intolerant	  kinases	  means	  that,	  with	  modification,	  this	  method	  should	  be	  successful	  with	  any	  kinase	  investigated	  (Zhang	  et	  al.	  2005),	  including	  LRRK2.	  	  
7.1.2.4	  	  Protein	  interaction	  studies	  The	   lack	   of	   antibodies	   able	   to	   recognise	   and	   immunoprecipitate	   endogenous	  protein	   is	   a	  problem	   for	  many	  areas	   in	   the	  PD	   field	   and	   indeed	   cell	   biology	   as	   a	  whole.	   As	   the	   results	   from	   experiments	   detailed	   here	   using	   the	   goat-­‐polyclonal	  against	  LRRK2	  (Everest),	  have	  shown	  (Figure	  5.7),	  promising	  antibodies	  that	  work	  for	  some	  applications	  (Alegre-­‐Abarrategui	  et	  al.	  2008)	  do	  not	  always	   translate	   to	  success	  when	  used	   in	  other	   techniques.	  The	   issue	  of	   low	  LRRK2	  expression	   is	  an	  important	   factor	   when	   attempting	   to	   immunoprecipitate	   endogenous	   protein,	  however	   these	   issues	   can	   be	   addressed	   through	   optimization	   of	   protocols	   to	  increase	   the	  amount	  of	   starting	  material	  used.	  Overexpression	  of	   tagged	  protein,	  has	  provided	  some	  good	  results	  for	  the	  LRRK2	  field	  recently	  with	  the	  identification	  of	   the	   14-­‐3-­‐3	   proteins	   as	   LRRK2	   interactors	   (Dzamko	   et	   al.	   2010,	   Nichols	   et	   al.	  2010,	   Li	   X.	   et	   al.	   2011).	   As	   discussed	   above,	   this	   technique	   runs	   the	   risk	   of	  generating	   false-­‐positive	   results,	   however	  when	   the	   right	   controls	   are	   used	   and	  interactions	   are	   verified	   using	   other	   models,	   use	   of	   overexpressed	   protein	   to	  dissect	  signaling	  pathways	  has	  been	  used	  with	  much	  success	  across	  a	  wide	  range	  of	  fields	  and	  as	  such	  may	  continue	  to	  prove	  useful	  in	  dissecting	  the	  role	  of	  LRRK2	  in	  normal	  and	  pathogenic	  signaling.	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7.2	  CONCLUSIONS	  
7.2.1	  	  Contribution	  of	  this	  work	  to	  our	  understanding	  of	  LRRK2	  
function	  and	  regulation	  The	   experiments	   detailed	   in	   this	   thesis	   have	   provided	   support	   for	   many	   of	   the	  ideas	   proposed	   by	   other	   groups	   regarding	   the	   way	   LRRK2	   self-­‐regulates;	  autophosphorylation	  was	   shown	   to	   be	   important	   for	   complex	   formation	   (Figure	  3.4)	  and	  the	  results	  of	  these	  experiments	  also	  support	  the	  idea	  that	  LRRK2	  is	  able	  to	  dimerise	  (Greggio	  et	  al.	  2008,	  Jorgensen	  et	  al.	  2009	  ,Sen	  et	  al.	  2009,	  Berger	  et	  al.	  2010).	  BN	  analysis	   of	  ΔN-­‐LRRK2	  and	  ROC	  domain	  quaternary	   structure,	   showed	  that,	   in	  the	  absence	  of	   interacting	  proteins,	  these	  fragments	  of	  LRRK2	  are	  able	  to	  dimerise	  (Figures	  3.1b,	  4.1),	  suggesting	  that	  they	  have	  an	  intrinsic	  ability	  to	  do	  so,	  which	   is	   not	  mediated	   by	   other	   proteins.	   Investigation	   into	   the	   effect	   of	   familial	  mutations	  on	  LRRK2	  quaternary	  structure	  using	  patient	  fibroblasts	  (Figure	  4.2b),	  has	   shown	   that	   familial	   point-­‐mutations	   are	   unlikely	   to	   affect	   binding	   of	  interacting	  proteins	  and	  subsequently	  the	  size	  of	  complex	  formation,	  as	  there	  was	  no	  difference	  in	  complex	  size	  between	  mutants	  and	  WT	  conditions	  (Figures	  4.1d,	  4.2b).	  The	  results	  of	  these	  experiments	  and	  those	  from	  other	  groups	  (Greggio	  et	  al.	  2009),	   instead	   support	   the	   idea	   that	  mutations	   are	   acting	   enzymatically	   and	   are	  affecting	   the	   regulation	  mechanisms	   of	   LRRK2,	   perhaps	   disturbing	   the	   ability	   of	  LRRK2	   to	   switch	   between	   an	   ‘on’	   and	   ‘off’	   state.	   G2019S	   has	   consistently	   been	  shown	  to	  increase	  LRRK2	  kinase	  activity	  in	  vitro	  (reviewed	  in	  Greggio	  et	  al.	  2009),	  however	  results	   from	  experiments	   in	   this	   thesis	  show	  that	   this	   is	  not	  always	   the	  case,	   as	   the	  difference	   in	  phosphorylation	  between	  WT	  and	  G2019S,	  depends	  on	  the	  substrate	  being	  used;	  for	  TUBB5	  (Figure	  6.5b)	  and	  DVLs	  2	  and	  3	  (Figure	  6.6d,	  f),	  G2019S	  ΔN-­‐LRRK2	  did	  not	  show	  increased	  phosphorylation	  of	  these	  substrates	  compared	   to	   WT,	   despite	   showing	   significantly	   increased	   activity	   towards	   MBP	  (Figure	  4.3c).	  This	  is	  also	  the	  case	  for	  G2019S	  autophosphorylation	  as	  experiments	  using	  TUBB5,	  and	  DVL2	  and	  3	  did	  not	  show	  higher	  autophosphorylation	  than	  WT	  
ΔN-­‐LRRK2	  in	  these	  conditions	  (Figures	  6.5b,	  6.6d,	  f).	  As	  such,	  these	  results	  support	  a	   model	   in	   which	   G2010S	   causes	   a	   dysregulation	   of	   enzymatic	   activation	   as	  opposed	   to	   a	   simple	   increase	   in	   the	   rate	   of	   kinase	   activity.	   Indeed,	   studies	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characterising	   the	   kinase	   activity	   of	   G2019S	   ΔN-­‐LRRK2	   have	   shown	   that	   this	  mutant	  has	  a	  lower	  affinity	  for	  ATP	  than	  the	  WT	  version,	  and	  it	  has	  been	  suggested	  that	  kinase	  activity	  is	  higher	  as	  a	  result	  (Jaleel	  et	  al.	  2007).	  In	  this	  case,	  the	  increase	  in	  kinase	  activity	  with	  some	  substrates	  such	  as	  MBP	  (Figure	  4.3c)	  could	  be	  caused	  by	  a	  greater	  propensity	  for	  ‘on’	  conformation.	  	  Dephosphorylating	   recombinant	  ΔN-­‐LRRK2	   allowed	   the	   role	   of	   phosphorylation	  on	   LRRK2	   dimer	   formation	   to	   be	   explored	   (Figures	   3.3b,	   3.4a).	   Results	   of	   these	  experiments	   suggest	   that	   phosphorylation	   is	   important	   for	   dimer	   formation	   and	  kinase	   activity.	   This	   data	  must	   be	   considered	   in	   the	   context	   of	   a	   protein	   tagged	  with	  GST,	  as	  GST	  is	  known	  to	  dimerise	  (Hayes	  et	  al.	  1982),	  and	  as	  such,	  important	  questions	  still	  remain,	  such	  as	  whether	  LRRK2	  would	  be	  able	  to	  dimerise	   in	  vitro	  without	  the	  tag.	  From	  the	  experiments	  described	  in	  this	  thesis,	  it	  can	  be	  concluded	  that	   dimerisation	   of	   LRRK2	   could	   be	  mediated	   by	   phosphorylation	   at	   important	  residues	  (Figure	  3.4a).	  These	  residues	  are	  more	   likely	  to	  be	  autophosphorylation	  targets,	   as	   kinase	   dead	   LRRK2	   showed	   minimal	   phosphorylation	   in	   these	  experiments	   (Figure	   3.3a)	   and	   in	  work	   done	   by	   other	   groups	   (Kamikawaji	   et	  al.	  2009).	   From	   experiments	   done	   using	   affinity-­‐purified	   ΔN-­‐LRRK2,	   it	   is	   apparent	  that	  lower	  molecular	  weight	  species	  have	  little	  or	  no	  kinase	  activity	  (Figure	  3.5b),	  results	   which	   agree	   with	   those	   published	   by	   other	   groups	   which	   also	   showed	  decreased	   kinase	   activity	   in	   lower	  molecular	   weight	   forms	   of	   LRRK2	   (Sen	   et	   al.	  2009,	  Berger	  et	  al.	   2010).	  Further	   investigation	  as	   to	   the	  exact	   role	  of	   individual	  autophosphorylated	   residues	   will	   lead	   to	   a	   better	   understanding	   as	   to	   the	  sequence	  of	  events	  that	  result	  in	  LRRK2	  activation.	  	  Taken	   together,	   the	   results	   detailed	   here	   contribute	   towards	   a	  model	   of	   LRRK2	  functioning	   whereby	   disruption	   of	   the	   finely-­‐tuned	   mechanisms	   regulating	  enzymatic	  activity	  are	  disrupted	  by	  familial	  mutations.	  This	  disruption	  is	  likely	  to	  be	  caused	  largely	  by	  changes	  to	  enzymatic	  function,	  which	  may	  affect	  the	  ability	  of	  LRRK2	  to	  modulate	   inputs	   from	  other	  proteins	  or	  to	  control	  subsequent	  outputs.	  This	   is	   likely	   to	   result	   in	   pathogenic	   changes	   to	   the	   homeostasis	   of	   signaling	  pathways	  that	  LRRK2	  is	  involved	  in	  and	  eventually	  neuronal	  death.	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7.2.2	  Current	  understanding	  of	  LRRK2	  functioning	  In	   the	   time	   that	   has	   elapsed	   since	   starting	   this	   thesis,	   there	   have	   been	   many	  significant	   advances	   in	   the	   LRRK2	   field,	   in	   terms	   of	   the	   tools	   available	   to	  researchers.	  A	  number	  of	  antibodies	  have	  been	  made	  available	  commercially	  and	  recently,	   access	   to	   phospho-­‐antibodies	   has	   been	   made	   available	   (Nichols	   et	   al.	  2010).	   Since	   finishing	   these	   experiments,	   a	   highly	   specific	   LRRK2	   inhibitor	   has	  been	   designed	   (Deng	   X.	   et	   al.	   2011)	   and	   there	   are	   currently	   numerous	   animal	  models	   now	   available	   for	   LRRK2.	   With	   the	   pace	   that	   techniques	   for	   LRRK2	  experimentation	   are	   gathering,	   the	  next	   few	  years	   should	  prove	   to	   be	   extremely	  exciting	  for	  this	  area	  of	  PD	  research.	  	  	  The	   likelihood	   that	   LRRK2	   is	   dimeric	   (Greggio	   et	   al.	   2008)	   was	   an	   important	  catalyst	   for	   understanding	   the	   sequence	   of	   events	   that	   lead	   to	   LRRK2	   activation	  and	  it	  now	  seems	  likely	  that	  LRRK2	  is	  monomeric	  in	  the	  cytosol,	  with	  low	  kinase	  activity,	   and	  dimeric	  when	  membrane	  bound,	   likely	   to	  be	   the	   active	   form	  of	   this	  protein	   (Sen	   et	  al.	   2009,	   Berger	   et	  al.	   2010).	   From	   these	   findings	   it	  would	   seem	  likely	   that	   LRRK2	   is	   activated	   when	   cytosolic	   and	   recruited	   to	   the	   membrane	  where	  it	  becomes	  activated.	  The	  interaction	  of	  LRRK2	  and	  the	  14-­‐3-­‐3	  proteins	  has	  been	  perhaps	   the	  most	   important	   finding	   in	  LRRK2	  research	   to	  date,	  as	   it	  places	  LRRK2	   in	   a	   dynamic	   signaling	   role,	   which	   likely	   encompasses	   a	   wide	   range	   of	  interactions	   and	   functions	   (Dzamko	   et	   al.	   2010,	   Nichols	   et	   al.	   2010,	   Li	   X.	   et	   al.	  2011).	   Importantly,	   these	   experiments	   have	   also	   identified	   two	   phosphorylation	  sites	   in	  the	  N-­‐terminus	  that	  mediate	  this	   interaction.	  These	  residues	  were	  shown	  to	   be	   targets	   for	   an	   interacting	   kinase	   (currently	   unknown)	   as	   opposed	   to	  autophosphorylation.	  Until	  this	  point,	  the	  majority	  of	  LRRK2	  phosphorylation	  sites	  that	  had	  been	  identified	  were	  thought	  to	  be	  autophosphorylation	  sites.	  	  	  Functionally,	   LRRK2	   has	   been	   linked	   to	   MAPK	   signal	   transduction	   pathways	  (Carballo-­‐Carbajal	   et	   al.	   2010)	   and	   the	   downstream	   effectors	   of	   these	   pathways	  such	  as	  autophagy	  (Macleod	  et	  al.	  2006,	  Plowey	  et	  al.	  2008,	  Alegre-­‐Abarrategui	  et	  
al.	  2009),	  and	  pathways	  involved	  in	  cytoskeletal	  dynamics	  (Gillardon,	  2009a,	  b.	  Lin	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et	  al.	  2009,	  Parisiadou	  et	  al.	  2009).	  Although	  the	  current	  role	  for	  LRRK2	  is	  yet	  to	  be	  conclusively	  defined,	  the	  recent	  advances	  in	  research	  tools,	  suggest	  that	  the	  exact	  function	  of	  this	  protein	  will	  soon	  be	  defined.	  	  
7.2.3	  	  PROPOSED	  FUNCTION	  OF	  LRRK2.	  Kinase	   activity	   of	   LRRK2	   is	   thought	   to	   be	   important	   for	   dimerisation	   (Sen	   et	   al.	  2009)	  and	  is	  likely	  to	  mediate	  the	  toxic	  effects	  of	  this	  protein	  (Greggio	  et	  al.	  2006,	  Smith	   et	   al.	   2006).	   Despite	   this,	   the	   role	   of	   LRRK2	   as	   a	   kinase	   is	   still	   heavily	  debated	   (Greggio	   et	   al.	   2009).	   As	   shown	   in	   Table	   7.1,	   numerous	   studies	   report	  kinase	   interactions	   of	   LRRK2	   in	   animal	   models	   and	   human	   cell	   lines,	   however	  there	   is	   a	   large	  degree	  of	  disparity	  between	   these	   studies;	  papers	  are	   frequently	  being	  published	  with	  new	  suggestions	  for	  kinase	  substrates,	  yet	  no	  two	  studies	  in	  human	  models,	  seem	  to	  directly	  support	  other	  findings	  in	  the	  literature.	  	  
Substrate	   Reference	   Technique	  used	  
Moesin	   Jaleel	  et	  al.	  2008	   Proteomic	  screen	  
4E-­‐BP	   Imai	  et	  al.	  2008	   Drosophila	  genetic	  interaction	  
MKKs	   Gloeckner	  et	  al.	  2009	   Overexpression	  and	  immunoprecipitation.	  	  
C.	  Elegans	  genetic	  interaction	  
β-­‐Tubulin	   Gillardon	  et	  al.	  2009a,	  b	   Endogenous	  mouse	  immunoprecipitation	  
α-­‐Synuclein	   Qing	  et	  al.	  2009	   Immunoprecipitation	   in	  human.	  	  
In	  vitro	  kinase	  assay.	  
Foxo1	   Kanao	  et	  al.	  2010	   Drosophila	  genetic	  interaction	  
Ste20	  Kinases	   Zach	  et	  al.	  2010	   Protein	  array	  
Table	  7.1.	  Reported	  kinase	  substrates	  of	  LRRK2.	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  The	   variable	   pathology	   reported	   for	   LRRK2,	   and	   the	   numerous	   protein-­‐protein	  interaction	  domains	  that	  it	  contains,	  make	  it	  likely	  that	  LRRK2	  has	  a	  wide	  range	  of	  interactors	  and	  therefore	  make	  it	  possible	  that	  these	  wide-­‐ranging	  results	  are	  not	  mutually	   exclusive,	   however	  more	   validation	   of	   individual	   substrates	   is	   needed.	  The	   robust	   interaction	   between	   LRRK2	   and	   4E-­‐BP	   that	   has	   been	   shown	   in	  
drosophila,	   has	   not	   been	   validated	   in	   humans	   and	   analysis	   of	   this	   interaction	   in	  
vitro	   suggests	   that	   LRRK2	   is	   less	   likely	   to	   be	   phosphorylating	   4E-­‐BP	   in	   humans	  (Kumar	   et	   al.	   2010).	   The	   use	   of	   in	   vitro	   conditions	   to	   model	   physiological	  interactions	  has	  been	  discussed,	  however	  the	  issue	  of	  modelling	  human	  disease	  in	  animals	   will	   always	   be	   problematic	   as	   there	   is	   always	   the	   risk	   that	   individual	  components	  even	  of	  well-­‐conserved	  pathways	  will	  differ	  between	  species.	  	  A	  common	  finding	  in	  studies	  looking	  for	  LRRK2	  kinase	  substrates	  is	  that	  the	  kinase	  activity	   of	   WT	   LRRK2	   is	   negligible.	   Proteomic	   approaches	   using	   whole	   brain	  homogenates	   have	   shown	   that	   overexpressed,	   full-­‐length	   WT	   LRRK2	   kinase	  activity	  is	  undetectable	  (Jaleel	  et	  al.	  2007).	  In	  this	  study,	  identification	  of	  a	  putative	  LRRK2	   kinase	   substrate	   was	   only	   possible	   by	   using	   protein	   with	   the	  hyperactivating	  G2019S	  mutation,	  instead	  of	  WT.	  Similarly	  G2019S,	  as	  opposed	  to	  WT	  LRRK2,	  was	  used	  to	  identify	  the	  phosphorylation	  consensus	  motif	  F/Y-­‐x-­‐T-­‐x-­‐
R/K	  as	  a	  likely	  target	  for	  LRRK2	  kinase	  activity,	  for	  the	  same	  reasons	  (Pungaliya	  et	  
al.	  2010).	  The	  low	  level	  activity	  in	  WT	  LRRK2,	  has	  led	  to	  the	  suggestion	  that	  kinase	  activity	   could	   serve	   as	   a	   self-­‐regulatory	   mechanism,	   as	   opposed	   to	   serving	  substrate	  phosphorylation	  (Greggio	  et	  al.	  2009)	  with	  LRRK2	  functioning	  mainly	  as	  a	  scaffold.	  	  	  Whether	  LRRK2	  is	  an	  authentic	  kinase	  or	  not,	  the	  role	  of	  this	  protein	  as	  a	  scaffold	  is	   likely	   to	   be	   central	   to	   its	   role	   in	   cellular	   functioning	   due	   to	   the	   numerous	  protein-­‐protein	   interaction	   domains	   it	   contains.	   As	   this	   is	   the	   case,	   membrane	  localisation	  of	  LRRK2	  may	  be	  important	  to	  its	  main	  functioning	  role	  (Hatano	  et	  al.	  2007,	  Alegre-­‐Abarrategui	  et	  al.	  2009,	  Berger	  et	  al.	  2010),	  suggesting	  the	  possibility	  of	   receptor-­‐mediated	  signaling	  or	  even	  receptor	   interaction,	   resulting	  perhaps	   in	  phosphorylation	  of	  the	  Y707	  residue.	  	  Indeed	  receptor	  involvement	  in	  signaling	  of	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the	   closely	   related	   leucine-­‐rich	   repeat	   protein	   LRRK1,	   has	   recently	   been	   shown	  with	   Grb2	   interaction	   (Titz	   et	   al.	   2010)	   and	   the	   discovery	   that	   LRRK1	  mediates	  EGF	  receptor	  recycling	  and	  sorting,	  via	  Grb2	  binding	  to	  PXXP	  sequences	  in	  the	  N-­‐terminal	  region	  of	  the	  protein	  (Hanafusa	  et	  al.	  2011).	  Given	  the	  close	  homology	  in	  sequence	  between	  LRRK1	  and	  LRRK2,	  it	  is	  likely	  that	  they	  share	  some	  elements	  of	  signaling	   commonality,	  whether	   this	   is	   through	   shared	   interactions,	   or	   acting	   in	  common	  pathways.	  A	  proposed	  model	  of	  LRRK2	  function	  is	  described	  here.	  
Figure	  7.1.	  Proposed	  mechanism	  for	  LRRK2	  functioning.	  1.	  Receptor	  activation	  causes	   activation	   of	   receptor	   mediated	   signaling	   and	   metabolic	   responses	   to	  signaling.	   2.	   LRRK2	   acts	   as	   a	   cytosolic	   sensor	   to	  maintain	   homeostasis.	   3.	  When	  signaling	  needs	  to	  be	  terminated,	  LRRK2	  is	  activated	  by	  phosphorylation.	  4.	  LRRK2	  relocates	  to	  the	  membrane.	  5.	  Autophosphorylation	  occurs	  and	  LRRK2	  dimerises.	  Further	  phosphorylation	  by	  other	  kinases?	  6.	  GTP	  binding	  activates	  kinase	  activity.	  
P
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Interacting	   proteins	   bind	   and	   signal	   is	   transduced.	   Metabolic	   signaling	  downstream	  of	  the	  receptor	  is	  switched	  off.	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7.3	  GENERAL	  CONCLUSIONS	  As	  a	  large	  protein	  with	  multiple	  domains	  in	  one	  molecule,	  LRRK2	  is	  able	  to	  do	  the	  same	  work	  that	  perhaps	  three	  or	  four	  proteins	  do.	  The	  benefit	  of	  having	  multiple	  components	   and	   a	   ‘cascade’	   of	   signaling	   is	   that	   each	   protein	   is	   subject	   to	   a	   high	  degree	   of	   regulation	   and	   so	   cumulatively,	   there	   are	  more	   quality	   control	   points.	  For	   LRRK2,	   having	   all	   these	   domains	   in	   one	   place	   means	   that	   dysregulation	   of	  functioning,	   for	  example	  by	  a	  point	  mutation,	   is	  more	   likely	   to	  be	   translated	   into	  the	  outputs	  of	  that	  cascade	  and	  thus	  upset	  a	  homeostatic	  balance.	  In	  this	  case,	  the	  likely	  effect	  of	  LRRK2	   familial	  mutations	  would	  be	  an	   increase	   in	  outputs	  of	   this	  protein.	  If	  LRRK2	  signaling	  is	  at	  the	  interface	  of	  proliferative	  signaling,	  then	  over-­‐stimulation	   could	   result	   in	   an	   upregulation	   of	   factors	   aimed	   to	   counteract	   this	  (Plun-­‐Favreau	   et	   al.	   2010).	   This	   could	   cause	   problems	   with	   mitochondrial	  homeostasis,	   resulting	   in	   disruption	   of	   ATP	   production	   (Vander	   Heiden	   et	   al.	  2000).	  Studies	  looking	  at	  putative	  functions	  of	  α-­‐syn	  have	  shown	  that	  this	  protein	  may	  play	   a	   role	   in	  mitochondrial	   function	   (Elkon	   et	  al.	   2002)	   and	   therefore	   it	   is	  plausible	   that	   dysregulation	   of	   LRRK2	   leads	   to	   increased	   α-­‐syn	   expression	   and	  signaling	   in	   response	   to	   mitochondrial	   damage.	   Downstream	   effects	   of	   this	  mitochondrial	   damage,	   such	   as	   proteasome	   inhibition	   and	   dyregulation	   of	   the	  cytoskeleton	  could	  be	  occurring	  as	  a	  knock-­‐on	  effect	  of	  this	  mitochondrial	  damage.	  	  Despite	  speculation	  however,	   the	  exact	   function	  of	  LRRK2	   in	   the	  cell	   is	  currently	  unknown.	   This	   knowledge	   is	   vital	   in	   understanding	   how	   mutations	   in	   LRRK2	  trigger	  the	  pathogenesis	  of	  PD.	  In	  the	  pursuit	  of	  this	  knowledge,	  the	  primary	  aim	  of	  research	  must	   be	   production	   of	   results	   that	  will	   ultimately	   result	   in	   therapeutic	  outcomes	   for	   patients.	   Although	   biochemical	   analyses	   of	   proteins	   implicated	   in	  disease	  is	  interesting,	  without	  understanding	  their	  contribution	  to	  normal	  cellular	  functioning,	   we	   cannot	   properly	   target	   the	   processes	   that	   are	   causing	   disease.	  Many	  papers	  discuss	  the	  possibility	  of	  LRRK2	  inhibitors	  for	  therapeutic	  use,	  but	  at	  this	  point	  in	  time,	  there	  is	  no	  conclusive,	  measurable	  output	  of	  LRRK2	  functioning	  and	   inhibition	   of	   LRRK2	   may	   not	   necessarily	   be	   beneficial	   and	   may	   even	   be	  detrimental	   to	   cellular	   functioning.	   It	   seems	  more	   likely	   that	   the	  most	   beneficial	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therapeutic	  approaches	  of	   the	   future	  will	   target	   the	   functional	  outputs	  of	  LRRK2	  signaling,	  once	  these	  have	  been	  determined.	  	  	  As	  with	  the	  majority	  of	  proteins	  of	  undetermined	  function,	  the	  proposed	  roles	  for	  LRRK2	  are	  subject	  to	  a	  large	  amount	  of	  dogma,	  and	  there	  are	  a	  number	  of	  separate	  schools	  of	  thought	  that	  have	  emerged	  regarding	  the	  function	  of	  LRRK2.	  As	  a	  large	  protein	  with	   numerous	   protein-­‐protein	   interaction	   domains,	   the	   function	   of	   this	  PD-­‐associated	  protein	  may	  actually	   encompass	  many	  of	   these	  pathways.	  As	   such	  the	  most	  valuable	  contributions	  to	  this	  field	  are	  likely	  to	  be	  those	  that	  are	  able	  to	  consolidate	  existing	  and	  conflicting	  data,	  as	  well	  as	  adding	  something	  new	  to	  our	  understanding.	  In	  this	  way,	  a	  unified	  theory	  of	  LRRK2	  function	  is	  needed	  to	  make	  sure	   that	   LRRK2	   research	   is	   as	   effectual	   as	   possible	   in	   order	   to	   bring	   us	   a	   step	  closer	  to	  effective	  treatment	  regimes	  for	  this	  debilitating	  disease.	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Unraveling LRRK2 Pathogenesis: Common Pathways for
Complex Genes?
Emma Deas and Laura Dunn
Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, LondonWC1N 3BG, United Kingdom
Review of Ng et al.
Parkinson’s disease (PD) is the second
most common neurodegenerative disease
affecting the Western world. The disease
in humans is characterized by the selective
loss of dopaminergic neurons in the sub-
stantia nigra pars compacta; however,
modeling this disease in transgenic ani-
mals has proven exceptionally difficult.
Until recently, knock-out murine mod-
els for the PD-associated genes LRRK2,
!-synuclein, Parkin, PINK1, and DJ-1
have typically failed to generate a compa-
rable pathological setting to aid basic and
therapeutic research into PD pathogene-
sis. Researchers have therefore used ge-
netic manipulation in Drosophila to gain
insight into the signaling pathways af-
fected in PD. Typically, these fly models
consist of either RNA-interference- or
P-element-generated knock-outs and/or
overexpression of themutated genes asso-
ciated with PD. One of the more recent
proteins to be assessed in Drosophila is
LRRK2, mutations of which can induce
dominantly inherited, late-onset PD.
LRRK2 is a formidable protein, which
can be difficult to express due to its large
size (280 kDa) and is likely to influence a
number of cellular functions due to its
multidomain structure including a Roc
(Ras of complex), COR (C terminal of
Roc), serine/threonine kinase domain,
and several WD40 repeat protein–protein
interaction domains. Although the PD-
associated mutations in LRRK2 are lo-
cated throughout the protein, several
studies have reported that an increase in
kinase activity is associated with patho-
genesis. Consequently, the identification
of LRRK2 substrates and inhibitors has
been a key focus of recent investigations
(Nichols et al., 2009).
The recent publication by Ng et al.
(2009) in The Journal of Neuroscience
assessed the effects of overexpressing
LRRK2 wild-type (wt) and PD-associated
mutations on age-dependent dopami-
nergic (DA), tyrosine hydroxylase-positive
(TH!) neuron loss, altered dopamine
levels, and climbing defects in flies. Unlike
most previous studies, in which the Dro-
sophila LRRK2 homolog (dLRRK) was
overexpressed or knocked out, Ng et al.
(2009) specifically expressed the human
wt, G2019S, Y1699C, andG2385R LRRK2
variant proteins in the wt fly eye and
brain. The location of these mutations
within the kinase, COR, and WD40 do-
mains, respectively, permit the authors to
determine whether mutations within the
different protein domains of LRRK2 can
induce similar phenotypes. Notably, Ng et
al. (2009) are the first group to assess the
functional consequences of mutations
within the WD40 domains of LRRK2 in
Drosophila.
Consistent with most studies (Lee et
al., 2007; Imai et al., 2008),Ng et al. (2009)
found no eye abnormalities in any of their
LRRK2 wt or PD-mutant overexpressing
flies. However, they observed a significant
age-dependent loss of TH! neurons spe-
cifically in thePPM(protocerebralposterior
medial) 1 and 3 neural clusters in flies ex-
pressing PD-associated forms of LRRK2.
This neuronal loss was associated with re-
duced lifespan, which was particularly
prominent in the G2019S lines. Climbing
deficits were also observed in the G2019S
and Y1699C lines, but surprisingly, de-
spite the loss of TH! neurons, no loco-
motor abnormalities were identified in
the G2385R mutant line.
Additional differences between the
LRRK2 mutant lines were observed when
the authors assessed the susceptibility of
the flies’ DA neurons to degeneration by
administering the PD-associated toxin ro-
tenone. Although, under normal condi-
tions, all the LRRK2 mutant fly lines
showed similar TH! neuron loss in the
PPM1 and PPM3 clusters with age, rote-
none exposure accelerated TH! neuron
loss in the PPM3 cluster in both the
G2019S and G2385R lines. Furthermore,
rotenone treatment induced a novel set of
TH! neurons to die in the PPM2 cluster
in both theG2019S andG2385R lines, and
neuron loss was observed in the PPL1 and
PAL clusters of theG2385Rmutant. Strik-
ingly, rotenone treatment had no effect on
flies overexpressing Y1966C.
Finally, the authors demonstrated that
co-overexpression of human Parkin (a
neuroprotective E3 ubiquitin ligase as-
sociated with early-onset recessive PD)
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in either the aged or rotenone-treated
G2019S flies rescued the PPM1/3 and
PPM2/3 TH! neuronal death, respectively.
The authors conclude that rotenone aggra-
vates, whereas Parkin overexpression allevi-
ates, the TH! neuronal death induced by
LRRK2 G2019S overexpression.
The finding that rotenone (a mito-
chondrial complex I inhibitor) accelerates
TH! neuron loss in a LRRK2 mutant
model suggests that both environmental
factors and genetics contribute to patho-
genesis. The authors propose that these
results, together with their previous work
suggesting a direct interaction between
LRRK2 and Parkin (Smith et al., 2005),
indicate that interactions between LRRK2,
Parkin, and mitochondria could have
both therapeutic and mechanistic impli-
cations for PD.
Although the results reported by Ng et
al. (2009) are intriguing and the mecha-
nism underlying resistance to rotenone in
their Y1699C line, is worthy of subsequent
investigation, it is unfortunate that the ex-
periments reported were not performed
on all the LRRK2 mutant lines, to give a
comprehensive assessment of all the phe-
notypes. Specifically, examination of do-
pamine levels in all fly lines, instead of just
the G2019S line, may have provided an
explanation for the lack of locomotor
deficits, despite TH! neuron loss, in the
G2385R flies. These findings could open
up an interesting possibility of compensa-
torymechanisms, perhaps similar to those
occurring in patients, which could be in-
vestigated in this Drosophilamodel.
In addition, the increased sensitivity of
the G2385R line to rotenone-induced
TH! neuronal death (compared to the
G2019S line), particularly in neural clus-
ters unaffected by aging, is worth noting.
Previous studies have shown that the ki-
nase activity of this LRRK2 mutant is not
increased above wt levels, suggesting that
pathogenesis is not induced by dysregu-
lated kinase activity. However, expression
of the G2385R protein induces cell death at
comparable levels to the G2019S protein,
which demonstrates increased kinase
activity (West et al., 2007). Given these
previous findings and the novel obser-
vations reported by Ng et al. (2009),
showing that co-overexpression of Par-
kin can rescue TH! neuron loss associ-
ated with age and rotenone treatment, it
would have been interesting to assess
the ability of Parkin co-overexpression
to rescue the rotenone-induced G2385R
phenotypes.
Another way Ng et al. (2009) could
have gained insight into the differences in
TH!neuron loss in the aged or rotenone-
treated fly lines would have been to assess
4E-BP phosphorylation levels. In 2008, it
was shown that phosphorylation of 4E-BP
on residues T37 andT46 are important for
the pathogenic effects of mutant LRRK2
in Drosophila i.e., DA neuron loss, sensi-
tivity to stress and reduced lifespan (Imai
et al., 2008) (Fig. 1). Furthermore, a recent
study by Tain et al. (2009) demonstrated
that 4E-BP is hypophosphorylated in
PINK1 and Parkin mutant fly lines and
the pathogenesis observed in these lines
can be rescued by either 4E-BP overex-
pression or rapamycin treatment (Fig. 1).
The combination of these studies strongly
suggests that 4E-BP phosphorylation lev-
els are directly linked to the pathogenic
phenotypes displayed in fly PD models
and subsequent studies to dissect the in-
volvement of the Akt/mTOR/4E-BP path-
way in human pathogenesis should be an
exciting area of future research. Given the
differences in TH! neuron loss, suscepti-
bility to stress and increased mortality
rates of their LRRK2 mutant lines, it is
surprising that Ng et al. (2009) did not
pursue this line of investigation, to gain
mechanistic insights into their models. In
particular, the group could have ad-
dressed (1) whether the prominent reduc-
tion in lifespan in the G2019Smutant flies
was associated with increased phosphory-
lation of 4E-BP compared to the other fly
lines, (2) whether the differential suscep-
tibility to stress, observed in their fly lines,
correlatedwith alterations in 4E-BP phos-
phorylation status, (3) whether the resis-
tance to rotenone in their Y1699C line is
associated with reduced 4E-BP phosphor-
ylation levels, and finally (4) whether an
alteration in 4E-BP phosphorylation state
is induced in the rescued G2019S mutant
line due to Parkin overexpression.
Finally, it would have been interesting
if additional aspects of the rescue pheno-
types in the G2019S-Parkin coexpressing
fly lines had been investigated. For example,
Parkin overexpression has been shown
to upregulate PINK1protein levels inDro-
sophila, and recently, PINK1 was shown to
phosphorylate Parkin, resulting in Parkin’s
relocalization to mitochondria (Yang et al.,
2006; Kim et al., 2008). Since PINK1 can
protect against oxidative stress, alleviatemi-
tochondrial damage induced by complex I
inhibitors and is tightly linked to Parkin
(Deas et al., 2009), it seems premature for
the authors to attribute all of the protective
effects observed exclusively to Parkin.
In summary, Ng et al. (2009) have pro-
vided novel insights into the effects of the
LRRK2 G2385R mutant protein in vivo, a
PD-associated mutation which has re-
ceived relatively little attention in the lit-
erature compared tomutations in the Roc
Figure 1. Modulation of 4E-BP phosphorylation status by PD-associated proteins. 4E-BP phosphorylation levels are regulated
by themTORkinase,whichacts downstreamofAkt. In its hypophosphorylated state, 4E-BPbinds to the transcription factor eIF-4E
and inhibits the subsequent transcription of survival factors. Upon phosphorylation, 4E-BP dissociates from eIF-4E and permits
transcription. Recently, the active LRRK2 kinase was shown to phosphorylate 4E-BP, whereas loss of either PINK1 or Parkin
function was shown to result in hypophosphorylated 4E-BP.
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and COR domains. The location of this
mutation in the protein–protein interaction
WD40 domains, rather than an enzymatic
domain of LRRK2, raises interesting ques-
tions about the mechanism by which mu-
tant LRRK2 mediates PD pathogenesis.
The generation of this particular flymodel
is therefore an important step toward
advancing our overall understanding of
LRRK2 function in PD. Furthermore, as
the second comprehensive, detailed anal-
ysis of TH! neuron loss in a combination
of LRRK2Drosophilamodels, these results
finally allow a direct comparison between
studies. The ability to compare studies is
essential because several groups investi-
gating the effects of PD-associated LRRK2
(or equivalent dLRRK) mutations on
photoreceptor degeneration, TH! neu-
ron loss, muscle pathology, locomotor
function, and lifespan have reported dis-
crepancies in fly phenotypes (Lee et al.,
2007; Imai et al., 2008; Liu et al., 2008; Ven-
darova et al., 2009). Specifically, LRRK2 wt
and PDmutant fly lines range from having
photoreceptor degeneration to having no
abnormal eye phenotype, significant re-
ductions in TH! neuron numbers in all
neuronal clusters to no apparent loss of
TH! neurons in any of the clusters, se-
vere muscle pathology resulting in abnor-
mal wing posture to no overt muscle
phenotype, and either decreased, normal,
or increased lifespan. On the surface, these
discrepancies are confusing given that the
authors all use the same GAL4 drivers, i.e.,
GMR (eye specific), elav (pan neuronal),
Ddc (DA neuron specific), and TH (DA
neuron specific), to selectively target
LRRK2 wt or mutant protein expression
to specific tissue regions. However, differ-
ent phenotypes can be caused by
insertion-site-specific effects on transgene
expression levels or dosage effects caused
by multiple transgene insertions in a sin-
gle embryo (Spradling and Rubin, 1983).
In addition, perhaps some of the discrep-
ancy, specifically in measures of TH!
neuron loss, could be attributed to the fact
that not all studies have assessed the same
neural clusters. Moreover, in some cases,
neurons assigned to different clusters by
some groups have been combined and ex-
amined as a single cluster by others, and
thismay have resulted in the TH!neuron
loss dropping below the level of signifi-
cance. However, before any of the pheno-
types are potentially ignored (based on a
consensus between studies), it is important
to remember that the pathology of LRRK2
patients carrying the same pathogenic
mutation is also varied (Giasson et al.,
2006). Given these observations in patients,
it is perhaps not surprising that a range of
phenotypes have been observed in fly mod-
els recapitulating the disease. As a conse-
quence, further assessments of LRRK2
pathogenic function in Drosophila will be
required to address these issues.
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